dacarbazine has been researched along with Melanoma in 1361 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 330 (24.25) | 18.7374 |
| 1990's | 273 (20.06) | 18.2507 |
| 2000's | 353 (25.94) | 29.6817 |
| 2010's | 352 (25.86) | 24.3611 |
| 2020's | 53 (3.89) | 2.80 |
| Authors | Studies |
|---|---|
| Lin, AJ; Loo, TL | 1 |
| Cosby, LA; Hrubiec, RT; Sartorelli, AC; Shyam, K | 1 |
| Benvenuto, J; Farquhar, D | 1 |
| Dalton, JT; Li, W; Lu, Y; Miller, DD; Wang, Z | 1 |
| Chen, J; Dalton, JT; Li, W; Lu, Y; Miller, DD; Wang, Z | 1 |
| Abrantes, AM; Botelho, MF; Gonçalves, AC; Laranjo, M; Rocha Gonsalves, AM; Sarmento-Ribeiro, AB; Serra, AC | 1 |
| Abdullah, SE; Baurain, JF; Butler, MO; Carvajal, RD; Curti, B; Demidov, L; Dummer, R; Gastaud, L; Goodall, H; Hamid, O; Hassel, JC; Holland, C; Joshua, AM; Kirkwood, JM; Mauch, C; Milhem, M; Nathan, P; Ochsenreither, S; Orloff, M; Piperno-Neumann, S; Piulats, JM; Rutkowski, P; Sacco, JJ; Salama, AKS; Schlaak, M; Shoushtari, AN; Sullivan, RJ; Yushak, M | 1 |
| Agorio, CI; Chabalgoity, JA; Chilibroste, S; Mónaco, A; Moreno, M; Plata, MC; Vola, M | 1 |
| Castañeda-Cardona, C; Castrillón-Correa, J; Gil-Rojas, Y; Hernández, F; Herrera, D; Lasalvia, P; Rosselli, D | 1 |
| Chen, P; Cun, B; Guo, Y; Li, X; Luo, N; Yang, C; Yang, Y | 1 |
| Bordini, HP; Cecchini, AL; Fagundes, TR; Luiz, RC; Madeira, TB; Marinello, PC; Melo, GP; Nixdorf, SL | 1 |
| Bagherzadeh, M; Barjasteh, M; Pooshang Bagheri, K; Vossoughi, M | 1 |
| Attaran, N; Esmailzadeh, A; Hejazi, SH; Hemati, S; Shanei, A | 1 |
| Googe, PB; Li, H; McKenna, EF; Moschos, SJ; Pergaris, A; Theocharis, S; Yan, Y | 1 |
| Bastos, V; Oliveira, H; Salvador, D | 1 |
| Chen, H; Fei, X; Huang, Q; Ji, X; Jiang, D; Meng, X; Qin, R; Sun, F; Wang, A; Wang, Z; Xie, X; Zhao, Y | 1 |
| Asahina, A; Katsumata, F; Nobeyama, Y; Waki, Y | 1 |
| Barbarić, M; Brala, CJ; Dabelić, N; Dabelić, S; Kugić, A | 1 |
| Lan, M; Li, AA; Li, F; Xie, D; Yan, MY; Zhang, Y | 1 |
| Hagelstein, V; Klee, G; Kurzhals, JK; Langan, EA; Terheyden, P; Zillikens, D | 1 |
| de Oliveira Junior, RG; Ferraz, CAA; Grougnet, R; Nicolau, E; Picot, L | 1 |
| Belenyuk, VD; Esimbekova, AR; Palkina, NV; Ruksha, TG; Savchenko, AA; Sergeeva, EY; Zinchenko, IS | 1 |
| Feng, S; Shi, H; Wan, Y; Xu, K; Yu, X; Yue, Y; Zhang, C | 1 |
| Asano, Y; Fujimura, T; Muto, Y | 1 |
| Ciardulli, MC; Della Porta, G; Guadagno, L; Longo, R; Mariconda, A; Raimondo, M; Sirignano, M; Vertuccio, L | 1 |
| Cui, H; Dong, Z; Guo, L; Hu, X; Ji, Y; Li, C; Liu, C; Liu, L; Liu, Y; Shi, Y; Wan, S; Wu, Z; Xu, J; Yang, Y; Zhang, X; Zhang, Y | 1 |
| Deng, Y; Li, J; Lu, Q; Pei, J; Su, Z; Yang, Y; Zeng, X; Zhang, Y; Zhong, Y | 1 |
| Amini, M; Baradaran, B; Firouzamandi, M; Mohammadi, A; Najafi, S | 1 |
| Azambuja, JH; Braganhol, E; de Cássia Sant'ana, R; de Souza, PO; Debom, GN; Fachel, FNS; Gelsleichter, NE; Lenz, GS; Michels, LR; Roliano, GG; Teixeira, FC; Teixeira, HF; Visioli, F | 1 |
| Amaral, JD; Francisco, AP; Gaspar, MM; Godinho-Santos, A; Matias, M; Mendes, E; Perry, MJ; Pinho, JO; Rodrigues, CMP | 1 |
| Agrawal, AK; Dubey, PK; Kumar, DN; Mohapatra, D; Pandey, V; Sahu, AN; Shreya, S | 1 |
| Palkina, N; Ruksha, T; Sergeeva, E | 1 |
| Ataabadi, FV; Etebari, M; Oveissi, F; Taheri, A | 1 |
| Barszczewska-Pietraszek, G; Czarny, P; Czyż, M; Drzewiecka, M; Gajos-Michniewicz, A; Hoser, G; Jaśniak, D; Piekarski, J; Radek, M; Sitarek, P; Skorski, T; Śliwiński, T | 1 |
| Charpentier, C; Dreno, B; Flet, L; Fronteau, C; Guile, R; Khammari, A; Nguyen, JM; Poinas, A; Riche, VP; Thomare, P; Varey, É | 1 |
| Cardoso, CO; Cunha-Filho, M; Gelfuso, GM; Gratieri, T; Uwai, TY | 1 |
| Edwards, CRW; Goff, PS; Gorelkin, PV; Korchev, Y; Sviderskaya, EV; Woodcock, E; Zhang, Y | 1 |
| Chen, TM; Chiu, CF; Hsu, TW; Lee, WR; Liao, PH; Su, YH; Tseng, PC; Tzeng, YS; Wang, CH; Yeh, YW | 1 |
| Beberok, A; Respondek, M; Rok, J; Rzepka, Z; Wrześniok, D | 1 |
| Ascierto, PA; Becker, JC; Cascinu, S; Catania, C; Danielli, R; Dummer, R; Eigentler, T; Elia, G; Garbe, C; Hauschild, A; Neri, D; Romanini, A; Trefzer, U; Weide, B | 1 |
| Franken, MG; Gheorghe, M; Haanen, JBAG; Leeneman, B; Uyl-de Groot, CA; van Baal, PHM | 1 |
| Sciumè, C; Sinagra, E | 1 |
| Ascierto, PA; Blank, CU; Chapman, PB; D'Amelio, A; Demidov, LV; Dutriaux, C; Gasal, E; Grob, JJ; Gutzmer, R; Haas, T; Hauschild, A; Kefford, R; Kiecker, F; Lebbé, C; Millward, M; Mookerjee, B; Ribas, A; Rutkowski, P; Schadendorf, D | 1 |
| Bentley, MVLB; Borgheti-Cardoso, LN; Caron, AL; Kravicz, M; Praça, FG; Silvestrini, AVP; Viegas, JSR | 1 |
| Chan, K; Cope, S; Jansen, JP | 1 |
| Ishimoto, K; Minami, K; Tsujiuchi, T; Ueda, N | 1 |
| Haghjooy Javanmard, S; Hajimoradi Javarsiani, M; Sajedianfard, J | 1 |
| Asano, T; Hata, H; Kato, T; Kitamura, S; Maeda, T; Narahira, A; Nozaki, A; Shimizu, H; Watari, H; Yanagi, T | 1 |
| Hide, M; Kan, T; Kawai, M; Matsubara, D; Takahagi, S; Tanaka, A | 1 |
| Alimohammadi, M; Bekeschus, S; Golpur, M; Hadavi, S; Niaki, HA; Rafiei, A; Sohbatzadeh, F; Valadan, R | 1 |
| Ascierto, PA; Dréno, B; Flaherty, KT; Hauschild, A; Larkin, J; Lewis, KD; McArthur, GA; McKenna, E; Mun, Y; Ribas, A; Zhu, Q | 2 |
| Barth, S; Biteghe, FAN; Chalomie, NET; Davids, LM; Ndong, JC; Padayachee, E | 1 |
| Jobani, BM; Mohebi, E; Najafzadeh, N | 1 |
| Costa, L; Lobo-Martins, S; Mansinho, A; Pais, HL; Soares-de-Almeida, L; Teixeira de Sousa, R | 1 |
| Alencar, LMR; Alexis, F; da Silva de Barros, AO; Dahoumane, SA; de Oliveira Siqueira, LB; do Reis, SRR; Helal-Neto, E; Pinto, SR; Portilho, FL; Ricci-Junior, E; Santos-Oliveira, R | 1 |
| Dong, L; Jiang, X; Meng, L; Qu, C; Wang, B; Wang, H; Wei, J; Xin, Y; Zhao, Q | 1 |
| Anisimov, VN; Baldueva, IA; Berstein, LM; Latipova, DK; Novik, AV; Protsenko, SA; Semenova, AI; Semiglazova, TY; Tkachenko, EV; Zhuk, IN | 1 |
| He, J; Huang, X; Sun, K; Teng, W; Tian, J; Yang, J; Zhan, X; Zhou, C; Zhou, L | 1 |
| Brisigotti, V; Campagna, R; Campanati, A; Emanuelli, M; Molinelli, E; Offidani, A; Pompei, V; Pozzi, V; Salvolini, E; Salvucci, A; Sartini, D | 1 |
| Beauchet, A; Blom, A; Bouchereau, S; Chapalain, M; Chaplain, L; Fort, M; Funck-Brentano, E; Gonzalez-Lara, L; Longvert, C; Saiag, P; Sidibé, T | 1 |
| Alexopoulos, LG; Charles, EM; Hellwig, CT; Rehm, M; Rožanc, J; Vetma, V | 1 |
| Furue, M; Hagihara, A; Ito, T; Nakahara, T; Tsuji, G; Uchi, H; Wada, M | 1 |
| Chen, YN | 1 |
| Beck, D; Bonin, M; Garbe, C; Kosnopfel, C; Krieg, K; Lasithiotakis, K; Meier, F; Niessner, H; Sinnberg, T; Wanke, I | 1 |
| Andersson, Y; Flatmark, K; Flem-Karlsen, K; Fodstad, Ø; Nunes-Xavier, CE; Tekle, C | 1 |
| Li, J; Liu, L; Liu, Q; Shen, C; Shezad, K; Tao, J; Xu, N; Zhang, L; Zhang, Y; Zhu, J | 1 |
| Chang, X; Lian, S; Zhang, H; Zhu, W | 1 |
| Bassett, RL; Bedikian, AY; Cain, S; Homsi, J; Hwu, P; Hwu, WJ; Kim, DW; Kim, KB; Papadopoulos, NE; Patel, SP; Washington, E | 1 |
| Han, F; Huang, CY; Kang, X; Luo, JS; Qin, XM; Xie, T | 1 |
| Glickson, JD; Lee, SC; Leeper, DB; Nath, K; Nelson, DS; Putt, ME; Roman, J | 1 |
| Amson, R; Appel, MH; Basílio, AB; Boia-Ferreira, M; Chaim, OM; Da Costa, CRV; Hamasaki, AE; Matsubara, FH; Senff-Ribeiro, A; Telerman, A; Veiga, SS | 1 |
| Hamidi, V; Klemp, M; Odgaard-Jensen, J; Pike, E; Saeterdal, I | 1 |
| Aiba, S; Fujimura, T; Furudate, S; Kakizaki, A; Kambayashi, Y; Lyu, C; Sato, Y; Tanita, K | 1 |
| Ascierto, PA; Caro, I; Chang, I; Chapman, PB; Coleman, S; Dummer, R; Flaherty, KT; Haanen, JB; Hamid, O; Hauschild, A; Hogg, D; Larkin, J; Lorigan, PC; McArthur, GA; Ribas, A; Robert, C; Sosman, JA; Testori, A | 1 |
| Atkins, MB; Flaherty, LE; Kirkwood, JM; Moon, J; Othus, M; Ribas, A; Samlowski, WE; Sondak, VK; Witter, M | 1 |
| Al-Qahtani, M; Barja-Fidalgo, TC; Bernardes, ES; de Jesus Andreoli Pinto, T; Dos Santos, SN; Ghisleni, DDM; Kozempel, J; Ricci-Junior, E; Rosa, TG; Santos-Oliveira, R | 1 |
| Barone, C; Blasi, MA; Cassano, A; Dadduzio, V; Pagliara, M; Quirino, M; Rossi, E; Schinzari, G | 1 |
| Chammas, R; Cirilo, PDR; Corrêa, BRS; de Sousa Andrade, LN; Furuya, TK; Penalva, LOF; Qiao, M | 1 |
| Anghel, RM; Haidar, A; Popescu, A | 1 |
| Hafeez, A; Kazmi, I | 1 |
| Saxena, S; Singh, RK; Varney, ML; Wu, S | 1 |
| Guo, Z; He, J; Huang, X; Sun, K; Wang, H; Yang, J; Zha, ZG; Zhang, H; Zhang, HT; Zhou, C | 1 |
| Caruntu, C; Constantin, C; Neagu, M; Surcel, M; Zurac, S | 1 |
| Ates, KE; Duzgun, O; Gokcay, S; Sarici, IS; Yılmaz, MB | 1 |
| Annovazzi, L; Battaglia, L; Biasibetti, E; Boggio, E; Cangemi, L; Capucchio, MT; Clemente, N; Dianzani, C; Dianzani, U; Ferrara, B; Gigliotti, CL; Mellai, M; Miglio, G; Muntoni, E; Schiffer, D | 1 |
| Cui, H; Huang, W; Li, X; Liao, X; Liu, X; Min, L; Shi, B; Sun, X; Xu, S; Yang, J; Zhang, M; Zheng, H; Zhu, Z | 1 |
| Cabezas, SS; Dos Santos, SN; Helal-Neto, E; Martínez-Máñez, R; Pinto, SR; Portilho, FL; Pozzo, L; Sancenón, F; Santos-Oliveira, R | 1 |
| Ellis, J; Hertel, N; Johnson, H; Lee, D; Meng, Y; Morais, E; Philips, Z; Roskell, N; Walker, A | 1 |
| Barker, P; Berking, C; Carvajal, RD; Chapman, PB; Chmielowski, B; Clemett, D; Cocquyt, V; Evans, TRJ; Frank, S; Gastaud, L; Ghiorghiu, D; Joshua, AM; Kapiteijn, E; Kilgour, E; Lai, Z; Linette, G; Lovick, S; Mariani, G; Nathan, P; Piperno-Neumann, S; Piulats, JM; Rodrigues, MJ; Schachter, J; Schwartz, GK; Shoushtari, AN; Spratt, S; Wolter, P | 1 |
| Caselli, A; Cirri, P; Livi, L; Lori, G; Mangoni, M; Marzocchini, R; Paoli, P; Raugei, G; Talamonti, C | 1 |
| Cen, Y; Chen, J; He, M; Li, H; Wang, X; Zhang, Z | 1 |
| Abramov, I; Khochenkov, D; Prokofieva, A; Ryabaya, O; Stepanova, E; Zasedatelev, A | 1 |
| Ekielski, A; Iqbal, Z; Jaggi, M; Mishra, H; Mishra, PK; Talegaonkar, S | 1 |
| Altomonte, M; Bova, G; Calabrò, L; Camerini, R; Cisternino, F; Danielli, R; Di Giacomo, AM; Dragonetti, R; Giannarelli, D; Maio, M; Savelli, V | 1 |
| Chmielowski, B; Copley-Merriman, C; Liu, FX; Mauskopf, J; Stevinson, K; Wang, J; Zimovetz, EA | 1 |
| Koskivuo, I; Lahtela, V; Mattila, K; Pyrhönen, S; Raanta, P; Vihinen, P | 1 |
| Arance, A; Ascierto, PA; Atkinson, V; Brady, B; Charles, J; Chiarion-Sileni, V; Cognetti, F; Di Giacomo, AM; Dutriaux, C; Gogas, H; Hassel, JC; Hernberg, MM; Jiang, J; Kalinka-Warzocha, E; Lebbé, C; Long, GV; Mauch, C; McNeil, C; Mihalcioiu, C; Mortier, L; Ny, L; Rizzo, J; Robert, C; Rutkowski, P; Saci, A; Savage, KJ; Schadendorf, D; Svane, IM | 1 |
| Hide, M; Hirakawa, K; Kawai, M; Saito, R; Takahagi, S; Tanaka, M | 1 |
| Alexopoulos, LG; Charles, EM; Rehm, M; Rožanc, J; Skoko, J | 1 |
| Alipour, M; Asiabi, H; Hosseinkhani, S; Shamsayei, M; Yamini, Y | 1 |
| Specenier, P | 1 |
| Assmann, CE; Bagatini, MD; da Cruz, IBM; de Andrade, CM; de Oliveira Alves, A; Mânica, A; Morsch, VMM; Palma, TV; Pelinson, LP; Pillat, MM; Schetinger, MRC; Stefanello, N; Ulrich, H; Weis, GCC | 1 |
| Beaugeard, L; Bonnet, A; Braconnier, E; da Silva Almeida, JRG; de Oliveira Júnior, RG; Ferraz, CAA; Grougnet, R; Groult, H; Picot, L; Prunier, G | 1 |
| Devji, T; Levine, O; Thabane, L; Xie, F; Zoratti, MJ | 1 |
| Bell Gorrod, H; Bullement, A; Latimer, NR | 1 |
| Flem-Karlsen, K; Flørenes, VA; Fodstad, Ø; Mælandsmo, GM; Nunes-Xavier, CE; Tekle, C; Øyjord, T | 1 |
| Piotrowska, A; Rybarczyk, A; Slominski, AT; Tuckey, RC; Wierzbicka, J; Żmijewski, MA | 1 |
| Corrêa, FM; Fernandes, RRA; Guerra, RL; Zimmerman, IR | 1 |
| Corrêa, FM; Fernandes, RRA; Guerra, RL; Souza, MC; Zimmermann, IR | 1 |
| Ishimoto, K; Maeda, H; Minami, K; Otagaki, S; Tsujiuchi, T; Ueda, N | 1 |
| Achberger, S; Aldrich, W; Binkley, E; Rybicki, L; Singh, A; Triozzi, PL | 1 |
| Aprea, P; Ascierto, PA; Botti, G; Caracò, C; Cavalcanti, E; Comella, G; Cossu, A; Daponte, A; Gallo, C; Grimaldi, AM; Lastoria, S; Maiorino, L; Massidda, B; Mozzillo, N; Palmieri, G; Petrillo, A; Signoriello, S; Simeone, E | 1 |
| Harris, PJ; Ivy, SP; Luke, JJ; Rubinstein, LV; Smith, GL | 1 |
| Abbattista, A; Calvert, H; Curtin, N; Dewji, R; Gallo, J; Lorigan, P; Middleton, MR; Mulligan, E; Plummer, R; Scott, L; Steven, N; Wang, D; Wilson, RH | 1 |
| Carlson, GW; Crocker, IR; Delman, KA; Khan, MK; Lawson, DH; Lowe, M; Marcus, DM; Maynard, N; Melton, A; Rizzo, M; Shelton, JW | 1 |
| Cheng, Q; Jiang, AJ; Jiang, G; Li, LT; Tian, H; Zheng, JN | 1 |
| Cliby, WA; Janco, JM; Markovic, SN; Weaver, AL | 1 |
| Cuellar, S; Culos, KA | 1 |
| Chi, Z; Cui, C; Gu, K; Guo, J; Kong, Y; Li, S; Lian, B; Lin, T; Mao, L; Qin, S; Ren, X; Sheng, X; Si, L; Song, X; Tao, M | 1 |
| Berge, EO; Birkeland, E; Busch, C; Geisler, J; Jönsson, G; Knappskog, S; Lillehaug, JR; Lønning, PE | 1 |
| Ancarani, V; Ascierto, PA; Baravelli, S; de Rosa, F; Fiammenghi, L; Gentilcore, G; Granato, AM; Guidoboni, M; Nicoletti, SV; Pancisi, E; Petrini, M; Riccobon, A; Ridolfi, L; Ridolfi, R; Scarpi, E; Simeone, E; Valmorri, L | 1 |
| Arance, A; Cantarini, M; Dummer, R; Gutzmer, R; Kim, KB; Liszkay, G; Lorigan, P; Middleton, MR; Nyakas, M; Robert, C; Schadendorf, D; Spencer, S | 1 |
| Benlalam, H; Caillou, B; Carré, T; Chouaib, S; Jalil, A; Noman, Z; Robert, C; Tittarelli, A; Vielh, P | 1 |
| Armstrong, AW; Ma, C | 1 |
| Ejaz, S; Habra, MA; Henderson, SA; Shawa, H | 1 |
| Chin, K; Kotapati, S; Sherrill, B; Wang, J | 1 |
| Czyz, ME; Hartman, ML; Koprowska, K; Sztiller-Sikorska, M | 1 |
| Gibney, GT; Sondak, VK | 1 |
| Chi, Z; Cui, C; Guo, J; Kong, Y; Li, S; Lian, B; Mao, L; Sheng, X; Si, L; Tang, B | 1 |
| Abdollahi, M; Nikfar, S; Teimouri, F | 1 |
| Chong, K; Hoon, DS; Huang, SK; Marzese, DM; Ohta, K; Sato, Y; Sim, MS | 1 |
| Hellwig, CT; Leverkus, M; Passante, E; Rehm, M; Würstle, ML | 1 |
| Eich, M; Kaina, B; Nikolova, T; Roos, WP | 1 |
| Andrés, R; Brown, E; Calvert, H; Chmielowska, E; Cullell-Young, M; de Miguel, B; Demidov, L; Extremera, S; Kahatt, C; Kudryavtseva, G; Lorigan, P; Moiseyenko, V; Plummer, R; Soriano, V; Szyldergemajn, S; Zaucha, R | 1 |
| Lewis, BC; Miners, JO | 1 |
| Agostinis, P; Govaere, O; Gremeaux, L; Maes, H; Roskams, T; Stas, M; Van den Broeck, A; van den Oord, JJ; Vankelecom, H; Wouters, J | 1 |
| Jia, HY; Jiang, G; Lei, TC; Li, RH; Liu, YQ; Sun, C | 1 |
| Anderson, JE; Davis, JE; Kim, KB; Trinh, VA | 1 |
| Iversen, TZ | 1 |
| Akiyama, M; Matsumoto, T; Nin-Asai, R; Saito, S; Sawada, M; Yokota, K | 1 |
| Fang, Q; Hu, X; Li, Y; Ma, D; Wang, J; Yang, Y; Zhang, W | 1 |
| Ascierto, PA; Dummer, R; Eggermont, AM; Flaherty, KT; Hauschild, A; Hennig, M; Kefford, R; Kirkwood, JM; Lee, SJ; Long, GV; Lorigan, P; Mackensen, A; McArthur, G; O'Day, S; Patel, PM; Robert, C; Schadendorf, D | 1 |
| Bodell, MA; Kraus, ES; Lipson, EJ; Sharfman, WH | 1 |
| Amonkar, MM; Casey, M; Demidov, LV; Dummer, R; Garbe, C; Grotzinger, K; Hassel, JC; Lefeuvre-Plesse, C; Milhem, M; Mohr, P; Patel, K; Robert, C; Rutkowski, P; Rutten, A; Schadendorf, D; Sherman, L; Steven, N; Trefzer, U; Ullenhag, G; Wolter, P; Wu, FS | 1 |
| Bedane, C; Combemale, P; Cupissol, D; Derrey, S; Dygai-Cochet, I; Lamant, L; Leccia, MT; Lubrano, V; Mazeau-Woynar, V; Mirabel, X; Modiano, P; Mourrégot, A; Planchamp, F; Rougé Bugat, ME; Sassolas, B; Siegrist, S; Thariat, J; Tiffet, O; Truc, G; Verdoni, L | 1 |
| Ascierto, PA; Caro, I; Chapman, PB; Cheng, S; Dréno, B; Dummer, R; Eggermont, AM; Flaherty, KT; Garbe, C; Haanen, JB; Hamid, O; Hauschild, A; Hogg, D; Jouary, T; Kirkwood, JM; Larkin, J; Lebbé, C; Lorigan, P; Maio, M; McArthur, GA; O'Day, SJ; Ribas, A; Robert, C; Schadendorf, D; Sosman, JA; Testori, A; Trunzer, K; Yin, M | 1 |
| Huang, X; Zhang, L; Zhang, X | 1 |
| Alavi, A; Goncalves, MD; Torigian, DA | 1 |
| Bauer, J; Büttner, P; Eigentler, TK; Garbe, C; Keim, U; Leiter, U; Meckbach, D; Pflugfelder, A; Richter, S; Weide, B | 1 |
| Koon, HB; Megahed, AI | 1 |
| Chen, J; Chi, M; Ye, Y; Zhang, XD | 1 |
| Kerr, J; Reyes, C; Satram-Hoang, S; Stepanski, EJ; Walker, MS | 1 |
| Augustine, CK; Beasley, GM; Davies, MA; Deng, W; Dewhirst, MW; Fontanella, A; Lidsky, ME; Padussis, JC; Tokuhisa, Y; Toshimitsu, H; Turley, RS; Tyler, DS | 1 |
| Bedikian, AY; Conry, R; Garbe, C; Grob, JJ; Lebbe, C | 1 |
| Barrera-Baena, P; Hervás-Molina, AJ; Jurado-García, J; Ruiz-Cuesta, P; Villar-Pastor, CM | 1 |
| Azimi, A; Egyházi Brage, S; Frostvik Stolt, M; Hansson, J; Hertzman Johansson, C; Lehtiö, J; Pernemalm, M | 1 |
| Alrwas, A; Bassett, R; Bedikian, AY; Cain, S; Davies, MA; Deburr, TL; Hwu, P; Hwu, WJ; Kim, KB; Papadopoulos, NE; Patel, SP; Woodman, SE | 1 |
| Amonkar, MM; Chiarion-Sileni, V; Demidov, LV; Goodman, V; Grob, JJ; Grotzinger, K; Haney, P; Hauschild, A; Kämpgen, E; Karaszewska, B; Martin-Algarra, S; Mauch, C; Miller, WH; Millward, M; Mirakhur, B; Rutkowski, P; Swann, S | 1 |
| Hutchinson, L | 2 |
| Dubóczki, Z; Liszkay, G; Lóránd, A; Mészáros, P; Plótár, V; Vörös, A; Zs Tóth, E | 1 |
| Bedikian, AY; Carvajal, RD; Gordon, MS; Lewis, KD; Pavlick, AC; Rojas, PB; Schwartz, JD; Thompson, JA; Wolchok, JD; Wong, MK | 1 |
| Abramson, DH; Albertini, MR; Ambrosini, G; Ancell, K; Bluth, M; Carvajal, RD; Chapman, PB; Dickson, MA; Doyle, A; Erinjeri, J; Flynn, PJ; Gajewski, TF; Hedvat, C; Joshua, AM; Kudchadkar, RR; Lao, CD; Lawson, DH; Lewis, K; Linette, GP; Lutzky, J; Marr, B; Milhem, MM; Panageas, KS; Quevedo, JF; Sato, T; Schwartz, GK; Sosman, JA; Wolchok, JD | 1 |
| Arozarena, I; Erice, O; Ferguson, J; Goicoechea, I; Margison, GP; Wellbrock, C | 1 |
| Arrighetti, N; Carenini, N; Ciniselli, CM; Ciusani, E; Cominetti, D; Corna, E; De Cesare, M; Gatti, L; Manenti, G; Perego, P; Rivoltini, L; Rodolfo, M; Sevko, A; Umansky, V; Verderio, P; Zaffaroni, N | 1 |
| Amaravadi, RK; Chang, YC; Davis, LE; DeMichele, AM; Evans, TL; Fecher, LA; Gallagher, M; Heitjan, DF; Kaiser, J; Kramer, A; Leone, R; Nathanson, KL; O'Dwyer, PJ; Piao, S; Pontiggia, L; Rangwala, R; Rodgers, G; Schuchter, LM; Tan, KS; Troxel, AB | 1 |
| Amaravadi, RK; Caro, I; Choe, CH; Kempen, JH; McArthur, GA | 1 |
| Deutsch, J; Frees, M; Laux, D; Leon-Ferre, R; Milhem, M; Smith, BJ; Xia, C | 1 |
| Bordeaux, JS; Koon, HB; Palathinkal, DM; Sharma, TR | 1 |
| Jiang, G; Li, RH; Liu, YQ; Sun, C; Wei, ZP; Zheng, JN | 1 |
| Abernethy, AP; Jiang, BS; Mosca, PJ; Speicher, PJ; Thomas, S; Tyler, DS | 1 |
| Augustine, CK; Beasley, GM; Dolber, PC; Mosca, PJ; Peterson, BL; Ross, M; Royal, R; Sharma, K; Speicher, P; Tyler, DS; Zager, JS | 1 |
| Apetoh, L; Bel, B; Dalac, S; Ghiringhelli, F; Hervieu, A; Jeudy, G; Mignot, G; Vabres, P | 1 |
| Bouchaab, H; Bucher, M; Gaide, O; Homicsko, K; Letovanec, I; Michielin, O; Peters, S; Zimmerman, S | 1 |
| Benhammane, H; Bensouda, Y; Boutayeb, S; El Khannoussi, B; Elghissassi, I; Errihani, H; Kharmoum, J; Kharmoum, S; Mohamed, M; Mrabti, H; Sbitti, Y; Setti, K; Touri, S | 1 |
| Andersen, MH; Iversen, TZ; Svane, IM | 1 |
| Egger, ME; Gomez-Gutierrez, JG; McMasters, KM; McNally, LR; Nitz, J | 1 |
| Indurthi, VS; Koladia, M; Law, B; Leclerc, E; Meghnani, V; Vetter, SW; Wagh, A | 1 |
| Atkins, MB; Flaherty, LE; Haluska, FG; Kirkwood, JM; Moon, J; Othus, M; Pappo, AS; Redman, BG; Ribas, A; Sondak, VK; Sosman, JA; Thompson, JA; Tuthill, RJ; Vetto, JT | 1 |
| Atanasov, G; Bartels, M; Hau, HM; Morgül, MH; Schmelzle, M; Schoenberg, MB; Seitz, AT; Simon, JC; Tautenhahn, HM; Uhlmann, D; Wiltberger, G | 1 |
| Aresu, L; Cancedda, S; Dacasto, M; Gracis, M; Leone, VF; Marconato, L; Pizzoni, S; Rohrer Bley, C | 1 |
| Arance, A; Ascierto, PA; Atkinson, V; Brady, B; Charles, J; Chiarion-Sileni, V; Cognetti, F; Dutriaux, C; Gogas, H; Hassel, JC; Hernberg, MM; Horak, C; Kalinka-Warzocha, E; Lebbé, C; Long, GV; Lundgren-Eriksson, L; Maio, M; Mauch, C; McNeil, C; Mihalcioiu, C; Mortier, L; Robert, C; Rutkowski, P; Savage, KJ; Schadendorf, D; Schmidt, H; Sharkey, B; Waxman, IM | 1 |
| Egyházi Brage, S; Frostvik Stolt, M; Hansson, J; Hertzman Johansson, C; Jewell, R; Johansson, H; Lindén, D; Lindholm, C; Newton-Bishop, J; Snowden, H; Stierner, U; Tuominen, R; van den Oord, JJ; Walker, C; Wolter, P | 1 |
| Longo, DL; Sznol, M | 1 |
| Jiang, G; Li, RH; Liu, YQ; Sun, C; Zheng, JN | 1 |
| Chen, TC; Cho, HY; Hofman, FM; Jhaveri, N; Nguyen, J; Rosenstein-Sisson, R; Schönthal, AH; Wang, W | 1 |
| Ahmad, MW; Alken, S; Colleran, GC; Fitzpatrick, D; Kavanagh, EC; Kelly, CM; Lyons, TG; Murray, B; O'Kane, GM | 1 |
| Christmann, M; Kaina, B; Krumm, A; Loquai, C; Merz, S; Quiros, S; Roos, WP; Switzeny, OJ | 1 |
| Dhermain, F; Grob, JJ; Guillot, B; Jouary, T; Le Rhun, É; Lebbe, C; Leccia, MT; Mateus, C; Mortier, L; Robert, C; Thomas, M | 1 |
| Bafaloukos, D; Fountzilas, G; Gogas, H; Linardou, H; Makatsoris, T; Pectasides, D; Pentheroudakis, G; Varthalitis, I | 1 |
| Armstrong, JL; Babatunde, F; Corazzari, M; Eleni Anagnostou, M; Hernandez-Tiedra, S; Hill, DS; Lopez-Valero, I; Lorente, M; Lovat, PE; McKee, CS; Redfern, CPF; Velasco, G | 1 |
| Ahn, JB; Choi, HJ; Chung, HC; Heo, SJ; Jung, M; Kim, HR; Kim, HS; Lee, CK; Rha, SY; Roh, MR; Shin, SJ | 1 |
| Aamdal, S; Bondarenko, I; Chen, TT; Chiarion-Sileni, V; Garbe, C; Grob, JJ; Maio, M; Robert, C; Testori, A; Thomas, L; Tschaika, M; Wolchok, JD | 1 |
| Faião-Flores, F; Fruet, AC; Maria, DA; Maria-Engler, SS; Pardi, PC; Quincoces Suarez, JA | 1 |
| Coco, P; Cocorocchio, E; Ferrucci, PF; Gandini, S; Minchella, I; Mosconi, M; Munzone, E; Pari, C; Passoni, C; Testori, A; Verrecchia, F | 1 |
| Gupta, K; Hardy, KM; Hendrix, MJ; Margaryan, NV; Murphy, GF; Scolyer, RA; Strizzi, L | 1 |
| Bilgi, O; Çelik, S; Emirzeoğlu, L; Karagöz, B; Özet, A; Özgün, A | 1 |
| Acosta, JC; Arozarena, I; Barriuso, J; Erice, O; Goicoechea, I; Jones, C; Margison, GP; Smith, MP; Wellbrock, C; White, R | 1 |
| Alfano, D; Caputo, E; Cavalcanti, E; Fico, A; Patriarca, EJ; Travali, S; Valentino, A; Vasta, V | 1 |
| Abhyankar, S; Chang, CL; Donga, P; Munakata, J; Reyes, CM; Schabert, VF; Yim, YM | 1 |
| Aricò, E; Belardelli, F; Belli, R; Buccione, C; Capone, I; Cappellini, GA; Carlei, D; Casorelli, I; Castiello, L; D'Agostino, G; Macchia, I; Marchetti, P; Monque, D; Montefiore, E; Moschella, F; Napolitano, M; Pavan, A; Proietti, E; Rizza, P; Rozera, C; Santodonato, L; Sestili, P; Urbani, F | 1 |
| Atkins, MB; Gibney, GT | 1 |
| Bagijn, M; Barber, B; Corrie, P; Jones, C; Saltman, D; Zhao, Z | 1 |
| Abrams, KR; Amonkar, MM; Latimer, NR; Stapelkamp, C; Swann, RS | 1 |
| Eastwood, A; Giannopoulou, C; McKenna, C; Moe-Byrne, T; Sideris, E; Wade, R | 1 |
| Carvajal, RD; Mann, H; Nathan, PD; Schwartz, GK; Smith, I | 1 |
| Chyla, B; Daud, A; Falotico, N; Friedlander, P; Giranda, VL; Hamid, O; Jiang, F; Luo, Y; McArthur, GA; McKee, M; McKeegan, E; Middleton, MR; Mostafa, NM; Plummer, R; Qian, J; Zhu, M | 1 |
| Li, W; Mahato, RI; Mundra, V | 1 |
| Chang, JW; Huang, WK; Wang, HM; Wu, CF | 1 |
| Kubo, Y; Shibuya, J; Shida, A; Suzuki, K; Takahashi, T; Yanagihara, M | 1 |
| Carlino, MS; Long, GV | 1 |
| Hou, XY; Jiang, G; Li, RH; Liu, WL; Liu, YQ; Tang, JQ; Yang, CS | 1 |
| Fukushima, S; Kiyohara, Y; Namikawa, K; Okuyama, R; Otsuka, Y; Shibagaki, N; Tokudome, T; Tsutsumida, A; Uchi, H; Uhara, H; Yamazaki, N | 1 |
| Agarwala, SS; Bhatia, S; Brachmann, C; Brown, MP; Clawson, A; Conry, R; Del Vecchio, M; Elias, I; Ernst, S; Grob, JJ; Gutzmer, R; Hauschild, A; Haydon, A; Hersh, EM; Homsi, J; Karnoub, M; Kefford, R; Kendra, K; Li, M; Loquai, C; Renschler, MF; Robert, C; Testori, A | 1 |
| Aleksic, T; Asher, R; Bridges, E; Gao, S; Kamdoum, WP; Li, JL; Macaulay, VM; Margison, GP; Middleton, MR; Pfister, SX; Ramcharan, R; Repapi, E; Tanner, J; Watson, AJ; Woodcock, M | 1 |
| Andresen, C; Falchook, GS; George, GC; Hong, DS; Kim, KB; Kurzrock, R; Kwak, J; Nemunaitis, J; Nguyen, LM; O'Brien, JP; Ren, M; Xu, L | 1 |
| Henderson, M; Heriot, AG; Knowles, J; Lynch, AC; Warrier, SK | 1 |
| Goormaghtigh, E; Le Corre, Y; Martin, L; Mathieu, V; Wald, N | 1 |
| Schuchter, LM; Wilson, MA | 1 |
| Bíró, T; Buzás, K; Endrész, V; Gyukity-Sebestyén, E; Harmati, M; Katona, RL; Kemény, L; Marton, A; Nagy, K; Németh, IB; Oláh, J; Tubak, V; Vígh, L; Vizler, C; Zvara, Á | 1 |
| Chen, TT | 1 |
| Arnold, A; Braun, R; Dummer, R; Guckenberger, M; Hunger, RE; Lindenblatt, N; Michielin, O; Mihic-Probst, D; Najafi, Y; Siano, M; von Moos, R | 1 |
| Asselain, B; Bidard, FC; Cassoux, N; Decaudin, D; Diallo, A; Etienne-Grimaldi, MC; Mariani, P; Piperno-Neumann, S; Plancher, C; Rodrigues, M; Servois, V | 1 |
| Chen, YP; Feng, SX; Hou, XY; Jiang, G; Jiang, XX; Liu, YQ; Xu, XF; Yang, CS; Yang, M | 1 |
| Beaumont, KA; Daignault, SM; Gabrielli, B; Haass, NK; Hill, DS; Lui, GYL; Sharp, DM; Weninger, W | 1 |
| Hou, XY; Huang, Q; Jiang, G; Tang, JQ; Xin, Y; Yang, M; Zhang, LZ; Zhang, P | 1 |
| Abrams, KR; Amonkar, MM; Bell, H; Casey, M; Latimer, NR | 1 |
| Briggs, A; Hatswell, AJ; Hertel, N; Lee, D; Porter, J | 1 |
| Ishikawa, M; Oashi, K | 1 |
| Fortunato, RS; Kajitani, GS; Menck, CF; Quinet, A; Rocha, CR | 1 |
| Abernethy, AP; Ascierto, PA; Atkinson, V; Coon, C; Dastani, HB; Gilloteau, I; Hassel, JC; Long, GV; Robert, C; Rutkowski, P; Savage, KJ; Taylor, F; Waxman, IM | 1 |
| Ding, B; Ding, X; Gao, S; Huang, X; Huang, Y; Wang, J; Wu, X; Xie, C; Xu, N; Zhan, S; Zhang, W; Zheng, Y | 1 |
| Averineni, RK; Guan, X; Sadhu, SS; Seefeldt, T; Wang, S; Yang, Y | 1 |
| Amaria, RN; Bassett, RL; Bedikian, AY; Cain, S; Davies, MA; Hwu, P; Hwu, WJ; Lecagoonporn, S; McQuade, JL; Patel, SP; Posada, LP | 1 |
| Blank, C; Cranmer, L; Daud, A; Dummer, R; Ebbinghaus, S; Hamid, O; Hauschild, A; Hille, D; Kang, SP; Loquai, C; Mehnert, JM; O'Day, S; Puzanov, I; Ribas, A; Robert, C; Salama, A; Schachter, J; Schadendorf, D; van den Eertwegh, A; Zhou, W | 1 |
| Cheng, P; Czyż, M; Dummer, R; Gajos-Michniewicz, A; Gritsyuk, D; Hoser, G; Levesque, M; Majchrzak, K; Nieborowska-Skorska, M; Skorski, T; Sliwinski, T; Szemraj, J; Toma, M | 1 |
| Musha, A; Nakano, T; Ohno, T; Saitoh, JI; Shirai, K; Yokoo, S | 1 |
| Dronca, RS; Ivanov, LV; Kottschade, LA; Leontovich, AA; Markovic, SN; Nevala, WK; Thompson, MA | 1 |
| Chmielowski, B; Dry, SM; Eilber, FC; Hoffman, RM; Igarashi, K; Kawaguchi, K; Kiyuna, T; Li, Y; Murakami, T; Nelson, SD; Russell, TA; Singh, A; Unno, M; Zhang, Y; Zhao, M | 1 |
| Ling, B; Michel, D; Sakharkar, MK; Yang, J | 1 |
| Biteghe, FN; Davids, LM | 1 |
| Chatard, M; Felder-Flesch, D; Perek, N; Prevot, N; Puech, C | 1 |
| Cao, H; Ding, M; Liu, N; Mao, LJ; Xu, K; Yang, C | 1 |
| Egorova, AV; Emelyanova, MA; Inshakov, AN; Khochenkov, DA; Nasedkina, TV; Ryabaya, OO; Stepanova, EV; Zasedatelev, AS | 1 |
| Barber, B; Kudlac, A; Ma, Q; Palmer, S; Quinn, C; Zhao, Z | 1 |
| Guo, W; Hou, X; Jiang, G; Li, R; Liu, Y; Ma, Y; Tang, J; Xin, Y; Yang, C | 1 |
| Kerger, J; Kourie, HR; Simon, A | 1 |
| Barber, BL; Batty, N; Chen, YJ; Hines, DM; Ma, Q; Munakata, J; Zhao, Z | 1 |
| Chibbaro, S; Clavier, JB; Goichot, B; Lhermitte, B; Proust, F; Todeschi, J | 1 |
| Chen, Q; Flowers, CR; Goldstein, DA; Kohn, CG; Montero, AJ; Zeichner, SB | 1 |
| Arance, A; Ascierto, PA; Bozón, V; Del Vecchio, M; Demidov, L; Di Giacomo, AM; Dummer, R; Dutriaux, C; Flaherty, K; Ford, J; Garbe, C; Gutzmer, R; Hogg, D; Jehl, V; Liszkay, G; Long, GV; Mandala, M; Queirolo, P; Rutkowski, P; Schadendorf, D; Sirulnik, LA; Thomas, L; Wasserman, E; Weill, M | 1 |
| Hata, H; Homma, S; Ichikawa, N; Imafuku, K; Kawamura, H; Kitamura, S; Miyazawa, H; Ohno, Y; Shimizu, H; Taketomi, A; Uehara, J; Yamaguchi, Y; Yanagi, T; Yoshida, T | 1 |
| Kudriavtsev, DV; Kudriavtseva, GT; Mardynskiĭ, IuS | 1 |
| Bedikian, AY; Hwu, P; Hwu, WJ; Johnson, MM; Kim, K; McIntyre, S; Papadopoulos, N; Warneke, CL | 1 |
| Adamina, M; Guller, U; Heberer, M; Rosenthal, R; Spagnoli, GC; Viehl, CT; Weber, WP; Zuber, M | 1 |
| Ugurel, S | 1 |
| Both-Skalsky, J; Dummer, R; Egberts, F; Fink, W; Hauschild, A; Kaehler, KC; Laetsch, B; Schadendorf, D; Ugurel, S | 1 |
| Chi, ZH; Cui, CL; Guo, J; Lian, HY; Si, L; Yuan, XQ | 1 |
| Bar-Eli, M; Lev, DC; Melnikova, VO; Villares, GJ; Zigler, M | 1 |
| Agarwala, SS; Gooding, WE; Kirkwood, JM; Moschos, S; Tarhini, AA | 1 |
| Artamonova, EV; Demidov, LV; Kharkevitch, GY; Manziuk, LV; Pirogova, NA | 1 |
| Agarwala, S; Atkins, MB; Clark, JI; Curti, B; Dutcher, JP; Ernstoff, MS; Lawson, D; Logan, T; Margolin, KA; Sosman, JA; Weiss, G | 1 |
| Ballo, MT; Bartell, HL; Bedikian, AY; Dett, TK; Hwu, P; Kim, KB; Myers, JN; Papadopoulos, NE | 1 |
| Jones, C; Plummer, ER | 1 |
| Clynes, M; Crown, J; Eustace, AJ; O'Donovan, N | 1 |
| Hwu, P; Kim, K; Lazar, AJ; Quintás-Cardama, A; Ross, M; Woodman, SE | 1 |
| Kitai, R; Kodera, T; Kubota, T; Sato, K; Takeuchi, H; Yoshida, K | 1 |
| Aldrich, W; Dombos, C; Triozzi, PL | 1 |
| Kawano, N; Kihara, Y; Kume, K; Otsuki, M; Syukuwa, K; Taguchi, M; Tashiro, M; Yamasaki, M; Yoshikawa, I | 1 |
| Atkins, MB; Cohen, GI; Flaherty, LE; Hsu, J; Kirkwood, JM; Lee, S; Sondak, VK; Sosman, JA | 1 |
| Bedikian, AY; Camacho, LH; Frost, AM; Hernandez, IM; Hwu, P; Hwu, WJ; Jack, MA; Kim, KB; Ng, C; Papadopoulos, NE | 1 |
| Bar, J; Catane, R; Gutman, H; Kutchuk, I; Schachter, J; Shapira-Frummer, R; Sulkes, A; Yerushalmi, R | 1 |
| Mori, K; Nakao, Y; Wada, R; Watanabe, M; Yamamoto, T | 1 |
| Al-Jamal, RT; Eskelin, S; Kivelä, T; Pyrhönen, S | 1 |
| Cowan, DH; Gardere, S; Hussain, S | 1 |
| Ahmann, DL; Bisel, HF; Hahn, RG | 1 |
| Bocangel, D; Chada, S; Ekmekcioglu, S; Grimm, EA; Poindexter, N; Ramesh, R; Zheng, M | 1 |
| Campos, M; Flaherty, KT; Garbe, C; Gogel, J; Kulms, D; Lasithiotakis, K; Maczey, E; Meier, F; Niessner, H; Schittek, B; Sinnberg, T | 1 |
| Egberts, F; Hauschild, A; Hitschler, WN; Weichenthal, M | 1 |
| Belohlavek, C; Christmann, M; Jöst, E; Kaina, B; Lennerz, V; Naumann, SC; Roos, WP; Schmidt, CW | 1 |
| Ballarini, M; Contegno, F; Croci, D; Goldhirsch, A; Minucci, S; Munzone, E; Nolè, F; Pelicci, PG; Rocca, A; Salmaggi, A; Testori, A; Tosti, G | 1 |
| Ali-Osman, F; Augustine, CK; Friedman, HS; Nevins, JR; Potti, A; Tyler, DS; Yoo, JS; Yoshimoto, Y; Zipfel, PA | 1 |
| Dohmen-Scheufler, H; Guzel, A; Maciaczyk, J; Nikkhah, G; Ostertag, CB; Senturk, S; Volk, B | 1 |
| Becker, MR; Gaiser, T | 1 |
| Boeckmann, L; Emmert, S; Gutzmer, R; Has, C; Kunz, M; Kuschal, C; Laspe, P; Struever, D; Thoms, KM | 1 |
| Baloglu, A; Bezircioglu, I; Cetinkaya, B; Yavuzcan, A | 1 |
| Berger, W; Dehoux, M; DeNeve, N; Gaussin, JF; Kiss, R; Lefranc, F; Martin de Lassalle, E; Mathieu, V; Mijatovic, T; Pirker, C; Vernier, M | 1 |
| Heppner, FL; Ingold, B; Moch, H; Schraml, P | 1 |
| Lee, F; Richmond, A; Smykla, R; Thu, YM; Yang, J; Zaja-Milatovic, S | 1 |
| Casadevall, A; Dadachova, E; Guimaraes, AJ; Howell, RC; Jongco, AM; Koba, W; Nosanchuk, JD; Revskaya, E; Sellers, RS | 1 |
| Cuttone, G; Iannolo, G; Korićanac, LB; Petrović, IM; Privitera, G; Ristić-Fira, AM; Valastro, LM; Zakula, JJ | 1 |
| Abdi, E; Beith, J; Corrie, PG; Kefford, RF; Kotasek, D; Margison, GP; Middleton, MR; Mortimer, P; Palmer, C; Ranson, M; Thomas, NP; Watson, AJ | 1 |
| Beith, J; Davis, ID; Haydon, A; Hayward, O; Hersey, P; Kefford, R; Lorigan, P; Margison, GP; McArthur, G; McGown, G; Middleton, MR; Mortimer, P; Ranson, M; Sabharwal, A; Thomson, D; Thorncroft, M; Watson, AJ | 1 |
| Chang, PN; Lee, DT; Ling, MT; Wong, YC; Yap, WN; Yap, YL | 1 |
| Jin, S; Kang, X; Sun, W; Wang, J; Zhang, Q | 1 |
| Agarwala, SS; Bedikian, AY; Eggermont, AM; Gilles, E; Itri, LM; Kay, R; Keilholz, U; Stein, CA; Suciu, S; Wu, J | 1 |
| Alvarado, G; Anderson, CM; Bedikian, AY; Benjamin, RS; Buzaid, AC; Eton, O; Frost, AM; Gershenwald, JE; Gonzalez, R; Hwu, P; Hwu, WJ; Johnson, MM; Kim, KB; Lee, JE; Legha, SS; Liu, P; Mansfield, PF; Papadopoulos, NE; Plager, C; Prieto, VG; Ross, MI | 1 |
| Cubitt, CL; Daud, AI; Homsi, J; Jove, R; Messina, JL; Munster, PN; Sullivan, DM; Yu, H; Zhang, S | 1 |
| Chen, M; Orlow, SJ; Osman, I | 1 |
| Bedikian, AY; Cain, S; Glass, MR; Homsi, J; Hwu, P; Hwu, WJ; Kim, KB; Papadopoulos, NE; Rudewicz, P; Vernillet, L | 1 |
| Chang, JL; Farrell, K; Jones, A; Muggia, F; Oratz, R; Ott, PA; Pavlick, AC | 1 |
| Bedikian, A; Gerber, DL; Homsi, J; Hwu, P; Hwu, WJ; Kim, KB; Papadopoulos, NE; Ring, S | 1 |
| Castellón Rubio, V; Delgado Pérez, JR; González Astorga, B; González Flores, E; Jiménez Rubiano, B; Luque Caro, R; Sánchez Toro, C; Valdivia Bautista, J | 1 |
| Marshall, E; O'Day, S; Redman, B; Trefzer, U; van den Eertwegh, AJ; Wagner, S; Weber, JS; Zarour, H | 1 |
| Guenova, E; Hoetzenecker, W; Lichte, V; Moehrle, M; Roecken, M; Schaller, M; Woelbing, F | 1 |
| Cruz-Munoz, W; Kerbel, RS; Man, S | 1 |
| Subbiah, V; Wolff, JE | 1 |
| Collins, CM; Morgan, DS; Mosse, C; Sosman, J | 1 |
| Boeckmann, L; Brockmoeller, J; Emmert, S; Gutzmer, R; Has, C; Kunz, M; Kuschal, C; Laspe, P; Rosenberger, A; Schirmer, M; Schoen, MP; Struever, D; Thoms, KM | 1 |
| Bajetta, E; Cascinu, S; Crinò, L; Danova, M; Del Prete, S; Salvagni, S; Schiavetto, I; Siena, S; Vitali, M | 1 |
| Amatruda, T; Anderson, CM; Atkins, MB; Boasberg, P; Gonzalez, R; Hersh, EM; Lutzky, J; O'Day, SJ; Thompson, JA; Wang, HJ; Weber, JS | 1 |
| Clark, JI; Da Silva, DM; Flaherty, LE; Hutchins, LF; Kast, WM; Liu, PY; Moon, J; Sondak, VK; Sosman, JA; Thompson, JA | 1 |
| Chen, M; Doudican, N; Orlow, SJ; Osman, I; Rose, AE | 1 |
| Bracher, A; Loewe, R; Neumüller, K; Niederleithner, H; Pehamberger, H; Petzelbauer, P; Steele, S; Valero, T | 1 |
| Alvarado, GC; Bedikian, AY; Camacho, LH; Hwu, P; Kim, KB; McIntyre, S; Papadopoulos, NE; Yoon, C | 1 |
| Komori, T; Oguni, A; Shigeta, T; Takahashi, H; Umeda, M | 1 |
| Fuse, H; Imamura, Y; Nohara, T; Sakai, A | 1 |
| Alvino, E; Bonmassar, E; Brasca, MG; Caporali, S; Castiglia, D; Ciomei, M; Covaciu, C; D'Atri, S; Garbin, A; Levati, L; Starace, G | 1 |
| Amiri, KI; Ayers, GD; Horton, LW; Kelley, MC; Koehler, E; Puzanov, I; Richmond, A; Sosman, JA; Su, Y; Yu, Y | 1 |
| Bearden, JD; Behl, D; Brown, PD; Deming, RL; Markovic, SN; Rowland, KM; Sande, JR; Schild, SE | 1 |
| Bedane, C; Guillet, G; Guillot, B; Mourey, L; Sassolas, B; Tourani, JM; Wierzbicka-Hainaut, E | 1 |
| Brady, MS; Carvajal, RD; Chapman, PB; Coit, DG; Gold, JS; Panageas, KS; Shah, GD; Socci, ND; Viale, A; Wolchok, JD | 1 |
| Cranmer, LD; Hersh, EM; Khan, KD; Nichol, GM; O'Day, SJ; Pavlick, AC; Powderly, J; Samlowski, WE; Weber, JS; Yellin, MJ | 1 |
| Gundersen, S; Hager, B; Jacobsen, KD; Tausjø, J | 1 |
| Blaskovits, FM; Carson, WE; Chan, AN; Grignol, VP; Guenterberg, KD; Lesinski, GB; Mundy, BL; Nuovo, GJ; Raig, ET; Young, GS; Zimmerer, JM | 1 |
| Bedikian, A; Buzoianu, M; Gonzalez, R; Hammershaimb, L; Hersey, P; Kirkwood, JM; Logan, T; O'Day, S; Richards, J; Sharfman, W; Sosman, J; Weber, R | 1 |
| Bae, SY; Baek, HJ; Han, DK; Hwang, TJ; Kook, H; Lee, JB; Lee, JK; Lee, MC; Lee, SY; Yun, SJ | 1 |
| Ali-Osman, F; Angelica Selim, M; Augustine, CK; Friedman, HS; Padussis, JC; Pruitt, SK; Toshimitsu, H; Tyler, DS; Yoo, JS; Yoshimoto, Y | 1 |
| Jiang, G; Liu, YQ; Mao, LJ; Pei, DS; Wei, ZP; Zheng, JN | 1 |
| Camerini, R; Cognetti, F; Ferraresi, V; Garbe, C; Gascon, P; Gilde, K; Guillot, B; Jassem, J; Lesimple, T; Mackiewicz, A; Maio, M; Testori, A; Trefzer, U | 1 |
| Ballmer, A; Brady, B; Clingan, PR; Hersey, P; Kefford, RF; Morganti, A | 1 |
| Asselain, B; Barillot, E; Bessard, MA; Couturier, J; Dahmani, A; Decaudin, D; Desjardins, L; Donnadieu, MH; Gentien, D; Lantz, O; Laurent, C; Mariani, P; Némati, F; Péguillet, I; Piperno-Neumann, S; Plancher, C; Reyes, C; Robert, D; Roman-Roman, S; Sastre-Garau, X; Saule, S | 1 |
| Ali-Osman, F; Augustine, CK; Friedman, HS; Jung, SH; Olson, JA; Sohn, I; Tyler, DS; Yoo, JS; Yoshimoto, Y | 1 |
| Hernberg, M; Ivaska, J; Laukka, M; Lundin, J; Pyrhönen, S; Tyynelä, K; Vihinen, PP; Vuoristo, MS | 1 |
| Andersson, Y; Fodstad, O; Risberg, K | 1 |
| de Juan, M; Díaz, R; Fonfría, M; Mancheño, N; Moral, P; Tormo, A | 1 |
| Acland, K; Calonje, E; Harries, M; O'Doherty, M; Perez, A; Szyszko, T; Turajlic, S | 1 |
| Busch, C; Geisler, J; Knappskog, S; Lillehaug, JR; Lønning, PE | 1 |
| Kim, C; Klasa, R; Kovacic, L; Lee, CW; Savage, KJ; Shah, A | 1 |
| Burd, R; Limesand, KH; Mendoza, EE; Mitchell, GC; Radhakrishnan, VM; Sittadjody, S; Thangasamy, T | 1 |
| Busch, C; Geisler, J; Lillehaug, JR; Lønning, PE | 1 |
| Dorr, R; Gonzalez, R; Grenier, K; Hersh, E; O'Day, S; Ribas, A; Samlowski, WE; Sato, T; Stephenson, J; Weber, JS | 1 |
| Hwu, WJ; Neyns, B; Reardon, DA; Tosoni, A | 1 |
| Ali-Osman, F; Augustine, CK; Beasley, GM; Burchette, J; Jung, SH; McMahon, N; Padussis, J; Pruitt, SK; Selim, MA; Toshimitsu, H; Tyler, DS; Yoo, JS; Yoshimoto, Y; Zipfel, PA | 1 |
| Bito, T; Ikeda, T; Nishigori, C; Nishitani, N; Tokura, Y | 1 |
| Lee, N; Setton, J | 1 |
| Dianov, GL; Digweed, M; Eich, M; Kaina, B; Roos, WP | 1 |
| Dummer, R; Edler, L; Hassel, JC; Kurzen, H; Mauch, C; Moll, I; Rass, K; Schadendorf, D; Spieth, K; Stresemann, C; Sucker, A | 1 |
| Belardelli, F; Catricalà, C; Del Bello, D; Ferraresi, V; Ghidini, C; Gualtieri, N; Imberti, L; Natali, PG; Nisticò, P; Palermo, B; Proietti, E; Serana, F; Sottini, A | 1 |
| Augustine, CK; Osmond, GW; Padussis, J; Tyler, DS; Zipfel, PA | 1 |
| Agarwala, S; Bedikian, AY; Conry, R; DeConti, RC; Ernstoff, M; Kim, KB; Papadopoulos, N | 1 |
| Bassett, R; Bedikian, A; Hwu, P; Hwu, WJ; Kim, KB; Knight, RD; Papadopoulos, NE; Patnana, M | 1 |
| Davis, MD; Harlan, E; Pittelkow, MR | 1 |
| Doi, H; Iizuka, H; Ishida-Yamamto, A; Ito, Y; Tsuji, H | 1 |
| Drabick, JJ; Fateh, S; Gingrich, R; Neves, RI; Schell, TD | 1 |
| Davis, ME; Hsueh, T; Koya, RC; Ribas, A; Zuckerman, JE | 1 |
| Hatanaka, K; Hidemura, A; Ishimaru, M; Kojima, T; Sasaki, S; Uekusa, T | 1 |
| Fu, JH; Huang, XY; Li, Y; Wang, X; Xie, X; Yu, H; Zhang, LJ; Zhou, JL | 1 |
| Jiang, G; Liu, YQ; Zheng, JN | 1 |
| Fujimoto, M; Hayashida, N; Muto, M; Nakai, A; Nakamura, Y; Takii, R | 1 |
| Colucci, G; Cramarossa, A; Fistola, E; Giudice, G; Guida, M; Lubello, K; Porcelli, M | 1 |
| Guo, W; Hu, YJ; Li, J; Ren, GX; Yang, WJ; Yang, X; Zhang, CP; Zhong, LP; Zhou, GY | 1 |
| Boasberg, P; Hamid, O; O'Day, S | 1 |
| Di Giacomo, AM; Maio, M; Margolin, KA | 1 |
| Bedikian, AY; Homsi, J; Hwu, P; Hwu, WJ; Johnson, MM; Kim, KB; McIntyre, S; Papadopoulos, NE; Rohlfs, M; Warneke, CL | 1 |
| D'Atri, S; Graziani, G; Lacal, PM; Levati, L; Muzi, A; Ruffini, F; Umezawa, K | 1 |
| Bei, D; Meng, J; Youan, BB | 1 |
| Alamanda, V; Chellappan, S; Davis, R; Lawrence, N; Pernazza, D; Pireddu, R; Sebti, S; Singh, S | 1 |
| Lee, FC; Mangalik, A; Movva, S; Parks, V; Rabinowitz, I; Verschraegen, CF | 1 |
| Di, Y; Gong, J; Guo, JL; He, L; Jin, JL; Lu, YJ; Noteborn, MH; Qu, S; Sun, J; Xia, JJ; Xie, YY; Yin, TJ | 1 |
| Hackel, RE; He, SX; Heckenlively, JR; Johnson, MW; Khan, NW; Koreen, L | 1 |
| Dalle, S; Dumontet, C; Julia, F; Thomas, L | 1 |
| Ikeya, T; Nitta, Y; Sakakibara, A; Tomita, Y | 1 |
| Caccuri, AM; Cuzzocrea, S; Dorio, AS; Federici, G; Graziani, G; Mazzon, E; Muzi, A; Sau, A; Tentori, L; Vernole, P | 1 |
| Joffe, S; Miller, FG | 1 |
| Amaravadi, RK; Li, LZ; Lum, JJ; Ma, XH; McAfee, QW; Nathanson, KL; Piao, S; Wang, D | 1 |
| Burke, W; Califano, R; Carmichael, J; Gore, M; Greystoke, A; Khan, OA; Larkin, J; Lorigan, P; Margison, GP; McGown, G; Middleton, MR; Stone, J; Thorncroft, M; Watson, AJ; Wellman, S | 1 |
| Jiang, G; Liu, YQ; Pei, DS; Wei, ZP; Xin, Y; Zheng, JN | 1 |
| Boeckmann, L; Emmert, S; Kuschal, C; Nickel, AC; Schaefer, A; Schön, MP; Thomale, J; Thoms, KM | 1 |
| Kim, JH; Lee, HR; Lee, J; Lee, SI; Lim, DH; Park, KW; Yi, JH; Yi, SY | 1 |
| Abramov, ME; Artamonov, DN; Gorbacheva, LB; Tronov, VA | 1 |
| Belohlavek, C; Fritz, G; Jöst, E; Kaina, B; Nagel, G; Roos, WP | 1 |
| Engebråten, O; Engesæter, BO; Flørenes, VA; Hellenes, T; Holm, R; Mælandsmo, GM; Sathermugathevan, M | 1 |
| Cathomas, R; Dummer, R; Gillessen, S; Goldinger, SM; Mamot, C; Michielin, O; Mjhic-Probst, D; Moch, H; Ochsenbein, A; Schläppi, M; Schönewolf, N; Schraml, PH; Seifert, B; Simcock, M; von Moos, R | 1 |
| Algazi, AP; Cha, EN; Daud, AI; Soon, CW; Webb, EM | 1 |
| Aamdal, S; Dueland, S; Gaudernack, G; Julsrud, L; Kyte, JA; Trachsel, S | 1 |
| Agarwala, SS; Becker, J; Conry, R; Davidson, N; Dummer, R; Eggermont, AM; Engelen, K; Hwu, WJ; Keilholz, U; Kruit, WH; Mortier, L; Patel, PM; Punt, CJ; Robert, C; Schadendorf, D; Spatz, A; Suciu, S; Thompson, JA; Trefzer, U | 1 |
| Brugnara, S; Chiarion-Sileni, V; Colucci, G; De Salvo, GL; Del Bianco, P; Guida, M; Pigozzo, J; Ridolfi, L; Ridolfi, R; Romanini, A | 1 |
| Ascierto, P; Chapman, PB; Dreno, B; Dummer, R; Eggermont, AM; Flaherty, KT; Garbe, C; Haanen, JB; Hauschild, A; Hogg, D; Hou, J; Jouary, T; Kirkwood, JM; Larkin, J; Lebbe, C; Lee, RJ; Li, J; Lorigan, P; Maio, M; McArthur, GA; Nelson, B; Nolop, K; O'Day, SJ; Ribas, A; Robert, C; Schadendorf, D; Sosman, JA; Testori, A | 1 |
| Baurain, JF; Bondarenko, I; Chen, TT; Davidson, N; Francis, S; Garbe, C; Gascon, P; Grob, JJ; Harmankaya, K; Hauschild, A; Hoos, A; Humphrey, R; Ibrahim, R; Lebbe, C; Lotem, M; Maio, M; Miller, WH; O'Day, S; Richards, J; Robert, C; Testori, A; Thomas, L; Weber, J; Wolchok, JD | 1 |
| Abastado, JP; Audebourg, A; Avril, MF; Caignard, A; Garcette, M; Molina, TJ; Nardin, A; Prévost-Blondel, A; Tissier, F; Tow, C; Wong, WC | 1 |
| Caminal, JM; Fabra, A; Ferreres, JR; Marcoval, J; Penín, RM; Piulats, JM | 1 |
| Handler, MZ; Mruthyunjaya, P; Nelson, K | 1 |
| Tuma, RS | 1 |
| Andrieu-Abadie, N; Bedia, C; Casas, J; Fabriàs, G; Levade, T | 1 |
| Boulinguez, S | 1 |
| Blasius, E; Glas, M; Herrlinger, U; Moehlenbruch, M; Rasch, K; Schaefer, N; Scheffler, B; Stuplich, M; Urbach, H | 1 |
| Affolter, A; Ahmad, T; Chao, D; Chevreau, C; Corrie, P; Eisen, T; Gibbens, I; Gore, ME; Harries, M; James, MG; Jouary, T; Lorigan, P; Marais, R; Montegriffo, E; Nathan, PD; Negrier, S; Ottensmeier, C; Prendergast, S; Robert, C; Strauss, UP | 1 |
| Chao, D; de Boer, CJ; Gonzalez, R; Gore, ME; Gutzmer, R; Hait, W; Ho, P; Lang, Z; Lawson, D; Loquai, C; Marshall, D; Mohr, P; O'Day, S; Ottensmeier, C; Pavlick, A; Richards, J; Schadendorf, D; Thompson, JA; Trefzer, U; Uhlar, C; Zhong, B | 1 |
| Bedeir, A; Berger, W; Ghassemi, S; Grasl-Kraupp, B; Grusch, M; Heffeter, P; Heinzle, C; Held, G; Holzmann, K; Marian, B; Metzner, T; Micksche, M; Peter-Vörösmarty, B; Pirker, C; Spiegl-Kreinecker, S | 1 |
| Abramov, ME; Artamonov, DN; Gorbacheva, LB; Lichinitser, MR; Tronov, VA | 1 |
| Kirkwood, JM; Moschos, S; Radkowski, R; Shipe-Spotloe, J; Sulecki, M; Tarhini, A; Tawbi, HA; Villaruz, L; Viverette, F | 1 |
| Chow, HH; Dorr, RT; Samulitis, BK | 1 |
| Cooper, DA; Fujita, M; Goldstein, NB; Norris, DA; Partyka, KA; Reuland, SN; Shellman, YG | 1 |
| Berking, C; Flaig, MJ; Kunte, C; Roider, E; Ruzicka, T; Schneider, J | 1 |
| Abastado, JP; Avril, MF; Hong, M; Huang, C; Kato, M; Loumagne, L; Mackay, C; Nardin, A; Prévost-Blondel, A; Puaux, AL; Tow, C | 1 |
| Ding, B; Ding, X; Fan, W; Gao, J; Gao, S; Liu, J; Ma, L; Wu, X; Wu, Z; Xiang, W; Zhang, W; Zhu, Q | 1 |
| Craig, EA; Spiegelman, VS | 1 |
| Wilson, KS | 1 |
| Copur, MS; Obermiller, A | 1 |
| Kaplan, MG | 1 |
| Morita, H; Nagai, R | 1 |
| Dalle, S; Poulalhon, N; Thomas, L | 1 |
| Lott, JP | 1 |
| Mateus, C; Robert, C | 1 |
| Cella, D; Cormier, JN; Revicki, DA; Robinson, DW; Uhlar, CM; Zhao, N | 1 |
| de Braud, F; Eigentler, TK; Garbe, C; Giovannoni, L; González-Iglesias, R; Kaspar, M; Lovato, V; Menssen, HD; Neri, D; Pflugfelder, A; Romanini, A; Schwager, K; Spitaleri, G; Tasciotti, A; Trachsel, E; Weide, B | 1 |
| Larkin, J; Minchom, A; Young, K | 1 |
| Bastholt, L; Cantarini, M; Dummer, R; Hersey, P; Kemsley, K; Kirkwood, JM; Larkin, J; Middleton, M; Robert, C; Sosman, J; Zazulina, V | 1 |
| Drecoll, U; Garbe, C; Hauschild, A; Hofmann, MA; Kaatz, M; Mohr, P; Schadendorf, D; Tilgen, W; Trefzer, U; Ulrich, J; Weichenthal, M | 1 |
| Conte, H; Darrigade, AS; Ip Kan Fong, H; Jouary, T; Taïeb, A | 1 |
| Allegra, M; Bahadoran, P; Ballotti, R; Bertolotto, C; Deville, A; Giacchero, D; Lacour, JP; Ortonne, JP; Passeron, T; Ségalen, C; Thyss, A | 1 |
| Bhattacharya, A; Khaliq, A; Kochhar, R; Siddappa, PK; Singh, K; Thandassery, RB; Vaiphei, K | 1 |
| Algazi, AP; Andrews, SC; Daud, AI; DeConti, RC; Hwang, J; McCalmont, T; Messina, JL; Munster, PN; Sondak, VK; Urbas, P; Weber, JS | 1 |
| Czyż, M; Koprowska, K | 1 |
| Dzhabarov, FR; Nepomniashchaia, EM; Pozdniakova, VV; Rozenko, LIa | 1 |
| Aoude, LG; Bonazzi, VF; Brooks, BR; Brown, KM; Chow, D; Dutton-Regester, K; Ellis, JJ; Gartside, MG; Gibbs, R; Hayward, NK; Kobe, B; Lanagan, C; MacKeigan, JP; Muzny, D; Newsham, I; Niemi, NM; Palmer, JM; Pollak, T; Reid, J; Schmidt, CW; Sereduk, C; Stark, MS; Tang, N; Trent, J; Tyagi, S; Woods, SL; Wu, Y; Yin, H; Youngkin, D; Zismann, V | 1 |
| Chen, R; Devito, N; Pan, E; Yu, M | 1 |
| Borden, EC; Budd, TG; Elson, P; Hollovary, E; Jacobs, B; Mitsuhashi, M; Spiro, T; Triozzi, P; Yi, T | 1 |
| Bennett, DC; Chang, PJ; Chinen, M; Cleaver, JE; Demetriou, S; Huang, ZM; Millhauser, GL; Oh, DH; Patel, MP; Scherzer, R; Sviderskaya, EV; Wei, ML; Xie, T; Zhong, L | 1 |
| Arai, M; Hirano, T; Ishibashi, M; Onda, K; Tanaka, S | 1 |
| Abken, H; Bangard, C; Kurschat, P; Mauch, C; Schlaak, M; Schmidt, P | 1 |
| Cun, B; Fan, X; Ge, S; Jia, R; Song, X; Wang, H; Zhao, X | 1 |
| Queirolo, P; Spagnolo, F | 1 |
| Hartmann, G; Katoh, N; Kishimoto, S; Nakai, N; Nomiyama, T; Ozawa, A; Takenaka, H | 1 |
| Amin, S; Cheng, Y; Huber-Keener, KJ; Liao, J; Ren, X; Sharma, AK; Sk, UH; Sun, YW; Yang, JM; Zhang, L; Zhang, Y | 1 |
| Balañá, C; Bruna, J; Chacón, I; Gil, M; Langa, JM; Martín, M; Segura, PP | 1 |
| Dummer, R; Michielin, O; Mihic-Probst, D; Moch, H; Ochsenbein, A; Schläppi, M; Schraml, P; Seifert, B; Simcock, M; von Moos, R; von Teichman, A | 1 |
| Ahn, NG; Dallaglio, K; Ellis, LZ; Fujita, M; Gonzalez, R; Lewis, KD; Liu, W; Luo, Y; McCarter, MD; Norris, DA; Robinson, SE; Robinson, WA; Roop, DR; Spritz, RA; Takeda, M | 1 |
| Annereau, JP; Chartrain, M; Gairin, JE; Gomes, B; Guilbaud, N; Lamant, L; Meyer, N; Riond, J; Stennevin, A; Vandenberghe, I | 1 |
| Margolin, K | 1 |
| Blank, CU; Chapman, PB; Chiarion-Sileni, V; Demidov, LV; Goodman, V; Grob, JJ; Guckert, ME; Gutzmer, R; Haney, P; Hauschild, A; Jouary, T; Kaempgen, E; Karaszewska, B; Martin, AM; Martín-Algarra, S; Mauch, C; Miller, WH; Millward, M; Mirakhur, B; Rutkowski, P; Swann, S | 1 |
| Abe, N; Irisawa, R; Kurashige, Y; Saito, M; Tsuboi, R | 1 |
| Doñate, F; Fruehauf, JP; Lee, K; Mazar, AP; Trapp, V | 1 |
| Abrial, C; Durando, X; Gadea, E; Gimbergues, P; Planchat, E; Tatar, Z; Thivat, E | 1 |
| Becker, M; Gao, D; Gonzalez, R; Kounalakis, N; Lewis, K; McCarter, M; Pearlman, N; Poust, J; Robinson, W | 1 |
| Chen, Y; Dallaglio, K; Fujita, M; Gonzalez, R; Luo, Y; McCarter, MD; Norris, DA; Robinson, SE; Robinson, WA; Roop, DR; Thompson, DC; Vasiliou, V; Wang, J | 1 |
| Brocard, L; Daste, A; Durando, X; Gimbergues, P; Magné, N; Mansard, S; Thivat, E | 1 |
| Akiyama, S; Fukushige, T; Gunshin, K; Ikeda, R; Kanekura, T; Kawai, K; Matsushita, S; Okumura, H; Tajitsu, Y; Takeda, Y; Ushiyama, M; Yamada, K | 1 |
| Amatruda, TT; Cohen, PA; Geoffroy, FJ; Gross, HM; Jaslowski, AJ; Kaur, JS; Kosel, ML; Kottschade, LA; Markovic, SN; McWilliams, RR; Perez, DG; Suman, VJ | 1 |
| Koekkoek, JA; Oosterkamp, HM; Oosterkamp, RM; Taphoorn, MJ; Wiggenraad, RG; Zwinkels, H | 1 |
| Abasq, C; Charles-Pétillon, F; Coat, C; De Braekeleer, M; Marcorelles, P; Quintin-Roué, I; Talagas, M; Uguen, A | 1 |
| Engebraaten, O; Engesæter, B; Flørenes, VA; Mælandsmo, GM | 1 |
| Calabrò, L; Danielli, R; Di Giacomo, AM; Fonsatti, E; Maio, M | 1 |
| Byron, SA; Doudican, NA; Orlow, SJ; Pollock, PM | 1 |
| Chang, J; Cheng, X; Escano, C; Gandhi, A; Kannan, R; Liebes, L; Madden, K; Mendoza, S; Muren, C; Ott, PA; Pavlick, AC; Shao, Y | 1 |
| Ahmed, AS; Dellinger, RW; Duong, PH; Matundan, HH; Meyskens, FL | 1 |
| Ding, W; Jiang, H; Li, WP; Qian, C; Wu, BJ; Zhou, ZW | 1 |
| Beumer, JH; Buch, SC; Christner, S; Egorin, MJ; Kirkwood, JM; Lin, Y; Moschos, S; Tarhini, AA; Tawbi, HA | 1 |
| Achberger, S; Aldrich, W; Borden, EC; Grane, R; Singh, AD; Triozzi, PL | 1 |
| Bichakjian, CK; Fox, MC; Frohm, ML; Johnson, TM; Lao, CD; Schwartz, JL | 1 |
| Birdsell, CA; Crosby, NA; Ernstoff, MS; Poklepovic, A; Ramakrishnan, V; Roberts, JD; Winning, M; Youseffian, L; Youssefian, LE | 1 |
| Frank, S; Lotem, M; Merims, S; Ospovat, I; Peretz, T | 1 |
| Allred, JB; Creagan, ET; Dronca, RS; Kaur, JS; Lieser, EA; Maples, WJ; Marchello, BT; Markovic, SN; Moore, TD; Nevala, WK; Perez, DG; Pockaj, BA; Thompson, M | 1 |
| Faião-Flores, F; Maria, DA; Maria-Engler, SS; Pérez-Tomás, R; Soto-Cerrato, V; Suarez, JA | 1 |
| Danson, SJ; Middleton, MR | 1 |
| Donnelly, DJ; Margison, GP; McElhinney, RS; McMurry, TB; Middleton, MR; Thatcher, N | 1 |
| Egyházi, S; Hansson, J; Ma, S; Martenhed, G; Ringborg, U | 1 |
| Chapman, PB; Hwu, WJ; Livingston, PO; Panageas, KS; Quinn, C; Williams, L; Wolchok, JD | 1 |
| Fierlbeck, G; Metzger, S; Ulmer, A | 1 |
| Baumann, MA; Koduri, J | 1 |
| Becker, JC; Bröcker, EB; Fischer, WH; Kirst, A; Lutz, WK; Wack, C | 1 |
| Cappugi, P; Coronnello, M; Giannotti, B; Mini, E; Pimpinelli, N; Prignano, F | 1 |
| Emmert, S; Helmbold, P; Kretschmer, L; Marsch, WC | 1 |
| Ames, P; Boasberg, PD; Deck, R; Fournier, P; Gammon, G; Kim, H; Kristedja, TS; Martin, M; O'Day, SJ; Piro, L; Shinn, K; Wang, HJ | 1 |
| Christophers, E; Frick, S; Haacke, TC; Hauschild, A; Lischner, S; Rosien, F; Schäfer, F | 1 |
| Bernsen, MR; Gustafsson, B; Håkansson, A; Håkansson, L; Krysander, L; Rettrup, B; Ruiter, D | 2 |
| Atkins, MB; Gollob, JA; McDermott, DF; Mier, JW; Parker, RA; Sorokin, P; Sosman, JA; Tutin, L | 1 |
| Bernstein, Z; Drumea, K; Haim, N; Sklar, Z; Stein, ME; Steiner, M; Tsalic, M | 1 |
| Li, Y; McClay, EF | 1 |
| Aglione, S; Bajetta, E; Bernard-Marty, C; Buzzoni, R; Del Vecchio, M; Khayat, D; Nova, P; Rixe, O; Taillibert, S; Vitali, M | 1 |
| Aravantinos, G; Bafaloukos, D; Briasoulis, E; Fountzilas, G; Gogas, H; Kosmidis, P; Mylonakis, N; Samonis, G; Skarlos, DV; Stathopoulos, G | 1 |
| Eskelin, S; Hahka-Kemppinen, M; Kivelä, T; Muhonen, T; Nikkanen, V; Pyrhönen, S; Summanen, P; Tarkkanen, A | 1 |
| Bloem, A; De Gast, GC; Groenewegen, G | 1 |
| Camp, R; Hemming, AW; Lind, DS | 1 |
| Castel, T; Conill, C; Puig, S; Toscas, I | 1 |
| Balduzzi, A; Barbarino, M; Biroccio, A; Gold, B; Graziani, G; Levati, L; Lombardi, ML; Portarena, I; Tentori, L; Vergati, M | 1 |
| Agarwala, SS; Kirkwood, JM | 2 |
| Boiardi, A; Eoli, M; Lamperti, E; Salmaggi, A; Silvani, A | 1 |
| Bonmassar, E; D'Atri, S; Falcinelli, S; Fuggetta, MP; Jiricny, J; Marra, G; Pagani, E; Pepponi, R | 1 |
| Acito, L; Bacchi, M; Beretta, M; Carlini, P; Cocconi, G; Di Sarra, S; Foladore, S; Gebbia, V; Maiello, E; Marchi, M; Passalacqua, R | 1 |
| Ake Hofer, P; Andersson, R; Henriksson, R; Riklund-Ahlström, K | 1 |
| Dmitruk, A; Kozlowski, L; Ostrowska, K; Wojtukiewicz, MZ; Zacharski, LR | 1 |
| Dréno, B; Wallon-Dumont, G | 1 |
| Batchelor, D; Boogerd, W; de Gast, GC; de Waal, MA; Kersten, MJ; Nieweg, OE; Nooijen, WJ; Sein, J; van de Kasteele, WF; Vyth-Dreese, FA | 1 |
| Binder, B; Cerroni, L; Kerl, H; Richtig, E; Smolle, J; Wolf, IH | 1 |
| Neville, F; Nystrom, ML; Oliver, RT; Shamash, J; Steele, JP | 1 |
| Gore, M; Hahka-Kemppinen, M; Hansson, J; Humblet, Y; Kivelä, T; Kloke, O; Kruit, WH; Kumpulainen, E; Parvinen, LM; Pyrhönen, S; Suciu, S; Vuoristo, MS | 1 |
| Ames, P; Boasberg, PD; Deck, R; Kristedja, TS; Martin, M; O'Day, SJ; Petrovich, Z; Shinn, K; Tamar, B; Wang, H | 1 |
| De Salvo, GL; Foletto, M; Lejeune, FJ; Lise, M; Lopes, M; Mocellin, S; Pilati, PL; Pontes, L; Ribeiro, M; Rossi, CR | 1 |
| Bedikian, AY; Eton, O; Papadopoulos, N; Plager, C; Ring, S | 1 |
| Günsberg, P; Jansen, B; Maierhofer, H; Monia, BP; Pehamberger, H; Polterauer, P; Selzer, E; Thallinger, C; Wacheck, V; Wolff, K; Wolschek, MF | 1 |
| Ide, H; Nakamura, T | 1 |
| Alvino, E; Bonmassar, L; D'Atri, S; Falcinelli, S; Fuggetta, MP; Guadagni, F; Lacal, PM; Pagani, E; Passarelli, F; Pepponi, R; Prete, SP; Turriziani, M | 1 |
| Arance, A; Ashcroft, L; Clamp, A; Danson, S; Hodgetts, J; Lomax, L; Lorigan, P; Middleton, MR; Ranson, M; Thatcher, N | 1 |
| Chiarion-Sileni, V; Corgna, E; Dalla Palma, M; De Salvo, GL; Del Bianco, P; Labianca, R; Lo Presti, G; Lo Re, G; Nortilli, R; Ridolfi, R; Romanini, A | 1 |
| Hakozaki, H; Iijima, S; Kawano, H; Kawasaki, T; Mori, N; Nihei, T; Oka, K; Saito, H; Sandoh, N; Sasaki, M; Tateishi, Y | 1 |
| Akimov, MA; Barchuk, AS; Gel'fond, ML; Gershanovich, ML | 1 |
| Bar-Eli, M; Lev, DC; McGary, EC; Mills, L; Price, JE; Ruiz, M | 1 |
| Chapman, PB; Foster, T; Houghton, AN; Hwu, WJ; Krown, SE; Lamb, LA; Livingston, PO; Menell, JH; Merrell, J; Panageas, KS; Quinn, CJ; Williams, LJ; Wolchok, JD | 1 |
| Isobe, T; Kato, Y; Koga, M; Mizuguchi, J; Saito, M; Shibuya, H; Toyota, H; Tsuboi, R | 1 |
| Komorowski, AL; Mituś, J; Wysocki, WM | 1 |
| Egyházi, S; Hansson, J; Kreklau, EL; Lindholm, C; Ma, S; Ringborg, U; Stierner, U; Ueno, T | 1 |
| Apostolidis, C; Rapidis, AD; Valsamis, S; Vilos, G | 1 |
| Boxall, J; Marples, M; Meyer, T; Napier, MP; Rustin, GJ; Strauss, SJ | 1 |
| Eisen, TG; Lens, MB | 1 |
| Jelić, S; Jović, V; Jurisić, V; Konjević, G; Radulović, S; Spuzić, I | 1 |
| Gajewski, TF | 1 |
| Chapman, PB; Foster, T; Krown, SE; Livingston, PO; Quinn, C; Sepkowitz, KA; Sohn, S; Su, YB; Williams, L; Wolchok, JD | 1 |
| Jonas, DL; Kiebert, GM; Middleton, MR | 1 |
| Oubre, DN | 1 |
| Zelger, B; Zelger, BG | 1 |
| Busam, KJ; Chapman, P; Jungbluth, AA; Wolchok, J | 1 |
| Harkness, KA; Manford, MR | 1 |
| Aamdal, S; Avril, MF; Bieber, T; Bonerandi, JJ; Bonneterre, J; Fra, J; Gilde, K; Gonzalez Larriba, JL; Grob, JJ; Guillem Porta, V; Hauschild, A; Kamanabrou, D; Menu, Y; Mohr, P; Neuber, K; Pehamberger, H; Saïag, P; Scherrer, A; Sufliarsky, J; Weichenthal, M | 1 |
| Graziani, G; Tentori, L | 1 |
| Haluska, FG; Yang, S | 1 |
| Eigentler, TK; Garbe, C | 1 |
| Castel, T; Conill, C; Fernández-Ibiza, J; Malvehy, J; Puig, S; Sánchez, M | 1 |
| Agarwala, SS; Kirkwood, JM; Neuberg, D; Park, Y | 1 |
| Agarwala, SS; Tarhini, AA | 1 |
| Castel, T; Conill, C; González-Cao, M; Jorcano, S; Malvehy, J; Martí, R; Puig, S | 1 |
| Geilen, CC; Georgieva, J; Orfanos, CE; Treudler, R | 1 |
| Mitchell, MS | 1 |
| Ananthaswamy, HN; Bar-Eli, M; Lev, DC; McGary, EC; Melinkova, VO; Miller, C; Onn, A; Price, JE; Ruiz, M; Stone, V | 1 |
| Dvorak, J; Hadzi-Nikolov, D; Melichar, B; Petera, J; Zizka, J | 1 |
| Agarwala, SS; Atkins, M; Buzaid, A; Czarnetski, B; Dreno, B; Gore, M; Kirkwood, JM; Rankin, EM; Skarlos, D; Thatcher, N | 1 |
| Akimov, MA; Gershanovich, ML | 1 |
| Cannavò, E; D'Atri, S; Falchetti, R; Fuggetta, MP; Lanzilli, G; Ravagnan, G; Tricarico, M; Zambruno, G | 1 |
| Amiri, KI; Horton, LW; LaFleur, BJ; Richmond, A; Sosman, JA | 1 |
| Fialla, R; Forstinger, Ch; Fritsch, P; Hofmann-Wellenhof, R; Kehrer, H; Kerl, H; Kindermann-Glebowski, E; Klein, G; Koller, J; Konrad, K; Kos, C; Lang, A; Mischer, P; Pachinger, W; Pehamberger, H; Raml, J; Ratzinger, G; Richtig, E; Seeber, A; Smolle, J; Steiner, A; Ulmer, H; Wolff, K; Zelger, B | 1 |
| Eggermont, AM; Kirkwood, JM | 1 |
| Bafaloukos, D; Briassoulis, E; Christodoulou, C; Fountzilas, G; Gogas, H; Hatzichristou, H; Kalofonos, HP; Linardou, H; Panagiotou, P; Tsoutsos, D | 1 |
| Amaducci, L; Biasco, G; Guida, M; Leoni, M; Michiara, M; Poletti, P; Ravaioli, A; Ridolfi, R; Romanini, A; Sileni, VC | 1 |
| Cansiz, H; Güzel, MZ; Karakullukçu, B; Ozek, H; Oztürk, O | 1 |
| Bafaloukos, D; Bedikian, AY; Gogas, H | 1 |
| Négrier, S; Neidhardt-Bérard, EM | 1 |
| Bonenkamp, JJ; de Faria Lima, R; de Wilt, JH; Doubrovsky, A; Kam, PC; Thompson, JF | 1 |
| Friedman, HS; Grubbs, E; Ko, SH; Pruitt, SK; Tyler, DS; Ueno, T | 1 |
| Ballardini, B; Bassi, F; De Pas, T; Gatti, G; Luini, A; Mauri, E | 1 |
| Hahka-Kemppinen, MH; Hernberg, MM; Pyrhönen, SO | 1 |
| Harting, MS; Kim, KB | 1 |
| Argon, A; Camlica, H; Duranyildiz, D; Oguz, H; Tas, F; Topuz, E; Yasasever, V | 1 |
| Agarwala, SS | 1 |
| Kefford, R; Lim, I; Manolios, N | 1 |
| Buzaid, AC | 1 |
| Bessho, A; Mogami, H; Nakata, M; Okita, R; Teramoto, N; Yamashita, M | 1 |
| Grange, JD; Kodjikian, L; Rivoire, M | 1 |
| Piro, LD | 1 |
| Boasberg, P; Groshen, S; Kristedja, T; Liu, D; Milford, R; O'Day, SJ; Weber, J; Yang, D | 1 |
| Aravantinos, G; Bafaloukos, D; Bamias, A; Carina, M; Christodoulou, C; Klouvas, G; Linardou, H; Skarlos, D | 1 |
| Azzabi, A; Boddy, AV; Calvert, AH; Calvert, PM; Fishwick, K; Griffin, MJ; Hughes, AN; Kelly, C; Lind, MJ; Maraveyas, A; Plummer, ER; Todd, R | 1 |
| Feun, L; Hurley, J; Marini, A; Mazumder, A; Moffat, F; Savaraj, N | 1 |
| Bafaloukos, DI; Brountzos, EN; Kelekis, DA; Panagiotou, IE; Papathanasiou, MA | 1 |
| Kharoubi, S | 1 |
| Bafaloukos, D; Briassoulis, E; Chalkidou, S; Christodoulou, C; Efstathiou, E; Fountzilas, G; Gogas, H; Iconomou, T; Kalofonos, H; Kouroussis, C; Linardou, E; Panagiotou, P; Polyzos, A; Tsoutsos, D | 1 |
| Chapman, PB; Houghton, AN; Hwu, WJ; Krown, SE; Lamb, LA; Lis, E; Livingston, PO; Menell, JH; Merrell, J; Panageas, KS; Williams, LJ; Wolchok, JD | 1 |
| Boddy, AV; Calvert, AH; Curtin, NJ; Harris, AL; Hickson, I; Jones, C; Margison, GP; McGown, G; McHugh, P; Middleton, MR; Newell, DR; Olsen, A; Plummer, ER; Thorncroft, M; Watson, AJ | 1 |
| Di Lauro, V; Freschi, A; La Mura, N; Nigri, P; Scalone, S; Veronesi, A; Zanetti, M | 1 |
| Fink, D; Gleave, ME; Hoeller, C; Jansen, B; Kovacic, B; Pehamberger, H; Pratscher, B; Sexl, V; Thallinger, C; Wacheck, V; Winter, D | 1 |
| Aoyama, N; Minamide, J; Ogata, T; Suzuki, Y; Takata, K | 1 |
| Hahka-Kemppinen, M; Kellokumpu-Lehtinen, P; Korpela, M; Parvinen, LM; Pyrhönen, S; Seppä, H; Vuoristo, MS | 1 |
| Benedetti, G; Biasco, G; Pantaleo, MA; Poggi, R | 1 |
| Cupissol, D; Cuq, P; Depeille, P; Evrard, A; Passagne, I; Vian, L | 1 |
| Jović, V; Konjević, G; Radomirović, V; Spuzić, I | 1 |
| Birner, P; Boehm, J; Heere-Ress, E; Hoeller, C; Jansen, B; Pehamberger, H; Thallinger, C; Wacheck, V; Wolff, K | 1 |
| Anderson, C; Baron, A; Gibbs, P; Gonzalez, R; Lewis, KD; O'Day, S; Richards, J; Russ, P; Weber, J; Zeng, C | 1 |
| Bonaccorsi, P; Borroni, RG; Bottoni, U; Calvieri, S; Clerico, R; Devirgiliis, V; Panasiti, V; Trasimeni, G | 1 |
| Castel, T; Conill, C; Gascón, P; González Cao, M; Herrero, JE; Malvehy, J; Martí, RM; Mellado, B; Puig, S; Sánchez, M | 1 |
| Budach, V; Hofmann, M; Kiecker, F; Schlenger, L; Sterry, W; Trefzer, U; Wurm, R | 1 |
| Bogdahn, U; Koch, HJ; Kuchelmeister, K; Roeber, S; Schachenmayr, W; Schäfer, C; Steinbrecher, A; Villarrubia, V; Zimmermann, UW | 1 |
| Eggermont, AM; Gore, M; Keilholz, U; Kleeberg, U; Kruit, W; Lehman, F; Lienard, D; Negrier, S; Patel, P; Proebstle, TM; Punt, CJ; Schadendorf, D; Schmittel, A; Suciu, S; Thomas, J; Velu, T | 1 |
| Aronson, F; Kennedy, T; Ready, N; Wanebo, H | 1 |
| Narita, Y | 1 |
| Benimetskaya, L; Miller, P; Stein, CA | 1 |
| Kiss, R; Mathieu, V; Mijatovic, T; van Damme, M | 1 |
| Denny, SR; Harvey, WB; Kashani-Sabet, M; Madland, MT; Minor, DR | 1 |
| Amatruda, TT; Elashoff, RM; Gonzalez, R; Hoon, DS; Koyanagi, K; Lewis, K; O'Day, SJ; Robinson, WA; Takeuchi, H; Umetani, N; Wang, HJ | 1 |
| Allen, R; Ames, P; Cook, M; Cruickshank, S; Deck, R; Gonzalez, R; Good, J; Meyer, J; O'Day, S; Rose, M; Spitler, LE; Timmerman, M; Trautvetter, S; Weber, RW | 1 |
| Becker, JC; Dummer, R; Garbe, C; Kaufmann, R; Krengel, S; Kretschmer, L; Leiter, U; Linse, R; Mauch, C; Schadendorf, D; Sebastian, G; Spieth, K; Tilgen, W; Vogt, T; von den Driesch, P | 1 |
| Baur, A; Berger, TG; Dieckmann, D; Efferth, T; Funk, JO; Schuler, G; Schultz, ES | 1 |
| Sterry, W; Trefzer, U | 1 |
| Forini, O; Gold, B; Graziani, G; Lacal, PM; Leonetti, C; Li, W; Muzi, A; Ruffini, F; Scarsella, M; Tentori, L; Vergati, M; Zhang, J | 1 |
| Brennecke, S; Deichmann, M; Kurzen, H; Naeher, H | 1 |
| Argon, A; Camlica, H; Tas, F; Topuz, E | 1 |
| Hoon, DS; Kitago, M; Koyanagi, K; Kuo, C; Martinez, SR; Milford, R; Mori, T; Nguyen, SL; O'Day, SJ; Takeshima, TL; Umetani, N; Vu, VD; Wang, HJ | 1 |
| Conway, BR; Suppasansatorn, P; Wang, G; Wang, W; Wang, Y | 1 |
| Becker, JC; Berger, T; Bröcker, EB; Burg, G; Edler, L; Enk, A; Grabbe, S; Jonuleit, H; Kamarashev, J; Kämpgen, E; Keikavoussi, P; Nestle, FO; Rittgen, W; Schadendorf, D; Schuler, G; Schuler-Thurner, B; Sucker, A; Tüttenberg, A; Ugurel, S; Zimpfer-Rechner, C | 1 |
| Bai, CM; Lang, JH; Ma, SQ; Yu, XH; Zhong, S | 1 |
| Carrera, C; Castel, T; Conill, C; Gascón, P; González Cao, M; Herrero, J; Malvehy, J; Martí, R; Martín, M; Mellado, B; Puig, S; Sánchez, M | 1 |
| Asna, N; Inbar, MJ; Metser, U; Ron, IG; Ryvo, L; Safra, T; Sapir, EE; Sarid, D; Schneebaum, S | 1 |
| Bajetta, E; Bernengo, MG; Cascinelli, N; Daponte, A; Del Vecchio, M; Formisano, B; Fusi, A; Legha, SS; Nova, P; Queirolo, P; Sertoli, MR; Taveggia, P | 1 |
| Archimbaud, A; Basset-Seguin, N; Dubertret, L; Guitera, P; Kerob, D; Levy, A; Ollivaud, L | 1 |
| Chan, V; Chaudhry, AA; Clark, CT; Daw, HA; Kundranda, MN | 1 |
| Abdel-Wahab, OI; Abdel-Wahab, Z; Augustine, C; Cheng, TY; Friedman, HS; Grubbs, E; Ko, SH; Pruitt, SK; Tyler, DS; Ueno, T; Yoshimoto, Y | 1 |
| Fukunaga, T; Kageshita, T; Kojima, S; Ogawa, H; Ono, T; Sakamoto, T; Soejima, H; Sugamura, K; Sugiyama, S; Tanoue, T; Yoshimura, M | 1 |
| Aird, S; Chapman, PB; Houghton, AN; Hwu, WJ; Krown, SE; Lamb, LA; Livingston, PO; Menell, JH; Panageas, KS; Williams, LJ; Wolchok, JD | 1 |
| Castel, T; Conill, C; Domingo-Doménech, J; Gallego, R; Jorcano, S; Malvehy, J; Puig, S; Sánchez, M; Vilella, R | 1 |
| Butt, M; Eswar, CV; Gillis, P; Marshall, E; O'Neill, PA | 1 |
| Berger, Y; Bernasconi, CC; Juillerat-Jeanneret, L | 1 |
| Arce-Lara, C; Kloecker, GH; Laber, DA; McMasters, KM; Miller, DM; Okeke, RI; Schonard, CL; Taft, BS | 1 |
| Hansson, J | 1 |
| Bieber, T; Gollnick, H; Köhler, U; Linse, R; Luger, T; Schroth, K; Schubert, R; Stadler, R; Strannegård, O; Technau, K; Thoren, F; Vakilzadeh, F; Volkenandt, M; Von Eick, H | 1 |
| Barbaud, A; Schmutz, JL; Trechot, P | 1 |
| Amatruda, TT; Anderson, C; Baron, A; Becker, M; Dollarhide, S; Gonzalez, R; Lewis, KD; Matijevich, K; McCarter, M; O'Day, SJ; Pearlman, N; Robinson, WA; Zeng, C | 1 |
| Ekmekcioglu, S; Fok, JY; Mehta, K | 1 |
| Biasco, G; Casamassima, A; Chiarion-Sileni, V; Freschi, A; Galligioni, E; Guida, M; Nanni, O; Nortilli, R; Palma, MD; Picozzo, J; Ravaioli, A; Riccobon, A; Ridolfi, R; Romanini, A | 1 |
| Hansson, J; Månsson-Brahme, E; Masucci, GV; Nilsson, B; Ragnarsson-Olding, B; Wagenius, G | 1 |
| Crespo, C; del Muro, XG; Filipovich, E; García, M; Germà-Lluch, JR; López, JJ; Pérez, X; Rifà, J; Tres, A; Valladares, M | 1 |
| Dadban, A; Daneshpazhooh, M; Raafat, J; Shokoohi, A | 1 |
| Geng, B; Liu, YS; Sun, YF; Yang, CH; Zhang, WD | 1 |
| Andrews, S; Brem, S; Daud, AI; Ismail-Khan, R; Khan, MA; King, J; Munster, PN; Reintgen, DS; Sondak, VK | 1 |
| Alvino, E; Bonmassar, E; Caporali, S; Caporaso, P; Castiglia, D; D'Atri, S; Fischer, F; Jiricny, J; Lacal, PM; Marra, G; Pepponi, R; Zambruno, G | 1 |
| Bedikian, AY; Conry, R; DeConti, R; Gore, M; Haluska, FG; Hersey, P; Hersh, EM; Kirkwood, JM; Millward, M; Pavlick, AC; Pehamberger, H; Trefzer, U | 1 |
| Fountzilas, G; Frangia, K; Gogas, H; Mantzourani, M; Markopoulos, C; Middleton, M; Panagiotou, P; Papadopoulos, O; Pectasides, D; Polyzos, A; Stavrinidis, I; Tsoutsos, D; Vaiopoulos, G | 1 |
| Haluska, FG; Hodgson, L; Houghton, AN; Hwu, WJ; Krown, SE; Niedzwiecki, D | 1 |
| Egberts, F; Garbe, C; Hauschild, A; Kreissig, M; Linse, R; Mohr, P; Schadendorf, D; Thoelke, A; Tilgen, W; Trefzer, U; Ugurel, S; Vogt, T | 1 |
| Eggermont, AM; Gore, MA; Keilholz, U; Koller, J; Kruit, WH; Lienard, D; Patel, P; Punt, CJ; Suciu, S; Thomas, J | 1 |
| Cerny, T; Gillessen, S; Korte, W; Schlaeppi, MR; von Moos, R | 1 |
| Delaunay, M; Jouary, T; Taieb, A | 1 |
| Bate, SC; Beirne, DA; Eisen, TG; Gibbens, IM; Gore, ME; Hughes, SA; Larkin, JM; Patel, PM; Thomas, K | 1 |
| Boogerd, W; Dalesio, O; de Gast, GC | 1 |
| Bonmassar, E; Caporali, S; Caporaso, P; D'Atri, S; Falcinelli, S; Pagani, E; Pepponi, R; Turriziani, M | 1 |
| Becker, JC; Beiteke, U; Bröcker, EB; Durani, B; Jünger, M; Junghans, V; Kortüm, AK; Mauch, C; Remling, R; Schadendorf, D; Schulze, HJ; Terheyden, P | 1 |
| Cuttone, G; Korićanac, LB; Petrović, IM; Privitera, G; Ristić-Fira, AM; Todorović, DV; Valastro, LM | 1 |
| Engebraaten, O; Engesaeter, BO; Fodstad, O; Lillehammer, T; Maelandsmo, GM; Prasmickaite, L | 1 |
| Hofmann, MA; Sterry, W; Trefzer, U | 1 |
| Ali-Osman, F; Augustine, CK; Friedman, HS; Pruitt, SK; Selim, MA; Tyler, DS; Yoo, JS; Yoshimoto, Y; Zipfel, PA | 1 |
| De Neve, N; Gras, T; Kiss, R; Le Mercier, M; Lefranc, F; Mathieu, V; Roland, I; Sauvage, S | 1 |
| Joukhadar, C; Kovar, FM; Poeppl, W; Pratscher, B; Quehenberger, P; Thallinger, C; Valent, P; Werzowa, J | 1 |
| Ascierto, PA; Casula, M; Cossu, A; Palmieri, G; Tanda, F | 1 |
| Baka, S; Beith, J; Davis, ID; Harris, PA; Haydon, A; Hersey, P; Kefford, RF; Margison, GP; McArthur, GA; Middleton, MR; Mortimer, P; Ranson, M; Sabharwal, A; Seebaran, A; Thompson, D; Watson, AJ | 1 |
| Weller, M | 1 |
| Balafouta, MJ; Kolokouris, D; Kouloulias, VE; Kouvaris, JR; Miliadou, A; Papacharalampous, XN; Vlahos, LJ | 1 |
| Boucher, KM; Jensen, RL; Leachman, SA; Majer, M; Samlowski, WE; Shrieve, DC; Wang, M; Watson, GA | 1 |
| Conway, BR; Du, L; Nimmannit, U; Suppasansatorn, P; Wang, Y | 1 |
| Iwai, T; Kawada, K; Kawano, T; Nagai, K; Nakajima, Y; Nishikage, T; Ogiya, K; Tanaka, K; Tokairin, Y | 1 |
| Ahmadloo, N; Mohammadianpanah, M; Mosalaei, A; Omidvari, S; Shirazi, M | 1 |
| Lau, TK; Li, RH; Mok, TS; Ng, PC; Tam, B; Tam, WH | 1 |
| Anderson, R; Burdette-Radoux, S; Gehlsen, K; Hauschild, A; Hellstrand, K; Middleton, M; Naredi, P; Thomson, D | 1 |
| Hesse, A; Mainka, A; Nettelbeck, DM; Quirin, C | 1 |
| Agarwala, SS; Cai, C; Gooding, WE; Kirkwood, JM; Tarhini, AA | 1 |
| Cloud, GA; Fiveash, JB; Guthrie, BL; Markert, JM; Meredith, RF; Nordal, RA; Sawrie, SM; Spencer, SA | 1 |
| Camlica, H; Tas, F; Topuz, E | 1 |
| Bak, K; Charette, M; Petrella, T; Quirt, I; Verma, S | 1 |
| Cashin, R; Corey-Lisle, PK; Einarson, TR; Hemels, M; Lui, P; Machado, M | 1 |
| Adema, AD; Bhakat, KK; Boven, E; Fontijn, D; Peters, GJ; Pinedo, HM | 1 |
| Hayashi, K; Inaba, Y; Isobe, H; Miura, T; Moriya, T; Takiguchi, M; Tezuka, K; Watabe, S; Yanagawa, N | 1 |
| Stein, CA | 1 |
| Enk, A; Grabbe, S; Müller, ML; Nashan, D; Wustlich, S | 1 |
| Bayer, W; Heim, A; Hoffmann, D; Nettelbeck, DM; Potthoff, A; Wildner, O | 1 |
| Allen, J; Avery-Kiejda, KA; Hersey, P; Mhaidat, NM; Scott, RJ; Zhang, XD | 1 |
| Jelić, S; Jović, V; Konjević, G; Radulović, S; Spuzić, I; Vuletić, A | 1 |
| Bajetta, E | 1 |
| Brocard, A; Dréno, B; Quéreux, G | 1 |
| Bratta, M; Candeloro, G; Fumagalli, L; Necozione, S; Rea, S; Recchia, F | 1 |
| Becker, JC; Beyeler, M; Bröcker, EB; Dummer, R; Garbe, C; Gille, J; Hauschild, A; Kaehler, KC; Kaufmann, R; Leiter, U; Pföhler, C; Schadendorf, D; Spieth, K; Tilgen, W; Ugurel, S | 1 |
| Dummer, R; Eigentler, T; Ellwanger, U; Garbe, C; Gutzmer, R; Hauschild, A; Linse, R; Radny, P; Stadler, R; Ulrich, J; Weichenthal, M | 1 |
| Camacho, L; Gupta, R; Hoos, A; Kirkwood, JM; Lutzky, J; Mann, GB; Parmiani, G; Richards, J; Srivastava, PK; Testori, A; Tosti, G; Whitman, E; Yuh, L | 1 |
| Neff, WJ; Nystrom, KK; Pick, AM | 1 |
| Dimov, A; Gadjeva, V; Georgieva, N | 1 |
| Herrmann, R; Hess, V; Schwabe, M; Veelken, H | 1 |
| Bedane, C; Cupissol, D; Delaunay, M; Dereure, O; Dreno, B; Guillot, B; Khamari, A; Picot, MC | 1 |
| Bael, TE; Gollob, JA; Peterson, BL | 1 |
| Dorio, AS; Graziani, G; Lacal, PM; Muzi, A; Navarra, P; Ruffini, F; Tentori, L | 1 |
| Dutz, JP; Najar, HM | 1 |
| Schuh, T; Siedek, V; Wollenberg, A | 1 |
| Acres, B; Bleuzen, P; Dummer, R; Lacoste, G; Limacher, JM; Rochlitz, C; Romero, P; Slos, P; Urosevic, M; Velu, T | 1 |
| Kirkwood, JM; Lotze, MT; Mandic, M; Moschos, SJ; Storkus, WJ | 1 |
| Brell, J; Dehart, WK; Gilliam, AC; Lu, KQ | 1 |
| Agarwala, S; Beeram, M; Cranmer, L; Frenette, G; Gonzalez, R; Hersh, E; Hodi, FS; Jakub, JW; Kirkwood, J; Lewis, K; Linette, GP; McDermott, DF; Patel, K; Puzanov, I; Richards, J; Sosman, JA; Tarantolo, S; White, JM; Xia, C | 1 |
| Busam, K; Chapman, PB; Gerst, S; Jungbluth, AA; Krown, S; Orlow, I; Panageas, K; Rietschel, P; Smith, K; Wolchok, JD | 1 |
| Augustine, CK; Febbo, P; Gupta, M; Pendergast, AM; Peters, WP; Selim, MA; Tyler, DS; Yoshimoto, Y; Zipfel, PA | 1 |
| Komatsubara, H; Komori, T; Minamikawa, T; Ojima, Y; Shibuya, Y; Shigeta, T; Umeda, M; Yokoo, S | 1 |
| Hagen, S; Klepp, O; Stridsklev, IC | 1 |
| Czarnetzki, BM; Macher, E | 1 |
| Agrup, G; Arnbjörnsson, E; Hafström, L; Jönsson, PE; Rorsman, H | 1 |
| Fiedler, H; Wohlrab, W; Wozniak, KD; Zaumseil, RP | 1 |
| Thiers, BH | 1 |
| Baki, AV; Vaughan, K | 1 |
| Cheung, T; Cohen, SM; Holland, JF; Ohnuma, T | 1 |
| Khan, MS; Ross, WM | 1 |
| Kennealey, GT; Kirkwood, JM; Luikart, SD | 1 |
| Balch, CM; Hersey, P | 1 |
| Allegra, JC; Blumenreich, MS; Gentile, PS; Kubota, TT; Richman, SP; Woodcock, TM | 1 |
| Bychkov, MB; Perevodchikova, NI | 1 |
| Armand, JP; Bui, NB; Cappelaere, P; Chauvergne, J; Durand, M; Gary-Bobo, J; Guerrin, J | 1 |
| Bernengo, MG; Doveil, GC; Lisa, F; Meregalli, M | 1 |
| Kemeny, N | 1 |
| Al-Sarraf, M; Balcerzak, SP; Costanzi, JJ; Eyre, HJ; Fletcher, WS; Frank, J; O'Bryan, RM; Taylor, S | 1 |
| Hill, GJ; Hill, HZ; Krementz, ET | 1 |
| Balch, CM; Bartolucci, AA; Murray, D; Presant, C | 1 |
| Kendall, AR; Stein, BS | 1 |
| Barduagni, A; Di Lauro, L; Ganzina, F; Lopez, M; Papaldo, P; Perno, CF | 1 |
| Aigner, KR; Börger, G; Illig, L; Jungbluth, A; Link, KH; Müller, H; Ringenberg, T; Ruppel, R; Schwemmle, K; Walther, H | 1 |
| Ichihashi, M; Inoi, T; Mishima, Y; Mojamdar, M | 2 |
| Angelini, G; Bonifazi, E; Meneghini, CL | 1 |
| Baker, LH; Bhathena, DB; Cummings, G; McDonald, B; Samson, MK; Talley, RW | 1 |
| Jimbow, K; Kawamura, M; Maeda, K; Miura, S | 1 |
| Erichsen, C; Jönsson, PE | 1 |
| Hayward, IP; Parsons, PG | 1 |
| Osieka, R | 1 |
| Del Prete, SA; Forcier, RJ; LeMarbre, P; Maurer, LH; O'Donnell, J | 1 |
| Lüchtrath, H; Schmich, HR | 1 |
| Aubert, C; Rouge, F | 1 |
| Harada, M; Komi, N; Makinoya, T; Miyamoto, H; Miyoshi, Y; Tamura, T; Yamamoto, M | 1 |
| Bernengo, MG; Fra, P; Lisa, F; Meregalli, M; Zina, G | 1 |
| Bertelsen, CA; Kaiser, LR; Kern, DH; Korn, EL; Mann, BD; Morton, DL; Storm, FK | 1 |
| Dor, P; Jortay, AM; Lejeune, FJ | 1 |
| Ingvar, C; Jönsson, PE; Stridbeck, H | 1 |
| Metelmann, HR; Von Hoff, DD | 1 |
| Calbo, L; Gorgone, S; Melita, P; Palmeri, R; Salibra, M | 1 |
| Aigner, K; Schwemmle, K | 1 |
| Aigner, K; Henneking, K; Hild, P; Hundeiker, M; Paul, E | 1 |
| Giraldi, T; Lassiani, L; Nisi, C; Sava, G | 1 |
| Ariyan, S; Kirkwood, JM; Mitchell, MS | 1 |
| Hayasaka, K; Ikeda, S; Ishihara, K; Jimbow, K; Kukita, A; Seki, Y; Suzuki, M; Terakado, T | 1 |
| Hill, GJ; Hill, HZ; Raina, S; Rush, BF | 1 |
| Klemm-Mayer, H; Rasokat, H; Wagner, G | 1 |
| Kohlsmith, DJ; Luner, SJ; Vaughan, K | 1 |
| Hori, Y; Kawashima, M; Kukita, A; Mizoguchi, M; Shimada, S; Watanabe, S; Yamada, K | 2 |
| Balda, BR; Bassermann, R | 1 |
| Campbell, ED; Carter, WH; Stablein, DM; Wampler, GL | 1 |
| Féaux de Lacroix, W; Pullmann, H; Runne, U | 1 |
| Kirkwood, JM; Marsh, JC | 1 |
| Doepfmer, K; Féaux de Lacroix, W; Groth, W; Hauk, H; Runne, U; Wacker, D | 1 |
| Aigner, K; Hild, P; Hundeiker, M | 1 |
| Atassi, G; Dumont, P; Tagnon, HJ | 1 |
| Ding, YA; Hwang, WS; Lee, WC; Leu, FJ | 1 |
| Byrne, MJ; Reynolds, PM | 1 |
| Haruyama, H; Ijichi, H; Isemura, T; Nakagawa, M; Nakanishi, S; Okano, R; Sawada, S; Shimazaki, C; Tsuji, H; Ueda, K | 1 |
| Aiba, K; Domyo, M; Ezaki, K; Horikoshi, N; Inagaki, J; Inoue, K; Miyamoto, H; Nagata, T; Ogawa, M | 1 |
| Antz, H; Doepfmer, K; FEAUX DE Lacroix, W; Groth, W; Runne, U | 1 |
| Bolton, PM; Clunie, GJ; Dury, M; Furnival, CM; Gough, IR | 1 |
| Borisov, AI; Kogoniia, LM; Moroz, LV; Perevodchikova, NI; Platinskiĭ, LV | 1 |
| Fletcher, WS; Golomb, FM; Grage, TB; Hill, GJ; Krementz, ET; Minton, JP; Moss, SE | 1 |
| Jimbow, K; Nishio, C; Yanbe, H | 1 |
| Beretta, G | 1 |
| Banzet, P; Jacquillat, C; Maral, J | 1 |
| Behrendt, H; Czarnetzki, BM; Lejeune, F; Macher, E | 1 |
| Balch, C; Bartolucci, AA; Presant, CA; Troner, M | 1 |
| Greco, FA; Knost, JA; Oldham, RK; Reynolds, V | 1 |
| Bodey, GP; Gutterman, JU; Hersh, EM; Robidoux, A | 1 |
| Al-Sarraf, M; Bottomley, R; Costanzi, JJ; Dixon, D; Fabian, C; Groppe, C; Neidhart, J | 1 |
| Chiba, M; Homma, K; Jimbow, K; Kizukuri, K | 1 |
| Adamus, J; Aubert, C; Bajetta, E; Beretta, G; Bonadonna, G; Bufalino, R; Cascinelli, N; Cocconi, G; De Marsillac, J; Durand, J; Ikonopisov, RL; Kiss, B; Lejeune, F; MacKie, R; Madej, G; Mechl, Z; Milton, GW; Morabito, A; Mulder, H; Paul, E; Peter, H; Priario, J; Rumke, P; Sertoli, R; Tomin, R; Veronesi, U | 1 |
| Elliott, RS; Gomes, AS; Goodnight, JE; Harrison, WH; Kaiser, LR; Morton, DL; Storm, FK | 1 |
| Arlen, M; Cohen, M; Hollinshead, A; Kundin, WD; Scherrer, J; Tanner, K; Yonemoto, R | 1 |
| Hill, GJ; Hill, HZ | 1 |
| Hayward, IP; Morrison, LE; Parsons, PG; Smellie, SG | 1 |
| Cascinelli, N; Marolda, R; Orefice, S; Rovini, D; Vaglini, M; Veronesi, U | 1 |
| Muth, M; Pullmann, H | 1 |
| Swensson-Beck, H; Trettel, WH | 1 |
| Altenähr, E; Doering, C; Orfanos, CE; Pickartz, H | 1 |
| Boeva, M; Hadjikirova, M; Ikonopisov, R | 1 |
| Hayasaka, K; Ikeda, S; Ishihara, K; Jimbow, K; Kukita, A; Seki, Y; Takahashi, H; Terakado, T | 1 |
| Becher, R; Schmidt, CG; Seeber, S | 1 |
| Bowers, T; Charnsangavej, C; Chuang, VP; Soo, CS; Wallace, S | 1 |
| Koriech, OM; Shükla, VS | 1 |
| Fodstad, O; Olsnes, S; Pihl, A; Tveit, KM | 1 |
| Caselitz, J; Jänner, M; Voigt, H | 1 |
| Bettendorf, U; Frank, K; Reinhardt, P | 1 |
| Crone-Münzebrock, W; Kröger, E; Stritzke, P; Voigt, H | 1 |
| Lorincz, AL; Winston, EM; Yung, CW | 1 |
| Crone-Münzebrock, W; Denkhaus, H; Voigt, H | 1 |
| Adamczyk, B; Pawlicki, M; Zuchowska-Vogelgesang, B | 1 |
| Endresen, L; Fodstad, O; Pihl, A; Rugstad, HE; Tveit, KM | 1 |
| Blackledge, G; Crowther, D; Palmer, MK; Thatcher, N | 1 |
| Fodstad, O; Pihl, A; Tveit, KM | 1 |
| Gordy, DD; Murray, JL; Robertson, DM; Wilkinson, CP | 1 |
| Aass, N; Fodstad, O; Pihl, A | 2 |
| Bodey, GP; Burgess, MA; Gutterman, JU; Heilbrun, LK; Hersh, EM; Murphy, WK; Schwarz, MA; Stone, E; Turner-Chism, V | 1 |
| Arseneau, JC; Asbury, RF; Descalzi, ME; Ratcliffe, RL; Rosenthal, SN | 1 |
| Kollakowski, M; Kunze, J; Roeber, H | 1 |
| Duchková, H; Král, V; Kubíková, M; Ragan, J | 1 |
| Duchková, H; Hrivnáková, J; Kubíková, M; Kvasnicka, J; Peska, J; Ragan, J; Richter, J; Vohryzková, E | 1 |
| Nifontova, TP | 1 |
| Barber, NA; Didolkar, MS; Elias, EG; Moore, RH | 1 |
| Bolling, R; Meyer-Hamme, S; Schauder, S | 1 |
| Dufour, FD; Mah, SG; Morton, DL; Okada, GT | 1 |
| Hafström, L; Jönsson, PE | 1 |
| Dubois, JB; el Amrani, N; Mathieu-Daude, H; Melhouf, MM | 1 |
| Feun, LG; Hurley, J; Liebmann, A; Moffat, F; Raub, WA; Richman, SP; Robinson, D; Savaraj, N | 1 |
| Betticher, DC; Clemons, M; Lee, SM; Morris, C; Thatcher, N | 1 |
| Brossart, P; Geueke, AM; Hunstein, W; Jochim, A; Keilholz, U; Maclachlan, D; Möhler, T; Scheibenbogen, C | 1 |
| Algermissen, B; Czarnetzki, BM; Kohlmus, CM; Schadendorf, D; Worm, M | 1 |
| Dvorák, E; Haas, RE; Liebner, EJ | 1 |
| Hahka-Kemppinen, M; Muhonen, T; Pakkala, S; Pyrhönen, S | 1 |
| Gröhn, P; Korpela, M; Kumpulainen, E; Vuoristo, M | 1 |
| de Vries, EG; Koops, HS; Mulder, NH; Sleijfer, DT; van der Graaf, WT; Willemse, PH | 1 |
| Ishihara, K | 3 |
| Gröhn, P; Joensuu, H; Kellokumpu-Lehtinen, P; Korpela, M; Kumpulainen, E; Nevantaus, A; Tiusanen, K; Turunen, M; Vuoristo, MS | 1 |
| Asko-Seljavaara, S; Hahka-Kemppinen, M; Jekunen, A; Muhonen, T; Pyrhönen, S; Virolainen, M | 1 |
| Kishimoto, S; Ueda, E; Yasuno, H | 1 |
| Gillen, P; Keane, FB; Kerin, MJ; Monson, JR; Tanner, WA; Wilkie, J | 1 |
| Brossart, P; Hunstein, W; Keilholz, U; Möhler, T; Scheibenbogen, C; Tilgen, W | 1 |
| Dreno, B; Mansat-Krzyzanowska, E | 1 |
| Chmielowska, E; Pluzańska, A; Potemski, P | 1 |
| Atzpodien, J; Chaitchik, S; Duensing, S; Franzke, A; Kirchner, H; Körfer, A; Lopez Hänninen, E; Poliwoda, H; Schomburg, A; Volkenandt, M | 1 |
| Belliveau, JF; Darnowski, JW; Leenen, L; Turk, PS; Wanebo, HJ; Weinberg, MC | 1 |
| Asano, K; Ishihara, K; Yamazaki, N | 1 |
| Bleehen, NM; Brampton, M; Calvert, AH; Lee, SM; Newlands, ES; Rustin, GJ; Selby, P; Stevens, MF; Thatcher, N | 1 |
| Ameglio, F; Carpano, S; Cavaliere, R; Di Lauro, L; Frasca, AM; Lopez, M; Pignatti, F; Rosselli, M; Vici, P; Vitelli, G | 1 |
| Becker, JC; Burg, G; Dieleman, JP; Dummer, R; Gore, ME; Grobben, HC; Guillou, PJ; Hancock, BW; Oskam, R | 1 |
| Keilholz, U | 1 |
| A'Hern, R; Atkinson, H; Chang, J; Gore, ME; Lorentzos, A | 1 |
| Ali-Osman, F; Bedikian, A; Benjamin, R; Buzaid, AC; Eton, O; Grimm, EA; Legha, SS; Papadopoulos, NE; Plager, C; Ring, S | 1 |
| Borus, T; Edwards-Prasad, J; Hernandez, C; Nelson, J; Prasad, KN; Robinson, WA | 1 |
| Berd, D; Mastrangelo, MJ | 1 |
| Balch, CM; Benjamin, RS; Buzaid, A; el-Naggar, AK; Legha, SS; Papadopoulos, NE; Plager, C; Ring, S; Ross, M | 1 |
| Korovin, SI; Tolstopiatov, BA | 2 |
| Carmichael, J; Ganesan, TA; Harris, AL; Philip, PA; Tonkin, K | 1 |
| Buzaid, AC; Legha, SS | 2 |
| Asko-Seljavaara, S; Franssila, K; Kangas, L; Laasonen, A; Muhonen, T; Pyrhönen, S; Wasenius, VM | 1 |
| Atkins, MB; Ernest, ML; Fisher, RI; Kappler, K; Margolin, KA; Mier, JW; O'Boyle, KR; Sosman, JA; Sparano, JA; Weiss, GR | 1 |
| Bootz, F; Breuninger, H; Lindstedt-Hilden, M | 1 |
| Bos, G; Brown, D; Fletcher, WS; Lebredo, L; Moseley, HS; Small, K; Woltering, EA | 1 |
| Ferrone, S; Imai, K; Kageshita, T; Kimura, T; Kuriya, N; Ono, T; Tsujisaki, M; Yoshii, A | 1 |
| McClay, EF; McClay, ME | 1 |
| Crowther, D; Lee, SM; Margison, GP; Thatcher, N | 2 |
| Bajetta, E; Barduagni, M; Bernengo, MG; Comella, G; Di Leo, A; Giannotti, B; Queirolo, P; Sertoli, MR; Tribbia, G; Zampino, MG | 1 |
| Becker, JC; Bröcker, EB; Klingert, S; Winkler, B | 1 |
| Coates, AS; Segelov, E | 1 |
| Chaitchik, S; Eisenthal, A; Inbar, MJ; Mordish, Y; Ron, IG; Skornick, Y | 1 |
| Chaitchik, S; Eisenthal, A; Ron, I; Skornick, Y; Zakuth, V | 1 |
| Losada, R; Meelu, MA; Nathanson, L | 1 |
| Bureau, B; Célérier, P; Dreno, B; Litoux, P | 1 |
| Alevizakos, N; Asimakopoulos, G; Athanassiou, A; Bafaloukos, D; Dimitriadis, M; Pectasides, D; Tzonou, A; Varthalitis, I | 1 |
| Crowell, EB; Higa, GM | 1 |
| Dana, B; Daniels, DS; Fletcher, WS; Hutchins, LF; Hynes, HE; Pancoast, JR; Sondak, VK; Townsend, R | 1 |
| Beadle, G; Coates, A; Gill, PG; Hersey, P; Kefford, R; Lowenthal, RM; McLeod, GR; Olver, IN; Thomson, D; Walpole, E | 1 |
| Chaitchik, S; Merimsky, O | 2 |
| Czarnetzki, BM; Schadendorf, D; Worm, M | 1 |
| Gore, ME; Lorentzos, A; McKeage, MJ | 1 |
| Aliaga, A; Bizzari, JP; Cour, V; Lopez Lopez, JJ; Oliver, V; Perez, E; Ponchon, A | 1 |
| Dougal, M; Lee, SM; Margison, GP; Thatcher, N | 1 |
| Calvert, AH; Carmichael, J; Foster, BJ; Goodard, PM; Gumbrell, LA; Harris, AL; Jones, M; Newell, DR | 1 |
| Christophers, E; Clausen, M; Hauschild, A; Osterkamp, G | 1 |
| Burgess, MA; Hersh, EM; Legha, SS; Papadopoulos, N; Plager, C; Verschraegen, CF | 1 |
| Aamdal, S; Bizzari, JP; D'Incalci, M; Gerard, B; Lee, SM; Leyvraz, S; Lucas, C | 1 |
| Hoffman, KD | 1 |
| Flaherty, LE; Gonzalez, R; Kraut, M; Martino, S; Redman, BG; Robinson, W; Rudolph, AR; Valdivieso, M | 1 |
| Newlands, ES; Stevens, MF | 1 |
| Lee, SM; Margison, GP; Thatcher, N; Woodcock, AA | 1 |
| Chaitchik, S; Gutman, M; Inbar, MJ; Merimsky, O; Ron, IG | 1 |
| Appino, A; Bernengo, MG; Bertero, M; Colonna, S; Doveil, GC; Fierro, MT; Novelli, M | 1 |
| Adena, M; Beadle, GF; Coates, AS; Gill, PG; Hersey, P; Kefford, RF; Lowenthal, RM; McLeod, GR; Olver, IN; Thomson, DB | 1 |
| Borović, S; Hartleb, M; Ilić, Z; Jurin, M; Zarković, N | 1 |
| Clendeninn, NJ; Feun, LG; Gonzalez, R; Liebmann, A; Offenhauser, K; Robinson, WA; Savaraj, N | 1 |
| Chertoff, J; DelPrete, SA; Ernstoff, MS; Forcier, RJ; Lattanzi, SC; LeMarbre, PJ; Maurer, LH; Mott, L; O'Donnell, J; Tosteson, T | 1 |
| Falkson, CI | 1 |
| Aamdal, S; Boeryd, B; Carstensen, J; Jungnelius, U; Kågedal, B; Karlsson, M; Westberg, R; Wingren, S | 1 |
| Antoine, E; Auclerc, G; Benhammouda, A; Bizzari, JP; Borel, C; Paraiso, D; Petit, T; Rixe, O; Soubrane, C; Weil, M | 1 |
| Flaherty, LE; Fletcher, WS; Goodwin, JW; Liu, PY; Mitchell, MS; Sondak, VK; Stephens, RL; Walker, MJ | 1 |
| Alas, LG; Belanich, M; Citron, ML; Dolan, ME; Gander, M; Kibitel, JT; Lejeune, FJ; Li, BF; Pastor, MA; Randall, T; Schold, SC; Wasserman, P; White, AB; Yarosh, DB | 1 |
| Hahka-Kemppinen, M; Hernberg, M; Muhonen, T; Pyrhönen, S; Turunen, JP | 1 |
| Baba, N; Ichiyama, S; Matsuzaki, T; Miyagawa, K; Miyazawa, M; Nagatani, T; Nakajima, H; Onuma, R; Uchiyama, M | 1 |
| Guichard, M; Lartigau, E | 1 |
| Armitage, GR; Bennett, K; Bodurtha, AJ; Burdette-Radoux, S; Iscoe, NA; James, KW; Jensen, J; Lohmann, RC; McCulloch, PB; Quirt, IC; Rusthoven, JJ; Silver, HK; Verma, S; Zee, B | 1 |
| Benoit, F; Bertheas, MF; Cambazard, F; Graille, MC; Guy, C; Lanthier, K; Perrot, JL | 1 |
| Atzpodien, J; Kirchner, HH; Poliwoda, H | 1 |
| Bruske, T; Kreysel, HW; Reinhold, U | 1 |
| De Lena, M; Guida, M; Latorre, A; Mastria, A | 1 |
| Anderson, CM; Buzaid, AC; Legha, SS | 1 |
| Cavillon, C; Claude, R; Desplechain, C; Egloff, H; Franck, F; Goujon, N; Lautier, A; Plagne, R; Rigondet, G; Sale, JM | 1 |
| Ogasawara, H; Sakagami, M; Seo, W | 1 |
| Hahka-Kemppinen, M; Kangas, L; Muhonen, T; Pyrhönen, S | 1 |
| Hauschild, A | 1 |
| Rudolf, Z; Strojan, P | 2 |
| Vuoristo, MS | 1 |
| Lyng, H; Rofstad, EK | 1 |
| Benedicic, D; Stabuc, B | 1 |
| Keilholz, U; Proebstle, TM; Scheibenbogen, C; Sterry, W | 1 |
| Bedikian, A; Buzaid, AC; Eton, O; Legha, SS; Papadopoulos, N; Plager, C; Ring, S | 2 |
| Ang, PT; Tan, EH | 1 |
| Buda, BS; Didolkar, MS; Fitzpatrick, JL; Jackson, AJ; Johnston, GS; Lesko, LJ; Zech, LA | 1 |
| Chapman, PB; Houghton, AN; Meyers, ML | 1 |
| Saida, T | 1 |
| Egyházi, S; Hansson, J; Margison, GP; Ringborg, U | 1 |
| Ariyan, S; Bolognia, J; Poo, WJ | 1 |
| Drechsler, S; Faerber, L; Fiedler, H; Garbe, C; Kuehne, KH; Landthaler, M; Schroeder, K; Tilgen, W | 1 |
| Legha, SS | 1 |
| Fefer, A; Gold, PJ; Thompson, JA | 1 |
| Buzaid, AC; Poo, WJ; Schultz, MZ | 1 |
| Tachihara, R | 1 |
| de Mulder, PH; Jansen, RL; Muller, EW; Punt, CJ; van Herpen, CM; Vreugdenhil, G | 1 |
| Berd, D; De Potter, P; Mastrangelo, MJ; Nathan, FE; Sato, T; Shield, JA; Shields, CL | 1 |
| Hahka-Kemppinen, M; Muhonen, T; Nordling, S; Pyrhönen, S | 1 |
| Caponigro, F; Casaretti, R; Comella, G; Comella, P; Daponte, A; Fiore, F; Frasci, G; Gravina, A; Ionna, F; Mozzillo, N; Parziale, AP; Presutti, F | 1 |
| Driscoll, DL; Karakousis, CP; Kontzoglou, K | 1 |
| Burg, G; Dummer, R; Flace, A; Meyer, JC; Seifert, B; Wimmer, I | 1 |
| Dekio, S; Hayashi, S; Ohno, T; Takata, Y | 1 |
| Bouche, O; Cartier, H; Egreteau, JP; Lambolais, C; Quinio, P; Savry, C | 1 |
| Azevedo, MC; Lopes, M; Pontes, L; Ribeiro, M; Santos, JG | 1 |
| Bedikian, A; Eton, O; Legha, SS; Papadopoulos, N; Plager, C; Ring, S | 1 |
| Eggermont, AM; Keilholz, U; Lejeune, F; Punt, CJ; Scheibenbogen, C; Stoter, G | 1 |
| Byrd, DR; Fefer, A; Gold, PJ; Lindgren, CG; Markowitz, DR; Thompson, JA | 1 |
| Brown, BD; Bryan, RN; Eichler, HG; Jansen, B; Müller, M; Pehamberger, H; Schlagbauer-Wadl, H; van Elsas, A; Wolff, K | 1 |
| Hart, AA; Israels, SP; Kroon, BB; Nieweg, OE; Rümke, P; Strobbe, LJ | 1 |
| Flaherty, LE; Fletcher, WS; Liu, PY; Margolin, KA; Smith, JW; Sondak, VK; Sosman, JA; Unger, JM; Walker, MJ; Weiss, GR | 1 |
| Enk, AH; Knop, J; Nashan, D | 1 |
| Becker, JC; Bröcker, EB; Kämpgen, E; Schwaaf, A; Trcka, J | 1 |
| Ariyan, S; Poo, WJ | 1 |
| Broadley, K; Fisher, C; Gore, ME; Henk, M; Henson, G; Johnston, SR | 1 |
| Barth, NM; Dillman, RO; Honeycutt, PJ; Schulof, R; Soori, G; Stark, JJ; Wiemann, MC | 1 |
| A'Hern, RP; Atkinson, H; Constenla, DO; Dadian, G; Gore, ME; Johnston, SR; Moore, J; Riches, PG | 1 |
| Atkins, MB; Blum, RH; Coates, AS; Falkson, CI; Ibrahim, J; Kirkwood, JM | 1 |
| Punt, CJ | 1 |
| Akande, N; Ali-Osman, F; Bedikian, A; Benjamin, RS; Buzaid, AC; Eton, O; Grimm, EA; Lee, JJ; Legha, SS; Papadopoulos, N; Plager, C | 1 |
| Ali-Osman, F; Anderson, CM; Bedikian, A; Braunschweiger, PG; Buzaid, AC; Eton, O; Grimm, EA; Lee, JJ; Legha, SS; Papadopoulos, N; Plager, C; Sussman, J | 1 |
| Bassères, N; Bizzari, JP; Bonerandi, JJ; Gérard, B; Grob, JJ; Richard, MA; Zarrour, H | 1 |
| Casella, G; di Bonito, M; Fortuna, G; Iodice, F; Stellato, G; Tramontana, R; Tramontana, S | 1 |
| Dreno, B; Legoux, B; Litoux, P; Mansat, E; Tessier, MH | 1 |
| Cohen, GL; Falkson, CI | 1 |
| Egorova, NI; Garin, AM; Gorozhanskaia, EG; Koroleva, EIu; Kushlinskiĭ, NE; Larionova, VB | 1 |
| Berd, D; Mastrangelo, MJ; McClay, EF | 1 |
| Bénard, J | 1 |
| Bisighini, G; Di Lernia, V; Lo Scocco, G | 1 |
| Bauer, J; Biollaz, J; Buclin, T; Decosterd, LA; Gander, M; Lejeune, F; Leyvraz, S; Marzolini, C; Shen, F | 1 |
| Atzpodien, J; Buer, J; Franzke, A; Ganser, A; Hoffmann, R; Kirchner, H; Lassmann, S; Müller, I; Neuber, K; Oevermann, K; Probst, M | 1 |
| Aoki, K; Hayashi, O; Nishioka, K; Ohara, H; Tanaka, K; Umeda, T; Yokoyama, A | 1 |
| Ganesan, TS; Harris, AL; Kyrtopoulos, SA; Mitchell, K; Philip, PA; Salisbury, A; Souliotis, VL; Tates, AD; van Delft, JH | 1 |
| Day, R; Donnelly, S; Gerson, SL; Kirkwood, JM; Liu, L; Smith, DC; Trump, DL | 1 |
| Bleehen, NM; Brampton, MH; Calvert, AH; Lee, SM; Lind, MJ; Lunn, JM; Margison, GP; Middleton, MR; Morris, C; Newell, DR; Newlands, ES; Rustin, G; Thatcher, N; Wedge, SR | 1 |
| Aamdal, S; Andersson, R; Bjelkengren, G; Ingvar, C; Jungnelius, U; Karlsson, M; Malmström, P; Mattsson, J; Ringborg, U; Stierner, U; Westberg, R; Willman, K; Wist, E | 1 |
| Albert, DM; Chappell, R; Darjatmoko, SR; Howes, KA; Koop, BA; Lokken, JM; Mangold, G; Steeves, RA; Syed, NA; Wallow, IH; Windle, JJ | 1 |
| Arista, MC; Carpano, S; Conti, L; De Franceschi, L; Francavilla, V; Lopez, M; Valente, F; Vercillo, M | 1 |
| Haisa, M; Hara, K; Kamikawa, Y; Kenzo, A; Naomoto, Y; Perdomo, JA; Taguchi, K; Tanaka, N; Yamatsuji, T | 1 |
| Bedikian, A; Benjamin, R; Buzaid, AC; Colome, M; Eton, O; Lee, JE; Lee, JJ; Legha, SS; Mansfield, P; Papadopoulos, N; Plager, C; Rice, J; Ring, S; Ross, M; Strom, E | 1 |
| Fuchs, T; Keilholz, U; Proebstle, TM; Scheibenbogen, C; Sterry, W | 1 |
| Keilholz, U; Max, R; Scheibenbogen, C; Schmittel, A; Thiel, E | 1 |
| Bernstein, Z; Drumea, K; Haim, N; Shklar, Z; Stein, ME; Steiner, M; Zalik, M | 1 |
| Binder, M; Pehamberger, H; Seeber, A; Steiner, A; Wolff, K | 1 |
| Einhorn, JH; Hwu, P; Marincola, FM; Rosenberg, SA; Schwartzentruber, DJ; Seipp, CA; Steinberg, SM; Topalian, SL; White, DE; Yang, JC | 1 |
| Gale, D; Lestingi, T; Mehta, N; Richards, JM | 1 |
| Castro, MP; Legha, S; Spencer-Cisek, P; Sponzo, RW; VanAuken, J | 1 |
| Agarwala, SS; Ferri, W; Gooding, W; Kirkwood, JM | 1 |
| Jedrzejczak, WW | 1 |
| Flaherty, LE; Fletcher, WS; Hersh, EM; Hutchins, LE; Liu, PY; Margolin, KA; Smith, JW; Sondak, VK; Sosman, JA; Unger, JM; Urba, WJ; Weiss, GR | 1 |
| Belanich, M; Biollaz, J; Bonfanti, M; Colella, G; D'Incalci, M; Decosterd, L; Gander, M; Lejeune, F; Leyvraz, S; Liénard, D; Marzolini, C; Perey, L; Shen, F; Yarosh, D | 1 |
| Ishikawa, M; Wada, T; Yamamoto, A; Yamazaki, N | 1 |
| Comella, P; Daponte, A | 1 |
| Gademann, G; Gollnick, H; Ulrich, J | 1 |
| Creagan, ET; Dalton, RJ; Krook, JE; Long, HJ; Michalak, JC; Pitot, HC; Rowland, KM; Suman, VJ; Veeder, MH; Vukov, AM | 1 |
| Agarwala, SS; Begg, CB; Chapman, PB; Destro, AN; Einhorn, LH; Ernstoff, MS; Houghton, AN; Kirkwood, JM; Meyers, ML; Panageas, KS; Saxman, S; Schuchter, LM | 1 |
| Boasberg, PD; Cannon, M; Edwards, S; Essner, R; Fawzy, NW; Foshag, LJ; Fournier, P; Gammon, G; Guo, M; Johnson, TD; Kristedja, TS; Martin, MA; Morton, DL; O'Day, SJ; Stern, S; Weisberg, M | 1 |
| Batra, V; Beale, P; Brada, M; Cutler, D; Dugan, M; Judson, I; Moore, S; Reidenberg, P; Statkevich, P | 1 |
| Bedikian, A; Benjamin, RS; Buzaid, AC; Carrasco, CH; East, M; Eton, O; Gianan, M; Hodges, C; Legha, SS; Papadopoulos, N | 1 |
| Bajetta, E; Barduagni, L; Bernengo, MG; Bufalino, R; Cascinelli, N; Comella, G; Criscuolo, D; Del Vecchio, M; DelVecchio, M; Morabito, A; Queirolo, P; Sertoli, MR; Vecchio, S | 1 |
| Aamdal, S; Aaronson, N; Cebon, J; Coates, A; Dreno, B; Fierlbeck, G; Fraass, U; Gore, M; Grob, JJ; Henz, M; Kapp, A; Middleton, MR; Muller, M; Schadendorf, D; Seiter, S; Statkevich, P; Thatcher, N; Tilgen, W; Weiss, J | 1 |
| Donnelly, DJ; Kelly, J; Margison, GP; McCormick, JE; McElhinney, RS; McMurry, TB; Middleton, MR; Thatcher, N | 1 |
| Boeynaems, JM; Duhant, X; Ghanem, G; Jacquemotte, F; Kinnaert, E; Morandini, R | 1 |
| de Gast, GC; Groenewegen, G | 1 |
| Popova, L; Rohrbach, J; Sivkova, N; Steuhl, KP | 1 |
| Chollet, P; Cure, H; D'incan, M; Fargeot, P; Fumoleau, P; Hanauske, A; Lentz, MA; Ouabdesselam, R; Ravaud, A; Roche, H; Souteyrand, P; Viens, P | 1 |
| Braybrooke, JP; Crawley, JE; Harris, AL; Houlbrook, S; O'Byrne, KJ; Propper, DJ; Shuker, DE; Stratford, IJ; Talbot, DC | 1 |
| Flaherty, LE | 1 |
| Eggermont, AM; Keilholz, U | 1 |
| Ashcroft, L; Harper, P; Lee, SM; Lorigan, P; Middleton, MR; Owen, J; Thatcher, N | 1 |
| Agarwala, S; Hillner, BE; Middleton, MR | 1 |
| Kageshita, T; Kuribayashi, N; Ono, T | 1 |
| Allen, J; Becker, M; Gibbs, P; Gonzalez, R; Iannucci, A; McDowell, K; Murphy, J; O'Driscoll, M; Rosse, P; Williams, P | 1 |
| Garaci, E; Izzo, F; Pierimarchi, P; Ranuzzi, M; Rasi, G; Sinibaldi-Vallebona, P; Terzoli, E; Tuthill, C | 1 |
| Cohen, MH; Johnson, JR; Middleton, MR | 1 |
| Enk, AH; Knop, J; Nashan, D; Rübben, A | 1 |
| Braybrooke, JP; Christodoulos, K; Ganesan, TS; Han, C; Harris, AL; Levitt, NC; O'Byrne, K; Propper, DJ; Talbot, DC | 1 |
| Cognetti, F; Sega, FM; Serrone, L; Zeuli, M | 1 |
| Adler, A; Rakowsky, E; Schachter, J; Sulkes, A | 1 |
| Hahka-Kemppinen, M; Hemminki, K; Jansèn, CT; Kumar, R; Punnonen, K; Pyrhönen, S; Sauroja, I; Smeds, J; Talve, L; Vlaykova, T | 1 |
| Atkins, MB; Clancy, MA; Lawrence, DP; McDermott, DF; Mier, JW; Rubin, KM; van den Brink, MR | 1 |
| Eggermont, AM; Keilholz, U; Suciu, S | 1 |
| Calvert, H; Friedman, HS; Kerby, T | 1 |
| Egorov, GN; Gorbonova, VA; Orel, NF; Perevodchikova, NI | 1 |
| Chapman, PB; Houghton, AN; Hwu, WJ; Klimek, VM; Wolchok, JD | 1 |
| Deraemaecker, R; Sales, F; Vandeweyer, E | 1 |
| Christophers, E; Hauschild, A; Lischner, S | 1 |
| Buzaid, AC; Eton, O; Grimm, EA; Lee, JJ; Smid, CM; Tseng, CH | 1 |
| Arance, A; Lee, SM; Margison, GP; Middleton, MR; Thatcher, N; Wood, M | 1 |
| A'Hern, RP; Ayliffe, MJ; Eisen, T; Gore, ME; Hill, ME; Johnston, SR; Moore, J; Riches, PG; Thomas, JM; Vaughan, MM | 1 |
| Goos, M; Hillen, U; Willers, C | 1 |
| Kroon, BB; Nieweg, OE | 1 |
| Heere-Ress, E; Hoeller, C; Hoermann, M; Hollenstein, U; Jansen, B; Lucas, T; Pehamberger, H; Schlagbauer-Wadl, H; Wacheck, V; Wolff, K | 1 |
| Kretschmer, L; Marsch, WC; Neumann, C; Preusser, KP | 1 |
| Flaherty, LE; Philip, PA | 1 |
| Ascierto, PA; Cellerino, R; Comella, G; Comella, P; Daponte, A; DeLena, M; Gravina, A; Marini, G; Melucci, MT; Palmieri, G | 1 |
| Church, C; DePriest, CB; Dillman, RO; Dobbs, TW; Ruben, RH; Schulof, R; Soori, G; Wiemann, MC | 1 |
| Christophers, E; Hauschild, A; Lischner, S; Möller, M | 1 |
| Hwu, WJ | 1 |
| Caubet, JF; Huncharek, M; McGarry, R | 1 |
| Franke, W; Neumann, NJ; Ruzicka, T; Schulte, KW | 1 |
| Kamanabrou, D | 1 |
| Burg, G; Dummer, R | 1 |
| Achtelik, W; Dummer, R; Ellwanger, U; Fey, M; Garbe, C; Hauschild, A; Kaufmann, R; Linse, R; Mohr, P; Nashan, D; Sebastian, G; Seiter, S; Stolz, W; Tilgen, W; Ugurel, S; Ulrich, J | 1 |
| D'incan, M; Souteyrand, P | 1 |
| Appel, C; Atkins, M; Clark, JI; Du, W; Dutcher, J; Fisher, RI; Flaherty, LE; Gordon, MS; Lotze, M; Margolin, K; Mier, J; Sorokin, P; Sosman, J; Weiss, G | 1 |
| Retsas, S | 2 |
| Güven, K; Kittler, H; Pehamberger, H; Wolff, K | 1 |
| Gore, M; Stebbing, J; Thomas, M | 1 |
| Biasco, G; Casadei, S; Pantaleo, MA | 1 |
| Chan, C; O'Day, J | 1 |
| Dzodić, R; Jelić, S; Jović, V; Konjević, G; Radulović, S; Spuzić, I | 1 |
| Heere-Ress, E; Jansen, B; Joukhadar, C; Klein, N; Mader, RM; Müller, M; Pehamberger, H; Rizovski, B; Schrolnberger, C; Strauchmann, N | 1 |
| Bret-Dibat, C; Chevreau, C; Coulon, V; Courbon, F; Debled, M; Delaunay, M; Gualde, N; Nguyen Bui, B; Ravaud, A | 1 |
| Cansiz, H; Karakullukçu, B; Ozek, H; Oztürk, O | 1 |
| Bafaloukos, D; Briassoulis, E; Fountzilas, G; Georgoulias, V; Gogas, H; Kalofonos, Ch; Karabelis, A; Kosmidis, P; Samantas, E; Skarlos, D | 1 |
| Hahka-Kemppinen, M; Kähäri, VM; Nikkola, J; Pyrhönen, S; Vihinen, P; Vlaykova, T | 1 |
| Kennedy, RD; McAleer, JJ | 1 |
| Burton, A; Dunn, JA; Goodman, A; Marsden, J; Young, AM | 1 |
| Babovic, N; Jelić, S; Kovcin, V; Milanovic, N; Milicevic, N; Popov, I; Radosavljevic, D | 1 |
| Akiya, Y; Hagiwara, N; Matsutani, T; Miyashita, M; Onda, M; Sasajima, K; Takubo, K; Yamashita, K | 1 |
| Amicucci, G; Deraco, M; Fiorentini, G; Guadagni, S; Miotto, D; Palumbo, G; Pilati, PL; Rossi, CR; Russo, F; Santinami, M; Valenti, M | 1 |
| Atzpodien, J; Bröcker, EB; Fluck, M; Kamanabrou, D; Müller, I; Neuber, K; Neumann, C; Patzelt, T; Paul, E; Reitz, M; Rünger, TM; Schuler, G; von den Driesch, P | 1 |
| Brugnara, S; Chiarion-Sileni, V; Freschi, A; Guida, M; Labianca, R; Lo Re, G; Nanni, O; Nortilli, R; Ridolfi, R; Romanini, A; Vitali, P | 1 |
| Anderson, C; Becker, M; Gatlin, K; Gibbs, P; Gonzalez, R; LaClaire, S; O'Driscoll, M; Pearlman, N; Stephens, J | 1 |
| Herishanu, Y; Kitay-Cohen, Y; Lishner, M | 1 |
| Hwu, WJ; Lis, E; Panageas, KS; Raizer, J | 1 |
| Babović, N; Jelić, S; Kreacić, M; Matković, S; Popov, I; Stamatović, L | 1 |
| Schadendorf, D | 1 |
| Brampton, MH; Calvert, AH; Middleton, MR; Paul, MJ; Rustin, G; Summers, Y; Thatcher, N | 1 |
| Atkins, B; Clark, I; Dutcher, P; Ernstoff, S; Flaherty, L; Gollob, J; II Smith, W; Johnson, D; Longmate, J; Margolin, K; Sosman, J; Thompson, A; Weber, J; Weiss, G | 1 |
| Dedkov, AG; Korovin, SI; Medinets, IuR; Palivets, AIu; Protsenko, VV; Smakova, MS; Tolstopiatov, BA | 1 |
| Bedikian, AY; Benjamin, RS; Buzaid, AC; East, MJ; Eton, O; Hodges, C; Lee, JJ; Legha, SS; Papadopoulos, NE; Plager, C; Ring, SE; Zhan, F | 1 |
| Bernard-Marty, C; Khayat, D; Meric, JB; Rixe, O | 1 |
| Feun, LG; Hurley, J; Marini, A; Savaraj, N | 1 |
| Chapman, PB; Houghton, AN; Hwu, WJ; Krown, SE; Livingston, PO; Menell, JH; Panageas, KS; Quinn, CJ; Williams, LJ | 1 |
| Baker, LH; Izbicki, RM; Ratanatharathorn, V; Samson, MK | 1 |
| Bellet, RE; Berd, D; Catalano, RB; Mastrangelo, MJ | 2 |
| Diem, E; Kokoschka, EM; Kühböck, J; Mach, K; Pehamberger, H; Pötzi, P | 1 |
| Dowd, PM; Everall, JD | 1 |
| Boccardo, F; Musso, M; Porcile, G; Rosso, R; Santi, L | 1 |
| Bellet, RE; Berd, D; Danna, V; Mastrangelo, MJ | 1 |
| Zaumseil, RP | 1 |
| Banzet, P; Belaich, S; Chastang, C; Civatte, J; Cottenot, F; Israel, L; Jacquillat, C; Maral, J; Puissant, A | 1 |
| Jawalekar, K; Tretter, P | 1 |
| Rosenberg, SA | 1 |
| Westbury, G | 1 |
| Bolton, PM; Burnett, W; Clunie, GJ; Gough, IR | 1 |
| Buckley, JC; Coates, AS; Green, MD; MacKay, IR | 1 |
| Goldman, SL; Pollak, EW; Wolfman, EF | 1 |
| Klein, R; Krüger, GR; Sesterhenn, K | 1 |
| Einhorn, LH; Furnas, B | 1 |
| Colsky, J; Costanza, ME; Cunningham, T; Nathanson, L; Regelson, W; Schoenfeld, D; Sedransk, N; Wolter, J | 1 |
| Golbey, RB; Wittes, JT; Wittes, RE | 1 |
| McPherson, TA; Paterson, AH; Willans, DJ | 1 |
| Cooper, MR; Muss, HB; Ramseur, WL; Rhyne, L; Richards, F; Spurr, CL; Stuart, JJ; White, DR | 1 |
| Baker, LH; Fraile, RJ; McDonald, B; Samson, MK; Talley, RW | 1 |
| Chauvergne, J; Clavel, B; Klein, T; Pommatau, E | 1 |
| Lewis, MG | 1 |
| Agrup, G; Hafström, L; Jönsson, PE; Rorsman, H | 1 |
| Gallmeier, WM | 1 |
| Karrer, K | 1 |
| Grünewald, K; Huber, H | 1 |
| Kokoschka, EM | 1 |
| Blume, MR; Chan, EY; Cohen, RJ; Friedman, MA; Gershow, J; Glassberg, AB; Kaufman, DA; Resser, KJ; Rosenbaum, EH; Williams, JE | 1 |
| Goodnight, JE; Morton, DL | 1 |
| Benjamin, RS | 1 |
| Gutterman, JU; Hersh, EM; McBride, CM | 1 |
| Bartolucci, AA; Presant, CA; Smalley, RV; Vogler, WR | 1 |
| Wilczek, ZM | 1 |
| Hill, GJ; Hill, HZ; Szramowski, J | 1 |
| Galin, M; Hill, GJ; Hill, HZ; Miller, CL; Pfaller, M; Weiss, K | 1 |
| Berger, JL; Friedman, M; Holyoke, ED; Karakousis, CP; Lopez, R; Takita, H | 1 |
| Jassem, J; Kopacz, A; Wojszwiłło-Geppert, E | 1 |
| Aranha, GV; Grage, TB; Gunnarsson, A; McKhann, CF; Simmons, RL | 1 |
| Block, JB; Dietrich, M; Isacoff, W | 1 |
| Becker, B; Krupin, T; Singer, PR; Smith, ME | 1 |
| Kolarić, K; Malenica, B; Roth, A | 1 |
| Hagedorn, M; Meuret, G; Schmitt, E; Waldermann, F | 1 |
| Brown, SG; Parsons, PG | 1 |
| Legha, S; McCredie, KB; Spitzer, G; Verma, DS | 1 |
| Czarnetzki, BM; Frosch, PJ; Gottschalk, I; Grundmann, E; Macher, E | 1 |
| Braun-Falco, O; Landthaler, M; Ryckmanns, F | 1 |
| Fiedler, H; Lübbe, D; Zaumseil, RP | 1 |
| Crowther, D; Gasiunas, N; Palmer, MK; Thatcher, N | 1 |
| Baffi, RR; Catane, R; Didolkar, MS; Holyoke, ED; Kaufman, J | 1 |
| Crispen, R; Das Gupta, TK; El-Domeiri, AA; Sabet, TY; Simo, C; Trippon, M | 1 |
| Ahmann, DL; Bisel, HF; Edmonson, JH; Frytak, S; Kvols, LK; Rubin, J | 1 |
| Carey, RW; Cosimi, AB; Kaufman, SD; Wood, WC | 2 |
| Currie, GA; Hedley, DW; McElwain, TJ | 2 |
| Bellet, RE; Berkelhammer, J; Mastrangelo, MJ; Prehn, RT; Thibault, LH | 1 |
| Nagel, GA; Rufli, T | 1 |
| Chauvergne, J; Clavel, B; Klein, T; Pammatau, E | 1 |
| Kokron, O; Pridun, N; Zischinsky, W | 1 |
| Banzet, P; Chastang, C; Civatte, J; Cottenot, F; Israel, L; Jacquillat, C; Maral, J; Puissant, A | 1 |
| Luce, JK | 2 |
| Bartold, SL; Burgess, MA; Gehan, EA; Gutterman, JU; Hersh, EM; Kennedy, A; Mavligit, G; McBride, CM; Richman, SP | 1 |
| Domas, J; Gauci, L; Pujol, H; Serrou, B | 1 |
| Deicher, H; Deinhardt, J; Deutschmann, KE; Peter, HH | 1 |
| Beretta, G; Veronesi, U | 1 |
| Block, JB; Drakes, TP; Isacoff, W; Tabbarah, H | 1 |
| Brunk, SF; Colsky, J; Costanza, ME; Costello, WG; Hall, T; Nathanson, L; Oberfield, RA; Regelson, W; Wolter, J | 1 |
| Comis, RL | 1 |
| Burgess, MA; Gottlieb, J; Gutterman, JU; Hersh, EM; Mavligit, GM; Reed, R | 1 |
| Hill, G; Johnson, RO; Krementz, E; Metter, G; Wilson, W | 1 |
| Costanzi, JJ | 1 |
| Carbone, PP; Costello, W | 1 |
| Azzarelli, A; Bajetta, E; Beretta, G; Bonadonna, G; De Lena, M; Tancini, G; Veronesi, U | 1 |
| Ahmann, DL; Bisel, HF; Eagan, RT; Edmonson, JH; Frytak, S; Hahn, RG; O'Connell, MJ | 1 |
| Kleeberg, UR | 1 |
| Byrne, MJ | 1 |
| Bellett, RE; Bodurtha, AJ; Laucius, JF; Mastrangelo, MJ | 1 |
| Cruz, AB; Davis, HL; Fletcher, WS; Golomb, FM; Grage, T; Hill, GJ; Johnson, RO; Metter, G; Wilson, WL | 1 |
| Hersh, EM; Hewlett, JS; Luce, JK; McKelvey, EM; Moon, TE; Talley, RW | 1 |
| Cohen, SM; Greenspan, EM; Ratner, LH; Weiner, MJ | 1 |
| Bodey, GP; Lane, M; Luce, JK; McKelvey, EM; Moon, TE; Talley, RW; Vaitkevicius, VK | 1 |
| Bodurtha, A; Ghose, T; Guclu, A; MacDonald, AS; Norvell, ST; Tai, J | 1 |
| Brustad, T; Johannessen, JV; Mossige, J; Rofstad, EK | 1 |
| Davis, JM; Mitchell, MS; Mokyr, MB | 1 |
| Aranha, GV; Grage, TB | 1 |
| Elliott, P; Madden, FJ; Mould, RF; Newlands, ES; Newton, KA; Oon, CJ; Roberts, JT; Topham, C; Westbury, G | 1 |
| Carter, RD; Fletcher, WS; Golomb, FM; Grage, TB; Hill, GJ; Krementz, ET; Metter, GE; Minton, JP; Sparks, FC | 1 |
| Beretta, G; Bonadonna, G; Cascinelli, N; Morabito, A; Veronesi, U | 1 |
| Duchková, H; Kubíková, M; Richter, J; Rus, J | 1 |
| Biran, S; Brufman, G; Ratzkowski, E | 1 |
| Carmo-Pereira, J; Oliveira Costa, F; Pimentel, P | 1 |
| Gutterman, JU; Hersh, EM; Mavligit, GM | 1 |
| Blumenshein, G; Burgess, MA; Gutterman, JU; Hersh, EM; Mavligit, GM; McBride, CM | 1 |
| Dickey, C; Gerner, RE; Moore, GE | 1 |
| Jacobsen, GK; Povlsen, CO | 1 |
| Eidemiller, LR; Fletcher, WS; Yeager, RA | 1 |
| Currie, GA; McElwain, TJ | 1 |
| Klepp, O | 1 |
| Banzet, P; Dufourmentel, C; Jacquillat, C; Ricbourg, B | 1 |
| Falkson, G; Van Dyk, JJ | 1 |
| Calabresi, P; Cummings, FJ; Heppner, GH | 1 |
| Andersson, T | 1 |
| Barto, DA; Hendrickson, C; Sams, BJ; Susens, GP | 1 |
| Kleeberg, UR; Schreml, W | 1 |
| Hahka-Kemppinen, M; Muhonen, T; Pyrhönen, S | 1 |
| Doherty, VR; MacKie, RM; Stables, GI | 1 |
| Chaitchik, S; Inbar, M; Kovner, F; Merimsky, O; Reider-Groswasser, I | 1 |
| Chaitchik, S; Gerard, B; Inbar, M; Merimsky, O | 1 |
| Brunet, A | 1 |
| Boaziz, C | 1 |
| Garbe, C; Kreuser, ED; Orfanos, CE; Stadler, R; Zouboulis, CC | 1 |
| Chosidow, O; Guillaume, JC | 1 |
| Hodges, C; Legha, SS; Ring, S | 1 |
| Ichiyama, S; Miyakawa, K; Nagatani, T; Uchiyama, M | 1 |
| Avril, MF; Bonneterre, J; Cupissol, D; Fargeot, P; Fumoleau, P; Grob, JJ; Israel, L; Kalis, B; Kerbrat, P; Lambert, D | 1 |
| Binder, M; Dorffner, R; Glebowski, E; Pehamberger, H; Winkler, A; Wolff, K | 1 |
| Grabowski, T; Jez, W; Rzempołuch, J | 1 |
| Kubota, K; Kubota, R; Yamada, S | 1 |
| Barak, V; Ben-Bassat, H; Biran, S; Franks, CR; Gazit, Z; Isacson, R; Kalichman, I; Kedar, E; Schlesinger, M; Yurim, O | 1 |
| Kan, S; Miyasaka, Y; Murata, K; Ohbu, M; Saito, M; Takagi, H; Takano, S; Yada, K | 1 |
| Avril, MF; Bertrand, P; Bizzari, JP; Cour, V; Gerard, B; Khayat, D | 1 |
| Albright, KD; Christen, R; Eastman, A; Howell, SB; Jones, JA; McClay, EF | 1 |
| Maclennan, KA; Okon, E; Polliack, A; Shiloni, E | 1 |
| Chaitchik, S; Inbar, M; Merimsky, O | 2 |
| Basurto, C; Boschetti, E; Bracarda, S; Del Favero, A; Lupattelli, M; Picciafuoco, M; Roila, F; Sassi, M; Tonato, M | 1 |
| Guillou, PJ; Reynolds, JV; Somers, SS | 1 |
| Esteguy, M; Leiguarda, R; Merello, M; Perazzo, F | 1 |
| Gröhn, P; Hakala, T; Heikkinen, M; Jakobsson, M; Korpela, M; Kumpulainen, E; Numminen, S; Nuortio, L; Salmi, R; Vuoristo, MS | 1 |
| De Mulder, PH; Fiedler, W; Franks, CR; Hossfeld, DK; Jasmin, C; Oskam, R; Palmer, PA; Pyrhönen, S | 1 |
| Aamdal, S; Bohman, T; D'Incalci, M; Gerard, B | 1 |
| Buzaid, AC; Murren, J | 1 |
| Balcerzak, SP; Daniels, D; Flaherty, LE; Fletcher, WS; Goodwin, JW; Liu, PY; Sondak, VK; Stephens, RL | 1 |
| Gazit, Z; Kedar, E; Notter, M; Schirrmacher, V; Shouval, D; Walter, J; Weiss, DW; Yechezkeli, M | 1 |
| Mehta, N; Ramming, K; Richards, JM; Skosey, P | 1 |
| Champagne, MA; Silver, HK | 1 |
| Bella, M; Boni, C; Buzzi, F; Calabresi, F; Canaletti, R; Ceci, G; Cocconi, G; Corgna, E; Costa, P; Tonato, M | 1 |
| Guerry, D; Schuchter, LM | 1 |
| Baan, RA; Keizer, HJ; Ouwerkerk, J; van Delft, JH; van den Ende, AM | 1 |
| Cruse, CW; Klein, CJ; Reintgen, DS; Saba, HI; Wells, KE | 2 |
| Cocconi, G | 1 |
| Bliss, JM; Gore, ME; Lakhani, S; McElwain, TJ; Perren, TJ; Selby, P | 1 |
| Fiedler, H; Hetschko, I; Lübbe, D; Taube, KM; Wohlrab, W; Wozniak, KD | 1 |
| Agnifili, A; Carboni, M; D'Amore, L; Gianfelice, F; Giuliani, M; Gossetti, F; Negro, P | 1 |
| Ernstoff, MS; Kirkwood, JM | 1 |
| Hersey, P; McLeod, GR; Thomson, DB | 3 |
| Glover, DJ | 1 |
| Basile, M; Bennett, JM; Blumberg, N; Harris, J; Moskowitz, B | 1 |
| Doane, LL; Gilewski, TA; Mitchel, B; Ramming, K; Richards, JM; Vogelzang, NJ | 1 |
| Breistøl, K; Fodstad, O; Kjønniksen, I | 1 |
| Blackledge, GR; Brampton, MH; Hoffman, R; Newlands, ES; Quarterman, CP; Rustin, GJ; Slack, JA; Smith, DB; Stevens, MF; Stuart, NS | 1 |
| de Vries, EG; Mulder, NH; Schraffordt Koops, H; Sleijfer, DT; Willemse, PH | 3 |
| Burg, G; Dummer, R; Eilles, C; Miller, K | 1 |
| Baryshnikov, AIu; Cheremushkin, EA; Iavorskiĭ, VV; Kadagidze, ZG; Korotkova, OV; Savel'eva, EV; Solov'eva, EA | 1 |
| Castel, T; Castro, J; Daniels, M; Estapé, J; Gratacós, R; Grau, JJ; Mascaró, JM; Palou, J; Vilalta, A; Viñolas, N | 1 |
| Lee, SM; Margison, GP; Thatcher, N | 1 |
| Flokkmann, A; Gundersen, S | 1 |
| Bruce, L; Chapman, K; Dorreen, MS; Hancock, BW; Hayat, K; Reeder, S; Rees, RC; Rodgers, S; Sheridan, E; Sreenivasan, T | 1 |
| Chaitchik, S; Inbar, M; Merimsky, O; Reider-Groswasser, I | 1 |
| Boaziz, C; Breau, JL; Israël, L; Morere, JF | 1 |
| Baker, AR; Barth, RJ; Venzon, DJ | 1 |
| Bajorin, DF; Chapman, PB; Cody-Johnson, BV; Heelan, RT; Lovett, DR; Oettgen, HF; Portlock, CS; Steffens, TA; Templeton, MA; Wong, GY | 1 |
| Buzaid, AC; Durivage, HJ; Murren, JR | 1 |
| Aamdal, S; Cleton, FJ; Franks, CR; Iacobelli, S; Oskam, R; Rodenhuis, S; Shiloni, E; Stoter, G | 1 |
| Demirkazik, A; Dincol, D; Gunel, N; Icli, F; Karaoguz, H | 1 |
| Richards, JM | 1 |
| Joensuu, H | 1 |
| Davis, C; DeRosa, W; Durivage, HJ; Makuch, R; Murren, JR; Portlock, CS | 1 |
| Abbott, BJ; Boyd, MR; Dykes, DJ; Fodstad, O; Griswold, DP; Harrison, SD; Mayo, JG; Plowman, J; Shoemaker, RH | 1 |
| Chou, TH; Flaherty, L; Kaplan, J; Nakeff, A; Pillote, K; Redman, BG | 1 |
| Falkson, CI; Falkson, G; Falkson, HC | 1 |
| Avril, MF; Beerblock, K; Bonerandi, JJ; Chevrant-Breton, J; Delaunay, M; Dreno, B; Guillaume, JC; Kalis, B; Souteyrand, P; Verret, J | 1 |
| Chakalova, G; Karag'ozov, A; Kŭrlov, T | 1 |
| Bolhuis, RL; Braakman, E; Eggermont, AM; Goey, SH; Lamers, C; Slingerland, R; Stoter, G | 1 |
| Ho, VC; Sober, AJ | 1 |
| Costanzi, J; Ernstoff, MS; Gams, R; Giuliano, A; Grimm, M; Kirkwood, JM; Pouillart, P; Robinson, WA; Speyer, J; Spiegel, R | 1 |
| Arnold, J; Barth, NM; Birch, R; Dillman, RO; Oldham, RK; West, WH | 1 |
| Bajetta, E; Bernengo, MG; Brogelli, L; Brunetti, I; Giannotti, B; Maifredi, G; Negretti, E; Sertoli, MR; Sofra, MC; Zumiani, G | 1 |
| Daly, A; Drumm, JE; Harkin, KP; O'Brien, P | 1 |
| Baker, LH; Chabot, GG; Flaherty, LE; Valdivieso, M | 1 |
| Avril, MF; Bonneterre, J; Bugat, R; Cupissol, D; Delaunay, M; Fumoleua, P; Grosshans, E; Israel, L; Kerbrat, P; Namer, M | 1 |
| Ernstoff, MS; Kirkwood, JM; Luger, SM; Vlock, DR | 1 |
| Barth, V; Schönfelder, M | 1 |
| Colombel, F; Le Franc, P; Leroy, B; Scherpereel, P; Thomas, P | 1 |
| Chaitchik, S; Inbar, M; Merimsky, O; Ron, I; Shiloni, E | 1 |
| Fodstad, O; Kjønniksen, I; Nesland, JM; Pihl, A | 1 |
| Bizzari, JP; Deloffre, P; Etienne, MC; Fischel, JL; Formento, P; Frenay, M; Gioanni, J; Milano, G | 1 |
| Calabro, A; Carrasco, CH; Legha, SS; Singletary, SE | 1 |
| Bradley, EC; Chabot, GG; Flaherty, LE; Gualdoni, SM; Heilbrun, LK; Martino, S; Redman, BG; Valdivieso, M | 1 |
| Corstens, FH; De Mulder, PH; Franks, CR; Mattijssen, VJ; Van Liessum, PA; Wagener, DJ | 1 |
| Hansson, J; Jungnelius, U; Ringborg, U; Strander, H | 1 |
| Flaherty, LE; Redman, BG; Schwert, R | 1 |
| Ikegawa, S; Ishihara, K | 1 |
| Ikeda, S; Ikekawa, S; Ishihara, K; Tanaka, S | 1 |
| Balch, CM | 2 |
| Kato, T; Takematsu, H; Tomita, Y | 1 |
| Anderson, JR; Carey, RW; Ellison, RR; Green, M; Kennedy, BJ; Nathanson, L | 1 |
| Kopecný, J; Mechl, Z | 1 |
| De Vries, EG; Koops, HS; Mulder, NH; Sleijfer, DT; Smit, JM; Willemse, PH | 1 |
| Barnekow, A; Paul, E; Schartl, M | 1 |
| Kajikawa, H; Sakaguchi, H; Seguchi, T; Takada, M | 1 |
| Ballin, R; Klöppel, R; Lommatzsch, PK | 1 |
| Foltz, AT; York, RM | 1 |
| Epremian, BE; Gentile, PS; Hamm, JT; Seeger, J; Sheth, SP | 1 |
| Avril, MF | 1 |
| de Vries, EG; Mulder, NH; Samson, MJ; Schraffordt Koops, H; Sleijfer, DT; Willemse, PH | 1 |
| Atkinson, WE; Bucolo, AP; Farley, H; Guin, JD; Langston, HD; Prather, JL | 1 |
| Cartei, G; Ceschia, T; Clocchiatti, L; Fasola, G; Galletti, D; Marsilio, P; Morandini, G; Sibau, A | 1 |
| Cerny, T; Margison, GP; Maynard, K; Parsons, PG | 1 |
| English, JS; Lever, RS; MacKie, RM; Young, DW | 1 |
| Bijzet, J; Bouman, J; Jurjens, H; Mulder, NH; Sleijfer, DT; Smit, JM; Woldring, MG | 1 |
| Carr, T; Chadwick, G; Craig, P; Jones, R; Lind, M; Morgenstern, G; Thatcher, D | 1 |
| Hafström, L; Hansson, J; Ringborg, U; Rudenstam, CM; Stenstam, B; Strander, H | 1 |
| Aamdal, S; Bijman, JT; Cleton, FJ; Franks, CR; Iacobelli, S; Palmer, P; Rodenhuis, S; Shiloni, E; Stoter, G | 1 |
| Di Peri, T; Franks, CR; Janssens, J; Palmer, PA; Pouillart, P; Roest, GJ; Shiloni, E; Splinter, T; Symann, M | 1 |
| Bufalino, R; Cascinelli, N; MacKie, R; Morabito, A; Rümke, P | 1 |
| Marsh, JC | 1 |
| Eksborg, S; Ingvar, C; Jönsson, PE; Stigsson, L | 1 |
| Ames, FC; Boddie, AW; Edwards, MJ; McBride, CM | 1 |
| Lönn, S; Lönn, U; Nylen, U; Winblad, G | 1 |
| Bijman, JT; Cleton, FJ; Franks, CR; Gundersen, S; Iacobelli, S; Palmer, P; Rodenhuis, S; Shiloni, E; Stoter, G | 1 |
| Alevizakos, N; Athanassiou, A; Bafaloukos, D; Barbounis, V; Dimitriadis, M; Pectasides, D; Varthalitis, J; Yianniotis, H | 1 |
| Benjamin, R; Chawla, S; Legha, SS; Papadopoulos, N; Plager, C; Ring, S | 1 |
| Belli, F; Cascinelli, N; Rovini, D; Santinami, M; Vaglini, M | 1 |
| Engelhardt, R | 1 |
| Bellet, RE; Berd, D; Mastrangelo, MJ; McClay, EF; Sprandio, JD | 1 |
| Ambrosini, G; Amichetti, M; Piazza, M; Piffer, S; Valdagni, R | 1 |
| Klimek, M; Pawlicki, M | 1 |
| Lönn, S; Lönn, U | 2 |
| Gamel, JW; Niederkorn, JY; Sanborn, GE | 1 |
| Voigt, H | 1 |
| McLeod, GR | 1 |
| Milbradt, R; Neubert, J; Schneider, E | 1 |
| Dana, B; Fletcher, JR; Fletcher, WS; Green, S; Jewell, W; Townsend, RA | 1 |
| Gundersen, S; Høie, J; Pihl, A; Tveit, KM | 1 |
| Pályi, I | 1 |
| Martz, G; Stahel, RA | 1 |
| Abe, H; Doi, S; Murai, H; Sawamura, Y; Tashiro, K | 1 |
| Böckers, M; Bork, K; Keller, E | 1 |
| Bella, M; Bocchi, P; Ceci, G; Cocconi, G; Gabrielli, M; Melissari, M | 1 |
| Konz, B; Korting, HC; Strasser, S | 1 |
| de Garis, ST; Dische, S; Nelstrop, A; Rustin, GJ | 1 |
| Garbe, C; Guenther-Eymann, K; Orfanos, CE; Stadler, R | 1 |
| Czarnetzki, B; Kleeberg, UR; Mulder, J; Rozencweig, M; Rumke, P; Suciu, S; Thomas, D; Truchetet, F; Verschraegen, CF | 1 |
| Benjamin, RS; Bodey, GP; Burgess, AM; Legha, SS; Polyzos, A | 1 |
| Fujisaki, S; Inoue, S; Maeyama, M; Munemura, M; Shibata, S; Tohya, T | 1 |
| Allegra, JC; Richman, SP; Seeger, J | 1 |
| Banerjee, SS; Craig, P; Gleave, N; Mene, A; Orton, C; Thatcher, N | 1 |
| Little, JH; Maynard, KR; McLeod, GR; Parsons, PG | 1 |
| Kogonia, LM; Moros, LW; Perevodchikova, NJ | 1 |
| Biltz, H; Budde, U; Fiedler, U; Harbrecht, U; Kreysel, HW | 1 |
| Belli, F; Cascinelli, N; Marolda, R; Prada, A; Santinami, M; Vaglini, M | 1 |
| Kogoniia, LM; Manziuk, LV; Marenich, AF; Osmanov, DSh; Roshchin, EM | 1 |
| Abdi, EA; Hanson, J; McPherson, TA | 1 |
| Bellet, RE; Berd, D; Mastrangelo, MJ; McClay, EF | 1 |
| Carey, RW; Kunz, VS | 1 |
| Balcerzak, SP; Costanzi, JH; Dixon, D; Fabian, CJ; Maloney, T; Neidhart, J; Neilan, B; O'Bryan, RM; Quagliana, J; Tranum, BL | 1 |
| Carmo-Pereira, J; Costa, FO; Henriques, E | 1 |
| Dobrek, Z | 1 |
| Blum, R; Green, M; Muggia, FM; Oratz, R; Speyer, JL; Wernz, JC | 1 |
| Boddie, AW; Cangir, A | 1 |
| Gundersen, S | 1 |
| Emrich, LJ; Karakousis, CP | 1 |
| Anderson, H; Craig, P; Davenport, P; James, R; Thatcher, N | 1 |
| Aragon, V; Bröcker, EB; Bünte, H; Czarnetzki, BM; Krieg, V; Macher, E | 1 |
| Castello, G; Cerra, R; Comella, G; Comella, P; De Simone, G; Mastro, AA; Zarrilli, D | 1 |
| Creagan, ET; Green, SJ; Long, HJ; Schutt, AJ | 1 |
| Falkson, G; Sarli, R; Vorobiof, DA | 1 |
| Gundersen, S; Hager, B; Tausjø, J | 2 |
| Garbe, C; Orfanos, CE; Stadler, R | 1 |
| Harrison, BR; Hoelzer, KL; Luedke, DW; Mahanta, B | 1 |
| Craig, P; Mene, A; Orton, C; Smith, D; Thatcher, N; Wagstaff, J | 1 |
| Abdi, EA; McPherson, TA; Tan, YH | 1 |
| Braun-Falco, O; Hölzel, D; Konz, B; Landthaler, M; Schmoeckel, C | 1 |
| Karakousis, CP | 1 |
| Lusch, CJ; Mastrangelo, MJ; McClay, E | 1 |
| Nosek, H; Pawlicki, M; Skołyszewski, J; Stryjewska, B | 1 |
| Chessa, A; Desogus, A; Floris, C; Muggiano, A; Sulis, E; Tedde, A; Turno, R | 1 |
| Baker, LH; Cummings, G; Haas, CD; Samson, MK | 1 |
| Koh, H | 1 |
| Aron-Rosa, D; Auclerc, G; Dhermy, P; Jacquillat, C; Maral, J; Sellami, M; Weil, M | 1 |
| Clark, WH; Elder, D; Goldman, LI; Mastrangelo, MJ; Stennett, J | 1 |
| Didolkar, MS; Fitzpatrick, JL; Jackson, AJ; Johnston, GS | 1 |
| Case, LD; Cooper, MR; Jackson, DV; Muss, HB; Richards, F; Spurr, CL; Sterchi, JM; Stuart, JJ; Wells, HB; White, DR | 1 |
| Dunleavy, S; Golomb, F; Harris, M; Hochster, H; Levin, M; Muggia, F; Roses, D; Speyer, J | 1 |
| Hansson, J; Lagerlöf, B; Ringborg, U; Strander, H | 1 |
| Hypa, F; Leyh, F; Weber, M; Winzer, M | 1 |
| Dandu, VR; Didolkar, MS; Fiore, D; Jackson, AJ | 1 |
| Chuang, VP; Frost, DB; Mavligit, G; Patt, YZ; Wallace, S | 1 |
132 review(s) available for dacarbazine and Melanoma
| Article | Year |
|---|---|
Carotenoids from Marine Microalgae as Antimelanoma Agents.
Topics: Antineoplastic Agents; Carotenoids; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Humans; Melanoma; Microalgae; Mutation; NF-kappa B; Proto-Oncogene Proteins B-raf; Vemurafenib; Zeaxanthins | 2022 |
Immunotherapy for Melanoma: The Significance of Immune Checkpoint Inhibitors for the Treatment of Advanced Melanoma.
Topics: CTLA-4 Antigen; Dacarbazine; Humans; Immune Checkpoint Inhibitors; Immunotherapy; Ipilimumab; Melanoma | 2022 |
A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azetidines; Benzimidazoles; Cancer Vaccines; Carboplatin; Dacarbazine; gp100 Melanoma Antigen; Humans; Hydrazines; Imidazoles; Interleukin-2; Ipilimumab; Lenalidomide; Melanoma; Network Meta-Analysis; Nitrosourea Compounds; Nivolumab; Organophosphorus Compounds; Oximes; Paclitaxel; Piperidines; Progression-Free Survival; Proportional Hazards Models; Pyridones; Pyrimidinones; Skin Neoplasms; Sorafenib; Survival Rate; Temozolomide; Treatment Outcome; Vemurafenib | 2019 |
Ileal Melanoma, A Rare Cause of Small Bowel Obstruction: Report of a Case, and Short Literature Review.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Humans; Ileal Neoplasms; Ileum; Intestinal Obstruction; Male; Melanoma; Middle Aged; Positron-Emission Tomography | 2020 |
Nanotechnology approaches in the current therapy of skin cancer.
Topics: Administration, Cutaneous; Antineoplastic Agents; Dacarbazine; Drug Carriers; Drug Resistance, Neoplasm; Fluorouracil; Gold; Humans; Melanoma; Metal Nanoparticles; Nanoparticles; Nanotechnology; Particle Size; Skin Absorption; Skin Neoplasms; Skin Physiological Phenomena; Surface Properties | 2020 |
Impact of initial treatment and prognostic factors on postprogression survival in BRAF-mutated metastatic melanoma treated with dacarbazine or vemurafenib ± cobimetinib: a pooled analysis of four clinical trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azetidines; Dacarbazine; Humans; Melanoma; Mutation; Piperidines; Prognosis; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Vemurafenib | 2020 |
Prolonged survival following everolimus combined with temozolomide for metastatic malignant melanoma with FBXW7 mutation: a case report and literature review.
Topics: Adult; Brain Neoplasms; Dacarbazine; Everolimus; F-Box-WD Repeat-Containing Protein 7; Humans; Male; Melanoma; Mutation; Temozolomide | 2021 |
Multiple treatment comparison of seven new drugs for patients with advanced malignant melanoma: a systematic review and health economic decision model in a Norwegian setting.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Cost-Benefit Analysis; Dacarbazine; Drug Costs; Drug Therapy, Combination; Humans; Ipilimumab; Melanoma; Models, Economic; Network Meta-Analysis; Nivolumab; Norway; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Survival Analysis | 2017 |
Treating malignant melanoma when a rare BRAF V600M mutation is present: case report and literature review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Fatal Outcome; Humans; Interferons; Male; Melanoma; Melanoma, Cutaneous Malignant; Middle Aged; Neoplasm Metastasis; Point Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Vemurafenib | 2018 |
Direct costs associated with adverse events of systemic therapies for advanced melanoma: Systematic literature review.
Topics: Antineoplastic Agents; Dacarbazine; Health Expenditures; Health Resources; Humans; Indoles; Ipilimumab; Melanoma; Paclitaxel; Sulfonamides; Temozolomide; Vemurafenib | 2018 |
Efficacy of nab-paclitaxel in treating metastatic melanoma.
Topics: Albumins; Animals; Antineoplastic Agents, Phytogenic; Dacarbazine; Humans; Melanoma; Paclitaxel; Temozolomide | 2019 |
Network meta-analysis of therapies for previously untreated advanced BRAF-mutated melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azetidines; Dacarbazine; Humans; Imidazoles; Melanoma; Molecular Targeted Therapy; Mutation; Oximes; Piperidines; Proto-Oncogene Proteins B-raf; Pyridones; Pyrimidinones; Randomized Controlled Trials as Topic; Vemurafenib | 2019 |
Novel targets in the treatment of advanced melanoma: new first-line treatment options.
Topics: Antibodies, Monoclonal; Cancer Vaccines; Clinical Trials as Topic; Dacarbazine; Drugs, Investigational; Humans; Indoles; Ipilimumab; Melanoma; Molecular Targeted Therapy; Randomized Controlled Trials as Topic; Sulfonamides; Vemurafenib | 2013 |
Severe adverse events from the treatment of advanced melanoma: a systematic review of severe side effects associated with ipilimumab, vemurafenib, interferon alfa-2b, dacarbazine and interleukin-2.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Agents; Dacarbazine; Female; Humans; Indoles; Interferon alpha-2; Interferon-alpha; Interleukin-2; Ipilimumab; Male; Melanoma; Middle Aged; Recombinant Proteins; Skin Neoplasms; Sulfonamides; Vemurafenib | 2014 |
Efficacy and side effects of dacarbazine in comparison with temozolomide in the treatment of malignant melanoma: a meta-analysis consisting of 1314 patients.
Topics: Administration, Intravenous; Administration, Oral; Antineoplastic Agents, Alkylating; Dacarbazine; Disease Progression; Humans; Melanoma; Odds Ratio; Randomized Controlled Trials as Topic; Remission Induction; Risk Factors; Skin Neoplasms; Temozolomide; Time Factors; Treatment Outcome | 2013 |
Generation, validation, and application of a P450 homology model.
Topics: Antineoplastic Agents; Biocatalysis; Cytochrome P-450 CYP1A1; Dacarbazine; Humans; Kinetics; Melanoma; Methylation; Models, Molecular; Mutation; Prodrugs; Reproducibility of Results; Structure-Activity Relationship | 2013 |
Efficacy and safety between temozolomide alone and temozolomide-based double therapy for malignant melanoma: a meta-analysis.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Humans; Melanoma; Randomized Controlled Trials as Topic; Temozolomide; Treatment Outcome | 2014 |
Dabrafenib therapy for advanced melanoma.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Dacarbazine; Drug Resistance, Neoplasm; Humans; Imidazoles; Indoles; Melanoma; Mutation; Oximes; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Sulfonamides; Vemurafenib | 2014 |
Immune modulations during chemoimmunotherapy & novel vaccine strategies--in metastatic melanoma and non small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Carcinoma, Non-Small-Cell Lung; Dacarbazine; Epitopes; Humans; Immunotherapy; Indoleamine-Pyrrole 2,3,-Dioxygenase; Inhibitor of Apoptosis Proteins; Interferon alpha-2; Interferon-alpha; Interleukin-2; Lung Neoplasms; Lymphocyte Count; Lymphocytosis; Melanoma; Recombinant Proteins; Survivin; T-Lymphocytes; Temozolomide | 2013 |
Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials.
Topics: Antineoplastic Agents, Alkylating; Biomarkers; Dacarbazine; Disease-Free Survival; Humans; Melanoma; Randomized Controlled Trials as Topic | 2014 |
What is the role of chemotherapy in the treatment of melanoma?
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Carboplatin; Cisplatin; Clinical Trials as Topic; Dacarbazine; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Immunosuppression Therapy; Immunotherapy; Ipilimumab; Melanoma; Paclitaxel; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Temozolomide; Treatment Outcome | 2014 |
Current systemic therapies for melanoma.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Bridged-Ring Compounds; Dacarbazine; Humans; Imidazoles; Indoles; Interferon-alpha; Interleukin-2; Ipilimumab; Melanoma; Oximes; Platinum Compounds; Protein Kinase Inhibitors; Pyridones; Pyrimidinones; Skin Neoplasms; Sulfonamides; Taxoids; Temozolomide; Vemurafenib | 2014 |
The targeting of indoleamine 2,3 dioxygenase -mediated immune escape in cancer.
Topics: Antibodies, Monoclonal; Carcinoma, Non-Small-Cell Lung; Dacarbazine; Humans; Immunologic Factors; Immunotherapy; Indoleamine-Pyrrole 2,3,-Dioxygenase; Interferon alpha-2; Interferon-alpha; Interleukin-2; Ipilimumab; Lung Neoplasms; Male; Melanoma; Prostatic Neoplasms; Recombinant Proteins; Temozolomide; Tissue Extracts | 2015 |
Dacarbazine combined targeted therapy versus dacarbazine alone in patients with malignant melanoma: a meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Humans; Melanoma; Molecular Targeted Therapy; Safety | 2014 |
[Systemic treatment of melanoma brain metastases].
Topics: Abatacept; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Clinical Trials, Phase II as Topic; CTLA-4 Antigen; Dacarbazine; Humans; Imidazoles; Immunoconjugates; Immunotherapy; Indoles; Interleukin-2; Ipilimumab; Melanoma; Molecular Targeted Therapy; Neoplasm Proteins; Oximes; Point Mutation; Protein Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins B-raf; Sulfonamides; Vemurafenib | 2015 |
Ipilimumab for Previously Untreated Unresectable Malignant Melanoma: A Critique of the Evidence.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Dacarbazine; Drug Costs; Humans; Ipilimumab; Melanoma; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Survival Analysis; Technology Assessment, Biomedical | 2015 |
Nanoparticle-mediated drug delivery for treating melanoma.
Topics: Antineoplastic Agents; Dacarbazine; Drug Delivery Systems; Humans; Melanoma; Nanoparticles; Skin Neoplasms | 2015 |
Temozolomide for Treating Malignant Melanoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Humans; Melanoma; Melanoma, Cutaneous Malignant; Quality of Life; Skin Neoplasms; Temozolomide; Treatment Outcome | 2015 |
Chemotherapy for Melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dacarbazine; Humans; Melanoma; Neoplasm Staging; Palliative Care; Taxoids; Temozolomide | 2016 |
The updated Swiss guidelines 2016 for the treatment and follow-up of cutaneous melanoma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Chemotherapy, Adjuvant; Dacarbazine; Dermatologic Surgical Procedures; Humans; Imidazoles; Indoles; Ipilimumab; Lymph Node Excision; Melanoma; Neoplasm Staging; Nivolumab; Oximes; Practice Guidelines as Topic; Radiotherapy, Adjuvant; Sentinel Lymph Node Biopsy; Skin Neoplasms; Sulfonamides; Switzerland; Temozolomide; Vemurafenib | 2016 |
Meta-Analysis of the Safety and Efficacy of Interferon Combined With Dacarbazine Versus Dacarbazine Alone in Cutaneous Malignant Melanoma.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Humans; Immunologic Factors; Interferon-alpha; Melanoma; Melanoma, Cutaneous Malignant; Remission Induction; Skin Neoplasms; Treatment Outcome | 2016 |
Modelling Comparative Efficacy of Drugs with Different Survival Profiles: Ipilimumab, Vemurafenib and Dacarbazine in Advanced Melanoma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Clinical Trials as Topic; Cost-Benefit Analysis; Dacarbazine; Female; Humans; Indoles; Ipilimumab; Male; Melanoma; Middle Aged; Models, Statistical; Sulfonamides; Survival Analysis; Treatment Outcome; Vemurafenib | 2016 |
Relative Efficacy of Granulocyte-Macrophage Colony-Stimulating Factor, Dacarbazine, and Glycoprotein 100 in Metastatic Melanoma: An Indirect Treatment Comparison.
Topics: Antineoplastic Agents; Cancer Vaccines; Dacarbazine; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Melanoma; Neoplasm Metastasis; Treatment Outcome | 2017 |
Is there still a role for cytotoxic chemotherapy after targeted therapy and immunotherapy in metastatic melanoma? A case report and literature review.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Humans; Immunotherapy; Male; Melanoma; Middle Aged; Molecular Targeted Therapy; Mutation; Neoplasm Metastasis; Proto-Oncogene Mas; Proto-Oncogene Proteins B-raf; Treatment Outcome | 2017 |
Systemic therapy for unresectable metastatic melanoma: impact of biochemotherapy on long-term survival.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Databases, Factual; Disease-Free Survival; Female; Humans; Interferon-alpha; Interleukin-2; Male; Melanoma; Neoplasm Metastasis; Retrospective Studies; Skin Neoplasms; Survival Rate; Uveal Neoplasms; Vinblastine | 2008 |
Active specific immunotherapy phase III trials for malignant melanoma: systematic analysis and critical appraisal.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Cancer Vaccines; Clinical Trials, Phase III as Topic; Dacarbazine; Dendritic Cells; Epitopes; Gangliosides; Immunotherapy, Active; Interferons; Melanoma; Vaccinia virus | 2008 |
Tumor immunotherapy in melanoma: strategies for overcoming mechanisms of resistance and escape.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; CD146 Antigen; Dacarbazine; Disease Progression; Drug Resistance, Neoplasm; Humans; Immunotherapy; Interleukin-8; Melanoma; Neoplasm Metastasis; Skin Neoplasms | 2008 |
Multiple intracranial melanoma metastases: case report and review of the literature.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; Fatal Outcome; Female; Humans; Magnetic Resonance Imaging; Melanoma; Middle Aged; Skin Neoplasms; Temozolomide | 2009 |
Biochemotherapy in the treatment of metastatic melanoma in selected patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase III as Topic; Dacarbazine; Disease-Free Survival; Drug Evaluation; Female; Humans; Immunologic Factors; Immunotherapy; Interferon alpha-2; Interferon-alpha; Kaplan-Meier Estimate; Lung Neoplasms; Male; Melanoma; Meta-Analysis as Topic; Middle Aged; Multicenter Studies as Topic; Patient Selection; Randomized Controlled Trials as Topic; Recombinant Proteins; Remission Induction; Retrospective Studies; Soft Tissue Neoplasms; Vinblastine | 2009 |
[Metastatic malignant melanoma of the urinary bladder: a case report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Humans; Interferon-beta; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Nimustine; Skin Neoplasms; Urinary Bladder Neoplasms; Vincristine | 2009 |
Dose-dense temozolomide regimens: antitumor activity, toxicity, and immunomodulatory effects.
Topics: Antineoplastic Agents, Alkylating; Cancer Vaccines; Combined Modality Therapy; Dacarbazine; Drug Administration Schedule; Glioma; Humans; Immunologic Factors; Lymphopenia; Melanoma; Temozolomide; Treatment Outcome | 2010 |
Ipilimumab: unleashing the power of the immune system through CTLA-4 blockade.
Topics: Antibodies, Monoclonal; Antigens, CD; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; CTLA-4 Antigen; Dacarbazine; Drug-Related Side Effects and Adverse Reactions; Humans; Ipilimumab; Melanoma; Skin Neoplasms | 2010 |
Brain metastasis in melanoma: clinical activity of CTLA-4 antibody therapy.
Topics: Antibodies, Monoclonal; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; CTLA-4 Antigen; Dacarbazine; Humans; Ipilimumab; Italy; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Survival Analysis; Temozolomide; United States | 2010 |
Does complete response to systemic therapy in patients with stage IV melanoma translate into long-term survival?
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Dacarbazine; Female; Humans; Interferon-alpha; Interleukin-2; Logistic Models; Male; Melanoma; Neoplasm Metastasis; Paclitaxel; Proportional Hazards Models; Remission Induction; Sex Factors; Skin Neoplasms; Treatment Outcome; Vinblastine | 2011 |
Engineering nanomedicines for improved melanoma therapy: progress and promises.
Topics: Antineoplastic Agents; Carmustine; Cisplatin; Dacarbazine; Drug Delivery Systems; Humans; Melanoma; Nanomedicine; Tamoxifen | 2010 |
Targeted therapies in metastatic melanoma: toward a clinical breakthrough?
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Dacarbazine; Humans; Ipilimumab; Melanoma | 2010 |
A novel approach to overcome temozolomide resistance in glioma and melanoma: Inactivation of MGMT by gene therapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Gene Silencing; Genetic Therapy; Glioma; Humans; Melanoma; Skin Neoplasms; Temozolomide; Tumor Suppressor Proteins | 2011 |
[Anti-CTLA-4 monoclonal antibody: a major step in the treatment of metastatic melanoma].
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, Neoplasm; Antineoplastic Agents, Alkylating; Autoimmune Diseases; Cancer Vaccines; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Combined Modality Therapy; CTLA-4 Antigen; Dacarbazine; Digestive System Diseases; Drug Screening Assays, Antitumor; Humans; Immunotherapy; Immunotherapy, Active; Ipilimumab; Melanoma; Melanoma, Experimental; Mice; Monitoring, Immunologic; Nervous System Diseases; Vaccines, Subunit | 2011 |
Ipilimumab: showing survival benefit in metastatic melanoma.
Topics: Antibodies, Monoclonal; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; CTLA-4 Antigen; Dacarbazine; Humans; Ipilimumab; Male; Melanoma; Prostate-Specific Antigen; Prostatic Neoplasms; Treatment Outcome | 2011 |
[Dacarbazine, a chemotherapeutic against metastatic melanoma and a reference drug for new treatment modalities].
Topics: Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Dacarbazine; DNA Damage; Humans; Immunotherapy; Indoles; Ipilimumab; Melanoma; Randomized Controlled Trials as Topic; Sulfonamides; Temozolomide; Vemurafenib | 2011 |
Upcoming strategies for the treatment of metastatic melanoma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Dacarbazine; Humans; Indoles; Ipilimumab; MAP Kinase Kinase Kinases; Melanoma; Neoplasm Metastasis; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-kit; Skin Neoplasms; Sulfonamides; Vemurafenib | 2012 |
Temozolomide and unusual indications: review of literature.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Humans; Lung Neoplasms; Melanoma; Neoplasms; Neuroendocrine Tumors; Pituitary Neoplasms; Temozolomide | 2013 |
[Therapeutic strategies and systemic treatment of brain melanoma metastases].
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Humans; Immunotherapy; Indoles; Ipilimumab; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Palliative Care; Radiosurgery; Radiotherapy; Skin Neoplasms; Sulfonamides; Temozolomide; Vemurafenib | 2013 |
Thymosin α1 in melanoma: from the clinical trial setting to the daily practice and beyond.
Topics: Antineoplastic Agents, Alkylating; Clinical Trials, Phase II as Topic; Dacarbazine; Humans; Immunologic Factors; Immunotherapy; Melanoma; Randomized Controlled Trials as Topic; Thymosin | 2012 |
[Ctla-4 blockade: a new hope for the immunotherapy of malignant melanoma].
Topics: Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Autoimmunity; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; CTLA-4 Antigen; Dacarbazine; Drug Approval; Drug Monitoring; Humans; Immunotherapy; Ipilimumab; Melanoma; Pharmacovigilance; Proportional Hazards Models; Skin Neoplasms; T-Lymphocytes, Cytotoxic; Treatment Outcome | 2012 |
Temozolomide: a novel oral alkylating agent.
Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Administration Schedule; Glioma; Melanoma; Temozolomide | 2001 |
Systemic chemotherapy for the treatment of metastatic melanoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carmustine; Cisplatin; Clinical Trials as Topic; Dacarbazine; Humans; Melanoma; Nitrosourea Compounds; Paclitaxel; Tamoxifen; Taxoids; Temozolomide | 2002 |
Metastatic melanoma: chemotherapy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carboplatin; Cisplatin; Clinical Trials as Topic; Cytokines; Dacarbazine; Genetic Therapy; Humans; Immunotherapy; Interferon-alpha; Interleukin-2; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Paclitaxel; Tamoxifen; Taxoids; Thalidomide | 2002 |
[Treatment of melanoma].
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cell- and Tissue-Based Therapy; Cells, Cultured; Chemotherapy, Adjuvant; Clinical Trials as Topic; Dacarbazine; Drug Therapy, Combination; Forecasting; Humans; Immunization, Passive; Immunotherapy; Immunotherapy, Active; Interferon-alpha; Interleukin-2; Lymph Node Excision; Lymphatic Metastasis; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms; T-Lymphocytes, Cytotoxic; Temozolomide; Time Factors | 2003 |
[Malignant melanoma of the alimentary tract].
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Diagnosis, Differential; Esophageal Neoplasms; Female; Humans; Male; Melanoma; Nimustine; Rectal Neoplasms; Vincristine | 2003 |
Systemic chemotherapy in the treatment of malignant melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Dacarbazine; Humans; Lomustine; Melanoma; Neoplasm Metastasis; Skin Neoplasms; Tamoxifen; Treatment Outcome; Vincristine | 2003 |
[Therapy of malignant melanoma at the stage of distant metastasis].
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dacarbazine; Disease Progression; Humans; Immunotherapy; Interferon-alpha; Interleukin-2; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Melanoma; Neoplasm Metastasis; Nitrosourea Compounds; Organophosphorus Compounds; Palliative Care; Prognosis; Radiotherapy Dosage; Randomized Controlled Trials as Topic; Skin Neoplasms; Temozolomide; Time Factors; Tomography, X-Ray Computed; Vindesine | 2004 |
Management of brain metastases in patients with melanoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Central Nervous System; Chemotherapy, Adjuvant; Dacarbazine; Humans; Immunotherapy; Melanoma; Radiosurgery; Radiotherapy, Adjuvant; Radiotherapy, Computer-Assisted; Survival Rate; Temozolomide | 2004 |
Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years?
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Drug Evaluation; Hematologic Diseases; Humans; Melanoma | 2004 |
The role of taxanes in the treatment of metastatic melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials as Topic; Dacarbazine; Humans; Melanoma; Skin Neoplasms; Tamoxifen; Taxoids; Temozolomide; Treatment Outcome | 2004 |
[Disseminated melanoma treatment].
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Humans; Lymph Nodes; Lymphatic Metastasis; Melanoma; Prognosis; Skin Neoplasms | 2004 |
Management of metastatic cutaneous melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Dacarbazine; Humans; Immunotherapy; Interleukin-2; Melanoma; Multicenter Studies as Topic; Neoplasm Staging; Prognosis; Randomized Controlled Trials as Topic; Skin Neoplasms; Survival Analysis; Temozolomide; Thionucleotides; Treatment Outcome | 2004 |
Apoptosis, Bcl-2 antisense, and cancer therapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dacarbazine; Genes, bcl-2; Humans; Melanoma; Neoplasms; Oligonucleotides, Antisense; Proto-Oncogene Mas; Proto-Oncogene Proteins c-bcl-2; Randomized Controlled Trials as Topic; Thionucleotides; Transplantation, Heterologous | 2004 |
[Chemotherapy for brain metastases].
Topics: Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Dacarbazine; Dementia, Vascular; Humans; Lung Neoplasms; Melanoma; Metalloporphyrins; Prednisolone; Radiation-Sensitizing Agents; Radiotherapy, Adjuvant; Temozolomide | 2005 |
Temozolomide in advanced malignant melanoma with small brain metastases: can we withhold cranial irradiation?
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cranial Irradiation; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Randomized Controlled Trials as Topic; Survival Analysis; Temozolomide; Treatment Outcome | 2007 |
Temozolomide for the treatment of metastatic melanoma: a systematic review.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dacarbazine; Humans; Melanoma; Quality of Life; Randomized Controlled Trials as Topic; Survival Rate; Temozolomide; Treatment Outcome | 2007 |
Treatments for metastatic melanoma: synthesis of evidence from randomized trials.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Humans; Melanoma; Randomized Controlled Trials as Topic; Skin Neoplasms | 2007 |
Systemic therapy of disseminated malignant melanoma: an evidence-based overview of the state-of-the-art in daily routine.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Dacarbazine; Evidence-Based Medicine; Humans; Immunotherapy; Interferon-alpha; Interleukin-2; Melanoma; Neoplasm Metastasis; Prognosis | 2007 |
Focus on FOCIS: interleukin 2 treatment associated autoimmunity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autoimmunity; CD4-Positive T-Lymphocytes; Cell Line, Tumor; Dacarbazine; Humans; Immunotherapy; Interleukin-2; Male; Melanoma; Middle Aged; Temozolomide; Vitiligo | 2008 |
Immunotherapy of malignant melanoma.
Topics: Antigens, Neoplasm; BCG Vaccine; Cholera Vaccines; Clinical Trials as Topic; Dacarbazine; Dinitrochlorobenzene; Double-Blind Method; Humans; Immunotherapy; Interferons; Levamisole; Melanoma; Random Allocation; Skin Neoplasms; Skin Tests; Transfer Factor | 1982 |
Current status and future prospects for adjuvant therapy of melanoma.
Topics: Antigens, Neoplasm; Antigens, Viral, Tumor; Antineoplastic Combined Chemotherapy Protocols; Bacterial Vaccines; Combined Modality Therapy; Dacarbazine; Humans; Immunotherapy; Interferons; Interleukin-2; Melanoma; Skin Neoplasms; T-Lymphocytes, Regulatory | 1984 |
The systemic chemotherapy of hepatic metastases.
Topics: Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Colonic Neoplasms; Dacarbazine; Drug Therapy, Combination; Fluorouracil; Humans; Liver Neoplasms; Lung Neoplasms; Melanoma; Pancreatic Neoplasms; Rectal Neoplasms; Semustine; Stomach Neoplasms | 1983 |
Malignant melanoma of the genitourinary tract.
Topics: Adrenal Gland Neoplasms; Adult; Aged; BCG Vaccine; Carmustine; Combined Modality Therapy; Dacarbazine; Female; Humans; Kidney Neoplasms; Kidney Transplantation; Male; Melanoma; Middle Aged; Penile Neoplasms; Prostatic Neoplasms; Radiotherapy Dosage; Testicular Neoplasms; Ureteral Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Urogenital Neoplasms | 1984 |
[Chemotherapy of malignant melanoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chemotherapy, Adjuvant; Cisplatin; Dacarbazine; Humans; Immunotherapy, Adoptive; Melanoma; Neoplasm Metastasis; Nimustine; Peplomycin; Vincristine | 1995 |
Combination of chemotherapy with interleukin-2 and interferon-alfa for the treatment of advanced melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Dacarbazine; Drug Administration Schedule; Humans; Interferon-alpha; Interleukin-2; Melanoma; Vinblastine | 1994 |
Role of recombinant interleukin-2 in combination with interferon-alfa and chemotherapy in the treatment of advanced melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials as Topic; Dacarbazine; Humans; Interferon Type I; Interleukin-2; Melanoma; Recombinant Proteins | 1993 |
Tamoxifen: is it useful in the treatment of patients with metastatic melanoma?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Drug Synergism; Humans; Melanoma; Tamoxifen; Treatment Outcome | 1994 |
Systemic treatments for advanced cutaneous melanoma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Dacarbazine; Humans; Immunotherapy, Active; Interferon-alpha; Interleukin-2; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Remission Induction; Skin Neoplasms; Survival Rate; Temozolomide | 1995 |
Xenograft model systems for human melanoma.
Topics: Animals; Cell Transplantation; Dacarbazine; Humans; Immunohistochemistry; Melanoma; Mice; Mice, SCID; Neoplasm Metastasis; Neoplasms, Experimental; Tumor Cells, Cultured | 1996 |
Medical treatment of metastatic melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cytokines; Dacarbazine; Humans; Melanoma; Skin Neoplasms; Survival Analysis; Treatment Outcome | 1996 |
[Treatment of malignant melanoma: recent advances and perspectives].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Dacarbazine; Drug Administration Schedule; Humans; Immunotherapy; Interferon-alpha; Interleukin-2; Melanoma; Nimustine; Skin Neoplasms; Tamoxifen; Vincristine | 1997 |
Durable complete responses in metastatic melanoma treated with interleukin-2 in combination with interferon alpha and chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Dacarbazine; Humans; Interferon-alpha; Interleukin-2; Melanoma; Neoplasm Metastasis; Skin Neoplasms; Vincristine | 1997 |
Recombinant interleukin-2-based treatments for advanced melanoma: the experience of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Dacarbazine; Humans; Immunotherapy; Interferon-alpha; Interleukin-2; Melanoma; Recombinant Proteins; Survival Rate | 1997 |
The use of interferon-alpha in the treatment of cutaneous melanoma: a review.
Topics: Dacarbazine; Humans; Immunotherapy; Interferon-alpha; Interferon-gamma; Interleukin-2; Melanoma; Randomized Controlled Trials as Topic; Skin Neoplasms | 1998 |
Current treatment options for malignant melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cancer Vaccines; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Genetic Therapy; Humans; Interleukin-2; Melanoma; Neoplasm Metastasis | 1998 |
The Dartmouth Regimen: gone or going strong?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Clinical Trials as Topic; Dacarbazine; Humans; Melanoma; Tamoxifen | 1998 |
Acute tumor lysis syndrome associated with concurrent biochemotherapy of metastatic melanoma: a case report and review of the literature.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransferases; Calcium; Cisplatin; Creatinine; Dacarbazine; Fatal Outcome; Humans; Interferon-alpha; Interleukin-2; L-Lactate Dehydrogenase; Male; Melanoma; Middle Aged; Phosphorus; Skin Neoplasms; Tumor Lysis Syndrome; Uric Acid; Vinblastine | 1999 |
Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma.
Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Biological Availability; Brain Neoplasms; Dacarbazine; Humans; Melanoma; Skin Neoplasms; Temozolomide | 2000 |
Temozolomide and treatment of malignant glioma.
Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Glioblastoma; Glioma; Humans; Incidence; Melanoma; Temozolomide | 2000 |
Systemic chemotherapy.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Humans; Immunotherapy; Melanoma; Neoadjuvant Therapy; Palliative Care; Remission Induction; Skin Neoplasms; Survival Rate | 2000 |
[Surgical and adjuvant drug therapy in head and neck cutaneous melanoma].
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Dacarbazine; Head and Neck Neoplasms; Humans; Interferons; Lymph Node Excision; Melanoma; Sentinel Lymph Node Biopsy; Skin Neoplasms; Tumor Cells, Cultured | 2000 |
Melanoma erysipeloides: successful treatment by chemoimmunotherapy.
Topics: Adult; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Dacarbazine; Female; Humans; Immunotherapy; Melanoma; Skin Neoplasms | 2000 |
Management of malignant melanoma.
Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Case-Control Studies; Dacarbazine; Diagnosis, Differential; Female; Follow-Up Studies; Humans; Life Expectancy; Lymph Node Excision; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Practice Guidelines as Topic; Pregnancy; Pregnancy Complications, Neoplastic; Prognosis; Risk Factors; Skin; Skin Neoplasms; Sunscreening Agents; Survival Analysis; Time Factors | 2000 |
Biochemotherapy for melanoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dacarbazine; Drug Administration Schedule; Humans; Immunotherapy; Interferons; Interleukin-2; Melanoma; Mice; Tamoxifen | 2000 |
New approaches in the treatment of metastatic melanoma: thalidomide and temozolomide.
Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Temozolomide; Thalidomide | 2000 |
Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trials.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Databases, Factual; Humans; Immunotherapy; Interferons; Melanoma; Odds Ratio; Skin Neoplasms; Time Factors | 2001 |
[Adjuvant therapy of malignant melanoma].
Topics: BCG Vaccine; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Dacarbazine; Humans; Interferon alpha-2; Interferon-alpha; Melanoma; Neoplasm Staging; Recombinant Proteins; Skin Neoplasms | 2001 |
[Treatment of metastasized malignant melanoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Dacarbazine; Humans; Immunotherapy; Interferon-alpha; Interleukin-2; Killer Cells, Lymphokine-Activated; Melanoma; Skin Neoplasms; Survival Rate | 2001 |
[Dacarbazine].
Topics: Animals; Antineoplastic Agents, Alkylating; Dacarbazine; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Interactions; France; Humans; Melanoma; Reproduction | 2001 |
Melanoma-associated retinopathy: does autoimmunity prolong survival?
Topics: Adult; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Autoantibodies; Autoimmunity; Dacarbazine; Female; Humans; Immunosuppression Therapy; Interneurons; Lomustine; Melanoma; Membrane Proteins; Paraneoplastic Syndromes; Proteins; Retina; Retinal Diseases; Skin Neoplasms; Survival Rate | 2001 |
Adjuvant therapy of malignant melanoma: is there a choice?
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Dacarbazine; Follow-Up Studies; Humans; Interferons; Lymphatic Metastasis; Melanoma; Multicenter Studies as Topic; Neoplasm Metastasis; Neoplasm Staging; Premedication; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome; Vindesine | 2001 |
Primary malignant melanoma of the pharynx.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Combined Modality Therapy; Dacarbazine; Female; Humans; Immunotherapy, Active; Interferon-alpha; Interleukin-2; Lung Neoplasms; Magnetic Resonance Imaging; Melanoma; Pharyngeal Neoplasms | 2001 |
[Possibilities of immunotherapy in malignant melanoma].
Topics: Antigen-Antibody Reactions; BCG Vaccine; Dacarbazine; Humans; Immunization; Immunotherapy; Melanoma | 1978 |
[Chemotherapy of malignant melanomas].
Topics: Adjuvants, Immunologic; Antineoplastic Agents; BCG Vaccine; Dacarbazine; Drug Therapy, Combination; Female; Humans; Immunotherapy; Lymphatic Metastasis; Male; Melanoma; Mycobacterium bovis; Neoplasm Metastasis; Nitrosourea Compounds; Prognosis; Vincristine | 1978 |
[Pharmacology of DTIC (author's transl)].
Topics: Animals; Chemical Phenomena; Chemistry; Dacarbazine; Hodgkin Disease; Humans; Melanoma; Sarcoma; Soft Tissue Neoplasms; Triazenes | 1978 |
[Dacarbacine (DTIC) in the therapy of a malignant disease. A review (author's transl)].
Topics: Antineoplastic Agents; Dacarbazine; Drug Evaluation; Drug Therapy, Combination; Gastrointestinal Neoplasms; Hodgkin Disease; Humans; Melanoma; Sarcoma; Soft Tissue Neoplasms; Triazenes | 1978 |
[DTIC in malignant melanoma: a perspective (author's transl)].
Topics: Animals; Antineoplastic Agents; Dacarbazine; Drug Evaluation; Drug Evaluation, Preclinical; Drug Therapy, Combination; Humans; Immunotherapy; Melanoma; Mice; Triazenes | 1978 |
The role of immunotherapy in the management of patients with malignant melanoma.
Topics: Bacterial Vaccines; BCG Vaccine; Corynebacterium; Dacarbazine; Dinitrochlorobenzene; Drug Therapy, Combination; Humans; Immunotherapy; Melanoma; Skin Neoplasms | 1979 |
Chemotherapy of malignant melanoma.
Topics: Antineoplastic Agents; BCG Vaccine; Dacarbazine; Drug Therapy, Combination; Humans; Lomustine; Melanoma; Nitrosourea Compounds; Skin Neoplasms | 1979 |
Combined modality therapy of malignant melanoma.
Topics: Antineoplastic Agents; BCG Vaccine; Dacarbazine; Drug Therapy, Combination; Humans; Melanoma; Skin Neoplasms | 1979 |
DTIC (NSC-45388) in malignant melanoma: a perspective.
Topics: Animals; Antineoplastic Agents; Carmustine; Clinical Trials as Topic; Dacarbazine; Drug Evaluation; Drug Therapy, Combination; Humans; Lomustine; Melanoma; Mice; Neoplasm Metastasis; Nitrosourea Compounds; Remission, Spontaneous; Triazenes | 1976 |
[Treatment of disseminated malignant melanoma. Results are promising, but toxicity is high].
Topics: Antibodies, Monoclonal; Bone Marrow Transplantation; Cisplatin; Combined Modality Therapy; Dacarbazine; Drug Therapy, Combination; Humans; Interferon-alpha; Melanoma; Nitrosourea Compounds | 1992 |
[Contribution of a new nitrosourea compound: fotemustine].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Dacarbazine; Drug Therapy, Combination; Humans; Liver Neoplasms; Lung Neoplasms; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds | 1992 |
Combined treatment of metastatic melanoma with interferons and cytotoxic drugs.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Dacarbazine; Humans; Interferons; Melanoma; Vinblastine; Vindesine | 1992 |
[Treatment of metastatic melanoma with interleukin-2].
Topics: Cisplatin; Cyclophosphamide; Dacarbazine; Drug Therapy, Combination; Humans; Immunotherapy, Adoptive; Interferons; Interleukin-2; Killer Cells, Lymphokine-Activated; Lymphocytes, Tumor-Infiltrating; Melanoma | 1992 |
Fotemustine: an overview of its clinical activity in disseminated malignant melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Humans; Immunologic Factors; Interferon alpha-2; Interferon-alpha; Lung Neoplasms; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Recombinant Proteins; Remission Induction; Vindesine | 1992 |
Chemotherapy for advanced malignant melanoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cisplatin; Combined Modality Therapy; Dacarbazine; Drug Evaluation; Humans; Immunologic Factors; Incidence; Interferon-alpha; Melanoma; Pilot Projects; Skin Neoplasms; Tamoxifen; Transplantation, Autologous | 1992 |
Role of interferons in the therapy of melanoma.
Topics: Clinical Trials as Topic; Dacarbazine; Dose-Response Relationship, Drug; Drug Evaluation; Drug Therapy, Combination; Humans; Interferon alpha-2; Interferon-alpha; Interferon-gamma; Interferons; Melanoma; Recombinant Proteins | 1990 |
Clinical evaluation of interferons in malignant melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Dacarbazine; Dose-Response Relationship, Drug; Forecasting; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Melanoma; Recombinant Proteins | 1990 |
[Brain metastases of malignant melanomas].
Topics: Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Carmustine; Dacarbazine; Humans; Interleukin-2; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Semustine | 1991 |
[Malignant melanoma of the vulva and vagina (a report of 4 cases and review of the literature)].
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Dacarbazine; Female; Humans; Hysterectomy; Lymph Node Excision; Melanoma; Middle Aged; Postoperative Care; Vaginal Neoplasms; Vulva; Vulvar Neoplasms | 1990 |
Interleukin-2. The experience of the Rotterdam Cancer Institute; Daniel den Hoed Kliniek.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Drug Evaluation; Humans; Immunotherapy; Interferon Type I; Interleukin-2; Kidney Neoplasms; Killer Cells, Lymphokine-Activated; Melanoma; Meta-Analysis as Topic; Recombinant Proteins | 1990 |
Therapy for cutaneous melanoma: an update.
Topics: Adult; Biopsy; Chemotherapy, Cancer, Regional Perfusion; Combined Modality Therapy; Dacarbazine; Female; Humans; Immunotherapy; Lymph Node Excision; Melanoma; Neoplasm Staging; Pregnancy; Prognosis; Skin Neoplasms | 1990 |
[Diagnosis and prognosis of malignant melanoma].
Topics: Alkaline Phosphatase; Dacarbazine; Female; Humans; L-Lactate Dehydrogenase; Lymphatic Metastasis; Male; Melanoma; Neoplasm Metastasis; Neoplasm Staging; Palliative Care; Palpation; Prognosis; Radionuclide Imaging; Skin; Skin Neoplasms | 1985 |
[Chemotherapy of malignant melanoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Humans; Interferons; Interleukin-2; Lomustine; Melanoma; Prognosis; Skin Neoplasms; Tamoxifen | 1988 |
[An autopsy case of neurocutaneous melanosis associated with intracerebral malignant melanoma].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Humans; Male; Melanoma; Nevus, Pigmented; Nimustine; Nitrosourea Compounds; Skin Neoplasms; Vincristine | 1987 |
Systemic therapy of malignant melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Dacarbazine; Humans; Immunotherapy; Melanoma; Neoplasm Staging; Skin Neoplasms | 1986 |
416 trial(s) available for dacarbazine and Melanoma
| Article | Year |
|---|---|
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cytokine Release Syndrome; Dacarbazine; Exanthema; Female; Humans; Ipilimumab; Male; Melanoma; Middle Aged; Recombinant Fusion Proteins; Survival Analysis; Uveal Neoplasms | 2021 |
Theragnostic significance of tumor-infiltrating lymphocytes and Ki67 in BRAFV600-mutant metastatic melanoma (BRIM-3 trial).
Topics: Dacarbazine; Humans; Ki-67 Antigen; Lymphocytes, Tumor-Infiltrating; Melanoma; Neoplasms, Second Primary; Prognosis; Retrospective Studies; Vemurafenib | 2022 |
A phase II study of the L19IL2 immunocytokine in combination with dacarbazine in advanced metastatic melanoma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Staging; Recombinant Fusion Proteins; Skin Neoplasms; Survival Analysis; Young Adult | 2019 |
Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dacarbazine; Disease Progression; Female; Follow-Up Studies; Humans; Imidazoles; Male; Melanoma; Middle Aged; Oximes; Patient Selection; Progression-Free Survival; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Time Factors; Young Adult | 2020 |
A phase II study of ipilimumab plus temozolomide in patients with metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Agents, Immunological; Dacarbazine; Female; Humans; Ipilimumab; Male; Melanoma; Middle Aged; Skin Neoplasms; Temozolomide | 2017 |
Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Dacarbazine; Enzyme Inhibitors; Female; Humans; Indoles; Kaplan-Meier Estimate; Male; Melanoma; Middle Aged; Mutation; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Sulfonamides; Treatment Outcome; Vemurafenib; Young Adult | 2017 |
High frequency of brain metastases after adjuvant therapy for high-risk melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Dacarbazine; Disease Progression; Disease-Free Survival; Female; Follow-Up Studies; Humans; Interferon alpha-2; Interferon-alpha; Lymph Nodes; Lymphatic Metastasis; Male; Melanoma; Neoplasm Staging; Recombinant Proteins; Retrospective Studies; Skin Neoplasms; Skin Ulcer; Survival Rate; Vinblastine | 2017 |
Cisplatin, dacarbazine and vinblastine as first line chemotherapy for liver metastatic uveal melanoma in the era of immunotherapy: a single institution phase II study.
Topics: Cisplatin; Dacarbazine; Disease-Free Survival; Female; Humans; Immunotherapy; Male; Melanoma; Middle Aged; Uveal Neoplasms; Vinblastine | 2017 |
The cost-effectiveness of nivolumab monotherapy for the treatment of advanced melanoma patients in England.
Topics: Age Factors; Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Dacarbazine; Disease Progression; Disease-Free Survival; Female; Health Expenditures; Health Resources; Humans; Imidazoles; Ipilimumab; Kaplan-Meier Estimate; Male; Markov Chains; Melanoma; Middle Aged; Models, Economic; Nivolumab; Oximes; Proto-Oncogene Proteins B-raf; Quality-Adjusted Life Years; Sex Factors; Skin Neoplasms; Vemurafenib | 2018 |
Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Dacarbazine; Double-Blind Method; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Placebos; Progression-Free Survival; Uveal Neoplasms | 2018 |
Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunological; Dacarbazine; Disease Progression; Double-Blind Method; Female; Humans; Male; Melanoma; Middle Aged; Nivolumab; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Time Factors; Treatment Outcome; Young Adult | 2019 |
A prospective trial of adjuvant therapy for high-risk uveal melanoma: assessing 5-year survival outcomes.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Chemotherapy, Adjuvant; Dacarbazine; Disease-Free Survival; Female; Humans; Infusions, Intravenous; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Male; Melanoma; Middle Aged; Prospective Studies; Survival Rate; Uveal Neoplasms; Young Adult | 2020 |
Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-α in advanced malignant melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Humans; Interferon alpha-2; Interferon-alpha; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Recombinant Proteins; Survival Analysis | 2013 |
A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease-Free Survival; Drug Synergism; Female; Humans; Indoles; Male; Melanoma; Middle Aged; Poly(ADP-ribose) Polymerase Inhibitors; Skin Neoplasms; Survival Rate; Temozolomide; Treatment Outcome; Young Adult | 2013 |
A phase II, randomized, double-blind, placebo-controlled multicenter trial of Endostar in patients with metastatic melanoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dacarbazine; Disease-Free Survival; Double-Blind Method; Endostatins; Female; Humans; Kaplan-Meier Estimate; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Young Adult | 2013 |
Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Brazil; Dacarbazine; Disease-Free Survival; DNA Mutational Analysis; Double-Blind Method; Drug Administration Schedule; Europe; Female; Genetic Predisposition to Disease; Humans; Kaplan-Meier Estimate; Logistic Models; Male; Melanoma; Middle Aged; Mutation; Neoplasms, Unknown Primary; Phenotype; Proportional Hazards Models; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Time Factors; Treatment Outcome; United States | 2013 |
Q-TWiST analysis comparing ipilimumab/dacarbazine vs placebo/dacarbazine for patients with stage III/IV melanoma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Dacarbazine; Disease Progression; Disease-Free Survival; Double-Blind Method; Humans; Ipilimumab; Melanoma; Neoplasm Staging; Survival Analysis | 2013 |
Phase II randomized trial comparing high-dose IFN-α2b with temozolomide plus cisplatin as systemic adjuvant therapy for resected mucosal melanoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Dacarbazine; Female; Genotype; Humans; Interferon-alpha; Male; Melanoma; Middle Aged; Mucous Membrane; Mutation; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Temozolomide; Treatment Outcome; Young Adult | 2013 |
Phase I-II study of plitidepsin and dacarbazine as first-line therapy for advanced melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Depsipeptides; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Melanoma; Middle Aged; Peptides, Cyclic; Treatment Outcome; Young Adult | 2013 |
Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC study.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease-Free Survival; Health Status; Humans; MAP Kinase Kinase Kinases; Melanoma; Middle Aged; Mutation; Paclitaxel; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyridones; Pyrimidinones; Quality of Life; Surveys and Questionnaires | 2014 |
Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study.
Topics: Adult; Aged; Dacarbazine; Disease-Free Survival; Female; Follow-Up Studies; Humans; Indoles; Male; Melanoma; Middle Aged; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Sulfonamides; Vemurafenib | 2014 |
Dacarbazine with or without oblimersen (a Bcl-2 antisense oligonucleotide) in chemotherapy-naive patients with advanced melanoma and low-normal serum lactate dehydrogenase: 'The AGENDA trial'.
Topics: Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Female; Gene Expression Regulation, Neoplastic; Humans; Infusions, Intravenous; Male; Melanoma; Middle Aged; Oligonucleotides, Antisense; Prospective Studies; Proto-Oncogene Proteins c-bcl-2; Skin Neoplasms; Thionucleotides; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
Phase I trial of biochemotherapy with cisplatin, temozolomide, and dose escalation of nab-paclitaxel combined with interleukin-2 and interferon-α in patients with metastatic melanoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cohort Studies; Dacarbazine; Dose-Response Relationship, Drug; Female; Humans; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Skin Neoplasms; Temozolomide; Young Adult | 2014 |
Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine.
Topics: Antineoplastic Agents; Dacarbazine; Humans; Imidazoles; Melanoma; Neoplasm Metastasis; Oximes; Quality of Life | 2014 |
A phase 2 randomised study of ramucirumab (IMC-1121B) with or without dacarbazine in patients with metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Ramucirumab; Skin Neoplasms; Survival Analysis; Young Adult | 2014 |
Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Benzimidazoles; Dacarbazine; Disease Progression; Female; Humans; Male; Melanoma; Middle Aged; Survival Analysis; Temozolomide; Treatment Outcome; Uveal Neoplasms | 2014 |
Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Dacarbazine; Dose-Response Relationship, Drug; Female; Humans; Hydroxychloroquine; Male; Melanoma; Middle Aged; Neoplasm Staging; Neoplasms; Temozolomide; Treatment Outcome | 2014 |
Ocular toxicity in BRAF mutant cutaneous melanoma patients treated with vemurafenib.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Conjunctivitis; Dacarbazine; Dry Eye Syndromes; Eye Diseases; Female; Humans; Indoles; Male; Melanoma; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Retrospective Studies; Skin Neoplasms; Sulfonamides; Uveitis; Vemurafenib; Young Adult | 2014 |
Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide).
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Dacarbazine; Decitabine; DNA Modification Methylases; Dose-Response Relationship, Drug; Drug Monitoring; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Epigenomics; Eye Neoplasms; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Panobinostat; Skin Neoplasms; Temozolomide; Treatment Outcome | 2014 |
Quality of life after isolated limb infusion for in-transit melanoma of the extremity.
Topics: Aged; Antineoplastic Agents, Alkylating; Chemotherapy, Cancer, Regional Perfusion; Dacarbazine; Extremities; Female; Follow-Up Studies; Humans; Infusions, Intra-Arterial; Male; Maximum Tolerated Dose; Melanoma; Neoplasm Staging; Prognosis; Quality of Life; Temozolomide | 2015 |
A multicenter phase I dose escalation trial to evaluate safety and tolerability of intra-arterial temozolomide for patients with advanced extremity melanoma using normothermic isolated limb infusion.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Cohort Studies; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Extremities; Female; Follow-Up Studies; Humans; Infusions, Intra-Arterial; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Neoplasm Staging; Prognosis; Promoter Regions, Genetic; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Skin Neoplasms; Temozolomide; Tissue Distribution; Tumor Suppressor Proteins | 2015 |
Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Ch
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Cisplatin; Dacarbazine; Female; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukin-2; Male; Melanoma; Middle Aged; Recombinant Proteins; Vinblastine | 2014 |
Liver resection in multimodal concepts improves survival of metastatic melanoma: a single-centre case-matched control study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Cisplatin; Combined Modality Therapy; Dacarbazine; Female; Follow-Up Studies; Hepatectomy; Humans; Immunotherapy; Interferons; Interleukin-2; Liver Neoplasms; Male; Melanoma; Middle Aged; Neoplasm Staging; Prognosis; Retrospective Studies; Skin Neoplasms; Survival Rate | 2014 |
Efficacy and side effects of radiation therapy in comparison with radiation therapy and temozolomide in the treatment of measurable canine malignant melanoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Dacarbazine; Dog Diseases; Dogs; Melanoma; Radiotherapy; Temozolomide | 2016 |
Nivolumab in previously untreated melanoma without BRAF mutation.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents; Dacarbazine; Disease-Free Survival; Double-Blind Method; Female; Humans; Male; Melanoma; Middle Aged; Nivolumab; Programmed Cell Death 1 Receptor; Proto-Oncogene Proteins B-raf; Survival Rate; Young Adult | 2015 |
Results of a Phase II Study to Evaluate the Efficacy of Docetaxel and Carboplatin in Metastatic Malignant Melanoma Patients Who Failed First-Line Therapy Containing Dacarbazine.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dacarbazine; Docetaxel; Female; Humans; Male; Melanoma; Middle Aged; Patient Compliance; Taxoids; Young Adult | 2015 |
Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Diarrhea; Drug Administration Schedule; Exanthema; Female; Humans; Ipilimumab; Kaplan-Meier Estimate; Male; Melanoma; Middle Aged; Pruritus; Survival Analysis; Survival Rate; Time Factors; Treatment Outcome; Vitiligo | 2015 |
Dacarbazine in combination with bevacizumab for the treatment of unresectable/metastatic melanoma: a phase II study.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Dacarbazine; Drug Monitoring; Female; Humans; Infusions, Intravenous; Intention to Treat Analysis; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Skin; Skin Neoplasms; Survival Analysis; Tumor Burden | 2015 |
Intratumoral injection of IFN-alpha dendritic cells after dacarbazine activates anti-tumor immunity: results from a phase I trial in advanced melanoma.
Topics: Adult; Aged; Antigens, Neoplasm; Cancer Vaccines; Combined Modality Therapy; Dacarbazine; Dendritic Cells; Drug Therapy; Female; Gene Expression Profiling; gp100 Melanoma Antigen; Humans; Immunotherapy; Injections, Intralesional; Interferon-alpha; Leukocytes, Mononuclear; Male; Melanoma; Membrane Proteins; Microscopy, Confocal; Middle Aged; Monocytes; Monophenol Monooxygenase; Vitiligo | 2015 |
Adjusting for the Confounding Effects of Treatment Switching-The BREAK-3 Trial: Dabrafenib Versus Dacarbazine.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Dacarbazine; Disease-Free Survival; Female; Humans; Imidazoles; Kaplan-Meier Estimate; Male; Melanoma; Middle Aged; Mutation; Oximes; Proto-Oncogene Proteins B-raf; Treatment Outcome | 2015 |
Study design and rationale for a randomised, placebo-controlled, double-blind study to assess the efficacy of selumetinib (AZD6244; ARRY-142886) in combination with dacarbazine in patients with metastatic uveal melanoma (SUMIT).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Dacarbazine; Disease-Free Survival; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Uveal Neoplasms | 2015 |
Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Benzimidazoles; Brain Neoplasms; Dacarbazine; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Poly(ADP-ribose) Polymerase Inhibitors; Prognosis; Survival Rate; Temozolomide; Young Adult | 2015 |
Phase II study of the immune-checkpoint inhibitor ipilimumab plus dacarbazine in Japanese patients with previously untreated, unresectable or metastatic melanoma.
Topics: Adult; Aged; Alanine Transaminase; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransferases; Chemical and Drug Induced Liver Injury; CTLA-4 Antigen; Dacarbazine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Drug Eruptions; Endocrine System Diseases; Female; Humans; Immunosuppressive Agents; Ipilimumab; Japan; Kaplan-Meier Estimate; Maintenance Chemotherapy; Male; Melanoma; Middle Aged; Neoplasm Proteins; Remission Induction; Treatment Outcome | 2015 |
A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Agents, Alkylating; Dacarbazine; Disease-Free Survival; Female; Humans; Male; Melanoma; Middle Aged; Paclitaxel; Skin Neoplasms; Young Adult | 2015 |
Phase 1b study of lenvatinib (E7080) in combination with temozolomide for treatment of advanced melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Dose-Response Relationship, Drug; Female; Humans; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Phenylurea Compounds; Quinolines; Temozolomide; Young Adult | 2015 |
Adjusting for treatment switching in the METRIC study shows further improved overall survival with trametinib compared with chemotherapy.
Topics: Antineoplastic Agents; Dacarbazine; Disease Progression; Drug Substitution; Humans; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Melanoma; Middle Aged; Mutation; Paclitaxel; Proto-Oncogene Proteins B-raf; Pyridones; Pyrimidinones; Survival Analysis | 2016 |
Effect of nivolumab on health-related quality of life in patients with treatment-naïve advanced melanoma: results from the phase III CheckMate 066 study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; CTLA-4 Antigen; Dacarbazine; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Male; Melanoma; Middle Aged; Nivolumab; Programmed Cell Death 1 Receptor; Quality of Life; Surveys and Questionnaires | 2016 |
A phase I study of TPI 287 in combination with temozolomide for patients with metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Skin Neoplasms; Taxoids; Temozolomide | 2016 |
Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dacarbazine; Disease-Free Survival; Female; Health Status; Humans; Male; Melanoma; Middle Aged; Paclitaxel; Patient Reported Outcome Measures; Quality of Life; Skin Neoplasms; Temozolomide; Young Adult | 2016 |
Effect of the lymphocyte-to-monocyte ratio on the clinical outcome of chemotherapy administration in advanced melanoma patients.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Agents, Alkylating; CD11c Antigen; CD3 Complex; CD4 Antigens; Dacarbazine; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Lipopolysaccharide Receptors; Lymphocyte Count; Lymphocytes; Male; Melanoma; Middle Aged; Monocytes; Retrospective Studies; Skin Neoplasms; Temozolomide; Time Factors; Treatment Outcome | 2017 |
Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Dacarbazine; Female; Follow-Up Studies; GTP Phosphohydrolases; Humans; Male; Melanoma; Membrane Proteins; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Survival Rate | 2017 |
Combined treatment with pegylated interferon-alpha-2a and dacarbazine in patients with advanced metastatic melanoma: a phase 2 study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antiviral Agents; Bone Neoplasms; Dacarbazine; Drug Carriers; Drug Therapy, Combination; Female; Humans; Interferon alpha-2; Interferon-alpha; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoplasm Staging; Polyethylene Glycols; Prognosis; Prospective Studies; Recombinant Proteins; Survival Rate | 2008 |
[Hepatic intra-arterial bio-chemotherapy for the treatment of melanoma patients with liver metastasis: a phase II clinical study].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytokine-Induced Killer Cells; Dacarbazine; Disease-Free Survival; Female; Follow-Up Studies; Granulocyte-Macrophage Colony-Stimulating Factor; Hepatic Artery; Humans; Immunotherapy, Adoptive; Infusions, Intra-Arterial; Interleukin-2; Liver Neoplasms; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Recombinant Proteins; Remission Induction; Survival Rate; Thrombocytopenia; Young Adult | 2008 |
A phase 2 trial of sequential temozolomide chemotherapy followed by high-dose interleukin 2 immunotherapy for metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Drug Administration Schedule; Female; Humans; Interleukin-2; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Skin Neoplasms; Temozolomide | 2008 |
Adjuvant fermented wheat germ extract (Avemar) nutraceutical improves survival of high-risk skin melanoma patients: a randomized, pilot, phase II clinical study with a 7-year follow-up.
Topics: Adolescent; Adult; Aged; Chemotherapy, Adjuvant; Dacarbazine; Dietary Supplements; Drug Therapy, Combination; Female; Fermentation; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Melanoma; Middle Aged; Pilot Projects; Plant Extracts; Skin Neoplasms; Treatment Outcome; Triticum | 2008 |
Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: a phase II Cytokine Working Group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Temozolomide; Thalidomide | 2008 |
Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordin
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dacarbazine; Disease-Free Survival; Female; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-2; Kaplan-Meier Estimate; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Recombinant Proteins; Time Factors; Treatment Outcome; United States; Vincristine; Young Adult | 2008 |
Phase I study of the combination of docetaxel, temozolomide and cisplatin in patients with metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Cohort Studies; Dacarbazine; Docetaxel; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Neoplasm Staging; Neutropenia; Pulmonary Embolism; Skin Neoplasms; Taxoids; Temozolomide; Treatment Outcome | 2009 |
Treatment of metastatic malignant melanoma with a combination of 5-(3,3-dimethyl-1-triazeno) imidazole-4-carboxamide (NSC-45388), cyclophosphamide (NSC-26271), and vincristine (NSC-67574).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Cyclophosphamide; Dacarbazine; Drug Administration Schedule; Female; Granulocytes; Humans; Male; Melanoma; Middle Aged; Remission Induction; Treatment Outcome; Vincristine | 1972 |
Clinical evaluation of 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxam-ide (NSC-45388), melphalan (NSC-8806), and hydroxyurea (NSC-32065) in the treatment of disseminated malignant melanoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Dacarbazine; Female; Humans; Hydroxyurea; Leukocytes; Male; Melanoma; Melphalan; Middle Aged; Remission Induction; Treatment Outcome | 1972 |
Prospective monitoring of adjuvant treatment in high-risk melanoma patients: lactate dehydrogenase and protein S-100B as indicators of relapse.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuvant; Dacarbazine; Disease-Free Survival; Female; Follow-Up Studies; Humans; Interferon alpha-2; Interferon-alpha; L-Lactate Dehydrogenase; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoplasm Staging; Nerve Growth Factors; Prospective Studies; Recombinant Proteins; Recurrence; S100 Calcium Binding Protein beta Subunit; S100 Proteins; Skin Neoplasms; Vindesine | 2009 |
A phase I-II study of the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients with advanced melanoma.
Topics: Adult; Aged; Dacarbazine; Enzyme Inhibitors; Female; Histone Deacetylase Inhibitors; Humans; Interferon-alpha; Male; Melanoma; Middle Aged; Valproic Acid | 2009 |
A phase I study of extended dosing with lomeguatrib with temozolomide in patients with advanced melanoma.
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Child; Dacarbazine; Dose-Response Relationship, Drug; Female; Humans; Melanoma; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Neutropenia; Patient Selection; Purines; Skin Neoplasms; Temozolomide; Thrombocytopenia | 2009 |
O(6)-methylguanine-DNA methyltransferase depletion and DNA damage in patients with melanoma treated with temozolomide alone or with lomeguatrib.
Topics: Antineoplastic Agents; Biopsy; Dacarbazine; Disease Progression; DNA Damage; DNA Repair; DNA Replication; DNA, Neoplasm; Humans; Kinetics; Melanoma; O(6)-Methylguanine-DNA Methyltransferase; Purines; Temozolomide | 2009 |
Malignant melanoma therapy by chemotherapy and autoimmunity induced by cytokine.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Autoimmunity; Combined Modality Therapy; Dacarbazine; Drug Interactions; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Immunotherapy; Interleukin-2; Male; Melanoma; Middle Aged; T-Lymphocytes | 2009 |
LDH correlation with survival in advanced melanoma from two large, randomised trials (Oblimersen GM301 and EORTC 18951).
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Dacarbazine; Follow-Up Studies; Humans; L-Lactate Dehydrogenase; Liver Neoplasms; Melanoma; Prognosis; Skin Neoplasms; Survival Analysis; Thionucleotides; Treatment Outcome | 2009 |
A randomized phase III trial of biochemotherapy versus interferon-alpha-2b for adjuvant therapy in patients at high risk for melanoma recurrence.
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Dacarbazine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Interferon alpha-2; Interferon-alpha; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Recombinant Proteins; Survival Rate; Treatment Outcome; Vinblastine; Young Adult | 2009 |
A phase IB trial of intravenous INO-1001 plus oral temozolomide in subjects with unresectable stage-III or IV melanoma.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Chemical and Drug Induced Liver Injury; Dacarbazine; DNA Mismatch Repair; Drug Administration Schedule; Female; Humans; Indoles; Infusions, Intravenous; Male; Melanoma; Middle Aged; Neoplasm Proteins; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Temozolomide | 2009 |
Phase II trial of dacarbazine and thalidomide for the treatment of metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Dose-Response Relationship, Drug; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Skin Neoplasms; Thalidomide | 2009 |
Phase I/II study of a cisplatin-taxol-dacarbazine regimen in metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Drug Administration Schedule; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Paclitaxel; Skin Neoplasms; Survival Analysis; Treatment Outcome | 2009 |
Randomized phase 2/3 trial of CpG oligodeoxynucleotide PF-3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytokines; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Oligodeoxyribonucleotides; Skin Neoplasms; Survival Analysis; Treatment Outcome | 2009 |
Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II study.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Dacarbazine; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Palliative Care; Prospective Studies; Remission Induction; Salvage Therapy; Survival Rate; Temozolomide; Treatment Outcome | 2010 |
Phase II multicenter trial of maintenance biotherapy after induction concurrent Biochemotherapy for patients with metastatic melanoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Disease-Free Survival; Drug Administration Schedule; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interleukin-2; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Remission Induction; Skin Neoplasms; Survival Analysis; Vinblastine; Young Adult | 2009 |
Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Skin Neoplasms; Temozolomide; Thalidomide | 2010 |
A phase I trial of bortezomib with temozolomide in patients with advanced melanoma: toxicities, antitumor effects, and modulation of therapeutic targets.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chemokines; Dacarbazine; Drug Administration Schedule; Female; Humans; Male; Melanoma; Middle Aged; NF-kappa B; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Skin Neoplasms; Temozolomide; Treatment Outcome | 2010 |
Temozolomide and cisplatin combination in naive patients with metastatic cutaneous melanoma: results of a phase II multicenter trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Disease-Free Survival; Female; Humans; Male; Melanoma; Middle Aged; Skin Neoplasms; Temozolomide | 2010 |
Phase II trial of neoadjuvant temozolomide in resectable melanoma patients.
Topics: Adult; Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Humans; Male; Melanoma; Middle Aged; Promoter Regions, Genetic; Temozolomide; Tumor Suppressor Proteins | 2010 |
A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Demography; Female; Humans; Ipilimumab; Kaplan-Meier Estimate; Lymphocyte Subsets; Male; Melanoma; Middle Aged; Neoplasm Staging; Treatment Outcome | 2011 |
A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin alpha(v)beta(3), + or - dacarbazine in patients with stage IV metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease-Free Survival; Female; Humans; Integrin alphaVbeta3; Male; Melanoma; Middle Aged; Skin Neoplasms | 2010 |
Large randomized study of thymosin alpha 1, interferon alfa, or both in combination with dacarbazine in patients with metastatic melanoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Interferon-alpha; Male; Melanoma; Middle Aged; Thymalfasin; Thymosin | 2010 |
A randomized, double-blind, placebo-controlled study of high-dose bosentan in patients with stage IV metastatic melanoma receiving first-line dacarbazine chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bosentan; Dacarbazine; Double-Blind Method; Female; Humans; Kaplan-Meier Estimate; Male; Melanoma; Middle Aged; Neoplasm Staging; Skin Neoplasms; Sulfonamides | 2010 |
A phase II trial of bevacizumab with dacarbazine and daily low-dose interferon-alpha2a as first line treatment in metastatic melanoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Dacarbazine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Interferon alpha-2; Interferon-alpha; Male; Matrix Metalloproteinase 9; Melanoma; Middle Aged; Patient Compliance; Prognosis; Recombinant Proteins; Survival Rate; Vascular Endothelial Growth Factor A | 2010 |
A phase 1-2 study of imexon plus dacarbazine in patients with unresectable metastatic melanoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Hexanones; Humans; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Neoplasm Metastasis; Skin Neoplasms | 2010 |
Phase 3 study of docosahexaenoic acid-paclitaxel versus dacarbazine in patients with metastatic malignant melanoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Dacarbazine; Disease Progression; Disease-Free Survival; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Paclitaxel | 2011 |
Phase I safety study of lenalidomide and dacarbazine in patients with metastatic melanoma previously untreated with systemic chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Dacarbazine; Dose-Response Relationship, Drug; Female; Humans; Lenalidomide; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Survival Rate; Thalidomide | 2010 |
Phase I dose finding study of carboplatin, paclitaxel, and temozolomide in advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cohort Studies; Dacarbazine; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Paclitaxel; Skin Neoplasms; Small Cell Lung Carcinoma; Temozolomide | 2011 |
A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Drug Administration Schedule; Female; Humans; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Neoplasms; Neutropenia; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Thrombocytopenia | 2011 |
First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07).
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Skin Neoplasms; Temozolomide | 2012 |
Telomerase peptide vaccination combined with temozolomide: a clinical trial in stage IV melanoma patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Cancer Vaccines; Cytokines; Dacarbazine; Humans; Immunologic Memory; Melanoma; Middle Aged; Neoplasm Staging; Survival Analysis; T-Lymphocytes; Telomerase; Temozolomide; Treatment Outcome; Vaccines, Subunit; Young Adult | 2011 |
Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032).
Topics: Aged; Area Under Curve; Dacarbazine; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Melanoma; Middle Aged; Neoplasm Staging; Remission Induction; Safety; Skin Neoplasms; Temozolomide; Time Factors | 2011 |
Central nervous system failure in melanoma patients: results of a randomised, multicentre phase 3 study of temozolomide- and dacarbazine- based regimens.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Skin Neoplasms; Temozolomide | 2011 |
Improved survival with vemurafenib in melanoma with BRAF V600E mutation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dacarbazine; Disease-Free Survival; Female; Humans; Indoles; Intention to Treat Analysis; Male; Melanoma; Middle Aged; Mutation; Proto-Oncogene Proteins B-raf; Sulfonamides; Survival Analysis; Vemurafenib; Young Adult | 2011 |
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease Progression; Double-Blind Method; Female; Humans; Ipilimumab; Kaplan-Meier Estimate; Liver Function Tests; Male; Melanoma; Middle Aged; Proportional Hazards Models | 2011 |
Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Dacarbazine; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Skin Neoplasms; Sorafenib | 2011 |
A randomised, phase II study of intetumumab, an anti-αv-integrin mAb, alone and with dacarbazine in stage IV melanoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease-Free Survival; Female; Humans; Integrin alphaV; Male; Melanoma; Middle Aged; Skin Neoplasms; Uveitis | 2011 |
Inhibition of DNA repair with MGMT pseudosubstrates: phase I study of lomeguatrib in combination with dacarbazine in patients with advanced melanoma and other solid tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Drug Administration Schedule; Female; Humans; Male; Melanoma; Middle Aged; Neoplasms; O(6)-Methylguanine-DNA Methyltransferase; Purines | 2011 |
Health-related quality of life among patients with metastatic melanoma: results from an international phase 2 multicenter study.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Pain; Pain Measurement; Psychometrics; Quality of Life; Surveys and Questionnaires | 2012 |
A dose-escalation and signal-generating study of the immunocytokine L19-IL2 in combination with dacarbazine for the therapy of patients with metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Fever; Humans; Male; Melanoma; Metabolic Clearance Rate; Middle Aged; Neoplasm Metastasis; Recombinant Fusion Proteins; Survival Analysis; Survival Rate; Treatment Outcome | 2011 |
Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Benzimidazoles; Dacarbazine; Disease-Free Survival; DNA Mutational Analysis; Drug Substitution; Female; Humans; Kaplan-Meier Estimate; Male; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Melanoma; Middle Aged; Mutation; Neoplasm Staging; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Temozolomide; Treatment Outcome; Young Adult | 2012 |
Prospective evaluation of supportive care with or without CVD chemotherapy as a second-line treatment in advanced melanoma by patient's choice: a multicentre Dermatologic Cooperative Oncology Group trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Choice Behavior; Cooperative Behavior; Cyclophosphamide; Dacarbazine; Dermatology; Disease Progression; Female; Humans; Interdisciplinary Communication; Male; Medical Oncology; Melanoma; Middle Aged; Palliative Care; Patient Preference; Skin Neoplasms; Societies, Medical; Vincristine | 2011 |
Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Dasatinib; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Pyrimidines; src-Family Kinases; Survival Analysis; Thiazoles; Treatment Outcome | 2012 |
Phosphatase inhibitor, sodium stibogluconate, in combination with interferon (IFN) alpha 2b: phase I trials to identify pharmacodynamic and clinical effects.
Topics: Adult; Aged; Antimony Sodium Gluconate; Antineoplastic Agents; Breast Neoplasms; Cisplatin; Colorectal Neoplasms; Dacarbazine; Drug Therapy, Combination; Enzyme Inhibitors; Female; Gastrointestinal Stromal Tumors; Humans; Interferon alpha-2; Interferon-alpha; Male; Melanoma; Middle Aged; Phosphoric Monoester Hydrolases; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Recombinant Proteins; Sarcoma; Vinblastine | 2011 |
Veliparib plus temozolomide in metastatic melanoma trends toward increased PFS but results are not statistically significant.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Dacarbazine; Disease-Free Survival; Double-Blind Method; Humans; Melanoma; Neoplasm Staging; Temozolomide | 2011 |
Phase II trial of temozolomide for leptomeningeal metastases in patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Dacarbazine; Female; Follow-Up Studies; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Melanoma; Meningeal Neoplasms; Middle Aged; Neoplasm Staging; Prognosis; Prospective Studies; Survival Rate; Temozolomide | 2012 |
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Dacarbazine; Disease-Free Survival; Female; Humans; Imidazoles; Male; Melanoma; Middle Aged; Mutation; Oximes; Proto-Oncogene Proteins B-raf; Treatment Outcome; Young Adult | 2012 |
A randomized phase 2 study of temozolomide and bevacizumab or nab-paclitaxel, carboplatin, and bevacizumab in patients with unresectable stage IV melanoma : a North Central Cancer Treatment Group study, N0775.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Staging; Paclitaxel; Skin Neoplasms; Survival Analysis; Temozolomide; Treatment Outcome; Young Adult | 2013 |
Oblimersen in combination with temozolomide and albumin-bound paclitaxel in patients with advanced melanoma: a phase I trial.
Topics: Adult; Aged; Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Dacarbazine; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Oligonucleotides, Antisense; Paclitaxel; Skin Neoplasms; Temozolomide; Thionucleotides; Treatment Outcome | 2013 |
Safety and efficacy of decitabine in combination with temozolomide in metastatic melanoma: a phase I/II study and pharmacokinetic analysis.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Dacarbazine; Decitabine; Disease-Free Survival; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Skin Neoplasms; Temozolomide | 2013 |
The association of blood angioregulatory microRNA levels with circulating endothelial cells and angiogenic proteins in patients receiving dacarbazine and interferon.
Topics: Angiogenic Proteins; Cell Movement; Dacarbazine; Endothelial Cells; Humans; Interferon alpha-2; Interferon-alpha; Melanoma; MicroRNAs; Neovascularization, Pathologic; Recombinant Proteins; Uveal Neoplasms | 2012 |
Phase I trial of bortezomib and dacarbazine in melanoma and soft tissue sarcoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dacarbazine; Dose-Response Relationship, Drug; Female; Humans; Lung Neoplasms; Male; Medication Adherence; Melanoma; Middle Aged; Pyrazines; Radiography; Sarcoma; Treatment Outcome; Young Adult | 2013 |
Phase II study of temozolomide (TMZ) and everolimus (RAD001) therapy for metastatic melanoma: a North Central Cancer Treatment Group study, N0675.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease-Free Survival; Everolimus; Female; Humans; Induction Chemotherapy; Male; Melanoma; Middle Aged; Sirolimus; Skin Neoplasms; Temozolomide; TOR Serine-Threonine Kinases; Treatment Outcome; Vascular Endothelial Growth Factor A | 2014 |
[Long-term results of adjuvant chemotherapy after therapeutic lymph node dissection in patients with cutaneous malignant melanoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Female; Follow-Up Studies; Humans; Interferon-alpha; Lymph Node Excision; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoplasm Staging; Skin Neoplasms; Survival Rate | 2002 |
Maintenance biotherapy for metastatic melanoma with interleukin-2 and granulocyte macrophage-colony stimulating factor improves survival for patients responding to induction concurrent biochemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Drug Administration Schedule; Drug Eruptions; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Hyperthyroidism; Immunologic Factors; Interleukin-2; Life Tables; Melanoma; Neoplasm Metastasis; Prospective Studies; Remission Induction; Survival Analysis; Tamoxifen; Thrombocytopenia; Treatment Outcome; Vinblastine | 2002 |
A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Dacarbazine; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Pilot Projects; Recombinant Proteins; Temozolomide; Treatment Outcome; Vinblastine | 2002 |
Chemoimmunohormonal therapy with carmustine, dacarbazine, cisplatin, tamoxifen, and interferon for metastatic melanoma: a prospective phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Female; Humans; Interferon alpha-2; Interferon-alpha; Male; Melanoma; Middle Aged; Prospective Studies; Recombinant Proteins; Remission Induction; Survival Analysis; Tamoxifen | 2002 |
Docetaxel in combination with dacarbazine in patients with advanced melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Docetaxel; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Paclitaxel; Remission Induction; Skin Neoplasms; Survival Analysis; Taxoids | 2002 |
Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD), and human leukocyte interferon for metastatic uveal melanoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Disease-Free Survival; Female; Humans; Injections, Intravenous; Interferon-alpha; Lomustine; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Treatment Outcome; Uveal Neoplasms; Vincristine | 2002 |
Phase I/II study of sequential chemoimmunotherapy (SCIT) for metastatic melanoma: outpatient treatment with dacarbazine, granulocyte-macrophage colony-stimulating factor, low-dose interleukin-2, and interferon-alpha.
Topics: Adult; Aged; Dacarbazine; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; T-Lymphocytes | 2002 |
Temozolomide in combination with interferon alpha-2b in patients with metastatic melanoma: a phase I dose-escalation study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease-Free Survival; Female; Humans; Interferon alpha-2; Interferon-alpha; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Neoplasm Staging; Neutropenia; Recombinant Proteins; Skin Neoplasms; Temozolomide; Thrombocytopenia; Treatment Outcome | 2003 |
Temozolomide and cisplatin in the treatment of leptomeningeal metastatic involvement from melanoma: a case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Humans; Magnetic Resonance Imaging; Male; Melanoma; Meningeal Neoplasms; Spinal Cord Neoplasms; Temozolomide; Treatment Outcome | 2002 |
Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen, or vindesine plus tamoxifen: a prospective randomized study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Skin Neoplasms; Survival Rate; Tamoxifen; Treatment Outcome; Vindesine | 2003 |
Low molecular weight heparin treatment for malignant melanoma: a pilot clinical trial.
Topics: Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Dacarbazine; Enoxaparin; Feasibility Studies; Glycosaminoglycans; Humans; Melanoma; Neoplasm Staging; Pilot Projects; Radiotherapy, Adjuvant; Remission Induction; Survival Analysis; Tamoxifen; Treatment Outcome | 2003 |
Low-dose continuous chemotherapy for metastatic melanoma: a phase II trial.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chlorambucil; Dacarbazine; Disease Progression; Disease-Free Survival; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Injections, Subcutaneous; Lomustine; Male; Melanoma; Methotrexate; Middle Aged; Neoplasm Metastasis; Prognosis; Tamoxifen; Time Factors; Treatment Outcome; Vinblastine | 2003 |
Bleomycin, vincristine, lomustine and dacarbazine (BOLD) in combination with recombinant interferon alpha-2b for metastatic uveal melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Disease-Free Survival; Feasibility Studies; Female; Humans; Interferon alpha-2; Interferon-alpha; Lomustine; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Prospective Studies; Recombinant Proteins; Treatment Outcome; Uveal Neoplasms; Vincristine | 2003 |
Biochemotherapy for metastatic melanoma with limited central nervous system involvement.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cisplatin; Dacarbazine; Disease Progression; Female; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Neoplasm Staging; Radiosurgery; Recombinant Proteins; Survival Analysis; Treatment Outcome; Vinblastine | 2003 |
Phase I-II study on isolation antiblastic fotemustine perfusion after dacarbazine chemosensitization for advanced melanoma of the extremities.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusion; Dacarbazine; Extremities; Female; Humans; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms; Treatment Outcome | 2003 |
Phase II evaluation of temozolomide in metastatic choroidal melanoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Choroid Neoplasms; Dacarbazine; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Liver Neoplasms; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Prospective Studies; Temozolomide; Treatment Outcome | 2003 |
Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease Progression; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Recombinant Proteins; Skin Neoplasms; Survival; Temozolomide; Thalidomide | 2003 |
Quality of life evaluation in a randomised trial of chemotherapy versus bio-chemotherapy in advanced melanoma patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Female; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Multivariate Analysis; Prognosis; Quality of Life; Recombinant Proteins; Skin Neoplasms | 2003 |
On the effect of biochemotherapy in metastatic malignant melanoma: an immunopathological evaluation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; CD4 Lymphocyte Count; Cisplatin; Dacarbazine; Female; Humans; Immunotherapy; Interferon alpha-2; Interferon-alpha; Lymphocytes, Tumor-Infiltrating; Male; Melanoma; Middle Aged; Recombinant Proteins; Remission Induction; Skin Neoplasms; Treatment Outcome | 2003 |
[Chemotherapy in combination with laser coagulation or interstitial hyperthermia--effective combined therapy for disseminated skin melanoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chemotherapy, Adjuvant; Cisplatin; Dacarbazine; Extracellular Space; Female; Humans; Hyperthermia, Induced; Laser Coagulation; Male; Melanoma; Middle Aged; Skin Neoplasms; Survival Analysis; Tamoxifen; Treatment Outcome | 2003 |
Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Dose-Response Relationship, Drug; Female; Humans; Male; Melanoma; Middle Aged; Survival Analysis; Temozolomide; Thalidomide; Treatment Outcome | 2003 |
A phase I (tumour site-specific) study of carboplatin and temozolomide in patients with advanced melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Dacarbazine; Drug Interactions; Female; Humans; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Skin Neoplasms; Temozolomide; Thrombocytopenia | 2003 |
Health-related quality of life in patients with advanced metastatic melanoma: results of a randomized phase III study comparing temozolomide with dacarbazine.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Cognition; Dacarbazine; Emotions; Female; Health Status; Humans; Infusions, Intravenous; Male; Melanoma; Middle Aged; Quality of Life; Skin Neoplasms; Sleep; Survival Analysis; Temozolomide | 2003 |
Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Europe; Female; Humans; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Quality of Life; Skin Neoplasms; Statistics, Nonparametric; Survival Analysis | 2004 |
Mature results of a phase III randomized trial of bacillus Calmette-Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage I-III melanoma (E1673): a trial of the Eastern Onco
Topics: Adjuvants, Immunologic; Adult; Aged; Antineoplastic Agents, Alkylating; BCG Vaccine; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Disease Progression; Drug Therapy, Combination; Female; Humans; Male; Melanoma; Middle Aged; Skin Neoplasms; Survival Analysis; Treatment Outcome | 2004 |
Temozolomide as prophylaxis for melanoma brain metastases.
Topics: Adult; Aged; Antibiotic Prophylaxis; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Skin Neoplasms; Temozolomide | 2004 |
Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Female; Humans; Male; Melanoma; Middle Aged; Skin Neoplasms; Survival Rate; Temozolomide; United States | 2004 |
[Chemoimmunotherapy with dacarbazine and aranose combined with interferon-alpha in disseminated cutaneous melanoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Glycosides; Humans; Immunologic Factors; Interferon-alpha; Male; Melanoma; Methylnitrosourea; Middle Aged; Skin Neoplasms; Treatment Outcome | 2004 |
Temozolomide and interferon alpha 2b in metastatic melanoma stage IV.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Interferon alpha-2; Interferon-alpha; Liver Neoplasms; Lung Neoplasms; Male; Melanoma; Middle Aged; Proportional Hazards Models; Recombinant Proteins; Remission Induction; Skin Neoplasms; Survival Rate; Temozolomide | 2004 |
The effect of temozolomide-based chemotherapy in patients with cerebral metastases from melanoma.
Topics: Adult; Aged; Brain Neoplasms; Dacarbazine; Disease Progression; Drug Therapy, Combination; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Staging; Prognosis; Survival Rate; Temozolomide; Time Factors | 2004 |
Temozolomide and interferon-alpha in metastatic melanoma: a phase II study of the Italian Melanoma Intergroup.
Topics: Adult; Aged; Dacarbazine; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Interferon-alpha; Italy; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Survival Rate; Temozolomide; Treatment Outcome | 2004 |
Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with brain metastases from solid tumors: a Hellenic Cooperative Oncology Group (HeCOG) Phase II study.
Topics: Adult; Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Cisplatin; Dacarbazine; Female; Humans; Leukopenia; Lung Neoplasms; Male; Melanoma; Middle Aged; Nausea; Stomach Neoplasms; Temozolomide; Treatment Outcome | 2005 |
Phase I study of temozolomide plus paclitaxel in patients with advanced malignant melanoma and associated in vitro investigations.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Paclitaxel; Temozolomide | 2005 |
Cyclosporine A, alpha-lnterferon and interleukin-2 following chemotherapy with BCNU, DTIC, cisplatin, and tamoxifen: a phase II study in advanced melanoma.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Cyclosporine; Dacarbazine; Female; Humans; Immunosuppressive Agents; Interferon-alpha; Interleukin-2; Male; Melanoma; Skin Neoplasms; Tamoxifen; Treatment Outcome | 2005 |
Temozolomide and cisplatin versus temozolomide in patients with advanced melanoma: a randomized phase II study of the Hellenic Cooperative Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Temozolomide | 2005 |
Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Staging; Skin Neoplasms; Survival Rate; Temozolomide; Thalidomide; Treatment Outcome | 2005 |
Temozolomide pharmacodynamics in patients with metastatic melanoma: dna damage and activity of repair enzymes O6-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Comet Assay; Dacarbazine; DNA Damage; DNA Methylation; DNA Repair; DNA, Neoplasm; Female; Headache; Humans; Lymphocytes; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Neutropenia; O(6)-Methylguanine-DNA Methyltransferase; Poly(ADP-ribose) Polymerases; Temozolomide; Thrombocytopenia; Time Factors; Treatment Outcome | 2005 |
Combined chemoimmunotherapy of metastatic melanoma: a single institution experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Dacarbazine; Female; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Melanoma; Nausea; Neutropenia; Recombinant Proteins; Skin Neoplasms; Survival Analysis; Thrombocytopenia; Vinblastine; Vomiting | 2005 |
Randomized trial of dacarbazine versus bleomycin, vincristine, lomustine and dacarbazine (BOLD) chemotherapy combined with natural or recombinant interferon-alpha in patients with advanced melanoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Female; Humans; Interferon Type I; Interferon-alpha; Lomustine; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Recombinant Proteins; Skin Neoplasms; Survival Analysis; Treatment Outcome; Vincristine | 2005 |
A phase II study of biochemotherapy for advanced melanoma incorporating temozolomide, decrescendo interleukin-2 and GM-CSF.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Eye Neoplasms; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interleukin-2; Melanoma; Middle Aged; Neoplasm Metastasis; Reproducibility of Results; Skin Neoplasms; Survival Analysis; Temozolomide | 2005 |
Temozolomide with or without radiotherapy in melanoma with unresectable brain metastases.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; Female; Humans; Male; Melanoma; Middle Aged; Skin Neoplasms; Stereotaxic Techniques; Survival Analysis; Temozolomide; Treatment Outcome | 2006 |
Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Cisplatin; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Europe; Female; Follow-Up Studies; Humans; Immunohistochemistry; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Probability; Proportional Hazards Models; Recombinant Proteins; Reference Values; Skin Neoplasms; Survival Rate; Treatment Outcome | 2005 |
A low rate of central nervous system progression in a phase II trial of outpatient chemobiologic therapy with cisplatin, temozolomide, interleukin-2, and interferon alfa 2-B for metastatic malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Disease Progression; Female; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Recombinant Proteins; Temozolomide | 2005 |
Low-dose outpatient chemobiotherapy with temozolomide, granulocyte-macrophage colony stimulating factor, interferon-alpha2b, and recombinant interleukin-2 for the treatment of metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease Progression; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Neoplasm Staging; Recombinant Proteins; Survival Analysis; Temozolomide; Treatment Outcome | 2005 |
Temozolomide in combination with interferon-alfa versus temozolomide alone in patients with advanced metastatic melanoma: a randomized, phase III, multicenter study from the Dermatologic Cooperative Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Dacarbazine; Female; Humans; Interferon-alpha; Male; Melanoma; Middle Aged; Prognosis; Prospective Studies; Statistics, Nonparametric; Survival Rate; Temozolomide; Treatment Outcome | 2005 |
Decline in angiogenic factors, such as interleukin-8, indicates response to chemotherapy of metastatic melanoma.
Topics: Adult; Aged; Angiogenic Proteins; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Female; Fibroblast Growth Factor 2; Humans; Interferon-alpha; Interleukin-2; Interleukin-8; Male; Melanoma; Middle Aged; Neoplasm Staging; Platelet-Derived Growth Factor; Prospective Studies; Vascular Cell Adhesion Molecule-1; Vascular Endothelial Growth Factor A; Vindesine | 2005 |
Temozolomide in combination with cisplatin in patients with metastatic melanoma: a phase II trial.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Disease-Free Survival; Female; Humans; Infusions, Intravenous; Male; Melanoma; Middle Aged; Skin Neoplasms; Temozolomide | 2005 |
Predictive utility of circulating methylated DNA in serum of melanoma patients receiving biochemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; DNA Methylation; DNA, Neoplasm; Drug Administration Schedule; Female; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Odds Ratio; Predictive Value of Tests; Prognosis; Recombinant Proteins; Skin Neoplasms; Survival Analysis; Tamoxifen; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins; Vinblastine | 2005 |
Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG.
Topics: Cancer Vaccines; Dacarbazine; Dendritic Cells; Humans; Melanoma; Neoplasm Metastasis; Peptides | 2006 |
A biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, temozolomide (Temodal), interferon-alfa and interleukin-2 for metastatic melanoma: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Dacarbazine; Disease-Free Survival; Female; Humans; Infusions, Intravenous; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Recombinant Proteins; Skin Neoplasms; Survival Rate; Temozolomide; Treatment Outcome; Vinblastine | 2006 |
Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-alpha2b in metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Female; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Recombinant Proteins; Vinblastine | 2006 |
Phase II study of temozolomide plus pegylated interferon-alpha-2b for metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Eye Neoplasms; Female; Follow-Up Studies; Humans; Interferon alpha-2; Interferon-alpha; Male; Melanoma; Middle Aged; Mouth Neoplasms; Polyethylene Glycols; Recombinant Proteins; Remission Induction; Skin Neoplasms; Survival Rate; Temozolomide | 2006 |
A prospective single arm phase II study of dacarbazine and treosulfan as first-line therapy in metastatic uveal melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Prospective Studies; Thrombocytopenia; Uveal Neoplasms | 2006 |
A phase II study of extended dose temozolomide and thalidomide in previously treated patients with metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease Progression; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Skin Neoplasms; Survival Rate; Temozolomide; Thalidomide; Treatment Outcome | 2006 |
Long-term survival benefit after adjuvant treatment of cutaneous melanoma with dacarbazine and low dose natural interferon alpha: A controlled, randomised multicentre trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Dacarbazine; Female; Humans; Interferon-alpha; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prospective Studies; Skin Neoplasms; Survival Rate | 2006 |
Phase II multicenter study of neoadjuvant biochemotherapy for patients with stage III malignant melanoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Female; Humans; Interferon-alpha; Interleukin-2; Lymph Node Excision; Male; Melanoma; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Skin Neoplasms; Survival Analysis; Vinblastine | 2006 |
Basal level and behaviour of cytokines in a randomized outpatient trial comparing chemotherapy and biochemotherapy in metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytokines; Dacarbazine; Female; Humans; Immunologic Factors; Interleukin-10; Interleukin-12; Interleukin-2; Interleukin-6; Interleukin-8; Male; Melanoma; Middle Aged; Receptors, Interleukin-6; Skin Neoplasms; Survival Analysis; Survival Rate; Vinblastine | 2006 |
Alternating chemo-immunotherapy with temozolomide and low-dose interleukin-2 in patients with metastatic melanoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Immunotherapy; Injections, Subcutaneous; Interleukin-2; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Neoplasm Staging; Skin Neoplasms; Survival Rate; Temozolomide | 2006 |
Phase II multicentre study of temozolomide in combination with interferon alpha-2b in metastatic malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Immunologic Factors; Interferon alpha-2; Interferon-alpha; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Neoplasm Staging; Recombinant Proteins; Skin Neoplasms; Survival Rate; Temozolomide | 2006 |
Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Dacarbazine; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; L-Lactate Dehydrogenase; Male; Melanoma; Middle Aged; Oligonucleotides, Antisense; Proto-Oncogene Proteins c-bcl-2; Skin Neoplasms; Survival Analysis; Thionucleotides; Treatment Outcome | 2006 |
Temozolomide in combination with celecoxib in patients with advanced melanoma. A phase II study of the Hellenic Cooperative Oncology Group.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Celecoxib; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Dacarbazine; Female; Humans; Immunohistochemistry; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Pyrazoles; Skin Neoplasms; Sulfonamides; Survival Analysis; Temozolomide | 2006 |
Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain: high rate of thromboembolic events (CALGB 500102).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Humans; Melanoma; Middle Aged; Pulmonary Embolism; Skin Neoplasms; Survival Rate; Temozolomide; Thalidomide; Treatment Failure; Venous Thrombosis; Withholding Treatment | 2006 |
Dose-intensified bi-weekly temozolomide in patients with asymptomatic brain metastases from malignant melanoma: a phase II DeCOG/ADO study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Melanoma; Middle Aged; Skin Neoplasms; Survival Analysis; Temozolomide; Treatment Outcome | 2006 |
Chemoimmunotherapy with dacarbazine, cisplatin, interferon-alpha2b and interleukin-2 versus two cycles of dacarbazine followed by chemoimmunotherapy in patients with metastatic melanoma: a randomised phase II study of the European Organization for Researc
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Dacarbazine; Female; Humans; Immunotherapy; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Patient Compliance; Recombinant Proteins; Skin Neoplasms | 2006 |
A phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanoma.
Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Lomustine; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Neutropenia; Temozolomide; Thrombocytopenia; Treatment Failure | 2007 |
Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease Progression; Enzyme Inhibitors; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Staging; O(6)-Methylguanine-DNA Methyltransferase; Purines; Skin Neoplasms; Temozolomide; Treatment Outcome | 2007 |
Phase II study of temozolomide and concomitant whole-brain radiotherapy in patients with brain metastases from solid tumors.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; Female; Humans; Lung Neoplasms; Male; Melanoma; Middle Aged; Mouth Neoplasms; Neoplasms, Unknown Primary; Palliative Care; Rectal Neoplasms; Research Design; Temozolomide; Treatment Outcome | 2007 |
Results of a multicenter randomized study to evaluate the safety and efficacy of combined immunotherapy with interleukin-2, interferon-{alpha}2b and histamine dihydrochloride versus dacarbazine in patients with stage IV melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Histamine; Humans; Immunotherapy; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Multivariate Analysis; Neoplasm Staging; Recombinant Proteins | 2007 |
Durable complete responses with high-dose bolus interleukin-2 in patients with metastatic melanoma who have experienced progression after biochemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Disease Progression; Female; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Recombinant Proteins; Skin Neoplasms; Treatment Outcome; Vinblastine | 2007 |
Temozolomide in combination with fotemustine in patients with metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease-Free Survival; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Staging; Nitrosourea Compounds; Organophosphorus Compounds; Temozolomide | 2008 |
Multicenter phase II study of chemoimmunotherapy in the treatment of metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Dacarbazine; Dexamethasone; Diarrhea; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Therapy; Female; Humans; Immunotherapy; Interferon alpha-2; Interferon-alpha; Interleukin-2; Isotretinoin; Magnesium Sulfate; Male; Melanoma; Middle Aged; Neutropenia; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Treatment Outcome; Vinblastine | 2008 |
Temozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG).
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Interferon alpha-2; Interferon-alpha; Male; Melanoma; Middle Aged; Neoplasm Staging; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Skin Neoplasms; Temozolomide; Treatment Outcome | 2008 |
Adjuvant low-dose interferon {alpha}2a with or without dacarbazine compared with surgery alone: a prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis.
Topics: Adolescent; Adult; Antineoplastic Agents; Child; Child, Preschool; Dacarbazine; Female; Humans; Infant; Infant, Newborn; Interferon alpha-2; Interferon-alpha; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Prospective Studies; Quality of Life; Recombinant Proteins; Skin Neoplasms; Survival Analysis | 2008 |
Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group.
Topics: Adult; Aged; Antineoplastic Agents; Cancer Vaccines; Dacarbazine; Female; Heat-Shock Proteins; Humans; Interleukin-2; Kaplan-Meier Estimate; Male; Melanoma; Middle Aged; Neoplasm Staging; Odds Ratio; Skin Neoplasms; Temozolomide; Treatment Outcome | 2008 |
Influence of therapy on the antioxidant status in patients with melanoma.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Catalase; Dacarbazine; Female; Humans; Lipid Peroxidation; Lomustine; Male; Malondialdehyde; Melanoma; Middle Aged; Oxidative Stress; Superoxide Dismutase | 2008 |
Temozolomide associated with PEG-interferon in patients with metastatic melanoma: a multicenter prospective phase I/II study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Male; Melanoma; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Skin Neoplasms; Temozolomide | 2008 |
Phase II trial of arsenic trioxide and ascorbic acid with temozolomide in patients with metastatic melanoma with or without central nervous system metastases.
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Brain Neoplasms; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Oxides; Skin Neoplasms; Temozolomide | 2008 |
Intralesional adenovirus-mediated interleukin-2 gene transfer for advanced solid cancers and melanoma.
Topics: Adenoviridae; Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Dacarbazine; Female; Gene Transfer Techniques; Genetic Therapy; Genetic Vectors; Humans; Interleukin-2; Male; Melanoma; Middle Aged; Neoplasm Metastasis | 2008 |
Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group.
Topics: Administration, Oral; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Dacarbazine; Disease-Free Survival; Double-Blind Method; Female; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Melanoma; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Time Factors; Treatment Outcome; United States | 2008 |
Phase II study of extended-dose temozolomide in patients with melanoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Base Sequence; CD3 Complex; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Drug Administration Schedule; Female; Humans; Male; Melanoma; Middle Aged; Molecular Sequence Data; Promoter Regions, Genetic; Survival Rate; Temozolomide; Tumor Suppressor Proteins | 2008 |
Immunotherapy of malignant melanoma.
Topics: Antigens, Neoplasm; BCG Vaccine; Cholera Vaccines; Clinical Trials as Topic; Dacarbazine; Dinitrochlorobenzene; Double-Blind Method; Humans; Immunotherapy; Interferons; Levamisole; Melanoma; Random Allocation; Skin Neoplasms; Skin Tests; Transfer Factor | 1982 |
Randomized phase III trial of vinblastine, bleomycin, and cis-dichlorodiammine-platinum versus dacarbazine in malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Clinical Trials as Topic; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Mouth Diseases; Neutropenia; Random Allocation; Sepsis; Skin Neoplasms; Thrombocytopenia; Vinblastine | 1984 |
[Chemotherapy in advanced malignant melanoma. Results of a controlled trial comparing a combination of dacarbazine (DTIC) and detorubicin with dacarbazine alone].
Topics: Adult; Aged; Clinical Trials as Topic; Dacarbazine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Male; Melanoma; Middle Aged; Time Factors | 1982 |
Randomized controlled trial of adjuvant chemoimmunotherapy with DTIC and BCG after complete excision of primary melanoma with a poor prognosis or melanoma metastases.
Topics: Antineoplastic Agents; BCG Vaccine; Clinical Trials as Topic; Dacarbazine; Humans; Melanoma; Neoplasm Metastasis; Neoplasm Recurrence, Local; Postoperative Care; Prognosis; Random Allocation; Skin Neoplasms | 1983 |
The systemic chemotherapy of hepatic metastases.
Topics: Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Colonic Neoplasms; Dacarbazine; Drug Therapy, Combination; Fluorouracil; Humans; Liver Neoplasms; Lung Neoplasms; Melanoma; Pancreatic Neoplasms; Rectal Neoplasms; Semustine; Stomach Neoplasms | 1983 |
Combination chemotherapy plus levamisole in the treatment of disseminated malignant melanoma. A Southwest Oncology Group study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials as Topic; Dacarbazine; Dactinomycin; Humans; Hydroxyurea; Levamisole; Melanoma; Random Allocation; Skin Neoplasms | 1984 |
Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma. IV. Late results after complete response to chemotherapy (Central Oncology Group protocols 7130, 7131, and 7131A).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials as Topic; Dacarbazine; Female; Humans; Hydroxyurea; Lomustine; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Sex Factors; Skin Neoplasms; Soft Tissue Neoplasms; Time Factors; Vincristine | 1984 |
Ineffectiveness of adjuvant chemotherapy using DTIC and cyclophosphamide in patients with resectable metastatic melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Dacarbazine; Female; Humans; Immunotherapy; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Prognosis; Propionibacterium acnes; Prospective Studies; Random Allocation; Skin Neoplasms | 1984 |
Controlled study with imidazole carboxamide (DTIC), DTIC + bacillus Calmette-Guérin (BCG), and DTIC + corynebacterium parvum in advanced malignant melanoma. W.H.O. Collaborating Centres for Evaluation of Methods of Diagnosis and Treatment of Melanoma.
Topics: Bacterial Vaccines; BCG Vaccine; Brain Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Dacarbazine; Female; Fever; Humans; Leukopenia; Male; Melanoma; Middle Aged; Nausea; Propionibacterium acnes; Sex Factors; Time Factors | 1984 |
Controlled study of DTIC versus DTIC plus epirubicin in metastatic malignant melanoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Dacarbazine; Doxorubicin; Epirubicin; Female; Heart; Humans; Male; Melanoma; Middle Aged | 1984 |
Clinical trial of chlorozotocin, DTIC, and dactinomycin in metastatic malignant melanoma.
Topics: Adolescent; Adult; Bone Marrow; Clinical Trials as Topic; Dacarbazine; Dactinomycin; Digestive System; Drug Therapy, Combination; Female; Humans; Kidney; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Streptozocin | 1982 |
Predictability of response to clinical thermochemotherapy by the clonogenic assay.
Topics: Cells, Cultured; Colony-Forming Units Assay; Combined Modality Therapy; Dacarbazine; Drug Evaluation; Hot Temperature; Humans; Liver Neoplasms; Melanoma; Skin Neoplasms; Tumor Stem Cell Assay | 1983 |
A trial of imidazole carboxamide and corynebacterium parvum in disseminated melanoma: clinical and immunologic results.
Topics: Bacterial Vaccines; Clinical Trials as Topic; Dacarbazine; Female; Humans; Immunotherapy; Injections, Intramuscular; Male; Melanoma; Middle Aged; Nausea; Neoplasm Metastasis; Pancytopenia; Prognosis; Propionibacterium acnes; Skin Neoplasms; Vomiting | 1980 |
[Comparison of the efficacy of imidazole-carboxamide and of a combination of nitrosomethylurea, vincristine and dactinomycin in disseminated melanoma].
Topics: Adolescent; Adult; Aged; Clinical Trials as Topic; Dacarbazine; Dactinomycin; Drug Therapy, Combination; Female; Humans; Male; Melanoma; Methylnitrosourea; Middle Aged; Neoplasm Metastasis; Nitrosourea Compounds; Skin Neoplasms; Time Factors; Vincristine | 1981 |
DTIC and combination therapy for melanoma: III. DTIC (NSC 45388) Surgical Adjuvant Study COG PROTOCOL 7040.
Topics: Adolescent; Adult; Aged; Clinical Trials as Topic; Dacarbazine; Female; Follow-Up Studies; Humans; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Postoperative Care; Prospective Studies; Random Allocation; Skin Neoplasms | 1981 |
Chemoimmunotherapy for melanoma with DTIC, ACNU, VCR and OK432: evaluation of new combinations for survival rates, side effects and cellular immunity.
Topics: Biological Products; Clinical Trials as Topic; Dacarbazine; Drug Therapy, Combination; Female; Humans; Immunity, Cellular; Immunotherapy; Male; Melanoma; Nimustine; Nitrosourea Compounds; Picibanil; Vincristine | 1981 |
Trial 6: randomized study of prolonged chemotherapy, immunotherapy, and chemoimmunotherapy as an adjuvant to surgery for stage I and II melanoma: a progress report.
Topics: Clinical Trials as Topic; Dacarbazine; Female; Follow-Up Studies; Humans; Immunotherapy; Male; Melanoma; Mycobacterium bovis | 1982 |
Clinical trials of chemotherapy and chemoimmunotherapy in primary malignant melanoma.
Topics: Clinical Trials as Topic; Dacarbazine; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Immunotherapy; Male; Melanoma; Methotrexate; Procarbazine; Streptonigrin; Vinblastine | 1982 |
Current status of melanoma chemotherapy and immunotherapy.
Topics: Clinical Trials as Topic; Dacarbazine; Follow-Up Studies; Humans; Immunotherapy; Levamisole; Melanoma; Microscopy, Electron; Mycobacterium bovis; Neoplasm Staging | 1982 |
A randomized comparison of cyclophosphamide, DTIC with or without piperazinedione in metastatic malignant melanoma.
Topics: Antibiotics, Antineoplastic; Clinical Trials as Topic; Cyclophosphamide; Dacarbazine; Drug Therapy, Combination; Female; Humans; Male; Melanoma; Piperazines; Random Allocation; Skin Neoplasms | 1982 |
Adjuvant chemoimmunotherapy stage I/II malignant melanoma.
Topics: Adolescent; Adult; Aged; BCG Vaccine; Clinical Trials as Topic; Dacarbazine; Female; Humans; Lymph Node Excision; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Prospective Studies; Random Allocation; Semustine; Skin Neoplasms | 1982 |
Actinomycin-D plus 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamine (DTIC) with or without intravenous Corynebacterium parvum in metastatic malignant melanoma.
Topics: Adolescent; Adult; Aged; Clinical Trials as Topic; Dacarbazine; Dactinomycin; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Immunotherapy; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Propionibacterium acnes | 1982 |
Combination chemotherapy plus BCG in the treatment of disseminated malignant melanoma: a Southwest Oncology Group Study.
Topics: Adult; Age Factors; Antineoplastic Agents; BCG Vaccine; Clinical Trials as Topic; Dacarbazine; Drug Administration Schedule; Drug Therapy, Combination; Humans; Leukocyte Count; Melanoma; Middle Aged; Prognosis; Random Allocation; Skin Neoplasms; Skin Tests | 1982 |
A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma.
Topics: BCG Vaccine; Clinical Trials as Topic; Dacarbazine; Female; Humans; Lymphatic Metastasis; Male; Melanoma; Postoperative Care; Prognosis; Prospective Studies; Random Allocation; Skin Neoplasms | 1982 |
Phase II trial of recombinant interferon-alpha with BCNU, cisplatin, DTIC and tamoxifen in advanced malignant melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Combined Modality Therapy; Dacarbazine; Drug Administration Schedule; Female; Humans; Interferon Type I; Male; Melanoma; Middle Aged; Recombinant Proteins; Skin Neoplasms; Tamoxifen | 1995 |
Dacarbazine and interferon-alpha 2a in advanced malignant melanoma: high response rate and prolongation of response duration occur in different patient subpopulations.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dacarbazine; Female; Humans; Immunotherapy; Interferon alpha-2; Interferon-alpha; Male; Melanoma; Middle Aged; Neoplasm Staging; Prospective Studies; Recombinant Proteins | 1995 |
Addition of dacarbazine or cisplatin to interferon-alpha/interleukin-2 in metastatic melanoma: toxicity and immunological effects.
Topics: Adjuvants, Immunologic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Cytokines; Dacarbazine; Humans; Immunotherapy; Interferon Type I; Interleukin-2; Melanoma; Pilot Projects; Recombinant Proteins | 1995 |
Treatment of patients with metastatic melanoma with a one day regimen of dacarbazine, vincristine, bleomycin and lomustine plus interferon-alpha.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Female; Humans; Interferon-alpha; Lomustine; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Skin Neoplasms; Treatment Outcome; Vincristine | 1994 |
Dacarbazine (DTIC)-based chemotherapy or chemoimmunotherapy of patients with disseminated malignant melanoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Dacarbazine; Dactinomycin; Female; Granulocyte Colony-Stimulating Factor; Humans; Immunotherapy; Interferon-alpha; Male; Melanoma; Middle Aged; Treatment Outcome; Vinblastine | 1994 |
Intermittent interferon and polychemotherapy in metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Drug Administration Schedule; Evaluation Studies as Topic; Female; Humans; Interferon-alpha; Lomustine; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Vincristine | 1995 |
Results of a prospective randomized trial using DTIC and interferon as adjuvant therapy for stage I malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Interferons; Male; Melanoma; Middle Aged; Neoplasm Staging; Prospective Studies; Skin Neoplasms; Treatment Outcome | 1995 |
Interleukin-2-based immunotherapy and chemoimmunotherapy in metastatic melanoma.
Topics: Cisplatin; Combined Modality Therapy; Dacarbazine; Humans; Immunologic Factors; Interferon-alpha; Interleukin-2; Melanoma; Neoplasm Metastasis; Pilot Projects; Remission Induction; Salvage Therapy; Skin Neoplasms; Treatment Outcome | 1995 |
Chemoimmunotherapy of advanced malignant melanoma: sequential administration of subcutaneous interleukin-2 and interferon-alpha after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen.
Topics: Administration, Cutaneous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carmustine; Cisplatin; Dacarbazine; Female; Humans; Infusions, Intravenous; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Skin Neoplasms; Tamoxifen; Treatment Outcome | 1995 |
Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Dacarbazine; Female; Humans; Leukopenia; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Remission Induction; Survival Rate; Temozolomide; Thrombocytopenia; United Kingdom | 1995 |
Biochemotherapy with thymosin alpha 1, interleukin-2 and dacarbazine in patients with metastatic melanoma: clinical and immunological effects.
Topics: Adult; Aged; CD4 Antigens; CD8 Antigens; Combined Modality Therapy; Dacarbazine; Female; Humans; Interleukin-2; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Remission Induction; Skin Neoplasms; Thymalfasin; Thymosin | 1994 |
A multicenter phase II clinical trial using dacarbazine and continuous infusion interleukin-2 for metastatic melanoma. Clinical data and immunomonitoring.
Topics: Adult; Aged; Combined Modality Therapy; Dacarbazine; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Interleukin-2; Male; Melanoma; Middle Aged; Prognosis; Regression Analysis; Remission Induction; Skin Neoplasms; Survival Analysis; Treatment Outcome | 1995 |
A phase II study of the sequential administration of dacarbazine and fotemustine in the treatment of cerebral metastases from malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Drug Administration Schedule; Female; Humans; Leukopenia; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Thrombocytopenia; Treatment Outcome | 1994 |
Mechanism of the anti-tumour effect of biochemotherapy in melanoma: preliminary results.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cross-Linking Reagents; Dacarbazine; DNA Damage; DNA, Neoplasm; Drug Synergism; Humans; Immunologic Factors; Interferon alpha-2; Interferon-alpha; Interleukin-2; Killer Cells, Lymphokine-Activated; Killer Cells, Natural; Macrophage Activation; Melanoma; Models, Biological; Recombinant Proteins; Vinblastine | 1994 |
[Prevention and treatment of regional lymphatic metastasis of cutaneous melanoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Dacarbazine; Humans; Injections, Intralymphatic; Lymph Node Excision; Lymphatic Metastasis; Melanoma; Methotrexate; Neoplasm Staging; Preoperative Care; Prospidium; Skin Neoplasms; Survival Rate | 1993 |
A phase II study of high-dose hydroxyurea and dacarbazine (DTIC) in the treatment of metastatic malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Dacarbazine; Female; Gastrointestinal Neoplasms; Humans; Hydroxyurea; Liver Neoplasms; Lung Neoplasms; Male; Melanoma; Middle Aged; Sarcoma, Clear Cell; Treatment Outcome | 1994 |
Combination of chemotherapy with interleukin-2 and interferon-alfa for the treatment of advanced melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Dacarbazine; Drug Administration Schedule; Humans; Interferon-alpha; Interleukin-2; Melanoma; Vinblastine | 1994 |
Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Interleukin-2; Male; Melanoma; Middle Aged; Remission Induction; Tamoxifen | 1994 |
Inactivation of O6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells by temozolomide.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Dacarbazine; Female; Humans; Kinetics; Leukocytes, Mononuclear; Male; Melanoma; Methyltransferases; Middle Aged; Neoplasm Metastasis; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide; Time Factors | 1994 |
Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Interferon alpha-2; Interferon-alpha; Male; Melanoma; Middle Aged; Recombinant Proteins; Skin Neoplasms; Survival Analysis; Treatment Outcome | 1994 |
A phase II study of combined administration of dacarbazine and carboplatin with home therapy of recombinant interleukin-2 and interferon-alpha 2a in patients with advanced malignant melanoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dacarbazine; Female; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Prospective Studies; Recombinant Proteins; Survival Rate | 1994 |
Chemohormone therapy of metastatic melanoma with megestrol acetate plus dacarbazine, carmustine, and cisplatin.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Cachexia; Carmustine; Cisplatin; Dacarbazine; Drug Administration Schedule; Drug Tolerance; Female; Humans; Male; Megestrol; Megestrol Acetate; Melanoma; Middle Aged; Remission Induction; Survival Rate; Time Factors | 1994 |
Adjuvant chemotherapy with dacarbazine, vindesine, and cisplatin in pathological stage II malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Cisplatin; Dacarbazine; Female; Humans; Life Tables; Male; Melanoma; Middle Aged; Neoplasm Staging; Survival Analysis; Vindesine | 1994 |
Evaluation of cisplatin and DTIC in inoperable stage III and IV melanoma. A Southwest Oncology Group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Staging; Survival Analysis | 1993 |
Prognostic value of quality of life scores in a trial of chemotherapy with or without interferon in patients with metastatic malignant melanoma.
Topics: Adult; Aged; Dacarbazine; Female; Humans; Interferon alpha-2; Interferon-alpha; Male; Melanoma; Middle Aged; Predictive Value of Tests; Prognosis; Prospective Studies; Quality of Life; Recombinant Proteins | 1993 |
Preclinical, phase I and pharmacokinetic studies with the dimethyl phenyltriazene CB10-277.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Dacarbazine; Disease Models, Animal; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Melanoma; Mice; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Neoplasms; Species Specificity; Transplantation, Heterologous; Triazenes | 1993 |
Phase II study of vindesine and dacarbazine with or without non-specific stimulation of the immune system in patients with metastatic melanoma.
Topics: Adolescent; Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Dacarbazine; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Melanoma; Middle Aged; Prognosis; Vindesine | 1993 |
A phase II study of dacarbazine and cisplatin in combination with outpatient administered interleukin-2 in metastatic malignant melanoma.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Interleukin-2; Male; Melanoma; Middle Aged; Remission Induction | 1993 |
Sequential administration of varying doses of dacarbazine and fotemustine in advanced malignant melanoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Melanoma; Middle Aged; Neutropenia; Nitrosourea Compounds; Organophosphorus Compounds; Respiratory Distress Syndrome; Thrombocytopenia | 1993 |
Recombinant interferon alpha-2a in combination with dacarbazine in the treatment of metastatic malignant melanoma: analysis of long-term responding patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chi-Square Distribution; Dacarbazine; Drug Synergism; Female; Humans; Injections, Intravenous; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Prospective Studies; Recombinant Proteins; Skin Neoplasms; Survival Analysis | 1993 |
Therapy for metastatic melanoma: effective combination of dacarbazine, carmustine, cisplatin and tamoxifen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chemotherapy, Adjuvant; Cisplatin; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Soft Tissue Neoplasms; Tamoxifen | 1993 |
Interferon-alpha 2a does not improve response or survival when combined with dacarbazine in metastatic malignant melanoma: results of a multi-institutional Australian randomized trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; Interferon alpha-2; Interferon-alpha; Male; Melanoma; Middle Aged; Prospective Studies; Recombinant Proteins | 1993 |
Phase II trial of piritrexim and DTIC using an alternating dose schedule in metastatic melanoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Liver Neoplasms; Lung Neoplasms; Male; Melanoma; Middle Aged; Pyrimidines; Remission Induction | 1995 |
Dacarbazine, cisplatin and carmustine, with or without tamoxifen, for metastatic melanoma: 5-year follow-up.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Female; Follow-Up Studies; Humans; Male; Melanoma; Middle Aged; Sex Characteristics; Survival Rate; Tamoxifen | 1995 |
Experience with interferon alpha 2b combined with dacarbazine in the treatment of metastatic malignant melanoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Injections, Intravenous; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Prospective Studies; Recombinant Proteins; Remission Induction; Treatment Outcome | 1995 |
Correlation of DNA ploidy and S-phase fraction with chemotherapeutic response and survival in a randomized study of disseminated malignant melanoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; DNA, Neoplasm; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Ploidies; Regression Analysis; S Phase; Survival Analysis; Vindesine | 1996 |
Fotemustine, dacarbazine, vindesine combination chemotherapy in advanced malignant melanoma: a phase II study of 43 patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Follow-Up Studies; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Nitrosourea Compounds; Organophosphorus Compounds; Remission Induction; Risk; Salvage Therapy; Survival Rate; Treatment Outcome; Vindesine | 1995 |
The addition of tamoxifen to dacarbazine and cisplatin in metastatic malignant melanoma. A phase II trial of the Southwest Oncology Group, (SWOG-8921).
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Drug Administration Schedule; Estrogen Antagonists; Female; Follow-Up Studies; Humans; Male; Melanoma; Middle Aged; Remission Induction; Sex Factors; Tamoxifen | 1996 |
The use of DAV (DTIC, ACNU and VCR) and natural interferon-beta combination therapy in malignant melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Humans; Hutchinson's Melanotic Freckle; Interferon-beta; Melanoma; Nimustine; Skin Neoplasms; Survival Rate; Vincristine | 1995 |
Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Cancer Institute of Canada Clinical Trials Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Disease-Free Survival; Double-Blind Method; Female; Humans; Male; Melanoma; Middle Aged; Skin Neoplasms; Survival Rate; Tamoxifen | 1996 |
[Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carmustine; Cisplatin; Combined Modality Therapy; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Recombinant Proteins; Skin Neoplasms; Tamoxifen | 1996 |
[Chemohormonal therapy for malignant melanomas].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Dacarbazine; Estrogen Antagonists; Female; Head and Neck Neoplasms; Humans; Male; Melanoma; Middle Aged; Tamoxifen | 1996 |
[Protocol for optimal therapy of malignant melanoma in the metastatic stage by the Dermatologic Oncology Working Group].
Topics: Combined Modality Therapy; Dacarbazine; Humans; Interferon-alpha; Interleukin-2; Melanoma; Neoplasm Staging; Prospective Studies; Recombinant Proteins; Skin Neoplasms | 1996 |
DTIC vs. IFN-alpha plus DTIC in the treatment of patients with metastatic malignant melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Interferon-alpha; Male; Melanoma; Middle Aged; Skin Neoplasms | 1996 |
Complete responses and survival after polychemotherapy plus interferon-alpha for patients with metastatic melanoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Dacarbazine; Female; Humans; Immunotherapy; Interferon alpha-2; Interferon-alpha; Lomustine; Male; Melanoma; Middle Aged; Nimustine; Recombinant Proteins; Treatment Outcome; Vincristine | 1996 |
A phase II study of dacarbazine, cisplatin, interferon-alpha and high-dose interleukin-2 in 'poor-risk' metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cohort Studies; Combined Modality Therapy; Dacarbazine; Humans; Interferon-alpha; Interleukin-2; Melanoma; Middle Aged; Receptors, Interleukin-2; Remission Induction; Survival Analysis; Tumor Necrosis Factor-alpha | 1996 |
Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Cisplatin; Combined Modality Therapy; Dacarbazine; Drug Administration Schedule; Female; Humans; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Skin Neoplasms; Survival Rate; Treatment Outcome; Vinblastine | 1996 |
Combination chemotherapy (dacarbazine, carmustine, cisplastin, and tamoxifen) in advanced melanoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Disease-Free Survival; Female; Humans; Male; Melanoma; Middle Aged; Prognosis; Singapore; Skin Neoplasms; Survival Rate; Tamoxifen | 1996 |
Dose comparison of tropisetron (Navoban) 5 mg and 10 mg orally in the prophylaxis of dacarbazine-induced nausea and emesis.
Topics: Administration, Oral; Adult; Aged; Antiemetics; Antineoplastic Agents; Dacarbazine; Double-Blind Method; Drug Administration Schedule; Female; Humans; Indoles; Male; Melanoma; Middle Aged; Nausea; Quality of Life; Serotonin Antagonists; Tropisetron; Vomiting | 1994 |
Outpatient chemoimmunotherapy for the treatment of metastatic melanoma.
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Humans; Immunotherapy; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Recombinant Proteins; Skin Neoplasms; Tamoxifen; Treatment Outcome | 1997 |
A phase II study of interferon-alpha 2b with dacarbazine, carmustine, cisplatin and tamoxifen in metastatic melanoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Combined Modality Therapy; Confidence Intervals; Dacarbazine; Disease-Free Survival; Drug Administration Schedule; Humans; Interferon alpha-2; Interferon-alpha; Melanoma; Middle Aged; Neoplasm Metastasis; Recombinant Proteins; Tamoxifen | 1997 |
Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD) plus interferon alpha for metastatic melanoma: a multicentre phase II study.
Topics: Abdominal Neoplasms; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brain Neoplasms; Dacarbazine; Female; Humans; Immunotherapy; Interferon-alpha; Lomustine; Male; Melanoma; Middle Aged; Neoplasm Staging; Skin Neoplasms; Treatment Outcome; Vincristine | 1997 |
BOLD+interferon in the treatment of metastatic uveal melanoma: first report of active systemic therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Female; Humans; Interferon alpha-2; Interferon-alpha; Lomustine; Lung Diseases; Male; Melanoma; Middle Aged; Recombinant Proteins; Uveal Neoplasms; Vincristine | 1997 |
Fotemustine and dacarbazine plus recombinant interferon alpha 2a in thetreatment of advanced melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease-Free Survival; Female; Follow-Up Studies; Humans; Interferon alpha-2; Interferon-alpha; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Recombinant Proteins; Survival Rate | 1997 |
Isolated limb perfusion with fotemustine after chemosensitization with dacarbazine in melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Arm; Chemotherapy, Cancer, Regional Perfusion; Dacarbazine; Female; Humans; Leg; Male; Melanoma; Middle Aged; Neoplasm Staging; Nitrosourea Compounds; Organophosphorus Compounds; Pilot Projects; Skin Neoplasms | 1997 |
Development and results of biochemotherapy in metastatic melanoma: the University of Texas M.D. Anderson Cancer Center experience.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Dacarbazine; Drug Therapy, Combination; Humans; Immunotherapy; Interferon-alpha; Interleukin-2; Melanoma; Middle Aged; Recombinant Proteins; Survival Rate; Treatment Outcome; Vinblastine | 1997 |
Recombinant interleukin-2-based treatments for advanced melanoma: the experience of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Dacarbazine; Humans; Immunotherapy; Interferon-alpha; Interleukin-2; Melanoma; Recombinant Proteins; Survival Rate | 1997 |
Updated analysis of an outpatient chemoimmunotherapy regimen for treating metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Combined Modality Therapy; Dacarbazine; Female; Humans; Immunotherapy; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Interleukin-2; L-Lactate Dehydrogenase; Male; Melanoma; Middle Aged; Prognosis; Recombinant Proteins; Survival Rate; Tamoxifen; Treatment Outcome | 1997 |
Topical dinitrochlorobenzene combined with systemic dacarbazine in the treatment of recurrent melanoma.
Topics: Administration, Topical; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dacarbazine; Dinitrochlorobenzene; Female; Humans; Immunotherapy; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Skin Neoplasms | 1997 |
Phase II study of carmustine, dacarbazine, cisplatin, and tamoxifen in advanced melanoma: a Southwest Oncology Group study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Skin Neoplasms; Tamoxifen | 1998 |
[Treatment of lung metastases from malignant melanoma with IL-2 inhalation therapy].
Topics: Administration, Inhalation; Adult; Aged; Combined Modality Therapy; Dacarbazine; Female; Humans; Interleukin-12; Lung Neoplasms; Male; Melanoma; Middle Aged; Skin Neoplasms | 1997 |
Interferon-alpha and chemohormonal therapy for patients with advanced melanoma: final results of a phase I-II study of the Cancer Biotherapy Research Group and the Mid-Atlantic Oncology Program.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Combined Modality Therapy; Dacarbazine; Drug Administration Schedule; Female; Humans; Interferon alpha-2; Interferon-alpha; Liver Neoplasms; Lung Neoplasms; Male; Melanoma; Middle Aged; Recombinant Proteins; Tamoxifen | 1998 |
Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Disease-Free Survival; Female; Flow Cytometry; Humans; Interferon-alpha; Interleukin-2; Killer Cells, Natural; Lymphocyte Activation; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Survival Rate; T-Lymphocytes; Tamoxifen; Treatment Outcome | 1998 |
Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group st
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Interferon alpha-2; Interferon-alpha; Male; Melanoma; Middle Aged; Recombinant Proteins; Survival Rate; Tamoxifen; Treatment Failure | 1998 |
DNA damage in peripheral blood mononuclear cells correlates with response to biochemotherapy in melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Dacarbazine; Disease Progression; DNA Damage; Glutathione Transferase; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-2; Leukocytes, Mononuclear; Melanoma; Neoplasm Staging; Polymerase Chain Reaction; Recombinant Proteins; Skin Neoplasms; Vinblastine | 1998 |
Nitric oxide and neopterin levels and clinical response in stage III melanoma patients receiving concurrent biochemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Dacarbazine; Female; Humans; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Neoplasm Staging; Neopterin; Nitric Oxide; Skin Neoplasms; Vinblastine | 1998 |
Combined treatment with dacarbazine, cisplatin, fotemustine and tamoxifen in metastatic malignant melanoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Dacarbazine; Humans; Melanoma; Middle Aged; Neoplasm Metastasis; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms; Survival Rate; Tamoxifen | 1998 |
Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: comparison of oral, intravenous, and hepatic intra-arterial administration.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; Dacarbazine; Female; Glioma; Hepatic Artery; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Temozolomide | 1998 |
Risk and outcome in metastatic malignant melanoma patients receiving DTIC, cisplatin, BCNU and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha2a.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Female; Humans; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Prognosis; Risk; Survival Analysis; Tamoxifen; Treatment Outcome | 1998 |
Changes in immunological parameters after combination adjuvant therapy with intravenous DTIC, ACNU, and VCR, and local injection of IFN-beta (DAV + IFN-beta therapy) into malignant melanoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; CD4-CD8 Ratio; Chemotherapy, Adjuvant; Dacarbazine; Female; Flow Cytometry; Humans; Injections, Intralesional; Injections, Intravenous; Interferon-beta; Killer Cells, Natural; Leukocyte Count; Male; Melanoma; Middle Aged; Nimustine; Skin Neoplasms; Statistics, Nonparametric; T-Lymphocytes; Treatment Outcome; Vincristine | 1998 |
Carmustine and streptozocin in refractory melanoma: an attempt at modulation of O-alkylguanine-DNA-alkyltransferase.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Dacarbazine; Female; Glutathione; Humans; Male; Melanoma; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Streptozocin | 1996 |
O6-methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Biopsy; Dacarbazine; Female; Humans; Leukocytes, Mononuclear; Lymphatic Metastasis; Male; Melanoma; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Predictive Value of Tests; Prospective Studies; Temozolomide | 1998 |
Dacarbazine-vindesine versus dacarbazine-vindesine-cisplatin in disseminated malignant melanoma. A randomised phase III trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Female; Hematologic Diseases; Humans; Lung Neoplasms; Male; Melanoma; Middle Aged; Nausea; Prospective Studies; Regression Analysis; Skin Neoplasms; Survival Analysis; Treatment Outcome; Vindesine; Vomiting | 1998 |
Phase II study of neoadjuvant concurrent biochemotherapy in melanoma patients with local-regional metastases.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Melanoma; Melanoma, Amelanotic; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Recombinant Proteins; Skin Neoplasms; Time Factors; Treatment Outcome; Vinblastine | 1998 |
Long-term outcome of treatment with dacarbazine, cisplatin, interferon-alpha and intravenous high dose interleukin-2 in poor risk melanoma patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Dacarbazine; Humans; Interferon-alpha; Interleukin-2; L-Lactate Dehydrogenase; Melanoma; Middle Aged; Neoplasm Metastasis; Prognosis; Risk; Skin Neoplasms; Survival Rate; Time Factors; Treatment Outcome | 1998 |
Induction of tyrosinase-reactive T cells by treatment with dacarbazine, cisplatin, interferon-alpha +/- interleukin-2 in patients with metastatic melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Dacarbazine; Epitopes; HLA-A Antigens; HLA-B Antigens; HLA-B44 Antigen; Humans; Interferon-alpha; Interferon-gamma; Interleukin-2; Melanoma; Monophenol Monooxygenase; Neoplasm Staging; Peptide Fragments; T-Lymphocytes | 1999 |
Sustained complete remission after chemobiohormonal therapy for metastatic melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Female; Humans; Interferon-alpha; Lung Neoplasms; Male; Melanoma; Middle Aged; Prospective Studies; Remission Induction; Skin Neoplasms; Tamoxifen | 1999 |
Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Dacarbazine; Female; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Prospective Studies; Recombinant Proteins; Remission Induction; Tamoxifen | 1999 |
Combination of chemotherapy with interleukin-2 and interferon alfa for the treatment of metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Combined Modality Therapy; Dacarbazine; Female; Humans; Immunotherapy, Active; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Pilot Projects; Recombinant Proteins; Treatment Outcome | 1999 |
A phase III randomized trial of dacarbazine and carboplatin with and without tamoxifen in the treatment of patients with metastatic melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dacarbazine; Disease Progression; Female; Humans; Male; Melanoma; Middle Aged; Survival Rate; Tamoxifen; Treatment Outcome | 1999 |
Phase II trial of biochemotherapy with interferon alpha, dacarbazine, cisplatin and tamoxifen in metastatic melanoma: a Southwest Oncology Group trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Drug Administration Schedule; Female; Humans; Interferon-alpha; Male; Melanoma; Middle Aged; Southwestern United States; Tamoxifen; Treatment Outcome | 1999 |
Sequential administration of temozolomide and fotemustine: depletion of O6-alkyl guanine-DNA transferase in blood lymphocytes and in tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Glioma; Humans; Lymphocytes; Male; Melanoma; Middle Aged; Nitrosourea Compounds; O(6)-Methylguanine-DNA Methyltransferase; Organophosphorus Compounds; Temozolomide | 1999 |
Phase III clinical trial of the combination of cisplatin, dacarbazine, and carmustine with or without tamoxifen in patients with advanced malignant melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Disease-Free Survival; Eye Neoplasms; Female; Humans; Male; Melanoma; Middle Aged; Prospective Studies; Skin Neoplasms; Survival Rate; Tamoxifen; Treatment Outcome | 1999 |
Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Staging; Skin Neoplasms; Survival Analysis; Tamoxifen; Treatment Outcome | 1999 |
Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Alkylating; Biological Availability; Brain Neoplasms; Dacarbazine; Dose-Response Relationship, Drug; Eating; Female; Glioma; Humans; Male; Melanoma; Middle Aged; Neoplasms; Skin Neoplasms; Temozolomide; Treatment Outcome | 1999 |
Pilot study of intra-arterial cisplatin and intravenous vinblastine and dacarbazine in patients with melanoma in-transit metastases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Disease-Free Survival; Female; Humans; Infusions, Intra-Arterial; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoplasm, Residual; Pilot Projects; Skin Neoplasms; Survival Rate; Treatment Outcome; Vinblastine | 1999 |
Multi-institutional phase II randomized trial of integrated therapy with cisplatin, dacarbazine, vindesine, subcutaneous interleukin-2, interferon alpha2a and tamoxifen in metastatic melanoma. BREMIM (Biological Response Modifiers in Melanoma).
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Disease-Free Survival; Female; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Recombinant Proteins; Survival Rate; Tamoxifen; Treatment Outcome; Vindesine | 1999 |
Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biological Availability; Consumer Product Safety; Dacarbazine; Disease-Free Survival; Female; Humans; Male; Melanoma; Neoplasm Metastasis; Quality of Life; Regression Analysis; Survival Rate | 2000 |
GM-CSF can cause T cell activation; results of sequential chemo-immunotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Dacarbazine; Female; Follow-Up Studies; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Immunophenotyping; Lymphocyte Activation; Male; Melanoma; Middle Aged; T-Lymphocyte Subsets | 1999 |
Results of a phase II trial with cystemustine at 90 mg/m(2) as a first- or second-line treatment in advanced malignant melanoma: a trial of the EORTC Clinical Studies Group.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Dacarbazine; Female; Humans; Immunotherapy; Male; Melanoma; Middle Aged; Neoplasm Staging; Nitrosourea Compounds; Treatment Outcome | 1999 |
Rationale for intergroup trial E-3695 comparing concurrent biochemotherapy with cisplatin, vinblastine, and DTIC alone in patients with metastatic melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Humans; Interferon-alpha; Interleukin-2; Melanoma; Vinblastine | 2000 |
A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Combined Modality Therapy; Dacarbazine; Disease Progression; Female; Humans; Interferon-alpha; Male; Melanoma; Middle Aged; Skin Neoplasms; Survival Analysis; Tamoxifen; Treatment Outcome | 2000 |
Post hoc economic analysis of temozolomide versus dacarbazine in the treatment of advanced metastatic melanoma.
Topics: Administration, Oral; Adult; Antineoplastic Agents, Alkylating; Cost-Benefit Analysis; Dacarbazine; Female; Health Care Costs; Humans; Infusions, Intravenous; Male; Melanoma; Quality-Adjusted Life Years; Skin Neoplasms; Temozolomide | 2000 |
A phase II study of biochemotherapy for the treatment of metastatic malignant melanoma.
Topics: Abdominal Neoplasms; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Colorado; Combined Modality Therapy; Dacarbazine; Female; Follow-Up Studies; Humans; Hypotension; Immunologic Factors; Interferon alpha-2; Interferon-alpha; Interleukin-2; Life Tables; Liver Neoplasms; Lung Neoplasms; Male; Melanoma; Middle Aged; Neutropenia; Recombinant Proteins; Remission Induction; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome; Vinblastine | 2000 |
Combined treatment with thymosin-alpha1 and low dose interferon-alpha after dacarbazine in advanced melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Combined Modality Therapy; Dacarbazine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Feasibility Studies; Female; Humans; Immunologic Factors; Interferon alpha-2; Interferon-alpha; Killer Cells, Natural; Lymphopenia; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Recombinant Proteins; Safety; Survival Analysis; Thymalfasin; Thymosin; Treatment Outcome | 2000 |
Phase II study of second-line therapy with DTIC, BCNU, cisplatin and tamoxifen (Dartmouth regimen) chemotherapy in patients with malignant melanoma previously treated with dacarbazine.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Survival Analysis; Tamoxifen | 2000 |
A sequential four-drug chemotherapy and biotherapy with interferon alpha and GM-CSF--an innovative protocol for the treatment of metastatic melanoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cells, Cultured; Cisplatin; Dacarbazine; Dendritic Cells; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interferon alpha-2; Interferon-alpha; Macrophages; Male; Melanoma; Middle Aged; Recombinant Proteins; Survival Analysis; Time Factors | 1998 |
A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alpha-2B in patients with metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cisplatin; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Pilot Projects; Recombinant Proteins; Recurrence; Time Factors; Treatment Outcome; Vinblastine | 2000 |
Combined chemotherapy with or without interferon alpha N1 (IFN) for advanced malignant melanoma--a randomized pilot phase III study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Drug Administration Schedule; Female; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Pilot Projects; Recombinant Proteins; Skin Neoplasms | 2000 |
Unexpected cytokines in serum of malignant melanoma patients during sequential biochemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytokines; Dacarbazine; Enzyme-Linked Immunosorbent Assay; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-10; Interleukin-2; Interleukin-6; Interleukins; Macrophage Activation; Macrophages; Melanoma; Neopterin; Nitrites; Radioimmunoassay; Random Allocation; Receptors, Interleukin-2; Recombinant Proteins; Time Factors; Tumor Necrosis Factor-alpha; Vincristine | 2000 |
O6-methylguanine formation, repair protein depletion and clinical outcome with a 4 hr schedule of temozolomide in the treatment of advanced melanoma: results of a phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Dacarbazine; Drug Administration Schedule; Female; Guanine; Humans; Male; Melanoma; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide | 2000 |
GM-CSF with biochemotherapy (cisplatin, DTIC, tamoxifen, IL-2 and interferon-alpha): a phase I trial in melanoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cohort Studies; Dacarbazine; Dose-Response Relationship, Drug; Drug Evaluation; Feasibility Studies; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Skin Neoplasms; Survival Analysis; Tamoxifen; Treatment Outcome | 2000 |
Chemosensitisation of malignant melanoma by BCL2 antisense therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Dacarbazine; DNA, Antisense; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Fever; Follow-Up Studies; Hematologic Diseases; Humans; Male; Melanoma; Middle Aged; Proto-Oncogene Mas; Proto-Oncogene Proteins c-bcl-2; Skin; Skin Neoplasms; Survival Analysis; Treatment Outcome | 2000 |
Cisplatin, dacarbazine, and fotemustine plus interferon alpha in patients with advanced malignant melanoma. A multicenter phase II study of the Italian Cooperative Oncology Group.
Topics: Adult; Aged; Anemia; Antigens, CD; Antigens, Neoplasm; Antigens, Surface; Antineoplastic Combined Chemotherapy Protocols; CD146 Antigen; Cisplatin; Dacarbazine; Female; Fever; Follow-Up Studies; Humans; Interferon-alpha; Male; MART-1 Antigen; Melanoma; Melanoma-Specific Antigens; Membrane Glycoproteins; Middle Aged; Monophenol Monooxygenase; Nausea; Neoplasm Proteins; Neural Cell Adhesion Molecules; Neutropenia; Nitrosourea Compounds; Organophosphorus Compounds; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Analysis; Thrombocytopenia; Treatment Outcome; Vomiting | 2000 |
Phase II trial of subcutaneous interleukin-2, subcutaneous interferon-alpha, intravenous combination chemotherapy, and oral tamoxifen in the treatment of metastatic melanoma: final results of cancer biotherapy research group 94-11.
Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Recombinant Proteins; Skin Neoplasms; Survival Rate; Tamoxifen | 2000 |
Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trials.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Databases, Factual; Humans; Immunotherapy; Interferons; Melanoma; Odds Ratio; Skin Neoplasms; Time Factors | 2001 |
Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chills; Dacarbazine; Female; Fever; Follow-Up Studies; Hematologic Diseases; Humans; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Nausea; Remission Induction; Survival Analysis; Treatment Outcome; Vomiting | 2001 |
Outpatient biochemotherapy with interleukin-2 and interferon alfa-2b in patients with metastatic malignant melanoma: results of two phase II cytokine working group trials.
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Disease-Free Survival; Female; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Recombinant Proteins; Survival Rate | 2001 |
Granulocyte-macrophage colony-stimulating factor alone or with dacarbazine in metastatic melanoma: a randomized phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Male; Melanoma; Middle Aged; Survival Analysis; Treatment Outcome | 2001 |
Temozolomide in combination with docetaxel in patients with advanced melanoma: a phase II study of the Hellenic Cooperative Oncology Group.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Docetaxel; Female; Humans; Infusions, Intravenous; Male; Melanoma; Middle Aged; Neutropenia; Paclitaxel; Skin Neoplasms; Taxoids; Temozolomide; Thrombocytopenia | 2002 |
High expression levels of collagenase-1 and stromelysin-1 correlate with shorter disease-free survival in human metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cell Division; Collagenases; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Enzyme Induction; Female; Humans; Immunologic Factors; Immunotherapy; Interferon-alpha; Interleukin-2; Lomustine; Male; Matrix Metalloproteinase 3; Melanins; Melanocytes; Melanoma; Middle Aged; Neoplasm Proteins; Neoplastic Stem Cells; Prognosis; Radiotherapy, Adjuvant; Vincristine | 2002 |
Prospective randomized comparison of dacarbazine (DTIC) versus DTIC plus interferon-alpha (IFN-alpha) in metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Interferon-alpha; Male; Melanoma; Middle Aged; Pilot Projects; Prospective Studies; Quality of Life; Skin Neoplasms; Survival Rate | 2001 |
Comparison of the efficacy of two different dosage dacarbazine-based regimens and two regimens without dacarbazine in metastatic melanoma: a single-centre randomized four-arm study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Dacarbazine; Dose-Response Relationship, Drug; Female; Humans; Male; Melanoma; Middle Aged; Procarbazine; Skin Neoplasms; Time Factors; Treatment Outcome; Vincristine | 2002 |
Deliberate hypoxic pelvic and limb chemoperfusion in the treatment of recurrent melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusion; Cisplatin; Dacarbazine; Disease Progression; Disease-Free Survival; Epirubicin; Female; Hemodynamics; Humans; Hypoxia; Leg; Male; Melanoma; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Palliative Care; Pelvis; Skin Neoplasms; Treatment Outcome | 2002 |
Combination chemotherapy with or without s.c. IL-2 and IFN-alpha: results of a prospectively randomized trial of the Cooperative Advanced Malignant Melanoma Chemoimmunotherapy Group (ACIMM).
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Humans; Infusions, Intravenous; Injections, Subcutaneous; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Prospective Studies; Skin Neoplasms; Tamoxifen; Treatment Outcome | 2002 |
Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Female; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-2; Italy; Male; Melanoma; Middle Aged; Outpatients; Proportional Hazards Models; Prospective Studies; Quality of Life; Recombinant Proteins; Skin Neoplasms; Surveys and Questionnaires; Treatment Outcome | 2002 |
A phase II study of neoadjuvant biochemotherapy for stage III melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Disease Progression; Female; Granulocyte Colony-Stimulating Factor; Humans; Interferon-alpha; Interleukin-2; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Pilot Projects; Skin Neoplasms; Survival Rate; Treatment Outcome; Vinblastine | 2002 |
Vinblastin-carboplatin for metastatic cutaneous melanoma as first-line chemotherapy and in dacarbazine failures: a single-center study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dacarbazine; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Male; Melanoma; Middle Aged; Neutropenia; Salvage Therapy; Skin Neoplasms; Thrombocytopenia; Treatment Outcome; Vinblastine | 2001 |
Effect of temozolomide on central nervous system relapse in patients with advanced melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Case-Control Studies; Dacarbazine; Female; Humans; Lung Neoplasms; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Retrospective Studies; Soft Tissue Neoplasms; Survival Rate; Temozolomide; Treatment Outcome | 2002 |
Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the Cytokine Working Group.
Topics: Administration, Oral; Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Dose Fractionation, Radiation; Female; Humans; Male; Melanoma; Middle Aged; Skin Neoplasms; Temozolomide; Treatment Outcome | 2002 |
[Use of local magnitothermia in the treatment of patients with primary-confined skin melanoma].
Topics: Adjuvants, Immunologic; Adolescent; Adult; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Dacarbazine; Electromagnetic Fields; Female; Hot Temperature; Humans; Injections; Interferon Type I; Interferon-alpha; Lymphatic System; Male; Melanoma; Middle Aged; Recombinant Proteins; Skin Neoplasms; Survival Rate | 2002 |
Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Female; Humans; Immunologic Factors; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Recombinant Proteins; Survival Analysis; Vinblastine | 2002 |
Phase II trial of Paclitaxel and Dacarbazine with filgrastim administration in advanced malignant melanoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Infusions, Intravenous; Male; Melanoma; Middle Aged; Nervous System Diseases; Paclitaxel; Skin Neoplasms; Treatment Outcome | 2002 |
Temozolomide plus thalidomide in patients with advanced melanoma: results of a dose-finding trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Dose-Response Relationship, Drug; Female; Humans; Male; Melanoma; Middle Aged; Survival Rate; Temozolomide; Thalidomide | 2002 |
[Treatment of metastatic malignant melanoma (author's transl)].
Topics: Adult; Aged; Bleomycin; Dacarbazine; Doxorubicin; Drug Therapy, Combination; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Triazenes; Vincristine | 1978 |
Use of combination chemotherapy with CCNU, bleomycin, and vincristine in the treatment of metastatic melanoma in patients resistant to DTIC therapy.
Topics: Adult; Aged; Bleomycin; Clinical Trials as Topic; Dacarbazine; Drug Resistance; Drug Therapy, Combination; Female; Humans; Lomustine; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Nitrosourea Compounds; Vincristine | 1979 |
Chemoimmunotherapy in disseminated melanoma and colorectal carcinoma.
Topics: Bacterial Vaccines; Colonic Neoplasms; Corynebacterium; Dacarbazine; Female; Fluorouracil; Humans; Immunotherapy; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Rectal Neoplasms; Triazenes | 1978 |
Combination chemotherapy for disseminated malignant melanoma with DTIC, vincristine, and methyl-CCNU.
Topics: Adult; Aged; Clinical Trials as Topic; Dacarbazine; Drug Therapy, Combination; Female; Humans; Leukocyte Count; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Nitrosourea Compounds; Semustine; Triazenes; Vincristine | 1977 |
Results with methyl-CCNU and DTIC in metastatic melanoma.
Topics: Brain Neoplasms; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Dacarbazine; Drug Therapy, Combination; Female; Humans; Liver Neoplasms; Male; Melanoma; Neoplasm Metastasis; Nitrosourea Compounds; Prognosis; Remission, Spontaneous; Semustine; Thrombocytopenia; Time Factors; Triazenes | 1977 |
Combination chemotherapy in metastatic malignant melanoma: a randomized study of three DTIC-containing combination.
Topics: Adult; Antineoplastic Agents; Clinical Trials as Topic; Cyclophosphamide; Dacarbazine; Drug Therapy, Combination; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Procarbazine; Remission, Spontaneous; Time Factors; Triazenes; Vinblastine | 1978 |
Malignant melanoma (stage IIIB): a pilot study of adjuvant chemo-immunotherapy.
Topics: Adult; Aged; Antigens, Neoplasm; BCG Vaccine; Carmustine; Clinical Trials as Topic; Dacarbazine; Female; Humans; Hydroxyurea; Male; Melanoma; Middle Aged; Pilot Projects | 1978 |
Chemoimmunotherapy for disseminated malignant melanoma: a prospective randomized study.
Topics: BCG Vaccine; Clinical Trials as Topic; Dacarbazine; Dactinomycin; Evaluation Studies as Topic; Humans; Immunotherapy; Melanoma; Mycobacterium bovis; Neoplasm Metastasis; Prospective Studies; Triazenes | 1978 |
Phase I--II study of intermittent bolus administration of DTIC and actinomycin D in metastatic malignant melanoma.
Topics: Adult; Aged; Clinical Trials as Topic; Dacarbazine; Dactinomycin; Drug Administration Schedule; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Injections, Intravenous; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Triazenes | 1978 |
[Chemotherapy of malignant melanoma. Results of a controlled clinical trial comparing vincristine + dacarbazin (DTIC) with and without duborimycin (author's transl)].
Topics: Antibiotics, Antineoplastic; Clinical Trials as Topic; Dacarbazine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Male; Melanoma; Triazenes; Vincristine | 1978 |
[Treatment of malignant melanoma with DTIC--therapeutic effects determined by 5-S-cysteinyldopa changes in the urine (proceedings)].
Topics: Clinical Trials as Topic; Cysteinyldopa; Dacarbazine; Dihydroxyphenylalanine; Drug Evaluation; Humans; Melanoma; Skin Neoplasms; Triazenes | 1978 |
Combined DTIC and cis-dichlorodiammineplatinum(II) therapy for patients with disseminated melanoma: a Northern California Oncology Group study.
Topics: Adolescent; Adult; Aged; Child; Cisplatin; Clinical Trials as Topic; Dacarbazine; Drug Therapy, Combination; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Triazenes | 1979 |
Cyclophosphamide plus 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide (DTIC) with or without Corynebacterium parvum in metastatic malignant melanoma.
Topics: Bone Marrow; Clinical Trials as Topic; Cyclophosphamide; Dacarbazine; Drug Therapy, Combination; Humans; Immunotherapy; Melanoma; Middle Aged; Propionibacterium acnes | 1979 |
Randomized trial of adjuvant therapy for "high risk" primary malignant melanoma.
Topics: Adult; Aged; BCG Vaccine; Dacarbazine; Drug Therapy, Combination; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Risk; Skin Neoplasms; Triazenes | 1978 |
[Chemotherapy of disseminated malignant melanoma].
Topics: Dacarbazine; Daunorubicin; Drug Therapy, Combination; Humans; Melanoma; Remission, Spontaneous; Triazenes; Vincristine | 1978 |
Results of a randomized study comparing DTIC with TIC mustard in malignant melanoma.
Topics: Clinical Trials as Topic; Dacarbazine; Drug Evaluation; Female; Humans; Imidazoles; Male; Melanoma; Nitrogen Mustard Compounds; Prospective Studies; Triazenes | 1976 |
DTIC (NSC-45388) in malignant melanoma: a perspective.
Topics: Animals; Antineoplastic Agents; Carmustine; Clinical Trials as Topic; Dacarbazine; Drug Evaluation; Drug Therapy, Combination; Humans; Lomustine; Melanoma; Mice; Neoplasm Metastasis; Nitrosourea Compounds; Remission, Spontaneous; Triazenes | 1976 |
Phase I evaluation of DTIC (NSC-45388) and other studies in malignant melanoma in the Central Oncology Group.
Topics: Carmustine; Clinical Trials as Topic; Dacarbazine; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Leukopenia; Lomustine; Male; Melanoma; Middle Aged; Nausea; Sex Factors; Thrombocytopenia; Triazenes; Vincristine; Vomiting | 1976 |
DTIC (NSC-45388) studies in the southwest oncology group.
Topics: Carmustine; Chlorpromazine; Clinical Trials as Topic; Dacarbazine; Drug Evaluation; Drug Therapy, Combination; Hodgkin Disease; Humans; Leukopenia; Lymphoma; Melanoma; Nausea; Neoplasm Metastasis; Remission, Spontaneous; Thrombocytopenia; Triazenes; Vincristine; Vomiting | 1976 |
Eastern Cooperative Oncology Group studies with DTIC (NSC-45388).
Topics: Adult; Aged; Carmustine; Clinical Trials as Topic; Dacarbazine; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Lomustine; Male; Melanoma; Middle Aged; Sex Factors; Skin Neoplasms; Triazenes | 1976 |
Combination chemotherapy with DTIC (NSC-45388) in advanced malignant melanoma, soft tissue sarcomas, and Hodgkin's disease.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Dacarbazine; Doxorubicin; Drug Evaluation; Drug Therapy, Combination; Female; Hodgkin Disease; Humans; Male; Melanoma; Sarcoma; Skin Neoplasms; Soft Tissue Neoplasms; Triazenes | 1976 |
Clinical comparison of adriamycin and a combination of methyl-CCNU and imidazole carboxamide in disseminated malignant melanoma.
Topics: Adult; Aged; Clinical Trials as Topic; Dacarbazine; Doxorubicin; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Melanins; Melanoma; Middle Aged; Neoplasm Metastasis; Nitrosourea Compounds; Semustine; Triazenes | 1976 |
Cyclophosphamide, vincristine and procarbazine in the treatment of malignant melanoma.
Topics: Adult; Aged; Clinical Trials as Topic; Cyclophosphamide; Dacarbazine; Drug Therapy, Combination; Female; Humans; Male; Melanoma; Middle Aged; Procarbazine; Prospective Studies; Semustine; Vincristine | 1976 |
Randomized prospective trial of DTIC (NSC-45388) alone versus BCNU (NSC-409962) plus vincristine (NSC-67574) in the treatment of metastatic malignant melanoma.
Topics: Carmustine; Clinical Trials as Topic; Dacarbazine; Drug Therapy, Combination; Female; Humans; Male; Melanoma; Neoplasm Metastasis; Pennsylvania; Prospective Studies; Triazenes; Vincristine | 1976 |
Clinical trial of combination chemotherapy and specific active immunotherapy in disseminated melanoma.
Topics: Antigens, Neoplasm; BCG Vaccine; Dacarbazine; Drug Therapy, Combination; Female; Humans; Immunotherapy; Male; Melanoma; Piperazines; Prognosis; Razoxane; Triazenes | 1976 |
DTIC (nsc-45388) and combination therapy for melanoma. I. Studies with DTIC, BCNU (NSC-409962), CCNU (NSC-79037), vincristine (NSC-67574), and hydroxyurea (NSC-32065).
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carmustine; Dacarbazine; Drug Therapy, Combination; Humans; Hydroxyurea; Lomustine; Melanoma; Middle Aged; Triazenes; United States; Vincristine | 1976 |
Comparative evaluation of three combination regimens for advanced malignant melanoma: results of an international cooperative study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carmustine; Central Nervous System Diseases; Dacarbazine; Dactinomycin; Drug Therapy, Combination; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Remission, Spontaneous; Vincristine | 1976 |
Combination chemotherapy in disseminated melanoma and other solid tumors in adults.
Topics: Clinical Trials as Topic; Dacarbazine; Dose-Response Relationship, Drug; Doxorubicin; Drug Evaluation; Drug Therapy, Combination; Humans; Lomustine; Melanoma; Neoplasms; Nitrosourea Compounds; Triazenes | 1975 |
Fotemustine--an advance in the treatment of metastatic malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms | 1992 |
Phase II study of interferon alfa-2a and dacarbazine in advanced melanoma. Biological Response Modifiers in Melanoma (BREMIM) Italian Cooperative Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Drug Evaluation; Female; Follow-Up Studies; Humans; Interferon alpha-2; Interferon-alpha; Male; Melanoma; Recombinant Proteins; Time Factors | 1992 |
Our experience with interferon alpha: metastatic malignant melanoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Female; Humans; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged | 1992 |
Chemo-immunotherapy in patients with metastatic melanoma using sequential treatment with dacarbazine and recombinant human interleukin-2: evaluation of hematologic and immunologic parameters and correlation with clinical response.
Topics: Adolescent; Adult; Cytokines; Dacarbazine; Drug Administration Schedule; Female; Humans; Immunophenotyping; Immunotherapy; Infusions, Intravenous; Interleukin-2; Killer Cells, Lymphokine-Activated; Killer Cells, Natural; Leukocyte Count; Leukocytes; Lymphocyte Subsets; Male; Melanoma; Middle Aged; Recombinant Proteins | 1992 |
Fotemustine: an overview of its clinical activity in disseminated malignant melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Humans; Immunologic Factors; Interferon alpha-2; Interferon-alpha; Lung Neoplasms; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Recombinant Proteins; Remission Induction; Vindesine | 1992 |
In vivo depletion of O6-alkylguanine-DNA-alkyltransferase in lymphocytes and melanoma of patients treated with CB 10-277, a new DTIC analogue.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Female; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Lymphocytes; Male; Melanoma; Methyltransferases; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Skin Neoplasms; Triazenes | 1992 |
Fotemustine and DTIC combination in patients with disseminated malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Prospective Studies; Remission Induction | 1992 |
Antiemetic activity of two different high doses and schedules of metoclopramide in dacarbazine-treated cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Dexamethasone; Diphenhydramine; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Melanoma; Methylprednisolone; Metoclopramide; Middle Aged; Nausea; Sarcoma; Vomiting | 1992 |
A phase II study of metastatic melanoma treated with a combination of interferon alfa 2b, dacarbazine and nimustine.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dacarbazine; Drug Evaluation; Female; Humans; Interferon alpha-2; Interferon-alpha; Male; Melanoma; Middle Aged; Nimustine; Recombinant Proteins | 1992 |
A phase II study of sequential recombinant interleukin-2 followed by dacarbazine in metastatic melanoma.
Topics: Adult; Combined Modality Therapy; Dacarbazine; Drug Evaluation; Female; Humans; Interleukin-2; Male; Melanoma; Middle Aged; Recombinant Proteins | 1992 |
Chemotherapy for advanced malignant melanoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cisplatin; Combined Modality Therapy; Dacarbazine; Drug Evaluation; Humans; Immunologic Factors; Incidence; Interferon-alpha; Melanoma; Pilot Projects; Skin Neoplasms; Tamoxifen; Transplantation, Autologous | 1992 |
Dacarbazine and outpatient interleukin-2 in treatment of metastatic malignant melanoma: phase II Southwest Oncology Group trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Drug Evaluation; Female; Humans; Interleukin-2; Male; Melanoma; Middle Aged; Neoplasm Staging; Outpatients; Sex Characteristics | 1992 |
Sequential chemoimmunotherapy in the treatment of metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Combined Modality Therapy; Dacarbazine; Drug Administration Schedule; Drug Evaluation; Female; Humans; Immunotherapy; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Recombinant Proteins; Survival Analysis; Treatment Outcome | 1992 |
Intrathecal dacarbazine treatment of leptomeningeal malignant melanoma.
Topics: Adult; Arachnoid; Dacarbazine; Female; Humans; Injections, Spinal; Male; Melanoma; Meningeal Neoplasms; Middle Aged; Pia Mater | 1992 |
Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Dacarbazine; Female; Humans; Male; Melanoma; Menopause; Middle Aged; Neoplasm Metastasis; Prospective Studies; Sex Factors; Survival Rate; Tamoxifen | 1992 |
Disseminated melanoma--is there a new standard therapy?
Topics: Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Humans; Melanoma; Neoplasm Metastasis; Tamoxifen | 1992 |
High-dose cisplatin with dacarbazine and tamoxifen in the treatment of metastatic melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; Male; Melanoma; Tamoxifen | 1992 |
[Results of a randomized polychemotherapy study in malignant melanoma].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Dacarbazine; Follow-Up Studies; Humans; Lomustine; Lymphatic Metastasis; Melanoma; Middle Aged; Neoplasm Staging; Prospective Studies; Randomized Controlled Trials as Topic; Skin Neoplasms; Vincristine | 1990 |
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacarbazine; Drug Administration Schedule; Drug Evaluation; Female; Glioma; Humans; Kidney Neoplasms; Male; Melanoma; Middle Aged; Neoplasms; Stomach Neoplasms; Temozolomide | 1992 |
The skin: an immunoreactive target organ during interleukin-2 administration?
Topics: Biopsy; Combined Modality Therapy; Cytokines; Dacarbazine; Dermatitis; Humans; Immunohistochemistry; Immunoradiometric Assay; Interferon-gamma; Interleukin-2; Melanoma; Skin Neoplasms; T-Lymphocyte Subsets; Tumor Necrosis Factor-alpha | 1991 |
Adjuvant treatment in stage I and II malignant melanoma: a randomized trial between chemoimmunotherapy and immunotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Combined Modality Therapy; Dacarbazine; Female; Follow-Up Studies; Humans; Hydroxyurea; Male; Melanoma; Middle Aged; Skin Neoplasms; Vincristine | 1991 |
A phase II trial of high-dose cisplatin and dacarbazine. Lack of efficacy of high-dose, cisplatin-based therapy for metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Drug Administration Schedule; Drug Evaluation; Female; Hematologic Diseases; Humans; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Remission Induction; Skin Neoplasms; Survival Rate | 1991 |
High-dose cisplatin with dacarbazine and tamoxifen in the treatment of metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Cisplatin; Dacarbazine; Drug Evaluation; Female; Hematologic Diseases; Humans; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Remission Induction; Skin Neoplasms; Tamoxifen | 1991 |
Sequential administration of recombinant human interleukin-2 and dacarbazine in metastatic melanoma: a multicenter phase II study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Catheterization, Central Venous; Dacarbazine; Drug Administration Schedule; Drug Evaluation; Female; Humans; Interleukin-2; Male; Melanoma; Recombinant Proteins | 1991 |
Association between chemotherapy response and rate of disease progression in disseminated melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Lomustine; Male; Melanoma; Middle Aged; Prognosis; Time Factors | 1991 |
High-dose cisplatin plus dacarbazine in the treatment of metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Drug Evaluation; Female; Hematologic Diseases; Humans; Kidney Diseases; Male; Melanoma; Middle Aged; Nervous System Diseases; Remission Induction; Survival Rate | 1991 |
Improved results with the addition of interferon alfa-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Interferon alpha-2; Interferon-alpha; Life Tables; Male; Melanoma; Middle Aged; Nervous System Diseases; Recombinant Proteins; Survival Rate | 1991 |
[Treatment of metastatic melanoma with dacarbazine recombinant interferon alfa 2A combination: results of multicentric study].
Topics: Adolescent; Adult; Aged; Combined Modality Therapy; Dacarbazine; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Interferon alpha-2; Interferon-alpha; Male; Melanoma; Middle Aged; Recombinant Proteins | 1990 |
Interferon alpha-2a and dacarbazine in melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Dacarbazine; Humans; Interferon alpha-2; Interferon Type I; Interferon-alpha; Melanoma; Random Allocation; Recombinant Proteins | 1990 |
Recombinant interleukin-2 and adoptive immunotherapy alternated with dacarbazine therapy in melanoma: a National Biotherapy Study Group trial.
Topics: Adult; Aged; Combined Modality Therapy; Dacarbazine; Female; Humans; Immunization, Passive; Interleukin-2; Killer Cells, Lymphokine-Activated; Male; Melanoma; Middle Aged; Multicenter Studies as Topic; Recombinant Proteins | 1990 |
Phase II study of interferon alpha-2a and dacarbazine in advanced melanoma.
Topics: Adolescent; Adult; Aged; Combined Modality Therapy; Dacarbazine; Drug Evaluation; Female; Humans; Interferon alpha-2; Interferon-alpha; Italy; Male; Melanoma; Middle Aged; Recombinant Proteins; Remission Induction; Skin Neoplasms; Survival Rate | 1990 |
Combination chemotherapy of dacarbazine and fotemustine in disseminated malignant melanoma. Experience of the French Study Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds | 1990 |
High-dose cisplatin and dacarbazine in the treatment of metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Remission Induction; Sex Factors | 1990 |
[Current results with surgery and adjuvant chemotherapy in malignant melanoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Bleomycin; Cisplatin; Clinical Trials as Topic; Dacarbazine; Humans; Melanoma; Random Allocation; Vinblastine | 1986 |
Dacarbazine versus dacarbazine-vindesine in disseminated malignant melanoma: a randomized phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Drug Evaluation; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Prospective Studies; Randomized Controlled Trials as Topic; Remission Induction; Vindesine | 1989 |
Sequential administration of recombinant human interleukin-2 and dacarbazine in metastatic melanoma. A multicentre phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dacarbazine; Drug Evaluation; Female; Humans; Interleukin-2; Male; Melanoma; Middle Aged; Multicenter Studies as Topic; Recombinant Proteins | 1989 |
Sequential dacarbazine chemotherapy followed by recombinant interleukin-2 in metastatic melanoma. A pilot multicentre phase I-II study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dacarbazine; Drug Evaluation; Female; Humans; Interleukin-2; Male; Melanoma; Middle Aged; Multicenter Studies as Topic; Pilot Projects; Recombinant Proteins | 1989 |
The significance of conversion of skin reactivity to efficacy of bacillus Calmette-Guérin (BCG) vaccinations given immediately after radical surgery in stage II melanoma patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Staging; Prospective Studies; Random Allocation; Risk Factors; Skin Tests | 1989 |
[Results of the treatment of advances melanoma of the skin with high daily doses of dacarbazine].
Topics: Adult; Aged; Clinical Trials as Topic; Dacarbazine; Female; Humans; Infusions, Intravenous; Male; Melanoma; Middle Aged; Neoplasm Staging; Remission Induction; Skin Neoplasms; Time Factors | 1988 |
Phase II study of AMSA alone and in combination with DTIC in patients with metastatic melanoma.
Topics: Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Drug Evaluation; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis | 1988 |
Randomized study of Corynebacterium parvum adjuvant therapy following surgery for (stage II) malignant melanoma.
Topics: Adjuvants, Immunologic; Adult; Aged; Clinical Trials as Topic; Combined Modality Therapy; Dacarbazine; Dactinomycin; Female; Humans; Male; Melanoma; Middle Aged; Postoperative Period; Propionibacterium acnes; Prospective Studies; Random Allocation; Skin Neoplasms | 1986 |
[Combination chemotherapy of disseminated skin melanoma with nitrosomethylurea].
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Dacarbazine; Dactinomycin; Drug Administration Schedule; Humans; Lomustine; Melanoma; Methylnitrosourea; Prognosis; Skin Neoplasms; Vincristine | 1986 |
Lack of benefit of adjunctive chemotherapy in stage I malignant melanoma: a Southwest Oncology Group Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Dacarbazine; Female; Humans; Hydroxyurea; Male; Melanoma; Middle Aged; Neoplasm Staging; Prognosis | 1987 |
Cytotoxic chemotherapy of disseminated cutaneous malignant melanoma--a prospective and randomized clinical trial of procarbazine, vindesine and lomustine versus procarbazine, DTIC and lomustine.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Drug Evaluation; Female; Humans; Lomustine; Male; Melanoma; Middle Aged; Procarbazine; Prospective Studies; Random Allocation; Skin Neoplasms; Vindesine | 1986 |
Adjuvant treatment of malignant melanoma with DTIC + estracyt or BCG.
Topics: Administration, Oral; Adult; Aged; BCG Vaccine; Combined Modality Therapy; Dacarbazine; Estramustine; Female; Humans; Injections, Intravenous; Male; Melanoma; Middle Aged; Nitrogen Mustard Compounds; Prospective Studies; Random Allocation | 1987 |
[Adjuvant chemotherapy in addition to radical surgical treatment of regional lymph node metastases in malignant melanoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Dacarbazine; Humans; Hydroxyurea; Inguinal Canal; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Melanoma; Neoplasm Staging; Prognosis | 1986 |
Corynebacterium parvum followed by chemotherapy (actinomycin D and DTIC) compared with chemotherapy alone for metastatic malignant melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Dactinomycin; Humans; Melanoma; Neoplasm Metastasis; Propionibacterium acnes; Prospective Studies; Random Allocation | 1986 |
A randomized trial of adjuvant chemotherapy and immunotherapy in Stage I and Stage II cutaneous melanoma. An interim report.
Topics: Adult; Aged; BCG Vaccine; Combined Modality Therapy; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Random Allocation; Skin Neoplasms | 1985 |
Adjuvant chemotherapy of malignant melanoma. A pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dacarbazine; Female; Humans; Lomustine; Male; Melanoma; Middle Aged; Pilot Projects; Random Allocation; Skin Neoplasms; Vincristine | 1985 |
821 other study(ies) available for dacarbazine and Melanoma
| Article | Year |
|---|---|
Synthesis and antitumor activity of halogen-substituted 4-(3,3-dimethyl-1-triazeno)quinolines.
Topics: Animals; Antineoplastic Agents; Chemical Phenomena; Chemistry; In Vitro Techniques; Leukemia L1210; Melanins; Melanoma; Mice; Neoplasms, Experimental; Quinolines; Triazenes | 1978 |
Synthesis and evaluation of 1-(arylsulfonyl)-2-[(methoxycarbonyl)sulfenyl]-1-methylhydrazines++ + as antineoplastic agents.
Topics: Animals; Chemical Phenomena; Chemistry; Drug Evaluation; Leukemia L1210; Melanoma; Methylhydrazines; Mice; Mice, Inbred C57BL; Neoplasms, Experimental; Structure-Activity Relationship | 1986 |
1-Aryl-3,3-dimethyltriazenes: potential central nervous system active analogues of 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (DTIC).
Topics: Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Dacarbazine; Drug Evaluation, Preclinical; Ependymoma; Leukemia L1210; Melanoma; Mice; Mice, Inbred Strains; Structure-Activity Relationship | 1984 |
Synthesis and antiproliferative activity of thiazolidine analogs for melanoma.
Topics: Cell Line, Tumor; Cell Proliferation; Humans; Melanoma; Thiazolidines | 2007 |
Synthesis and antiproliferative activity of imidazole and imidazoline analogs for melanoma.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Imidazoles; Imidazolines; Melanoma; Structure-Activity Relationship; Thiazolidines | 2008 |
Synthesis of new 2-galactosylthiazolidine-4-carboxylic acid amides. Antitumor evaluation against melanoma and breast cancer cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Carboxylic Acids; Cell Line, Tumor; Cell Survival; Chemistry Techniques, Synthetic; Dose-Response Relationship, Drug; Humans; Melanoma | 2012 |
Preclinical Evaluation of LVR01 Attenuated Salmonella as Neoadjuvant Intralesional Therapy in Combination with Chemotherapy for Melanoma Treatment.
Topics: Animals; Dacarbazine; Humans; Melanoma; Mice; Neoadjuvant Therapy; Salmonella typhimurium; Skin Neoplasms; Tumor Microenvironment | 2022 |
Cost-Effectiveness of the Dabrafenib Schedule in Combination With Trametinib Compared With Other Targeted Therapies, Immunotherapy, and Dacarbazine for the Treatment of Unresectable or Metastatic Melanoma With BRAFV600 Mutation in Colombia.
Topics: Colombia; Cost-Benefit Analysis; Dacarbazine; Humans; Imidazoles; Immunotherapy; Melanoma; Mutation; Oximes; Pyridones; Pyrimidinones | 2021 |
Ubiquitination and degradation of MGMT by TRIM72 increases the sensitivity of uveal melanoma cells to Dacarbazine treatment.
Topics: Adult; Cell Line, Tumor; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Humans; Melanoma; Tripartite Motif Proteins; Tumor Suppressor Proteins; Ubiquitination; Uveal Neoplasms | 2022 |
Caffeine improves the cytotoxic effect of dacarbazine on B16F10 murine melanoma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Caffeine; Cell Line, Tumor; Dacarbazine; Melanoma; Mice | 2022 |
Green synthesis of PEG-coated MIL-100(Fe) for controlled release of dacarbazine and its anticancer potential against human melanoma cells.
Topics: Dacarbazine; Delayed-Action Preparations; Humans; Melanoma; Metal-Organic Frameworks; Polyethylene Glycols | 2022 |
Sonodynamic Therapy Using Dacarbazine-Loaded AuSiO
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Dacarbazine; Melanoma; Mice; Nanoparticles | 2022 |
Combined Therapy with Dacarbazine and Hyperthermia Induces Cytotoxicity in A375 and MNT-1 Melanoma Cells.
Topics: Cell Line, Tumor; Cell Survival; Dacarbazine; Humans; Hyperthermia, Induced; Melanoma; Reactive Oxygen Species | 2022 |
Proteomics analysis: inhibiting the expression of P62 protein by chloroquine combined with dacarbazine can reduce the malignant progression of uveal melanoma.
Topics: Animals; Cell Line, Tumor; Chloroquine; Dacarbazine; Humans; Melanoma; Mice; Mice, Nude; Proteomics; Tumor Microenvironment; Uveal Neoplasms | 2022 |
Successful treatment with dacarbazine against a parathyroid hormone-related protein-producing melanoma causing hypercalcemia after immune checkpoint inhibitor failure.
Topics: Aged; Dacarbazine; Female; Humans; Hypercalcemia; Hypoxia; Immune Checkpoint Inhibitors; Melanoma; Parathyroid Hormone-Related Protein; Pleural Effusion; Proto-Oncogene Proteins B-raf | 2022 |
Extra Virgin Olive Oil Secoiridoids Modulate the Metabolic Activity of Dacarbazine Pre-Treated and Treatment-Naive Melanoma Cells.
Topics: Dacarbazine; Humans; Iridoids; Melanoma; Olive Oil; Plant Oils | 2022 |
A novel endoplasmic reticulum stress-related lncRNA prognostic risk model for cutaneous melanoma.
Topics: Cisplatin; Dacarbazine; Endoplasmic Reticulum Stress; Gene Expression Regulation, Neoplastic; Humans; Melanoma; Melanoma, Cutaneous Malignant; Paclitaxel; Prognosis; RNA, Long Noncoding; RNA, Messenger; Skin Neoplasms; Tumor Microenvironment | 2022 |
Dacarbazine in the management of metastatic melanoma in the era of immune checkpoint therapy: a valid option or obsolete?
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Immune Checkpoint Inhibitors; Male; Melanoma; Neoplasms, Second Primary; Retrospective Studies; Skin Neoplasms; Tumor Microenvironment | 2022 |
Focal adhesion alterations in G0-positive melanoma cells.
Topics: Cell Cycle; Cell Division; Cell Line, Tumor; Dacarbazine; Humans; Melanoma | 2023 |
Bilberry Anthocyanins (
Topics: Animals; Anthocyanins; Apoptosis; Dacarbazine; Melanoma; Mice; Mice, Inbred C57BL; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Vaccinium myrtillus | 2023 |
Bottom-Up Strategy to Forecast the Drug Location and Release Kinetics in Antitumoral Electrospun Drug Delivery Systems.
Topics: Anti-Inflammatory Agents; Dacarbazine; Drug Delivery Systems; Drug Liberation; Excipients; Humans; Melanoma; Nanofibers; Pharmaceutical Preparations | 2023 |
Morusinol extracted from Morus alba induces cell cycle arrest and apoptosis via inhibition of DNA damage response in melanoma by CHK1 degradation through the ubiquitin-proteasome pathway.
Topics: Animals; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Dacarbazine; DNA Damage; Flavonoids; Humans; Melanoma; Mice; Proteasome Endopeptidase Complex; Ubiquitins | 2023 |
Protocatechuic aldehyde acts synergistically with dacarbazine to augment DNA double-strand breaks and promote apoptosis in cutaneous melanoma cells.
Topics: Apoptosis; Dacarbazine; DNA; Humans; Melanoma; O(6)-Methylguanine-DNA Methyltransferase; Skin Neoplasms | 2023 |
B7H6 silencing increases chemosensitivity to dacarbazine and suppresses cell survival and migration in cutaneous melanoma.
Topics: Apoptosis; Caspase 3; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Dacarbazine; Humans; Melanoma; Melanoma, Cutaneous Malignant; RNA, Messenger; RNA, Small Interfering; Skin Neoplasms | 2023 |
Metastatic Melanoma: A Preclinical Model Standardization and Development of a Chitosan-Coated Nanoemulsion Containing Temozolomide to Treat Brain Metastasis.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Chitosan; Dacarbazine; Humans; Melanoma; Mice; Temozolomide | 2023 |
A step forward on the in vitro and in vivo assessment of a novel nanomedicine against melanoma.
Topics: Animals; Apoptosis; Cell Line, Tumor; Dacarbazine; Humans; Melanoma; Mice; Nanomedicine; Skin Neoplasms | 2023 |
Quality by design-based development and optimization of fourth-generation ternary solid dispersion of standardized Piper longum extract for melanoma therapy.
Topics: Animals; Biological Availability; Calorimetry, Differential Scanning; Dacarbazine; Melanoma; Mice; Mice, Inbred C57BL; Solubility; Spectroscopy, Fourier Transform Infrared; X-Ray Diffraction | 2023 |
miR 204-5p inhibits apoptosis in dacarbazine-treated melanoma cells.
Topics: Apoptosis; Dacarbazine; Humans; Ki-67 Antigen; Melanoma; MicroRNAs | 2021 |
Preparation of chitosan nanoparticles for simultaneous drug delivery of dacarbazine and enoxaparin in melanoma.
Topics: Chitosan; Dacarbazine; Drug Delivery Systems; Enoxaparin; Humans; Melanoma; Nanoparticles | 2023 |
Histone Deacetylases (HDAC) Inhibitor-Valproic Acid Sensitizes Human Melanoma Cells to Dacarbazine and PARP Inhibitor.
Topics: Alkylating Agents; Antineoplastic Agents; Dacarbazine; DNA; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Melanoma; Poly(ADP-ribose) Polymerase Inhibitors; Valproic Acid | 2023 |
Analysis of cost-effectiveness of chemotherapeutic agents and new therapies for the management of unresectable and metastatic melanoma.
Topics: Cost-Benefit Analysis; Cost-Effectiveness Analysis; Dacarbazine; Female; Humans; Male; Melanoma; Neoplasms, Second Primary; Retrospective Studies | 2023 |
Chromatographic method for dacarbazine quantification in skin permeation experiments.
Topics: Chromatography, High Pressure Liquid; Dacarbazine; Humans; Melanoma; Skin; Skin Absorption | 2023 |
Measuring Melanoma Nanomechanical Properties in Relation to Metastatic Ability and Anti-Cancer Drug Treatment Using Scanning Ion Conductance Microscopy.
Topics: Actins; Antineoplastic Agents; Cisplatin; Dacarbazine; Humans; Melanoma; Microscopy, Atomic Force; Paclitaxel | 2023 |
Silencing of Dicer enhances dacarbazine resistance in melanoma cells by inhibiting ADSL expression.
Topics: Adenylosuccinate Lyase; Dacarbazine; Humans; Melanoma | 2023 |
MIM1 induces COLO829 melanoma cell death through mitochondrial membrane breakdown, GSH depletion, and DNA damage.
Topics: Antineoplastic Agents; Apoptosis; Cell Death; Cell Line, Tumor; Cell Survival; Dacarbazine; DNA Damage; DNA Fragmentation; Glutathione; Humans; Melanoma; Mitochondrial Membranes; Myeloid Cell Leukemia Sequence 1 Protein; Skin Neoplasms | 2020 |
Multivariate network meta-analysis of survival function parameters.
Topics: Dacarbazine; Data Interpretation, Statistical; Humans; Likelihood Functions; Melanoma; Multivariate Analysis; Network Meta-Analysis; Proportional Hazards Models; Randomized Controlled Trials as Topic; Research Design; Software; Survival Analysis; Time Factors; Treatment Outcome | 2020 |
Lysophosphatidic acid receptor-2 (LPA
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Cisplatin; Dacarbazine; Drug Resistance, Neoplasm; Gene Knockdown Techniques; Humans; Lysophospholipids; Melanoma; Pertussis Toxin; Receptors, Lysophosphatidic Acid; Signal Transduction | 2020 |
The effects of metformin on the hippo pathway in the proliferation of melanoma cancer cells: a preclinical study.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Cell Proliferation; Dacarbazine; Hippo Signaling Pathway; Humans; Melanoma; Metformin; Signal Transduction; Trans-Activators; YAP-Signaling Proteins | 2022 |
Advanced malignant melanoma successfully treated with dacarbazine following anti-PD-1/CTLA-4 treatment.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; CTLA-4 Antigen; Dacarbazine; Female; Humans; Immunotherapy; Melanoma; Skin Neoplasms | 2020 |
Rechallenge of programmed cell death 1 inhibitor after an interval with dacarbazine treatment may be effective for advanced malignant melanoma.
Topics: Apoptosis; Dacarbazine; Humans; Melanoma; Nivolumab; Skin Neoplasms | 2020 |
Cold Atmospheric Plasma Is a Potent Tool to Improve Chemotherapy in Melanoma In Vitro and In Vivo.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Cell Survival; Combined Modality Therapy; Dacarbazine; Drug Therapy; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; Lipid Peroxidation; Melanoma; Mice; Nitric Oxide; Plasma Gases; Xenograft Model Antitumor Assays | 2020 |
Desensitization of metastatic melanoma cells to therapeutic treatment through repeated exposure to dacarbazine.
Topics: Anthracenes; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Dacarbazine; Drug Resistance, Neoplasm; Gene Expression Regulation; Humans; Melanoma; Neoplasm Proteins; Perylene; Photochemotherapy; Photosensitizing Agents | 2020 |
In Vitro Anticancer Effects of All-trans Retinoic Acid in Combination with Dacarbazine against CD117+ Melanoma Cells.
Topics: Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; Drug Synergism; G1 Phase; Humans; Melanoma; Melanoma, Cutaneous Malignant; Proto-Oncogene Proteins c-kit; Resting Phase, Cell Cycle; Skin Neoplasms; Tretinoin | 2020 |
BRAF L597K mutation: an opportunity to treat.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azetidines; Back; Dacarbazine; Humans; Imidazoles; Male; Melanoma; Middle Aged; Mutation; Oximes; Piperidines; Proto-Oncogene Proteins B-raf; Pyridones; Pyrimidinones; Skin Neoplasms; Vemurafenib | 2021 |
Dual Encapsulated Dacarbazine and Zinc Phthalocyanine Polymeric Nanoparticle for Photodynamic Therapy of Melanoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Survival; Dacarbazine; Drug Carriers; Drug Compounding; Endothelial Cells; Humans; Isoindoles; Male; Melanoma; Mice; Nanoparticles; Organometallic Compounds; Photochemotherapy; Photosensitizing Agents; Polyesters; Polyvinyl Alcohol; Skin Neoplasms; Tissue Distribution; Zinc Compounds | 2021 |
Melatonin and Metformin Failed to Modify the Effect of Dacarbazine in Melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Humans; Melanoma; Melatonin; Metformin; Quality of Life | 2021 |
CD47-mediated DTIC-loaded chitosan oligosaccharide-grafted nGO for synergistic chemo-photothermal therapy against malignant melanoma.
Topics: CD47 Antigen; Cell Line, Tumor; Chitosan; Dacarbazine; Doxorubicin; Humans; Melanoma; Nanoparticles; Oligosaccharides; Phototherapy; Photothermal Therapy; Skin Neoplasms | 2021 |
Nicotinamide N-methyltransferase gene silencing enhances chemosensitivity of melanoma cell lines.
Topics: Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Gene Silencing; Humans; Melanoma; Neoplasm Proteins; Nicotinamide N-Methyltransferase | 2021 |
Impact of prior treatment with immune checkpoint inhibitors on dacarbazine efficacy in metastatic melanoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Dacarbazine; Disease-Free Survival; Female; Humans; Immune Checkpoint Inhibitors; Male; Melanoma; Middle Aged; Retrospective Studies; Treatment Outcome | 2021 |
Examining the In Vitro Efficacy of the IAP Antagonist Birinapant as a Single Agent or in Combination With Dacarbazine to Induce Melanoma Cell Death.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Death; Cell Line, Tumor; Dacarbazine; Dipeptides; Humans; Indoles; Melanoma; Mutation; Skin Neoplasms | 2017 |
Acral lentiginous melanoma versus other melanoma: A single-center analysis in Japan.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemotherapy, Adjuvant; Child; Child, Preschool; Dacarbazine; Dermatologic Surgical Procedures; Disease-Free Survival; Female; Follow-Up Studies; Humans; Immunotherapy; Japan; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Prognosis; Retrospective Studies; Sentinel Lymph Node Biopsy; Skin; Treatment Outcome; Young Adult | 2017 |
Dacarbazine inhibits proliferation of melanoma FEMX-1 cells by up-regulating expression of miRNA-200.
Topics: Apoptosis Regulatory Proteins; Cell Line, Tumor; Dacarbazine; Humans; Melanoma; MicroRNAs | 2017 |
Combined activity of temozolomide and the mTOR inhibitor temsirolimus in metastatic melanoma involves DKK1.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; Early Growth Response Protein 1; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Transfer Techniques; Humans; Indoles; Intercellular Signaling Peptides and Proteins; Lentivirus; Melanoma; Membrane Proteins; Oligonucleotide Array Sequence Analysis; Signal Transduction; Sirolimus; Skin; Skin Neoplasms; Sulfonamides; Temozolomide; TOR Serine-Threonine Kinases; Vemurafenib | 2017 |
Immunoregulatory protein B7-H3 promotes growth and decreases sensitivity to therapy in metastatic melanoma cells.
Topics: B7 Antigens; Benzimidazoles; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Everolimus; Gene Knockdown Techniques; Glycolysis; Humans; Indoles; Melanoma; Molecular Targeted Therapy; Mutation; Neoplasm Metastasis; Protein Kinase Inhibitors; Sulfonamides; Vemurafenib | 2017 |
Dacarbazine-Loaded Hollow Mesoporous Silica Nanoparticles Grafted with Folic Acid for Enhancing Antimetastatic Melanoma Response.
Topics: Dacarbazine; Folic Acid; Humans; Melanoma; Nanoparticles; Porosity; Silicon Dioxide | 2017 |
Sensitization of melanoma cells to temozolomide by overexpression of microRNA 203 through direct targeting of glutaminase-mediated glutamine metabolism.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Down-Regulation; Drug Resistance, Neoplasm; Glutaminase; Glutamine; Humans; Melanoma; MicroRNAs; Temozolomide | 2017 |
A Network Meta-Analysis of Short and Long-Term Efficacy of Targeted Therapy With Single or Double-Drug Regimens in the Treatment of Stage III/IV Malignant Melanoma Based on 16 Randomized Controlled Trials.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azetidines; Dacarbazine; Humans; Imidazoles; Indoles; Ipilimumab; Melanoma; Molecular Targeted Therapy; Neoplasm Staging; Network Meta-Analysis; Nivolumab; Odds Ratio; Oximes; Piperidines; Pyridones; Pyrimidinones; Randomized Controlled Trials as Topic; Sulfonamides; Survival Analysis; Treatment Outcome; Vemurafenib | 2018 |
Effect of Lonidamine on Systemic Therapy of DB-1 Human Melanoma Xenografts with Temozolomide.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Synergism; Heterografts; Humans; Indazoles; Melanoma; Mice; Mice, Nude; Temozolomide; Transplantation, Heterologous | 2017 |
TCTP as a therapeutic target in melanoma treatment.
Topics: Animals; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Dacarbazine; Female; Gene Expression; Gene Silencing; Humans; Melanoma; Melanoma, Experimental; Mice; Mice, Inbred C57BL; RNA, Messenger; RNA, Small Interfering; Sertraline; Skin Neoplasms; Transfection; Tumor Protein, Translationally-Controlled 1; Tumor Stem Cell Assay; Tumor Suppressor Protein p53 | 2017 |
Cytotoxic antimelanoma drugs suppress the activation of M2 macrophages.
Topics: Animals; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Agents; B7-H1 Antigen; Dacarbazine; Female; Japan; Lectins, C-Type; Leukocytes, Mononuclear; Macrophages; Mannose Receptor; Mannose-Binding Lectins; Melanoma; Melanoma, Cutaneous Malignant; Melanoma, Experimental; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Monocytes; Nimustine; Receptors, Cell Surface; RNA, Messenger; Skin Neoplasms; Vincristine | 2018 |
Microradiopharmaceutical for Metastatic Melanoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Survival; Dacarbazine; Drug Delivery Systems; Female; Melanoma; Mice, Inbred BALB C; Mice, Nude; Radium; Technetium; Tissue Distribution | 2017 |
MicroRNA-195 acts as an anti-proliferative miRNA in human melanoma cells by targeting Prohibitin 1.
Topics: Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cisplatin; Dacarbazine; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Indoles; Male; Melanoma; MicroRNAs; Prohibitins; Repressor Proteins; Sulfonamides; Temozolomide; Transfection; Vemurafenib | 2017 |
Dacarbazine nanoparticle topical delivery system for the treatment of melanoma.
Topics: Administration, Topical; Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Survival; Dacarbazine; Drug Carriers; Drug Delivery Systems; Drug Liberation; Hydrogen-Ion Concentration; Melanoma; Melanoma, Experimental; Mice; Nanoparticles; Particle Size; Permeability; Viscosity | 2017 |
CXCR1/2 Chemokine Network Regulates Melanoma Resistance to Chemotherapies Mediated by NF-κB.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Melanoma; NF-kappa B; Receptors, Interleukin-8A; Receptors, Interleukin-8B; Signal Transduction; Tumor Cells, Cultured | 2017 |
Effect of dacarbazine on CD44 in live melanoma cells as measured by atomic force microscopy-based nanoscopy.
Topics: Actins; Animals; Cell Line, Tumor; Cell Survival; Dacarbazine; Hyaluronan Receptors; Kinetics; Melanoma; Mice; Microscopy, Atomic Force; Quantum Dots; Single Molecule Imaging; Tubulin | 2017 |
Inflammatory Cytokine Pattern Is Sex-Dependent in Mouse Cutaneous Melanoma Experimental Model.
Topics: Animals; Antineoplastic Agents, Alkylating; Carcinogenesis; Cytokines; Dacarbazine; Disease Models, Animal; Disease Progression; Female; Humans; Inflammation Mediators; Male; Melanoma; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Sex; Skin Neoplasms | 2017 |
Effects of nivolumab in peritoneal carcinamatosis of malign melanoma in mouse model.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Dacarbazine; Disease Models, Animal; Drug Evaluation, Preclinical; Hyperthermia, Induced; Male; Melanoma; Mice; Neoplasm Grading; Nivolumab; Peritoneal Neoplasms; Peritoneum; Random Allocation; Regression Analysis | 2017 |
Solid Lipid Nanoparticles Carrying Temozolomide for Melanoma Treatment. Preliminary In Vitro and In Vivo Studies.
Topics: Animals; Biomarkers; Cell Line, Tumor; Dacarbazine; Disease Models, Animal; Drug Stability; Female; Humans; Immunohistochemistry; Melanoma; Melanoma, Experimental; Mice; Molecular Structure; Nanoparticles; Neoplastic Stem Cells; Temozolomide | 2018 |
Senescence-associated secretory factors induced by cisplatin in melanoma cells promote non-senescent melanoma cell growth through activation of the ERK1/2-RSK1 pathway.
Topics: A549 Cells; Animals; Antineoplastic Agents; Cell Proliferation; Cellular Senescence; Cisplatin; Cyclin-Dependent Kinase Inhibitor p21; Dacarbazine; Drug Resistance, Neoplasm; HeLa Cells; Humans; Interleukin-1alpha; Melanoma; Melanoma, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Ribosomal Protein S6 Kinases, 90-kDa; Secretory Pathway; Signal Transduction; Skin Neoplasms; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2018 |
Magnetic core mesoporous silica nanoparticles doped with dacarbazine and labelled with 99mTc for early and differential detection of metastatic melanoma by single photon emission computed tomography.
Topics: Animals; Cell Line, Tumor; Cell Transformation, Neoplastic; Dacarbazine; Diagnosis, Differential; Early Detection of Cancer; Humans; Isotope Labeling; Magnets; Melanoma; Mice; Mice, Inbred BALB C; Nanoparticles; Neoplasm Metastasis; Porosity; Silicon Dioxide; Technetium; Tomography, Emission-Computed, Single-Photon | 2018 |
Targeting LMW-PTP to sensitize melanoma cancer cells toward chemo- and radiotherapy.
Topics: Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; Drug Resistance, Neoplasm; Drug Synergism; Drug Therapy; Flavonoids; Fluorouracil; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Melanoma; Molecular Targeted Therapy; Protein Tyrosine Phosphatases; Proto-Oncogene Proteins; Radiation Tolerance; Radiotherapy; Up-Regulation | 2018 |
Nodal induced by hypoxia exposure contributes to dacarbazine resistance and the maintenance of stemness in melanoma cancer stem‑like cells.
Topics: Apoptosis; Cell Hypoxia; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glycolysis; Humans; Melanoma; Neoplastic Stem Cells; Nodal Protein; Reactive Oxygen Species; Signal Transduction | 2018 |
Inhibition of endoplasmic reticulum stress-induced autophagy sensitizes melanoma cells to temozolomide treatment.
Topics: Animals; Apoptosis; Autophagy; Caspase 7; Cell Line, Tumor; Dacarbazine; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Gene Expression Regulation, Neoplastic; Heat-Shock Proteins; Humans; Melanoma; Mice; Proto-Oncogene Proteins B-raf; Temozolomide; Xenograft Model Antitumor Assays | 2018 |
Functionalized nanoliposomes loaded with anti survivin and anti angiogenic agents to enhance the activity of chemotherapy against melanoma by 4-pronged action.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Cell Proliferation; Dacarbazine; Female; Fibroblast Growth Factor 2; Humans; Hyaluronan Receptors; Inhibitor of Apoptosis Proteins; Liposomes; Male; Melanoma; Models, Theoretical; Nanoparticles; Neovascularization, Pathologic; Skin Neoplasms; Survivin; Vascular Endothelial Growth Factor A | 2018 |
Long-term follow up of metastatic melanoma patients treated with Thymosin alpha-1: investigating immune checkpoints synergy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle Checkpoints; Clinical Trials, Phase II as Topic; CTLA-4 Antigen; Dacarbazine; Drug Synergism; Female; Follow-Up Studies; Humans; Ipilimumab; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic; Skin Neoplasms; Survival Analysis; Thymalfasin; Time Factors; Young Adult | 2018 |
Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600-Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical Trials.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azetidines; Dacarbazine; Female; Humans; Kaplan-Meier Estimate; Male; Melanoma; Middle Aged; Mutation; Neoplasm Metastasis; Piperidines; Prognosis; Proto-Oncogene Proteins B-raf; Randomized Controlled Trials as Topic; Retrospective Studies; Skin Neoplasms; Treatment Outcome; Vemurafenib | 2018 |
Long-term Survival of Stage IV Melanoma Patients Treated with BOLD Combination Chemotherapy and Intermediate-dose Subcutaneous Interferon-alpha.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Drug Administration Schedule; Female; Humans; Injections, Subcutaneous; Interferon-alpha; Lomustine; Male; Melanoma; Middle Aged; Neoplasm Staging; Survival Analysis; Treatment Outcome; Vincristine; Young Adult | 2018 |
Case of malignant melanoma responding to dacarbazine following nivolumab.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Melanoma; Nivolumab; Treatment Outcome | 2019 |
Post-treatment de-phosphorylation of p53 correlates with dasatinib responsiveness in malignant melanoma.
Topics: Cell Cycle Checkpoints; Cell Death; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Dasatinib; Drug Resistance, Neoplasm; Drug Synergism; Humans; Melanoma; Phosphoproteins; Phosphorylation; Tumor Suppressor Protein p53 | 2018 |
Synthesis and characterization of a novel biocompatible pseudo-hexagonal NaCa-layered double metal hydroxides for smart pH-responsive drug release of dacarbazine and enhanced anticancer activity in malignant melanoma.
Topics: Antineoplastic Agents, Alkylating; Biocompatible Materials; Calcium; Cell Line, Tumor; Dacarbazine; Delayed-Action Preparations; Drug Delivery Systems; Drug Liberation; Drug Screening Assays, Antitumor; Half-Life; Humans; Hydrogen-Ion Concentration; Hydroxides; MCF-7 Cells; Melanoma; Sodium | 2019 |
Antiproliferative and apoptotic effects of caffeic acid on SK-Mel-28 human melanoma cancer cells.
Topics: Adult; Antineoplastic Agents; Apoptosis; Caffeic Acids; Caspases; Cell Cycle; Cell Cycle Proteins; Cell Division; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; Female; Healthy Volunteers; Humans; Male; Melanoma; Melanoma, Cutaneous Malignant; Skin Neoplasms | 2019 |
Bixin, an apocarotenoid isolated from Bixa orellana L., sensitizes human melanoma cells to dacarbazine-induced apoptosis through ROS-mediated cytotoxicity.
Topics: Antineoplastic Agents; Apoptosis; Bixaceae; Carotenoids; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dacarbazine; G2 Phase Cell Cycle Checkpoints; Humans; Melanoma; Oxidative Stress; Plant Extracts; Reactive Oxygen Species; Seeds; Skin Neoplasms; Vemurafenib | 2019 |
Survival Extrapolation in Cancer Immunotherapy: A Validation-Based Case Study.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunological; Case-Control Studies; Clinical Trials, Phase III as Topic; Dacarbazine; Double-Blind Method; Humans; Immunotherapy; Ipilimumab; Melanoma; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Survival Rate | 2019 |
p38 MAPK activation through B7-H3-mediated DUSP10 repression promotes chemoresistance.
Topics: Animals; Antineoplastic Agents; B7 Antigens; Cell Line, Tumor; Cisplatin; Dacarbazine; Drug Resistance, Neoplasm; Dual-Specificity Phosphatases; Humans; Melanoma; Mice; Mitogen-Activated Protein Kinase Phosphatases; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Signal Transduction | 2019 |
Vitamin D and its low calcemic analogs modulate the anticancer properties of cisplatin and dacarbazine in the human melanoma A375 cell line.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cisplatin; Dacarbazine; Drug Resistance, Neoplasm; Drug Synergism; G1 Phase Cell Cycle Checkpoints; Humans; Inhibitory Concentration 50; Melanoma; Reactive Oxygen Species; Skin Neoplasms; Vitamin D | 2019 |
Custo-utilidade de terapias-alvo comparadas à dacarbazina para o tratamento de primeira linha do melanoma avançado não-cirúrgico e metastático no Sistema Único de Saúde do Brazil.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azetidines; Brazil; Cost-Benefit Analysis; Dacarbazine; Drug Costs; Health Care Costs; Humans; Imidazoles; Melanoma; Oximes; Piperidines; Pyridones; Pyrimidinones; Vemurafenib | 2019 |
Target therapy versus dacarbazine in first-line treatment of advanced non-surgical and metastatic melanoma: budget impact analysis from the perspective of the Brazilian National Health System, 2018-2020.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brazil; Budgets; Dacarbazine; Female; Humans; Male; Melanoma; Molecular Targeted Therapy; National Health Programs; Skin Neoplasms | 2019 |
Modulation of chemoresistance by lysophosphatidic acid (LPA) signaling through LPA
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Survival; Cisplatin; Dacarbazine; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Lysophospholipids; Melanoma; Receptors, Lysophosphatidic Acid; Signal Transduction | 2019 |
Similar efficacy for phase I trials in comparison with DTIC for advanced malignant melanoma: an analysis of melanoma outcomes in CTEP-sponsored phase I trials 1995-2011.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Clinical Trials, Phase III as Topic; Dacarbazine; Female; Humans; Immunotherapy; Male; Melanoma; Middle Aged; Retrospective Studies; Skin Neoplasms | 2013 |
Prognostic factors for overall survival after radiosurgery for brain metastases from melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Studies; Dacarbazine; Female; Humans; Kaplan-Meier Estimate; L-Lactate Dehydrogenase; Male; Melanoma; Middle Aged; Multivariate Analysis; Prognosis; Proportional Hazards Models; Radiosurgery; Radiotherapy; Retrospective Studies; Skin Neoplasms; Temozolomide; Young Adult | 2014 |
A dual-regulated oncolytic adenovirus expressing interleukin-24 sensitizes melanoma cells to temozolomide via the induction of apoptosis.
Topics: Adenoviridae; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Cell Cycle; Cell Proliferation; Combined Modality Therapy; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Genetic Therapy; Genetic Vectors; Humans; Immunoenzyme Techniques; Interleukins; Ki-67 Antigen; Melanoma; Oncolytic Virotherapy; Temozolomide; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2013 |
Vulvar and vaginal melanoma: case series and review of current management options including neoadjuvant chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Dacarbazine; Female; Humans; Lymphatic Metastasis; Melanoma; Neoadjuvant Therapy; Paclitaxel; Survival Rate; Temozolomide; Treatment Outcome; Vaginal Neoplasms; Vulvar Neoplasms | 2013 |
Low BRAF and NRAS expression levels are associated with clinical benefit from DTIC therapy and prognosis in metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Dacarbazine; Disease-Free Survival; Female; GTP Phosphohydrolases; Humans; Male; Melanoma; Membrane Proteins; Middle Aged; Neoplasm Metastasis; Prognosis; Proto-Oncogene Proteins B-raf; RNA, Messenger | 2013 |
Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4+CD25++Foxp3+ regulatory T-cells in advanced melanoma patients.
Topics: Adult; Aged; Cancer Vaccines; CTLA-4 Antigen; Dacarbazine; Dendritic Cells; Female; Forkhead Transcription Factors; Hemocyanins; Humans; Interleukin-2; Interleukin-2 Receptor alpha Subunit; Male; Melanoma; Middle Aged; T-Lymphocytes, Regulatory; Temozolomide; Treatment Outcome | 2013 |
Regulation of gap junctions in melanoma and their impact on Melan-A/MART-1-specific CD8⁺ T lymphocyte emergence.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Connexin 43; Cytotoxicity, Immunologic; Dacarbazine; Gap Junctions; Gene Expression; Humans; Hypoxia; Immunological Synapses; Interferon-gamma; MART-1 Antigen; Melanoma; Oxidative Stress; Protein Transport; T-Lymphocytes, Cytotoxic | 2013 |
Melanoma of unknown primary origin presenting as a rapidly enlarging adrenal mass.
Topics: Adrenal Gland Neoplasms; Aged; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Diagnosis, Differential; Female; Humans; Melanoma; Neoplasm Metastasis; Neoplasms, Unknown Primary; Radiosurgery; Temozolomide; Tomography, X-Ray Computed | 2013 |
Parthenolide enhances dacarbazine activity against melanoma cells.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; Dose-Response Relationship, Drug; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Humans; Interleukin-8; Melanoma; NF-kappa B; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Sesquiterpenes; Skin Neoplasms; Vascular Endothelial Growth Factor A | 2013 |
Has targeted therapy for melanoma made chemotherapy obsolete?
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Male; Melanoma; Mutation; Neoplasms, Unknown Primary; Proto-Oncogene Proteins B-raf; Skin Neoplasms | 2013 |
Selumetinib increases the efficacy of first-line dacarbazine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Dacarbazine; Disease-Free Survival; Humans; Melanoma; Mutation; Proto-Oncogene Proteins B-raf; Skin Neoplasms | 2013 |
Selumetinib shows promise in metastatic uveal melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Clinical Trials, Phase II as Topic; Dacarbazine; Disease-Free Survival; Eye Neoplasms; Humans; Melanoma; Neoplasm Metastasis; Temozolomide; Uveal Neoplasms | 2013 |
Epigenetic regulation of REG1A and chemosensitivity of cutaneous melanoma.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cisplatin; Dacarbazine; DNA Methylation; Epigenesis, Genetic; Female; Gene Expression; Humans; Lithostathine; Lymphatic Metastasis; Male; Melanoma; Prognosis; Promoter Regions, Genetic; Skin Neoplasms | 2013 |
Systems analysis of apoptosis protein expression allows the case-specific prediction of cell death responsiveness of melanoma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Apoptosis Regulatory Proteins; Cell Line, Tumor; Dacarbazine; Humans; Melanoma; Models, Biological; Neoplasm Proteins | 2013 |
Contribution of ATM and ATR to the resistance of glioblastoma and malignant melanoma cells to the methylating anticancer drug temozolomide.
Topics: Antineoplastic Agents, Alkylating; Ataxia Telangiectasia Mutated Proteins; Cell Line, Tumor; Checkpoint Kinase 1; Dacarbazine; DNA Breaks, Double-Stranded; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Gene Knockdown Techniques; Glioblastoma; Guanine; Humans; Melanoma; Methylnitronitrosoguanidine; Phosphorylation; Protein Kinases; Signal Transduction; Temozolomide; Tumor Suppressor Proteins | 2013 |
The human melanoma side population displays molecular and functional characteristics of enriched chemoresistance and tumorigenesis.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Dacarbazine; Disease Progression; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Jumonji Domain-Containing Histone Demethylases; Male; Melanoma; Mice; Mice, SCID; Neoplasm Proteins; Neoplasm Staging; Neoplasm Transplantation; Neoplastic Stem Cells; Nuclear Proteins; Repressor Proteins; Side-Population Cells; Skin Neoplasms; Tumor Burden | 2013 |
Therapy-related myelodysplastic syndrome after alkylating agents and platinum-based therapy for malignant melanoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Humans; Male; Melanoma; Myelodysplastic Syndromes; Nimustine; Skin Neoplasms | 2014 |
Targeted delivery of CYP2E1 recombinant adenovirus to malignant melanoma by bone marrow-derived mesenchymal stem cells as vehicles.
Topics: Adenoviridae; Adolescent; Adult; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Bone Marrow; Cell Line, Tumor; Cell Movement; Cytochrome P-450 CYP2E1; Dacarbazine; Female; Gene Transfer Techniques; Humans; Male; Melanoma; Mesenchymal Stem Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Young Adult | 2014 |
Successful administration of ipilimumab to two kidney transplantation patients with metastatic melanoma.
Topics: Administration, Oral; Aged; Antibodies, Monoclonal; Antineoplastic Agents; Dacarbazine; Drug Administration Schedule; Fluorodeoxyglucose F18; Humans; Immunosuppressive Agents; Ipilimumab; Kidney Transplantation; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Mycophenolic Acid; Platinum Compounds; Positron-Emission Tomography; Prednisone; Radiopharmaceuticals; Skin Neoplasms; Tacrolimus; Temozolomide; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
[Management of patients with metastatic cutaneous melanoma: French national guidelines. French National Cancer Institute].
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Bone Neoplasms; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Management; France; Humans; Indoles; Ipilimumab; Liver Neoplasms; Lung Neoplasms; Melanoma; Molecular Targeted Therapy; Neoplasm Staging; Nitrosourea Compounds; Oncogenes; Organophosphorus Compounds; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Sulfonamides; Temozolomide; Vemurafenib | 2014 |
Comment on Jiang G. et al.: efficacy and safety between temozolomide alone and temozolomide-based double therapy for malignant melanoma: a meta-analysis.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Humans; Melanoma | 2014 |
FDG-PET/CT assessment of differential chemotherapy effects upon skeletal muscle metabolism in patients with melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Fluorodeoxyglucose F18; Humans; Male; Melanoma; Middle Aged; Multimodal Imaging; Muscle, Skeletal; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Temozolomide; Tomography, X-Ray Computed; Whole Body Imaging | 2014 |
BRAF-V600 mutations have no prognostic impact in stage IV melanoma patients treated with monochemotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Follow-Up Studies; Humans; Male; Melanoma; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Survival Rate; Temozolomide | 2014 |
Insulin induces drug resistance in melanoma through activation of the PI3K/Akt pathway.
Topics: Animals; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Humans; Indoles; Insulin; Melanoma; Mice; Mutation; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Signal Transduction; Sulfonamides | 2014 |
Treatment patterns and outcomes among patients with metastatic melanoma treated in community practice.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Community Health Services; Dacarbazine; Disease Progression; Disease-Free Survival; Female; Humans; Male; Melanoma; Middle Aged; Platinum Compounds; Practice Patterns, Physicians'; Retrospective Studies; Skin Neoplasms; Survival Rate; Temozolomide; Treatment Outcome | 2014 |
Targeting N-cadherin increases vascular permeability and differentially activates AKT in melanoma.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Blotting, Western; Cadherins; Capillary Permeability; Cell Line, Tumor; Chemotherapy, Cancer, Regional Perfusion; Dacarbazine; Melanoma; Melphalan; Neoplasm Transplantation; Oligopeptides; Peptides, Cyclic; Phosphatidylinositol 3-Kinases; Protein Array Analysis; Proto-Oncogene Proteins c-akt; Rats; Rats, Nude; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Skin Neoplasms; Temozolomide | 2015 |
[Late gastric metastasis from cutaneous melanoma].
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Female; Humans; Leg; Lung Neoplasms; Melanoma; Middle Aged; Palliative Care; Skin Neoplasms; Stomach Neoplasms; Time Factors | 2014 |
Proteomics analysis of melanoma metastases: association between S100A13 expression and chemotherapy resistance.
Topics: Adult; Aged; Antineoplastic Agents; Cystatin B; Dacarbazine; Drug Resistance, Neoplasm; Factor XIII; Female; Gene Expression Profiling; Humans; Lymphatic Metastasis; Male; Melanoma; Melanoma, Cutaneous Malignant; Middle Aged; Myo-Inositol-1-Phosphate Synthase; Neoplasm Proteins; Prospective Studies; Proteomics; S100 Proteins; Skin Neoplasms; Tandem Mass Spectrometry; Temozolomide; Young Adult | 2014 |
Melanoma: you can have your cake and eat it!
Topics: Antineoplastic Agents; Dacarbazine; Humans; Imidazoles; Melanoma; Neoplasm Metastasis; Oximes; Quality of Life | 2014 |
[Metastatic malignant melanoma of the oesophagus: case report].
Topics: Antineoplastic Agents, Alkylating; Biopsy; Dacarbazine; Esophageal Neoplasms; Esophagectomy; Female; Humans; Melanoma; Middle Aged; Neoplasm Staging; Polyps; Skin Neoplasms; Treatment Outcome | 2014 |
Differential chemosensitivity to antifolate drugs between RAS and BRAF melanoma cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dacarbazine; DNA; DNA Methylation; Enzyme Inhibitors; GTP Phosphohydrolases; Humans; Melanoma; Membrane Proteins; Mutation; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Temozolomide | 2014 |
Histone deacetylase inhibitor-temozolomide co-treatment inhibits melanoma growth through suppression of Chemokine (C-C motif) ligand 2-driven signals.
Topics: Animals; Apoptosis; Cell Survival; Chemokines; Dacarbazine; Disease Models, Animal; Drug Synergism; Histone Deacetylase Inhibitors; Humans; Melanoma; Mice; Mice, Transgenic; Temozolomide; Tumor Microenvironment | 2014 |
Enhanced antitumor efficacy of a novel oncolytic adenovirus combined with temozolomide in the treatment of melanoma in vivo.
Topics: Adenoviridae; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Cell Proliferation; Combined Modality Therapy; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Flow Cytometry; Genetic Therapy; Humans; Immunoenzyme Techniques; Interleukins; Ki-67 Antigen; Male; Melanoma; Mice; Mice, Inbred BALB C; Mice, Nude; Oncolytic Virotherapy; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Temozolomide; Tumor Cells, Cultured; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2015 |
Prospective study of the evolution of blood lymphoid immune parameters during dacarbazine chemotherapy in metastatic and locally advanced melanoma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; CD4-Positive T-Lymphocytes; Cell Line, Tumor; Cell Survival; Dacarbazine; Female; Flow Cytometry; Gene Expression; Humans; Killer Cells, Natural; Leukocyte Count; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Prognosis; Prospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Skin Neoplasms; T-Lymphocytes, Regulatory; Transcription Factors; Treatment Outcome | 2014 |
Uveal melanoma therapy on the horizon?
Topics: Antineoplastic Agents, Alkylating; Benzimidazoles; Dacarbazine; Female; Humans; Male; Melanoma; Uveal Neoplasms | 2014 |
Dramatic response of vemurafenib-induced cutaneous lesions upon switch to dual BRAF/MEK inhibition in a metastatic melanoma patient.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biopsy; Cell Proliferation; Dacarbazine; Female; Humans; Incidence; Indoles; Ipilimumab; MAP Kinase Kinase Kinases; MAP Kinase Signaling System; Melanoma; Mutation; Neoplasm Metastasis; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Sulfonamides; Treatment Outcome; Vemurafenib | 2014 |
Conjonctival melanoma metastatic to the breast: a case report.
Topics: Adult; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Biopsy; Breast Neoplasms; Conjunctival Neoplasms; Dacarbazine; Drug Administration Schedule; Fatal Outcome; Female; Humans; Immunohistochemistry; Melanoma; Nasopharyngeal Neoplasms; Oropharyngeal Neoplasms; Palliative Care; Time Factors; Treatment Outcome | 2014 |
Adenovirus-mediated FKHRL1/TM sensitizes melanoma cells to apoptosis induced by temozolomide.
Topics: Adenoviridae; Animals; Apoptosis; Cell Line, Tumor; Cell Survival; Dacarbazine; Forkhead Box Protein O3; Forkhead Transcription Factors; Genetic Therapy; Humans; Male; Melanoma; Mice; Mice, Inbred BALB C; Temozolomide; Transcription Factors; Xenograft Model Antitumor Assays | 2014 |
The receptor for advanced glycation end products influences the expression of its S100 protein ligands in melanoma tumors.
Topics: Animals; Antibodies, Monoclonal; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Female; Humans; Ligands; Melanoma; Mice; Mice, SCID; Random Allocation; Receptor for Advanced Glycation End Products; Receptors, Immunologic; S100 Proteins; Xenograft Model Antitumor Assays | 2014 |
MGMT promoter methylation is associated with temozolomide response and prolonged progression-free survival in disseminated cutaneous melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Dacarbazine; Disease-Free Survival; DNA Methylation; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Male; Melanoma; Melanoma, Cutaneous Malignant; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Outcome Assessment, Health Care; Prognosis; Promoter Regions, Genetic; Proportional Hazards Models; Reverse Transcriptase Polymerase Chain Reaction; Skin Neoplasms; Temozolomide | 2015 |
Release the hounds! Activating the T-cell response to cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Dacarbazine; Female; Hodgkin Disease; Humans; Immunotherapy; Male; Melanoma; Nivolumab; Programmed Cell Death 1 Receptor | 2015 |
Skin cancer. Golden age of melanoma therapy.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Cell Transformation, Neoplastic; Dacarbazine; Female; Humans; Male; Melanoma; Programmed Cell Death 1 Receptor; Proto-Oncogene Proteins B-raf | 2015 |
A novel temozolomide analog, NEO212, with enhanced activity against MGMT-positive melanoma in vitro and in vivo.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Cell Survival; Dacarbazine; Disease Models, Animal; DNA Damage; DNA Methylation; Dose-Response Relationship, Drug; Humans; Inhibitory Concentration 50; Melanoma; Mice; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Late-onset paraplegia after complete response to two cycles of ipilimumab for metastatic melanoma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Colitis; Dacarbazine; Fluorodeoxyglucose F18; Humans; Ipilimumab; Magnetic Resonance Imaging; Male; Melanoma; Middle Aged; Multimodal Imaging; Myelitis; Paraplegia; Positron-Emission Tomography; Radiopharmaceuticals; Skin Neoplasms; Temozolomide; Tomography, X-Ray Computed | 2014 |
B-Raf inhibitor vemurafenib in combination with temozolomide and fotemustine in the killing response of malignant melanoma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Dacarbazine; Drug Synergism; Humans; Indoles; Melanoma; Neoplasm Recurrence, Local; Nitrosourea Compounds; Organophosphorus Compounds; Proto-Oncogene Proteins B-raf; Sulfonamides; Temozolomide; Vemurafenib | 2014 |
Predictive biomarkers to chemotherapy in patients with advanced melanoma receiving the combination of cisplatin--vinblastine--temozolomide (PVT) as first-line treatment: a study of the Hellenic Cooperative Oncology Group (HECOG).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cisplatin; Dacarbazine; Humans; Melanoma; Middle Aged; Temozolomide; Vinblastine | 2015 |
Exploiting cannabinoid-induced cytotoxic autophagy to drive melanoma cell death.
Topics: Adaptor Proteins, Signal Transducing; Animals; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Cannabidiol; Cannabinoids; Cannabinol; Cell Death; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; Dronabinol; Drug Combinations; Humans; Male; Melanoma; Membrane Proteins; Mice; Mice, Nude; Microscopy, Confocal; Neoplasm Metastasis; Neoplasm Transplantation; Neoplasms; Plant Extracts; Proto-Oncogene Proteins B-raf; ras Proteins; Skin Neoplasms; Temozolomide | 2015 |
Curcumin analog DM-1 in monotherapy or combinatory treatment with dacarbazine as a strategy to inhibit in vivo melanoma progression.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Cell Proliferation; Curcumin; Dacarbazine; Disease Progression; Drug Therapy, Combination; Male; Melanoma; Mice; Skin Neoplasms | 2015 |
Targeting nodal in conjunction with dacarbazine induces synergistic anticancer effects in metastatic melanoma.
Topics: Antibiotics, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Melanoma; Molecular Targeted Therapy; Neoplasm Metastasis; Nodal Protein; Skin Neoplasms | 2015 |
Long term survival with the combination of interferon and chemotherapy in metastatic melanoma.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Fatal Outcome; Female; Humans; Indoles; Interferon alpha-2; Interferon-alpha; Ipilimumab; Melanoma; Middle Aged; Recombinant Proteins; Skin Neoplasms; Sulfonamides; Vemurafenib | 2015 |
MGMT Expression Predicts PARP-Mediated Resistance to Temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Proliferation; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Melanoma; Mice; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Temozolomide; Tumor Suppressor Proteins | 2015 |
c-Myc modulation: a key role in melanoma drug response.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Dacarbazine; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Gene Expression; Humans; Hydrogen Peroxide; Melanoma; Paclitaxel; Protein Phosphatase 2; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-myc; Skin Neoplasms; Temozolomide | 2015 |
Comparative healthcare costs in patients with metastatic melanoma in the USA.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Dacarbazine; Female; Health Care Costs; Humans; Immunotherapy; Indoles; Ipilimumab; Male; Managed Care Programs; Melanoma; Middle Aged; Molecular Targeted Therapy; Paclitaxel; Retrospective Studies; Skin Neoplasms; Sulfonamides; Temozolomide; United States; Vemurafenib | 2015 |
Swinging for the Fences: Long-Term Survival With Ipilimumab in Metastatic Melanoma.
Topics: Adrenal Insufficiency; Adult; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Dacarbazine; Hormone Replacement Therapy; Humans; Hypopituitarism; Hypothyroidism; Interferon-alpha; Interleukin-2; Ipilimumab; Lung Neoplasms; Lymphatic Metastasis; Male; Melanoma; Neoplasm Staging; Parietal Lobe; Radiosurgery; Sentinel Lymph Node Biopsy; Shoulder; Skin Neoplasms; Treatment Outcome; Vinblastine | 2015 |
Treatment patterns in advanced melanoma: findings from a survey of European oncologists.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Cancer Care Facilities; Dacarbazine; Europe; France; Germany; Hospitals, Community; Hospitals, University; Humans; Indoles; Ipilimumab; Italy; Medical Oncology; Melanoma; Practice Patterns, Physicians'; Spain; Sulfonamides; Surveys and Questionnaires; United Kingdom; Vemurafenib | 2015 |
Efficacy and safety of bio-chemotherapy with dacarbazine plus interleukin-2 in patients with unresectable malignant melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Dacarbazine; Female; Humans; Interferon-alpha; Male; Melanoma; Middle Aged; Remission Induction; Retrospective Studies; Safety; Survival Rate; Treatment Outcome; Young Adult | 2015 |
[A Case of Advanced Malignant Melanoma of the Esophagus with Distant Metastases].
Topics: Aged; Antineoplastic Agents, Alkylating; Bone Neoplasms; Brain Neoplasms; Dacarbazine; Esophageal Neoplasms; Fatal Outcome; Female; Humans; Lymphatic Metastasis; Melanoma; Positron-Emission Tomography; Tomography, X-Ray Computed | 2015 |
Is chemotherapy still an option in the treatment of melanoma?
Topics: Albumins; Dacarbazine; Female; Humans; Male; Melanoma; Paclitaxel; Skin Neoplasms | 2015 |
IGF-1R inhibition induces schedule-dependent sensitization of human melanoma to temozolomide.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Survival; Dacarbazine; DNA Breaks, Double-Stranded; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Synergism; G1 Phase Cell Cycle Checkpoints; Humans; Imidazoles; Melanoma; Mice, Inbred BALB C; Mice, Nude; Mutation; Proto-Oncogene Proteins B-raf; Pyrazines; Receptor, IGF Type 1; Survival Analysis; Temozolomide; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2015 |
A case series of anal melanoma including the results of treatment with imatinib in selected patients.
Topics: Adult; Aged; Aged, 80 and over; Anal Canal; Antineoplastic Agents; Anus Neoplasms; Dacarbazine; Digestive System Surgical Procedures; Disease-Free Survival; Female; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Male; Melanoma; Middle Aged; Mutation; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-kit; Retrospective Studies; Sorafenib; Survival Rate | 2016 |
Infrared spectra of primary melanomas can predict response to chemotherapy: The example of dacarbazine.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Humans; Melanoma; Models, Biological; Principal Component Analysis; Prognosis; ROC Curve; Spectroscopy, Fourier Transform Infrared | 2016 |
Bacterial Sepsis Increases Survival in Metastatic Melanoma: Chlamydophila Pneumoniae Induces Macrophage Polarization and Tumor Regression.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chlamydophila Infections; Chlamydophila pneumoniae; Dacarbazine; Humans; Lomustine; Lung Neoplasms; Macrophage Activation; Macrophages; Melanoma; Mice; Mice, Inbred C57BL; Neoplasm Metastasis; Neoplasms; Sepsis; Skin Neoplasms; Treatment Outcome; Vincristine | 2016 |
Predicting analysis times in randomized clinical trials with cancer immunotherapy.
Topics: Algorithms; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Dacarbazine; Humans; Immunotherapy; Ipilimumab; Kaplan-Meier Estimate; Melanoma; Models, Theoretical; Neoplasms; Outcome Assessment, Health Care; Prognosis; Randomized Controlled Trials as Topic; Reproducibility of Results; Research Design; Retrospective Studies; Time Factors | 2016 |
Phase II Trial of Bevacizumab in Combination With Temozolomide as First-Line Treatment in Patients With Metastatic Uveal Melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Dacarbazine; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Male; Melanoma; Middle Aged; Perfusion Imaging; Temozolomide; Tomography, X-Ray Computed; Treatment Outcome; Uveal Neoplasms; Vascular Endothelial Growth Factor A | 2016 |
DNA methylation and histone acetylation regulate the expression of MGMT and chemosensitivity to temozolomide in malignant melanoma cell lines.
Topics: Acetylation; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Chromatin Immunoprecipitation; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Histones; Humans; Melanoma; Reverse Transcriptase Polymerase Chain Reaction; Skin Neoplasms; Temozolomide; Tumor Suppressor Proteins | 2016 |
Cell Cycle Phase-Specific Drug Resistance as an Escape Mechanism of Melanoma Cells.
Topics: Alkylating Agents; Apoptosis; Bortezomib; Cell Cycle Checkpoints; Cell Division; Cyclin-Dependent Kinase Inhibitor p21; Dacarbazine; Drug Resistance, Neoplasm; G1 Phase; G2 Phase; Humans; MAP Kinase Signaling System; Melanoma; Mitogen-Activated Protein Kinases; Phosphorylation; Skin Neoplasms; Temozolomide | 2016 |
Case of hypophysitis caused by nivolumab.
Topics: Adrenal Insufficiency; Adrenocorticotropic Hormone; Anorexia; Antibodies, Monoclonal; Antineoplastic Agents; Conjunctiva; Dacarbazine; Hormone Replacement Therapy; Humans; Hydrocortisone; Hypophysitis; Hypothyroidism; Lung Diseases, Interstitial; Magnetic Resonance Imaging; Male; Melanoma; Middle Aged; Myalgia; Nausea; Nivolumab; Programmed Cell Death 1 Receptor; Withholding Treatment | 2017 |
NRF2 and glutathione are key resistance mediators to temozolomide in glioma and melanoma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Buthionine Sulfoximine; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Female; Glioma; Glutathione; Humans; Melanoma; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Mice, Nude; NF-E2-Related Factor 2; Temozolomide; Xenograft Model Antitumor Assays | 2016 |
DR5 mAb-conjugated, DTIC-loaded immuno-nanoparticles effectively and specifically kill malignant melanoma cells in vivo.
Topics: Alanine Transaminase; Animals; Antibodies, Monoclonal; Apoptosis; Cell Line, Tumor; Creatinine; Dacarbazine; Drug Delivery Systems; Humans; Immunotherapy; Leukocytes; Male; Melanoma; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Neoplasm Transplantation; Receptors, TNF-Related Apoptosis-Inducing Ligand; Skin Neoplasms | 2016 |
In-vitro and in-vivo inhibition of melanoma growth and metastasis by the drug combination of celecoxib and dacarbazine.
Topics: Animals; Celecoxib; Cell Proliferation; Cyclooxygenase 2 Inhibitors; Dacarbazine; Disease Models, Animal; Female; Humans; Melanoma; Mice; Mice, Inbred C57BL; Neoplasm Metastasis; Skin Neoplasms | 2016 |
PARP1 inhibitor olaparib (Lynparza) exerts synthetic lethal effect against ligase 4-deficient melanomas.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Dacarbazine; Disease Models, Animal; DNA Breaks, Double-Stranded; DNA Ligase ATP; DNA Repair; Drug Synergism; Histones; Humans; Melanocytes; Melanoma; Mice; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Synthetic Lethal Mutations; Xenograft Model Antitumor Assays | 2016 |
Oral mucosal melanoma treated with carbon ion radiotherapy: a case report.
Topics: Aged; Antineoplastic Agents, Phytogenic; Combined Modality Therapy; Dacarbazine; Heavy Ion Radiotherapy; Humans; Male; Melanoma; Mouth Mucosa; Mouth Neoplasms; Mucous Membrane; Neoplasm Recurrence, Local; Nimustine; Radiation Injuries; Radiotherapy Dosage; Treatment Outcome; Vincristine | 2016 |
Tumor-targeting Salmonella typhimurium A1-R combined with temozolomide regresses malignant melanoma with a BRAF-V600E mutation in a patient-derived orthotopic xenograft (PDOX) model.
Topics: Aged; Animals; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Humans; Melanoma; Mice; Mice, Nude; Mutation; Proto-Oncogene Proteins B-raf; Salmonella typhimurium; Temozolomide; Xenograft Model Antitumor Assays | 2016 |
Evaluating the cytotoxic effects of the water extracts of four anticancer herbs against human malignant melanoma cells.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Cell Line, Tumor; Chromatography, High Pressure Liquid; Dacarbazine; Dose-Response Relationship, Drug; Drug Synergism; Hedyotis; Humans; Lobelia; Melanoma; Phytotherapy; Plant Extracts; Plants, Medicinal; Reactive Oxygen Species; Scutellaria; Skin Neoplasms; Solanum nigrum; Solvents; Tandem Mass Spectrometry; Temozolomide; Water | 2016 |
A combination of photodynamic therapy and chemotherapy displays a differential cytotoxic effect on human metastatic melanoma cells.
Topics: Anthracenes; Antineoplastic Agents; Cell Line, Tumor; Dacarbazine; Humans; Melanoma; Neoplasm Metastasis; Perylene; Photochemotherapy; Skin Neoplasms | 2017 |
Umbelliferone Decreases Intracellular pH and Sensitizes Melanoma Cell Line A375 to Dacarbazin. Comparison with Acetazolamide.
Topics: Acetazolamide; Apoptosis; Carbonic Anhydrase Inhibitors; Carbonic Anhydrase IX; Cell Line, Tumor; Dacarbazine; Humans; Hydrogen-Ion Concentration; Intracellular Space; Melanoma; Umbelliferones | 2018 |
Oncolytic adenovirus expressing interleukin-18 improves antitumor activity of dacarbazine for malignant melanoma.
Topics: Adenoviridae; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Synergism; Drug Therapy, Combination; Humans; Interleukin-18; Lung Neoplasms; Melanoma; Mice; Mice, Nude; Oncolytic Virotherapy; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2016 |
Autophagy inhibitors chloroquine and LY294002 enhance temozolomide cytotoxicity on cutaneous melanoma cell lines in vitro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Cell Line, Tumor; Cell Proliferation; Chloroquine; Chromones; Dacarbazine; Drug Synergism; Humans; Melanoma; Morpholines; Skin Neoplasms; Temozolomide | 2017 |
Formulation of temozolomide-loaded nanoparticles and their targeting potential to melanoma cells.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Dendrimers; Drug Delivery Systems; Fluorescein-5-isothiocyanate; Humans; Magnetic Resonance Spectroscopy; Melanoma; Microscopy, Electron, Transmission; Nanoparticles; Peptides; Spectroscopy, Fourier Transform Infrared; Temozolomide | 2017 |
Patterns of use of systemic therapies among patients with metastatic melanoma: a retrospective claims database analysis in the United States.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Dacarbazine; Databases, Factual; Female; Humans; Indoles; Insurance Claim Review; Ipilimumab; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Retrospective Studies; Skin Neoplasms; Sulfonamides; Temozolomide; United States; Vemurafenib; Young Adult | 2017 |
An unusual pituitary stalk lesion: What is the place of surgery?
Topics: Adult; Antineoplastic Agents; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; Diabetes Insipidus; Endoscopy; Fatal Outcome; Female; Hemianopsia; Humans; Hypopituitarism; Indoles; Melanoma; Pituitary Neoplasms; Sulfonamides; Temozolomide; Tomography, X-Ray Computed; Vemurafenib | 2016 |
Cost-Effectiveness of Immune Checkpoint Inhibition in BRAF Wild-Type Advanced Melanoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cell Cycle Checkpoints; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Dacarbazine; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Health Care Costs; Humans; Ipilimumab; Markov Chains; Melanoma; Models, Economic; Nivolumab; Paclitaxel; Proto-Oncogene Proteins B-raf; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Survival Rate | 2017 |
Two cases of melanomas paradoxically metastasizing to the intestinal tract during nivolumab therapy.
Topics: Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents; C-Reactive Protein; Colonic Neoplasms; Colonoscopy; Dacarbazine; Endoscopy, Gastrointestinal; Fatal Outcome; Female; Humans; Ileocecal Valve; Intussusception; Lung Neoplasms; Lymphatic Metastasis; Male; Melanoma; Nivolumab; Occult Blood; Skin; Skin Neoplasms; Tomography, X-Ray Computed | 2017 |
[Adjuvant chemotherapy as a component of complex treatment for skin melanoma].
Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Cyclophosphamide; Dacarbazine; Disease-Free Survival; Doxorubicin; Female; Fluorouracil; Humans; Lymph Node Excision; Male; Melanoma; Methotrexate; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Radiotherapy, Adjuvant; Skin Neoplasms; Survival Analysis; Treatment Outcome; Vincristine | 2008 |
[In vitro drug sensitivity profiling in melanoma].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease Progression; Humans; In Vitro Techniques; Melanoma; Randomized Controlled Trials as Topic; Skin Neoplasms; Survival Rate; Tumor Stem Cell Assay | 2008 |
Biochemotherapy in patients with advanced head and neck mucosal melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Drug Therapy, Combination; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; Immunologic Factors; Injections, Intravenous; Interferon-alpha; Interleukin-2; Male; Medical Records; Melanoma; Middle Aged; Mucous Membrane; Neoplasm Staging; Retrospective Studies; Skin Neoplasms; Survival Analysis; Treatment Outcome; Vinblastine | 2008 |
PARP inhibitors and cancer therapy - early results and potential applications.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Breast Neoplasms; Dacarbazine; Enzyme Inhibitors; Female; Humans; Melanoma; Mice; Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Temozolomide | 2008 |
Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Benzenesulfonates; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dacarbazine; Dasatinib; Drug Screening Assays, Antitumor; Drug Synergism; Focal Adhesion Protein-Tyrosine Kinases; Humans; Melanoma; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins pp60(c-src); Pyridines; Pyrimidines; Receptor, EphA2; Sorafenib; Temozolomide; Thiazoles | 2008 |
Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib.
Topics: Aged; Antineoplastic Agents; Anus Neoplasms; Benzenesulfonates; Dacarbazine; Humans; Male; Melanoma; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-kit; Pyridines; Sorafenib; Temozolomide; Treatment Outcome | 2008 |
Melanocytoma in the orbital apex.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dacarbazine; Diagnosis, Differential; Humans; Immunohistochemistry; Interferon-beta; Male; Melanocytes; Melanoma; Meningeal Neoplasms; Middle Aged; Neurosurgical Procedures; Nimustine; Orbital Neoplasms; Tomography, X-Ray Computed; Vincristine | 2009 |
Differential effects of imatinib mesylate against uveal melanoma in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzamides; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Humans; Imatinib Mesylate; Melanoma; Mice; Piperazines; Pyrimidines; Temozolomide; Uveal Neoplasms; Xenograft Model Antitumor Assays | 2008 |
[Combined treatment with dacarbazine, nimustine, cisplatin, and tamoxifen plus interferon-beta in a patient with advanced anorectal malignant melanoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Cisplatin; Dacarbazine; Humans; Interferon-beta; Liver Neoplasms; Male; Melanoma; Neoplasm Staging; Nimustine; Rectal Neoplasms; Tamoxifen; Treatment Outcome | 2008 |
Concurrent chemobiotherapy with cisplatin, dacarbazine, decrescendo interleukin-2 and interferon alpha2b in patients with metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Disease-Free Survival; Female; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Recombinant Proteins; Skin Neoplasms; Treatment Outcome | 2008 |
Intra-axial brainstem malignant melanoma mimicking cavernous angioma--case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Stem Neoplasms; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Cranial Nerve Diseases; Craniotomy; Dacarbazine; Diagnosis, Differential; Female; Hemangioma, Cavernous, Central Nervous System; Humans; Intracranial Hemorrhages; Magnetic Resonance Imaging; Melanoma; Nimustine; Radiotherapy, Adjuvant; Reoperation; Tamoxifen | 2008 |
Long-term progression-free survival in metastatic uveal melanoma after chemoimmunotherapy and consolidation thermoablation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Catheter Ablation; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Humans; Immunotherapy; Interferon Type I; Liver Neoplasms; Lomustine; Magnetic Resonance Imaging; Male; Melanoma; Middle Aged; Prognosis; Recombinant Proteins; Treatment Outcome; Uveal Neoplasms; Vincristine | 2009 |
Interleukin-24 overcomes temozolomide resistance and enhances cell death by down-regulation of O6-methylguanine-DNA methyltransferase in human melanoma cells.
Topics: Antineoplastic Agents, Alkylating; Cell Death; Cell Line, Tumor; Dacarbazine; Dose-Response Relationship, Drug; Down-Regulation; Drug Resistance, Neoplasm; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Interleukins; Melanoma; O(6)-Methylguanine-DNA Methyltransferase; Skin Neoplasms; Temozolomide; Tumor Suppressor Protein p53 | 2008 |
Inhibition of PI3K-AKT-mTOR signaling sensitizes melanoma cells to cisplatin and temozolomide.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Cisplatin; Dacarbazine; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Humans; MAP Kinase Signaling System; Melanoma; Neoplasm Invasiveness; Phosphatidylinositol 3-Kinases; Protein Kinases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Temozolomide; TOR Serine-Threonine Kinases | 2009 |
Temozolomide- and fotemustine-induced apoptosis in human malignant melanoma cells: response related to MGMT, MMR, DSBs, and p53.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Caspases; Collagen Type XI; Dacarbazine; DNA Breaks, Double-Stranded; DNA Mismatch Repair; DNA Modification Methylases; DNA Repair Enzymes; Enzyme Activation; Everolimus; Humans; Melanoma; Necrosis; Phosphorylation; Sirolimus; Temozolomide; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2009 |
Genomic and molecular profiling predicts response to temozolomide in melanoma.
Topics: Antineoplastic Agents, Alkylating; Area Under Curve; Cell Line, Tumor; Dacarbazine; DNA Methylation; Drug Screening Assays, Antitumor; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genomics; Humans; Inhibitory Concentration 50; Melanoma; Microsatellite Repeats; Neoplasm Metastasis; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide | 2009 |
Impressive regression of visceral and cerebral melanoma metastases under combination treatment including dacarbacine, radiotherapy and celecoxib.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Celecoxib; Combined Modality Therapy; Cyclooxygenase Inhibitors; Dacarbazine; Female; Humans; Melanoma; Pyrazoles; Skin Neoplasms; Sulfonamides; Tongue Neoplasms | 2009 |
Modulation of the efficacy of temozolomide and dacarbazine melanoma treatment by DNA-repair factors in vivo and in vitro.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Survival; Clinical Trials as Topic; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Lymphocytes; Melanoma; Methylation; MutL Protein Homolog 1; MutS Homolog 2 Protein; Nuclear Proteins; Prodrugs; Promoter Regions, Genetic; RNA, Messenger; Temozolomide; Tumor Suppressor Proteins | 2009 |
Primary malignant melanoma of the vagina.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Female; Humans; Interferon-alpha; Lymphatic Metastasis; Melanoma; Middle Aged; Temozolomide; Vaginal Neoplasms | 2009 |
The sodium pump alpha1 sub-unit: a disease progression-related target for metastatic melanoma treatment.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Cardenolides; Cell Line, Tumor; Dacarbazine; Disease Progression; Female; Gene Expression Regulation, Neoplastic; Humans; Melanoma; Mice; Mice, Nude; Microscopy, Video; Neoplasm Metastasis; Neoplasm Transplantation; Sodium-Potassium-Exchanging ATPase; Temozolomide | 2009 |
Homogeneous MGMT immunoreactivity correlates with an unmethylated MGMT promoter status in brain metastases of various solid tumors.
Topics: Alkylating Agents; Brain Neoplasms; Breast Neoplasms; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Immunohistochemistry; Kidney Neoplasms; Lung Neoplasms; Melanoma; Polymerase Chain Reaction; Promoter Regions, Genetic; Temozolomide; Tumor Suppressor Proteins | 2009 |
Molecular determinants of melanoma malignancy: selecting targets for improved efficacy of chemotherapy.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Dacarbazine; Drug Delivery Systems; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Melanoma; Mice; Mice, Inbred BALB C; Mice, Nude; Models, Biological; Niacinamide; Phenylurea Compounds; Pyridines; Quinoxalines; Skin Neoplasms; Sorafenib; Substrate Specificity; Temozolomide; Treatment Outcome; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2009 |
Radioimmunotherapy of experimental human metastatic melanoma with melanin-binding antibodies and in combination with dacarbazine.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Combined Modality Therapy; Dacarbazine; Female; Humans; Melanins; Melanoma; Mice; Mice, Nude; Neoplasm Metastasis; Organometallic Compounds; Positron-Emission Tomography; Radioimmunotherapy; Skin Neoplasms | 2009 |
Effects of fotemustine or dacarbasine on a melanoma cell line pretreated with therapeutic proton irradiation.
Topics: Cell Line, Tumor; Cell Survival; Dacarbazine; Humans; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Protons | 2009 |
Evidence of gamma-tocotrienol as an apoptosis-inducing, invasion-suppressing, and chemotherapy drug-sensitizing agent in human melanoma cells.
Topics: Antineoplastic Agents; Apoptosis; Cadherins; Cell Line, Tumor; Cell Proliferation; Chromans; Dacarbazine; Docetaxel; Humans; JNK Mitogen-Activated Protein Kinases; Melanoma; Neoplasm Invasiveness; Signal Transduction; Taxoids; Vitamin E | 2009 |
Src activation in melanoma and Src inhibitors as therapeutic agents in melanoma.
Topics: Aniline Compounds; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cisplatin; Dacarbazine; Dasatinib; Drug Synergism; Enzyme Activation; Humans; Inhibitory Concentration 50; Melanoma; Nitriles; Paclitaxel; Phosphorylation; Protein Kinase Inhibitors; Pyrimidines; Quinolines; Skin Neoplasms; src-Family Kinases; Temozolomide; Thiazoles | 2009 |
Antifolate activity of pyrimethamine enhances temozolomide-induced cytotoxicity in melanoma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; DNA Damage; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Folic Acid Antagonists; Glioma; Humans; Melanoma; Molecular Structure; Poly(ADP-ribose) Polymerases; Pyrimethamine; Temozolomide | 2009 |
Nodular malignant melanoma and multiple cutaneous neoplasms under immunosuppression with azathioprine.
Topics: Aged; Antineoplastic Agents, Alkylating; Azathioprine; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Dacarbazine; Drug Therapy, Combination; Early Detection of Cancer; Humans; Immunosuppressive Agents; Kidney Transplantation; Lymphatic Metastasis; Male; Melanoma; Neoplasms, Multiple Primary; Skin Neoplasms; Splenic Neoplasms; Temozolomide | 2009 |
Effective treatment of advanced human melanoma metastasis in immunodeficient mice using combination metronomic chemotherapy regimens.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Survival; Cyclophosphamide; Dacarbazine; Female; Humans; Lung Neoplasms; Melanoma; Mice; Mice, SCID; Skin Neoplasms; Vinblastine; Xenograft Model Antitumor Assays | 2009 |
Rapid response to therapy of neurocutaneous melanosis with leptomeningeal melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Child, Preschool; Cyclophosphamide; Dacarbazine; Female; Humans; Melanoma; Melanosis; Meningeal Neoplasms; Neurocutaneous Syndromes; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Temozolomide; Treatment Outcome | 2010 |
Dacarbazine induced acute myeloid leukemia in melanoma.
Topics: Dacarbazine; Humans; Leukemia, Myeloid, Acute; Male; Melanoma; Skin Neoplasms | 2009 |
Effect of DNA repair host factors on temozolomide or dacarbazine melanoma treatment in Caucasians.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Dacarbazine; DNA Repair; DNA, Neoplasm; Female; Humans; Male; Melanoma; Middle Aged; MutL Protein Homolog 1; MutS Homolog 2 Protein; Nuclear Proteins; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide; Tumor Cells, Cultured; White People | 2009 |
Celastrol synergistically enhances temozolomide cytotoxicity in melanoma cells.
Topics: Cell Death; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Dacarbazine; Drug Screening Assays, Antitumor; Drug Synergism; Gene Knockdown Techniques; Humans; I-kappa B Proteins; Inhibitory Concentration 50; Melanoma; Mitogen-Activated Protein Kinases; NF-kappa B; NF-KappaB Inhibitor alpha; Pentacyclic Triterpenes; Phosphorylation; Proteasome Endopeptidase Complex; Protein Transport; RNA, Small Interfering; Temozolomide; Triterpenes; Tumor Necrosis Factor-alpha; Ubiquitinated Proteins | 2009 |
Combination of dacarbazine and dimethylfumarate efficiently reduces melanoma lymph node metastasis.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Movement; Chemokine CXCL11; Chemokine CXCL2; Dacarbazine; Dermatologic Agents; Dimethyl Fumarate; Drug Therapy, Combination; Fumarates; Humans; Lymphatic Metastasis; Lymphatic Vessels; Melanoma; Mice; Mice, SCID; RNA, Messenger; Sentinel Lymph Node Biopsy; Skin Neoplasms; Xenograft Model Antitumor Assays | 2010 |
The clinical efficacy of combination of docetaxel and temozolomide in previously treated patients with stage IV melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease Progression; Docetaxel; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Retrospective Studies; Skin Neoplasms; Taxoids; Temozolomide; Treatment Outcome | 2010 |
The influence of surgical procedure and the effect of chemotherapy on nodal and distant metastases of human malignant melanomas that have been grafted into nude mice.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Chemotherapy, Adjuvant; Cisplatin; Dacarbazine; Disease Models, Animal; Female; Humans; Injections, Intraperitoneal; Lung Neoplasms; Lymphatic Metastasis; Melanoma; Mice; Mice, Inbred BALB C; Mice, Inbred Strains; Mice, Nude; Mouth Neoplasms; Neoadjuvant Therapy; Neoplasm Seeding; Neoplasm Transplantation; Punctures; Subcutaneous Tissue | 2010 |
The cyclin-dependent kinase inhibitor PHA-848125 suppresses the in vitro growth of human melanomas sensitive or resistant to temozolomide, and shows synergistic effects in combination with this triazene compound.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Coloring Agents; Cyclin-Dependent Kinase Inhibitor p16; Cyclin-Dependent Kinases; Dacarbazine; DNA Mutational Analysis; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; Genes, p53; Humans; Melanoma; O(6)-Methylguanine-DNA Methyltransferase; Pyrazoles; Quinazolines; Temozolomide; Tetrazolium Salts; Thiazoles | 2010 |
Brain metastases from melanoma: is there a role for concurrent temozolomide in addition to whole brain radiation therapy?
Topics: Administration, Oral; Aged; Antineoplastic Agents; Brain Neoplasms; Cohort Studies; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Melanoma; Middle Aged; Radiotherapy Dosage; Retrospective Studies; Risk Assessment; Skin Neoplasms; Survival Analysis; Temozolomide; Treatment Outcome | 2010 |
[Treatment of metastatic malignant melanoma localized to an extremity].
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Female; Humans; Infusions, Intra-Arterial; Lower Extremity; Male; Melanoma; Middle Aged; Prognosis; Radiotherapy, Adjuvant; Registries; Remission Induction; Retrospective Studies; Skin Neoplasms; Survival Rate; Treatment Outcome; Upper Extremity | 2010 |
Interleukin-29 binds to melanoma cells inducing Jak-STAT signal transduction and apoptosis.
Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Dacarbazine; Gene Expression Regulation, Neoplastic; Humans; Interferons; Interleukins; Janus Kinase 1; Melanoma; Oligonucleotide Array Sequence Analysis; Phosphorylation; Pyrazines; Signal Transduction; Skin Neoplasms; STAT Transcription Factors; Temozolomide | 2010 |
Congenital pigment synthesizing melanoma of the scalp.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Female; Humans; Infant; Interferon-alpha; Interleukin-2; Lymphatic Metastasis; Melanins; Melanoma; Skin Neoplasms; Vinblastine | 2010 |
Inhibition of poly(ADP-ribose) polymerase enhances the effect of chemotherapy in an animal model of regional therapy for the treatment of advanced extremity malignant melanoma.
Topics: Alkylating Agents; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Dacarbazine; Disease Models, Animal; Extremities; Humans; In Vitro Techniques; Indoles; Melanoma; Poly(ADP-ribose) Polymerase Inhibitors; Rats; Rats, Nude; Severity of Illness Index; Temozolomide; Treatment Outcome | 2010 |
Enhanced anti-tumor activity by the combination of a conditionally replicating adenovirus mediated interleukin-24 and dacarbazine against melanoma cells via induction of apoptosis.
Topics: Adenoviridae; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; Cell Line, Tumor; Cell Survival; Combined Modality Therapy; Dacarbazine; Down-Regulation; Genetic Therapy; Humans; Interleukins; Melanoma; Microscopy, Fluorescence; Mitochondria; Myeloid Cell Leukemia Sequence 1 Protein; Oncolytic Virotherapy; Proto-Oncogene Proteins c-bcl-2; Transduction, Genetic; Up-Regulation | 2010 |
Establishment and characterization of a panel of human uveal melanoma xenografts derived from primary and/or metastatic tumors.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Dacarbazine; Female; Gene Expression Profiling; Humans; In Situ Hybridization, Fluorescence; Male; Melanoma; Mice; Mice, SCID; Middle Aged; Neoplasm Metastasis; Nitrosourea Compounds; Oligonucleotide Array Sequence Analysis; Organophosphorus Compounds; Polymorphism, Single Nucleotide; Temozolomide; Tumor Cells, Cultured; Uveal Neoplasms; Xenograft Model Antitumor Assays | 2010 |
Gene expression signatures as a guide to treatment strategies for in-transit metastatic melanoma.
Topics: Aged; Aged, 80 and over; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Intracellular Space; Male; Melanoma; Melphalan; Middle Aged; Neoplasm Metastasis; Regression Analysis; Signal Transduction; Temozolomide; Transcription, Genetic | 2010 |
Anti-melanoma activity of the 9.2.27PE immunotoxin in dacarbazine resistant cells.
Topics: Antineoplastic Agents, Alkylating; Bacterial Toxins; Caspases; Cell Line, Tumor; Cell Survival; Dacarbazine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enzyme Activation; Gene Expression Regulation, Neoplastic; Humans; Immunotoxins; Melanoma; Membrane Potential, Mitochondrial; Oligonucleotide Array Sequence Analysis; Poly(ADP-ribose) Polymerases; Protein Biosynthesis; Reverse Transcriptase Polymerase Chain Reaction | 2010 |
Multimodality management of a locally advanced primary oesophageal melanoma with radical surgery and adjuvant chemoimmunoradiotherapy.
Topics: Adenocarcinoma, Follicular; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Esophageal Neoplasms; Esophagectomy; Female; Humans; Hypertension; Immunotherapy; Interferons; Melanoma; Middle Aged; Neoplasms, Second Primary; Radiotherapy, Adjuvant; Thyroid Neoplasms | 2010 |
Generalized melanosis and melanuria in a patient with metastatic melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Diphosphonates; Humans; Imidazoles; Male; Melanins; Melanoma; Melanosis; Middle Aged; Positron-Emission Tomography; Skin Neoplasms; Zoledronic Acid | 2010 |
Alterations in the p53 pathway and p16INK4a expression predict overall survival in metastatic melanoma patients treated with dacarbazine.
Topics: Animals; Antineoplastic Agents, Alkylating; Cyclin-Dependent Kinase Inhibitor p16; Dacarbazine; Humans; Melanoma; Predictive Value of Tests; Skin Neoplasms; Tumor Suppressor Protein p53 | 2010 |
Long-term survival in patients with metastatic melanoma treated with DTIC or temozolomide.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Remission Induction; Skin Neoplasms; Survival Analysis; Survivors; Temozolomide; Treatment Outcome; Young Adult | 2010 |
Quercetin abrogates chemoresistance in melanoma cells by modulating deltaNp73.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Proteins; Cell Line, Tumor; Dacarbazine; DNA Damage; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Humans; Melanins; Melanoma; Mutation; Nuclear Proteins; Phosphorylation; Poly(ADP-ribose) Polymerases; Protein Serine-Threonine Kinases; Protein Transport; Quercetin; RNA Interference; Temozolomide; Time Factors; Tumor Protein p73; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2010 |
MGMT expression levels predict disease stabilisation, progression-free and overall survival in patients with advanced melanomas treated with DTIC.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Dacarbazine; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Eye Neoplasms; Female; Humans; Kaplan-Meier Estimate; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prognosis; Prospective Studies; Skin Neoplasms; Tumor Suppressor Proteins | 2010 |
Sorafenib, a multikinase inhibitor, enhances the response of melanoma to regional chemotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; Blotting, Western; Butadienes; Cell Line, Tumor; Cell Survival; Dacarbazine; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Melanoma; Melphalan; Mutation; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Nitriles; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-bcl-2; Pyridines; Rats; Rats, Nude; Sorafenib; Temozolomide; Tumor Burden; Xenograft Model Antitumor Assays | 2010 |
Complete remission of metastatic malignant melanoma after surgery in association with development of systemic vitiligo.
Topics: Antineoplastic Agents; Dacarbazine; Disease-Free Survival; Humans; Interferon-beta; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Nimustine; Osteomyelitis; Skin Neoplasms; Vincristine; Vitiligo | 2010 |
Melanoma metastatic to multiple visceral organs: further considerations.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Dose Fractionation, Radiation; Humans; Melanoma; Neoplasm Metastasis; Nose Neoplasms; Palliative Care; Prognosis | 2010 |
Nijmegen breakage syndrome protein (NBN) causes resistance to methylating anticancer drugs such as temozolomide.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Caspase 7; Cell Cycle Proteins; Cell Line, Transformed; Cell Line, Tumor; Dacarbazine; DNA Methylation; Drug Resistance, Neoplasm; Fibroblasts; Guanine; Homozygote; Humans; Melanoma; Methylnitronitrosoguanidine; Mutagens; Mutation; Necrosis; Nijmegen Breakage Syndrome; Nuclear Proteins; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Temozolomide; Uveal Neoplasms | 2010 |
MGMT gene promoter methylation correlates with tolerance of temozolomide treatment in melanoma but not with clinical outcome.
Topics: Antineoplastic Agents; Base Sequence; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Primers; DNA Repair Enzymes; Female; Humans; Immunohistochemistry; Male; Melanoma; Middle Aged; Promoter Regions, Genetic; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins | 2010 |
Dacarbazine treatment before peptide vaccination enlarges T-cell repertoire diversity of melan-a-specific, tumor-reactive CTL in melanoma patients.
Topics: Antibody Affinity; Antigens, Neoplasm; Cancer Vaccines; CD8-Positive T-Lymphocytes; Combined Modality Therapy; Dacarbazine; Epitopes, T-Lymphocyte; Humans; K562 Cells; MART-1 Antigen; Melanoma; Neoplasm Proteins; Receptors, Antigen, T-Cell; T-Lymphocytes, Cytotoxic; Vaccines, Subunit | 2010 |
Enhancing melanoma treatment with resveratrol.
Topics: Animals; Antineoplastic Agents; Cell Line; Cell Line, Tumor; Chemotherapy, Adjuvant; Dacarbazine; Disease Models, Animal; Drug Therapy, Combination; Humans; In Vitro Techniques; Melanoma; Melphalan; Mice; Mice, Nude; Mice, SCID; Resveratrol; Skin Neoplasms; Stilbenes; Temozolomide; Treatment Outcome; Xenograft Model Antitumor Assays | 2012 |
Positron emission tomography/computed tomography: use for initial staging of malignant melanoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Axilla; Dacarbazine; Fatal Outcome; Humans; Liver Neoplasms; Male; Melanoma; Neoplasm Staging; Positron-Emission Tomography; Skin Neoplasms; Temozolomide; Tomography, X-Ray Computed | 2010 |
Malignant melanoma of the breast: N-isopropyl-p-(123) I-iodoamphetamine single photon emission computed tomography ((123) I-IMP SPECT) is useful for the detection of metastasis.
Topics: Adrenal Gland Neoplasms; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Cisplatin; Dacarbazine; Fatal Outcome; Female; Humans; Interferon-beta; Iofetamine; Liver Neoplasms; Lung Neoplasms; MART-1 Antigen; Mastectomy, Modified Radical; Melanoma; Middle Aged; Neoplasm Staging; Nimustine; Nipples; Radiopharmaceuticals; S100 Proteins; Skin Neoplasms; Tamoxifen; Tomography, Emission-Computed, Single-Photon; Vincristine | 2010 |
Unsuccessful high dose IL-2 therapy followed immediately by near continuous low dose temozolomide can result in rapid durable complete and near-complete remissions in metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Interleukin-2; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Remission Induction; Skin Neoplasms; Temozolomide; Treatment Outcome | 2010 |
siRNA knockdown of ribonucleotide reductase inhibits melanoma cell line proliferation alone or synergistically with temozolomide.
Topics: Antineoplastic Agents, Alkylating; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dacarbazine; G1 Phase; Gene Silencing; Humans; Melanoma; Ribonucleoside Diphosphate Reductase; RNA, Small Interfering; S Phase; Skin Neoplasms; Temozolomide | 2011 |
[A case report of anorectal malignant melanoma showing a complete response after DTIC/ACNU/VCR therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Combined Modality Therapy; Dacarbazine; Humans; Liver Neoplasms; Male; Melanoma; Middle Aged; Nimustine; Remission Induction; Tomography, X-Ray Computed; Vincristine | 2010 |
Primary malignant melanoma of the esophagus: a study of clinical features, pathology, management and prognosis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Dacarbazine; Esophageal Neoplasms; Female; Follow-Up Studies; Humans; Male; Melanoma; Middle Aged; Nimustine; Prognosis; Retrospective Studies; Treatment Outcome; Vincristine | 2011 |
Down-regulation of O6-methylguanine-DNA methyl transferase enhances the effect of temozolomide in melanoma cells.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Down-Regulation; Humans; Melanoma; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide | 2011 |
Silencing HSF1 by short hairpin RNA decreases cell proliferation and enhances sensitivity to hyperthermia in human melanoma cell lines.
Topics: Adenoviridae; Antineoplastic Agents, Alkylating; Apoptosis; Base Sequence; Cell Line; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Dacarbazine; DNA-Binding Proteins; Drug Resistance, Neoplasm; G1 Phase; Gene Silencing; Heat Shock Transcription Factors; Heat-Shock Response; Humans; Hyperthermia, Induced; Keratinocytes; Melanoma; RNA, Small Interfering; Transcription Factors | 2010 |
High activity of sequential low dose chemo-modulating Temozolomide in combination with Fotemustine in metastatic melanoma. A feasibility study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Dose-Response Relationship, Drug; Feasibility Studies; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Nitrosourea Compounds; Organophosphorus Compounds; Temozolomide | 2010 |
Neck dissection and post-operative chemotherapy with dimethyl triazeno imidazole carboxamide and cisplatin protocol are useful for oral mucosal melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Mouth Mucosa; Mouth Neoplasms; Neck Dissection; Postoperative Period; Prognosis; Retrospective Studies | 2010 |
Placenta growth factor induces melanoma resistance to temozolomide through a mechanism that involves the activation of the transcription factor NF-κB.
Topics: Dacarbazine; Drug Resistance, Neoplasm; Humans; Melanoma; NF-kappa B; Placenta Growth Factor; Pregnancy Proteins; RNA, Antisense; Temozolomide; Transfection; Vascular Endothelial Growth Factor Receptor-1 | 2011 |
Rb-Raf-1 interaction disruptor RRD-251 induces apoptosis in metastatic melanoma cells and synergizes with dacarbazine.
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Synergism; Humans; Melanoma; Mice; Neoplasm Metastasis; Phosphorylation; Protein Binding; Proto-Oncogene Proteins c-raf; Retinoblastoma Protein; Thiourea; Xenograft Model Antitumor Assays | 2010 |
PTD4-apoptin protein and dacarbazine show a synergistic antitumor effect on B16-F1 melanoma in vitro and in vivo.
Topics: Animals; Antineoplastic Agents, Alkylating; Capsid Proteins; Cell Line; Cell Line, Tumor; Dacarbazine; Drug Synergism; Female; Humans; Melanoma; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Recombinant Fusion Proteins | 2011 |
Anti-retinal pigment epithelium antibodies in acute exudative polymorphous vitelliform maculopathy: a new hypothesis about disease pathogenesis.
Topics: Acute Disease; Antineoplastic Agents, Alkylating; Autoantibodies; Autoantigens; Blotting, Western; Cells, Cultured; Dacarbazine; Electrophoresis, Gel, Two-Dimensional; Electroretinography; Exudates and Transudates; Fluorescein Angiography; Humans; Liver Neoplasms; Lymphatic Metastasis; Male; Mass Spectrometry; Melanoma; Middle Aged; Neoplasms, Unknown Primary; Paraneoplastic Syndromes; Peroxiredoxin III; Peroxiredoxins; Retinal Pigment Epithelium; Temozolomide; Tomography, Optical Coherence; Vitelliform Macular Dystrophy | 2011 |
Therapy-related myelodysplastic syndrome developed by dacarbazine, nimustine hydrochloride and vincristine sulfate (DAV) therapy for patient with malignant melanoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Fatal Outcome; Female; Foot Diseases; Humans; Melanoma; Middle Aged; Myelodysplastic Syndromes; Nimustine; Retrospective Studies; Vincristine | 2011 |
The glutathione transferase inhibitor 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol (NBDHEX) increases temozolomide efficacy against malignant melanoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Dacarbazine; DNA Methylation; Drug Synergism; Glutathione Transferase; Humans; Inhibitory Concentration 50; Male; Melanoma; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Oxadiazoles; Temozolomide | 2011 |
Equipoise and the dilemma of randomized clinical trials.
Topics: Antineoplastic Agents; Dacarbazine; Ethics, Research; Humans; Indoles; Melanoma; Randomized Controlled Trials as Topic; Sulfonamides; Therapeutic Equipoise; Treatment Outcome; Uncertainty; Vemurafenib | 2011 |
Measurements of tumor cell autophagy predict invasiveness, resistance to chemotherapy, and survival in melanoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Benzenesulfonates; Cell Count; Clinical Trials, Phase II as Topic; Dacarbazine; Drug Resistance, Neoplasm; Humans; Melanoma; Mice; Mice, Nude; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Skin Neoplasms; Sorafenib; Survival Analysis; Temozolomide; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2011 |
Temozolomide chemoresistance heterogeneity in melanoma with different treatment regimens: DNA damage accumulation contribution.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Cycle; Cell Line, Tumor; Dacarbazine; DNA Damage; DNA Methylation; DNA Repair; Drug Resistance, Neoplasm; Gene Expression; Humans; Melanoma; O(6)-Methylguanine-DNA Methyltransferase; Promoter Regions, Genetic; Temozolomide | 2011 |
Dacarbazine-based chemotherapy as first-line treatment in noncutaneous metastatic melanoma: multicenter, retrospective analysis in Asia.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Asia; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Retrospective Studies; Young Adult | 2011 |
[Cellular markers based on DNA damage and repair (BER, MMR), expression of MLHI, MSH2, FasR, and cell death of lymphocytes as predictive parameters for clinical response to chemotherapy of melanoma].
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Death; Cisplatin; Dacarbazine; DNA Breaks, Double-Stranded; DNA Repair; Female; Gene Expression; Humans; Interferon-gamma; Ki-1 Antigen; Lomustine; Lymphocyte Count; Lymphocytes; Male; Melanoma; MutL Protein Homolog 1; MutS Homolog 2 Protein; Nuclear Proteins; Prognosis; Recombinant Proteins; Skin Neoplasms; Treatment Outcome | 2011 |
Intrinsic anticancer drug resistance of malignant melanoma cells is abrogated by IFN-β and valproic acid.
Topics: Animals; Antineoplastic Agents; Apoptosis; Caspase 8; Cell Line, Tumor; Dacarbazine; DNA Breaks, Double-Stranded; DNA Mismatch Repair; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Female; Humans; Interferon-beta; Male; Melanoma; Mice; Temozolomide; Tumor Suppressor Proteins; Valproic Acid | 2011 |
Targeting inhibitor of apoptosis proteins in combination with dacarbazine or TRAIL in melanoma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Baculoviral IAP Repeat-Containing 3 Protein; BH3 Interacting Domain Death Agonist Protein; Caspases; Cell Line, Tumor; Cell Survival; Dacarbazine; DNA Fragmentation; Drug Resistance, Neoplasm; Humans; Inhibitor of Apoptosis Proteins; Melanoma; Poly(ADP-ribose) Polymerases; RNA, Small Interfering; Survivin; TNF-Related Apoptosis-Inducing Ligand; Tumor Stem Cell Assay; Ubiquitin-Protein Ligases; X-Linked Inhibitor of Apoptosis Protein | 2011 |
NRAS-mutant melanoma: response to chemotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Genes, ras; Humans; Male; Melanoma; Mutation; Proto-Oncogene Proteins p21(ras); Skin Neoplasms; Temozolomide | 2011 |
Dacarbazine promotes stromal remodeling and lymphocyte infiltration in cutaneous melanoma lesions.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biopsy; Dacarbazine; Disease Progression; Extracellular Matrix; Female; Gene Expression Regulation, Neoplastic; Humans; In Vitro Techniques; Kaplan-Meier Estimate; Lymphocytes; Male; Melanoma; Middle Aged; Osteonectin; Skin Neoplasms; Stromal Cells; Tumor Microenvironment; Young Adult | 2011 |
[Descriptive analysis of cutaneous recurrence patterns in patients with melanoma].
Topics: Aged; Aged, 80 and over; Aminoquinolines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dacarbazine; Female; Humans; Imiquimod; Kaplan-Meier Estimate; Lymph Node Excision; Male; Melanoma; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasms, Multiple Primary; Prognosis; Skin Neoplasms; Skin Ulcer | 2011 |
Melanoma-associated retinopathy: a presenting sign of metastatic disease.
Topics: Antineoplastic Agents, Alkylating; Biopsy, Fine-Needle; Dacarbazine; Follow-Up Studies; Humans; Immunohistochemistry; Injections, Intralesional; Male; Melanoma; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Retinal Neoplasms; Risk Assessment; Skin Neoplasms; Temozolomide; Treatment Outcome; Visual Acuity; Visual Fields | 2011 |
Strides in melanoma announced: maximizing value comes next.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Dacarbazine; Humans; Indoles; Ipilimumab; Melanoma; Molecular Targeted Therapy; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Secondary Prevention; Skin Neoplasms; Sulfonamides; Survival Analysis; Treatment Outcome; Vemurafenib | 2011 |
Acid ceramidase expression modulates the sensitivity of A375 melanoma cells to dacarbazine.
Topics: Acid Ceramidase; Antineoplastic Agents, Alkylating; Autophagy; Dacarbazine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Melanoma; Neoplasm Metastasis | 2011 |
[News on melanoma from the 2010 Dermatology Days in Paris].
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Biomarkers, Tumor; Chemotherapy, Adjuvant; Dacarbazine; Dermatology; Evidence-Based Medicine; Humans; Melanoma; Mutation; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Pyridines; Radiotherapy, Adjuvant; Skin Neoplasms; Sorafenib; Temozolomide; Treatment Outcome | 2011 |
Leptomeningeal melanomatosis: stabilization of disease due to radiation, temozolomide and intrathecal liposomal cytarabine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Dacarbazine; Humans; Injections, Spinal; Liposomes; Male; Melanoma; Meningeal Neoplasms; Middle Aged; Temozolomide | 2011 |
Fibroblast growth factor receptors as therapeutic targets in human melanoma: synergism with BRAF inhibition.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; Cell Line, Tumor; Dacarbazine; Drug Screening Assays, Antitumor; Genes, Dominant; Humans; Indoles; Melanocytes; Melanoma; Niacinamide; Phenylurea Compounds; Prognosis; Proto-Oncogene Proteins B-raf; Pyridines; Receptors, Fibroblast Growth Factor; Signal Transduction; Skin Neoplasms; Sorafenib; Sulfonamides; Vemurafenib | 2011 |
[Effectiveness of DNA repair and expression of MLH1, MSH2 and FASR in lymphocytes of patients with chemotherapy-responsive, disseminated cutaneous melanoma].
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; DNA Damage; DNA Repair; fas Receptor; Female; Gene Expression Regulation, Neoplastic; Humans; Interferon-gamma; Lomustine; Lymphocytes; Male; Melanoma; Middle Aged; MutL Protein Homolog 1; MutS Homolog 2 Protein; Nuclear Proteins; Predictive Value of Tests; Prognosis; Skin Neoplasms; Treatment Outcome | 2011 |
Interaction of dacarbazine and imexon, in vitro and in vivo, in human A375 melanoma cells.
Topics: Animals; Antineoplastic Agents; Area Under Curve; Cell Line, Tumor; Comet Assay; Dacarbazine; Drug Interactions; Drug Screening Assays, Antitumor; Hexanones; Humans; In Vitro Techniques; Male; Melanoma; Mice; Mice, SCID | 2011 |
The combination of BH3-mimetic ABT-737 with the alkylating agent temozolomide induces strong synergistic killing of melanoma cells independent of p53.
Topics: Alkylating Agents; Animals; Apoptosis; Biomimetic Materials; Biphenyl Compounds; Cell Line, Tumor; Dacarbazine; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Humans; Melanoma; Mice; Nitrophenols; Piperazines; Protein Structure, Tertiary; Proto-Oncogene Proteins c-bcl-2; Sulfonamides; Temozolomide; Time Factors; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2011 |
Hypopigmentation in the sites of regressed melanoma metastases after successful dacarbazine therapy.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Forearm; Head and Neck Neoplasms; Humans; Hyperpigmentation; Male; Melanoma; Middle Aged; Scalp; Skin Neoplasms; Torso | 2012 |
Chemotherapy induces intratumoral expression of chemokines in cutaneous melanoma, favoring T-cell infiltration and tumor control.
Topics: Animals; Cell Movement; Chemokine CCL5; Chemokine CXCL9; Chemokines; Dacarbazine; Humans; Melanoma; Mice; Mice, Inbred C57BL; Skin Neoplasms; T-Lymphocytes; Temozolomide | 2011 |
Anti-DR5 monoclonal antibody-mediated DTIC-loaded nanoparticles combining chemotherapy and immunotherapy for malignant melanoma: target formulation development and in vitro anticancer activity.
Topics: Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Flow Cytometry; Humans; Immunotherapy; Melanoma; Microscopy, Confocal; Nanoconjugates; Receptors, TNF-Related Apoptosis-Inducing Ligand; Skin Neoplasms | 2011 |
Inhibition of coding region determinant binding protein sensitizes melanoma cells to chemotherapeutic agents.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Dacarbazine; Down-Regulation; Drug Resistance, Neoplasm; Etoposide; Gene Knockdown Techniques; Humans; Melanoma; Microphthalmia-Associated Transcription Factor; Neoplasm Proteins; RNA-Binding Proteins; RNA, Small Interfering; Temozolomide; Vinblastine | 2012 |
Ipilimumab plus dacarbazine in melanoma.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Male; Melanoma | 2011 |
Ipilimumab plus dacarbazine in melanoma.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Male; Melanoma | 2011 |
Ipilimumab plus dacarbazine in melanoma.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Male; Melanoma | 2011 |
Vemurafenib in melanoma with BRAF V600E mutation.
Topics: Antineoplastic Agents; Dacarbazine; Female; Humans; Indoles; Male; Melanoma; Proto-Oncogene Proteins B-raf; Sulfonamides | 2011 |
Vemurafenib in melanoma with BRAF V600E mutation.
Topics: Antineoplastic Agents; Dacarbazine; Female; Humans; Indoles; Male; Melanoma; Proto-Oncogene Proteins B-raf; Sulfonamides | 2011 |
Vemurafenib in melanoma with BRAF V600E mutation.
Topics: Antineoplastic Agents; Dacarbazine; Female; Humans; Indoles; Male; Melanoma; Proto-Oncogene Proteins B-raf; Sulfonamides | 2011 |
[Linear porokeratosis].
Topics: Aged; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Dacarbazine; Female; Foot Diseases; Humans; Immunotherapy, Active; Lasers, Gas; Low-Level Light Therapy; Melanoma; Porokeratosis; Skin Neoplasms; Toes | 2011 |
Signalling and chemosensitivity assays in melanoma: is mutated status a prerequisite for targeted therapy?
Topics: Adolescent; Antineoplastic Agents; Benzenesulfonates; Butadienes; Cell Survival; Dacarbazine; Drug Therapy, Combination; Extracellular Signal-Regulated MAP Kinases; Fatal Outcome; Female; Genes, ras; Humans; Melanoma; Molecular Targeted Therapy; Mutation; Niacinamide; Nitriles; Nitrosourea Compounds; Organophosphorus Compounds; Phenylurea Compounds; Phosphorylation; Precision Medicine; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-kit; Pyridines; Signal Transduction; Sorafenib; Treatment Outcome | 2011 |
Melanoma of stomach.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Female; Humans; Lymphatic Metastasis; Melanoma; Middle Aged; Stomach Neoplasms | 2012 |
[The usefulness of neo- and adjuvant therapy in the treatment of cutaneous melanoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cyclophosphamide; Dacarbazine; Disease Progression; Dose Fractionation, Radiation; Female; Humans; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Radiotherapy, Adjuvant; Retrospective Studies; Skin Neoplasms; Surgical Procedures, Operative; Treatment Outcome; Vincristine | 2011 |
Frequent somatic mutations in MAP3K5 and MAP3K9 in metastatic melanoma identified by exome sequencing.
Topics: Antineoplastic Agents; Base Sequence; Cell Line, Tumor; Dacarbazine; Exome; Humans; Loss of Heterozygosity; MAP Kinase Kinase Kinase 5; MAP Kinase Kinase Kinases; Melanoma; Molecular Sequence Data; Mutation; Sequence Analysis, DNA; Sequence Homology, Nucleic Acid; Skin Neoplasms; Temozolomide; Tumor Cells, Cultured | 2011 |
Retrospective study of patients with brain metastases from melanoma receiving concurrent whole-brain radiation and temozolomide.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Radiotherapy; Retrospective Studies; Temozolomide; Time Factors | 2011 |
Targeting protein-trafficking pathways alters melanoma treatment sensitivity.
Topics: Amino Acid Sequence; Antineoplastic Agents; Carboplatin; Cell Line, Tumor; Cisplatin; Dacarbazine; DNA Repair; Down-Regulation; Drug Resistance, Neoplasm; Humans; Immunoblotting; Intracellular Signaling Peptides and Proteins; Melanoma; Melanosomes; Microscopy, Electron; Microscopy, Fluorescence; Molecular Sequence Data; Mutation; Protein Transport; Receptor, Melanocortin, Type 1; RNA Interference; Temozolomide; Up-Regulation; Vesicular Transport Proteins | 2012 |
Antiproliferative and apoptosis-inducing effects of lipophilic vitamins on human melanoma A375 cells in vitro.
Topics: Annexin A5; Antineoplastic Agents; Apoptosis; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cholecalciferol; Dacarbazine; Drug Resistance, Neoplasm; Humans; Hydrophobic and Hydrophilic Interactions; Inhibitory Concentration 50; Melanoma; Tretinoin; Vitamin K; Vitamins | 2012 |
Regression of metastatic melanoma in a patient by antibody targeting of cancer stem cells.
Topics: Aged; Antibodies; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Foot; Humans; Male; Melanoma; Molecular Targeted Therapy; Neoplastic Stem Cells; Remission Induction; Rituximab; Skin Neoplasms; Tumor Burden | 2012 |
Combination of oncolytic adenovirus and dacarbazine attenuates antitumor ability against uveal melanoma cells via cell cycle block.
Topics: Adenoviridae; Antineoplastic Agents, Alkylating; Apoptosis; Cell Cycle; Cell Line, Tumor; Combined Modality Therapy; Cytopathogenic Effect, Viral; Dacarbazine; Drug Synergism; Humans; Melanoma; Oncolytic Virotherapy; Oncolytic Viruses; Time Factors; Uveal Neoplasms; Virus Replication | 2012 |
Immunohistological analysis of in-transit metastasis in a patient with advanced melanoma treated with combination therapy of cytosine guanine dinucleotide oligodeoxynucleotide, dacarbazine and beta-interferon: a case report.
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Dinucleoside Phosphates; Fatal Outcome; Female; Humans; Interferon-beta; Lymphatic Metastasis; Melanoma; T-Lymphocytes | 2012 |
Rational incorporation of selenium into temozolomide elicits superior antitumor activity associated with both apoptotic and autophagic cell death.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Brain Neoplasms; Calpain; Cell Line, Tumor; Dacarbazine; Glioma; Humans; Male; Melanoma; Membrane Proteins; Mice; Mice, Inbred BALB C; Mice, Nude; Selenium; Skin Neoplasms; Temozolomide; Xenograft Model Antitumor Assays | 2012 |
Predictive value of the MGMT promoter methylation status in metastatic melanoma patients receiving first-line temozolomide plus bevacizumab in the trial SAKK 50/07.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Dacarbazine; DNA Methylation; Epigenomics; Female; Humans; Immunohistochemistry; Male; Melanoma; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Predictive Value of Tests; Promoter Regions, Genetic; Temozolomide; Treatment Outcome | 2012 |
Side population cells from human melanoma tumors reveal diverse mechanisms for chemoresistance.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Coloring Agents; Dacarbazine; Drug Resistance, Neoplasm; Female; Humans; In Vitro Techniques; Interleukin-8; Melanoma; Mice; Mice, Nude; Paclitaxel; Side-Population Cells; Skin Neoplasms; Temozolomide; Up-Regulation; Xenograft Model Antitumor Assays | 2012 |
Melanoma chemotherapy leads to the selection of ABCB5-expressing cells.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Cell Membrane; Cell Survival; Dacarbazine; Female; Gene Expression Regulation, Neoplastic; Humans; Melanoma; Mice; Mice, Nude; Neoplasm, Residual; Skin Neoplasms; Xenograft Model Antitumor Assays | 2012 |
BRAF inhibition and beyond in advanced melanoma.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Female; Humans; Imidazoles; Male; Melanoma; Oximes | 2012 |
Two cases of malignant melanoma of the toe developed skin ulcers following local injection of natural beta-interferon.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Foot Diseases; Humans; Interferon-beta; Melanoma; Nimustine; Skin Neoplasms; Skin Ulcer; Vincristine | 2012 |
Redox-related antimelanoma activity of ATN-224.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Buthionine Sulfoximine; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Disulfiram; Drug Synergism; Enzyme Inhibitors; Glutathione; Humans; Melanins; Melanoma; Molybdenum; Oxidation-Reduction; Oxides; Reactive Oxygen Species; Superoxide Dismutase; Temozolomide | 2009 |
A neoadjuvant biochemotherapy approach to stage III melanoma: analysis of surgical outcomes.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biological Therapy; Chemotherapy, Adjuvant; Cisplatin; Dacarbazine; Female; Hematologic Diseases; Humans; Interferon-alpha; Interleukin-2; Lymph Node Excision; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Postoperative Complications; Prognosis; Retrospective Studies; Skin Neoplasms; Survival Analysis; Treatment Outcome; Vinblastine; Young Adult | 2012 |
ALDH1A isozymes are markers of human melanoma stem cells and potential therapeutic targets.
Topics: Aldehyde Dehydrogenase; Aldehyde Dehydrogenase 1 Family; Aldehyde Oxidoreductases; Animals; Apoptosis; Cell Transformation, Neoplastic; Dacarbazine; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Isoenzymes; Melanoma; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Transplantation; Neoplastic Stem Cells; Response Elements; Retinal Dehydrogenase; RNA, Small Interfering; Skin Neoplasms; Temozolomide; Tretinoin | 2012 |
p53R2 is a prognostic factor of melanoma and regulates proliferation and chemosensitivity of melanoma cells.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Child; Cisplatin; Cyclin-Dependent Kinase Inhibitor p21; Dacarbazine; Dose-Response Relationship, Drug; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Male; Melanoma; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Nimustine; Prognosis; Ribonucleotide Reductases; RNA Interference; Skin Neoplasms; Transfection; Vincristine; Young Adult | 2012 |
Survival over 6 years in a patient with brain metastases from melanoma treated with temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Female; Humans; Melanoma; Middle Aged; Temozolomide; Treatment Outcome | 2012 |
[A silent-growing and fast-killing melanoma in a teenager].
Topics: Adolescent; Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Back Pain; Combined Modality Therapy; Cyclin D1; Dacarbazine; Drug Resistance, Neoplasm; Fatal Outcome; Female; Gene Amplification; Head and Neck Neoplasms; Humans; Immunotherapy; In Situ Hybridization, Fluorescence; Ipilimumab; Lymphatic Metastasis; Melanoma; Nausea; Neoplasm Proteins; Neoplasms, Second Primary; Nevus; Osteolysis; Scalp; Skin Neoplasms; Weight Loss | 2012 |
Dacarbazine and the agonistic TRAIL receptor-2 antibody lexatumumab induce synergistic anticancer effects in melanoma.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Caspases; Cell Death; Cell Line, Tumor; Cell Survival; Dacarbazine; Drug Synergism; Female; Humans; Inhibitor of Apoptosis Proteins; Melanoma; Mice; Proto-Oncogene Proteins c-bcl-2; Receptors, TNF-Related Apoptosis-Inducing Ligand; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays | 2012 |
XIAP downregulation accompanies mebendazole growth inhibition in melanoma xenografts.
Topics: Animals; Apoptosis; Cell Line, Tumor; Dacarbazine; Down-Regulation; Drug Resistance, Neoplasm; Female; Humans; Mebendazole; Melanoma; Mice; Mice, Nude; Phosphorylation; Proto-Oncogene Proteins c-bcl-2; Temozolomide; Transplantation, Heterologous; X-Linked Inhibitor of Apoptosis Protein; Xenograft Model Antitumor Assays | 2013 |
Anti-cancer drugs elicit re-expression of UDP-glucuronosyltransferases in melanoma cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Dacarbazine; Doxorubicin; Drug Resistance, Neoplasm; Epirubicin; Gene Expression Regulation; Gene Knockdown Techniques; Glucuronosyltransferase; Humans; Indoles; Melanocytes; Melanoma; Sulfonamides; Temozolomide; Vemurafenib | 2012 |
Serum soluble MICB (sMICB) correlates with disease progression and survival in melanoma patients.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Cisplatin; Dacarbazine; Disease Progression; Disease-Free Survival; Female; Histocompatibility Antigens Class I; Humans; Interferon-alpha; Kaplan-Meier Estimate; Male; Melanoma; Temozolomide; Vincristine | 2013 |
Management options for metastatic melanoma in the era of novel therapies: a primer for the practicing dermatologist: part II: Management of stage IV disease.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Humans; Immunologic Factors; Indoles; Interleukin-2; Ipilimumab; Melanoma; Neoplasm Staging; Palliative Care; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Radiosurgery; raf Kinases; Skin Neoplasms; Sulfonamides; Vemurafenib | 2013 |
The curcumin analog DM-1 induces apoptotic cell death in melanoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Cell Proliferation; Curcumin; Dacarbazine; Flow Cytometry; Free Radicals; Humans; Lipid Peroxidation; Melanoma; Membrane Potential, Mitochondrial; Mice; Tumor Cells, Cultured | 2013 |
Effect of O6-(4-bromothenyl)guanine on different temozolomide schedules in a human melanoma xenograft model.
Topics: Adenosine Triphosphatases; Animals; Cell Division; Dacarbazine; Disease Models, Animal; Guanine; Humans; Male; Melanoma; Mice; Mice, Nude; Neoplasm Transplantation; Temozolomide; Time Factors | 2002 |
Analysis of O(6)-methylguanine-DNA methyltransferase in melanoma tumours in patients treated with dacarbazine-based chemotherapy.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; DNA Damage; DNA Methylation; DNA Repair; DNA, Neoplasm; Drug Resistance, Neoplasm; Female; Humans; Immunoenzyme Techniques; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoplasm Proteins; O(6)-Methylguanine-DNA Methyltransferase; Observer Variation; Prodrugs; Vindesine | 2002 |
Clinical results using biochemotherapy as a standard of care in advanced melanoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Cost-Benefit Analysis; Dacarbazine; Drug Costs; Female; Granulocyte Colony-Stimulating Factor; Humans; Immunologic Factors; Interferon alpha-2; Interferon-alpha; Interleukin-2; Life Tables; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Recombinant Proteins; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Analysis; Treatment Failure; Vinblastine | 2002 |
Successful palliation of stenosing anorectal melanoma by intratumoral injections with natural interferon-beta.
Topics: Aged; Antineoplastic Agents, Alkylating; Anus Neoplasms; Combined Modality Therapy; Constriction, Pathologic; Dacarbazine; Female; Gastrointestinal Hemorrhage; Humans; Immunologic Factors; Injections, Intralesional; Interferon-beta; Lung Neoplasms; Lymphatic Metastasis; Melanoma; Palliative Care; Quality of Life; Rectal Neoplasms; Rectal Prolapse; Remission Induction | 2002 |
Cisplatin and dacarbazine with or without subcutaneous interleukin-2 and interferon alfa-2b in advanced melanoma outpatients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Humans; Interferon alpha-2; Interferon-alpha; Melanoma; Recombinant Proteins | 2002 |
Chemoimmunotherapy for melanoma with dacarbazine and 2,4-dinitrochlorobenzene elicits a specific T cell-dependent immune response.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Dacarbazine; Dinitrochlorobenzene; Immunotherapy; Irritants; Lung Neoplasms; Lymphocytes, Tumor-Infiltrating; Melanoma; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Neoplasm Metastasis; Neoplasm Transplantation; Ribonucleases; RNA, Messenger; T-Lymphocytes; Time Factors; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 2002 |
Immunophenotypical markers, ultrastructure and chemosensitivity profile of metastatic melanoma cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cells, Cultured; Cisplatin; Dacarbazine; Dose-Response Relationship, Drug; Fluorescent Antibody Technique, Indirect; Humans; Immunophenotyping; Inhibitory Concentration 50; Interferon alpha-2; Interferon-alpha; Melanoma; Microscopy, Electron; Neoplasm Metastasis; Paclitaxel; Recombinant Proteins; Temozolomide; Time Factors; Tumor Cells, Cultured; Vindesine | 2002 |
[Temozolomide as therapeutic option for patients with metastatic melanoma and poor prognosis].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Humans; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Prognosis; Retrospective Studies; Skin Neoplasms; Temozolomide; Time Factors | 2002 |
Biochemotherapy of metastatic malignant melanoma. On down-regulation of CD28.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Agents, Alkylating; CD28 Antigens; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cisplatin; Dacarbazine; Down-Regulation; Female; Humans; Interferon alpha-2; Interferon-alpha; Male; Melanoma; Middle Aged; Recombinant Proteins; Time Factors | 2002 |
Combined liver and pancreas resection with biochemotherapy for metastatic ocular melanoma.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Eye Enucleation; Female; Hepatectomy; Humans; Interferon-alpha; Liver Neoplasms; Lymph Node Excision; Lymphatic Metastasis; Melanoma; Middle Aged; Pancreatectomy; Pancreatic Neoplasms; Uveal Neoplasms | 2002 |
[Complete response of cerebral metastasic melanoma after a combined treatment of radiotherapy and temozolomide].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Humans; Male; Melanoma; Middle Aged; Remission Induction; Skin Neoplasms; Temozolomide; Temporal Lobe | 2002 |
Inhibition of telomerase increases resistance of melanoma cells to temozolomide, but not to temozolomide combined with poly (adp-ribose) polymerase inhibitor.
Topics: Antineoplastic Agents, Alkylating; Carmustine; Cell Division; Dacarbazine; DNA Ligases; Drug Combinations; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Melanoma; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Sulfones; Telomerase; Temozolomide; Transfection; Tumor Cells, Cultured | 2003 |
The effect of O6-alkylguanine-DNA alkyltransferase and mismatch repair activities on the sensitivity of human melanoma cells to temozolomide, 1,3-bis(2-chloroethyl)1-nitrosourea, and cisplatin.
Topics: Alkyl and Aryl Transferases; Base Pair Mismatch; Carmustine; Cisplatin; Clone Cells; Dacarbazine; DNA Ligases; DNA Repair; Drug Resistance, Neoplasm; Enzyme Activation; Humans; Melanoma; Temozolomide; Tumor Cells, Cultured | 2003 |
Effects of interferon-alpha, verapamil and dacarbazine in the treatment of advanced malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Calcium Channel Blockers; Dacarbazine; Female; Humans; Interferon alpha-2; Interferon-alpha; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Neoplasm Staging; Radionuclide Imaging; Recombinant Proteins; Remission Induction; Skin Neoplasms; Survival Rate; Treatment Outcome; Uveal Neoplasms; Verapamil | 2003 |
Temozolomide followed by combined immunotherapy with GM-CSF, low-dose IL2 and IFN alpha in patients with metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Disease-Free Survival; Drug Therapy, Combination; Eye Neoplasms; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Immunotherapy; Interferon alpha-2; Interferon-alpha; Interleukin-2; Lymphocyte Activation; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Neoplasm Staging; Recombinant Proteins; Skin Neoplasms; T-Lymphocyte Subsets; Temozolomide; Treatment Outcome | 2003 |
Topical imiquimod in the treatment of metastatic melanoma to skin.
Topics: Adjuvants, Immunologic; Administration, Cutaneous; Aged; Aged, 80 and over; Aminoquinolines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Dacarbazine; Female; Humans; Imiquimod; Interferon alpha-2; Interferon-alpha; Knee; Leg; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Nitrosourea Compounds; Organophosphorus Compounds; Recombinant Proteins; Scalp; Skin Neoplasms; Treatment Outcome | 2003 |
Mcl-1 antisense therapy chemosensitizes human melanoma in a SCID mouse xenotransplantation model.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Dacarbazine; Drug Synergism; Drug Therapy, Combination; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Melanoma; Mice; Mice, SCID; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Neoplasm Transplantation; Oligonucleotides, Antisense; Proto-Oncogene Proteins c-bcl-2; Skin Neoplasms; Transplantation, Heterologous; Tumor Cells, Cultured | 2003 |
DNA repair enzymes and cytotoxic effects of temozolomide: comparative studies between tumor cells and normal cells of the immune system.
Topics: Antineoplastic Agents, Alkylating; Burkitt Lymphoma; Cell Division; Dacarbazine; DNA Damage; DNA Repair; Drug Resistance, Neoplasm; Humans; Interleukin-2; Killer Cells, Lymphokine-Activated; Leukemia, Erythroblastic, Acute; Leukocytes, Mononuclear; Lymphocytes; Melanoma; O(6)-Methylguanine-DNA Methyltransferase; Skin Neoplasms; Temozolomide; Tumor Cells, Cultured | 2003 |
Primary jejunal malignant melanoma first noticed because of the presence of parotid lymph node metastasis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Diagnostic Errors; Fatal Outcome; Humans; Jejunal Neoplasms; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Male; Melanoma; Neoplasms, Unknown Primary; Parotid Gland | 2003 |
Dacarbazine causes transcriptional up-regulation of interleukin 8 and vascular endothelial growth factor in melanoma cells: a possible escape mechanism from chemotherapy.
Topics: Cell Line, Tumor; Dacarbazine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Humans; Interleukin-8; Melanoma; Mitogen-Activated Protein Kinases; NF-kappa B; Transcription Factor AP-1; Transcription, Genetic; Transfection; Up-Regulation; Vascular Endothelial Growth Factor A | 2003 |
Induction of apoptosis and/or necrosis following exposure to antitumour agents in a melanoma cell line, probably through modulation of Bcl-2 family proteins.
Topics: Annexin A5; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Caspase 3; Caspases; Cell Death; Cell Line, Tumor; Cell Survival; Cisplatin; Coloring Agents; Dacarbazine; Dactinomycin; Dose-Response Relationship, Drug; Down-Regulation; Enzyme Activation; Flow Cytometry; Fluorescent Dyes; Humans; Melanoma; Necrosis; Proto-Oncogene Proteins c-bcl-2; Time Factors; Trypan Blue; Up-Regulation | 2003 |
Synchronous cancer and metastatic melanoma of the breasts.
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Ductal, Breast; Cisplatin; Dacarbazine; Female; Humans; Mammography; Melanoma; Retroperitoneal Neoplasms; Tamoxifen | 2004 |
O6-methylguanine-DNA-methyltransferase expression and gene polymorphisms in relation to chemotherapeutic response in metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Melanoma; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Polymorphism, Genetic; Skin Neoplasms; Treatment Outcome; Vindesine | 2003 |
Primary malignant melanoma of the oral mucosa.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Dacarbazine; Disease-Free Survival; Female; Humans; Liver Neoplasms; Lung Neoplasms; Male; Melanoma; Middle Aged; Mouth Mucosa; Mouth Neoplasms; Neck Dissection; Nimustine; Retrospective Studies; Vincristine | 2003 |
IL-2-mediated augmentation of NK-cell activity and activation antigen expression on NK- and T-cell subsets in patients with metastatic melanoma treated with interferon-alpha and DTIC.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Interferon-alpha; Interleukin-2; Killer Cells, Natural; Lymphocyte Activation; Lymphocyte Subsets; Male; Melanoma; Middle Aged; T-Lymphocytes; Tumor Necrosis Factor Receptor Superfamily, Member 7 | 2003 |
Temozolomide for melanoma: new toxicities and new opportunities.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Drug Administration Schedule; Humans; Lymphopenia; Melanoma; Opportunistic Infections; Temozolomide | 2004 |
Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; CD4-Positive T-Lymphocytes; Dacarbazine; Drug Administration Schedule; Female; Humans; Lymphopenia; Male; Melanoma; Middle Aged; Multivariate Analysis; Opportunistic Infections; Proportional Hazards Models; Retrospective Studies; Temozolomide | 2004 |
Quality of life, at what cost?
Topics: Antineoplastic Agents, Alkylating; Cost-Benefit Analysis; Dacarbazine; Drug Costs; Humans; Melanoma; Quality of Life; Skin Neoplasms; Temozolomide | 2003 |
Angiomatoid metastatic melanoma.
Topics: Antineoplastic Agents; Cancer Vaccines; Combined Modality Therapy; Dacarbazine; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interferon-alpha; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Skin Neoplasms; Surgical Procedures, Operative; Treatment Outcome | 2004 |
Diffuse melanosis after chemotherapy-induced tumor lysis syndrome in a patient with metastatic melanoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Dacarbazine; DNA, Neoplasm; Female; Humans; Interferon-alpha; Interleukin-2; Liver Neoplasms; Lung Neoplasms; Melanoma; Melanosis; Melanosomes; Microscopy, Electron; Polymerase Chain Reaction; Skin; Skin Neoplasms; Tumor Lysis Syndrome; Vinblastine | 2004 |
Metastatic malignant melanoma presenting as a cavernous sinus syndrome.
Topics: Adult; Antineoplastic Agents; Biomarkers, Tumor; Blepharoptosis; Cavernous Sinus Thrombosis; Cranial Nerves; Dacarbazine; Fatal Outcome; Headache; Humans; Lymph Nodes; Magnetic Resonance Imaging; Male; Melanoma; Neoplasm Metastasis; Ophthalmoplegia; Orbital Neoplasms; Risk Factors; Skin Neoplasms; Survival Rate; Temozolomide | 2004 |
Correspondence re: DC Lev et al., Dacarbazine causes transcriptional up-regulation of interleukin 8 and vascular endothelial growth factor in melanoma cells: a possible escape mechanism from chemotherapy. Mol Cancer Ther, 2003;2(8):753-63.
Topics: Cell Line, Tumor; Dacarbazine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Humans; Interleukin-8; Melanoma; Mitogen-Activated Protein Kinases; NF-kappa B; Transcription Factor AP-1; Transcription, Genetic; Transfection; Up-Regulation; Vascular Endothelial Growth Factor A | 2004 |
Treatment of melanoma with 5-fluorouracil or dacarbazine in vitro sensitizes cells to antigen-specific CTL lysis through perforin/granzyme- and Fas-mediated pathways.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Cell Line, Tumor; Cytotoxicity, Immunologic; Dacarbazine; Epitopes, T-Lymphocyte; Fas Ligand Protein; fas Receptor; Fluorouracil; Humans; Immune Sera; Ligands; Melanoma; Melanoma-Specific Antigens; Membrane Glycoproteins; Neoplasm Proteins; Peptide Fragments; Perforin; Pore Forming Cytotoxic Proteins; Protein Binding; Serine Endopeptidases; Signal Transduction; T-Lymphocytes, Cytotoxic | 2004 |
[Temozolomide in patients with melanoma brain metastases treated with whole brain irradiation].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Retrospective Studies; Survival Rate; Temozolomide | 2004 |
Dacarbazine but not temozolomide induces phototoxic dermatitis in patients with malignant melanoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Dermatitis, Phototoxic; Female; Humans; Male; Melanoma; Middle Aged; Skin Neoplasms; Temozolomide | 2004 |
Chemotherapy for melanoma: the resultant of conflicting vectors.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Humans; Melanoma; Mice; Skin Neoplasms | 2004 |
Exposure of melanoma cells to dacarbazine results in enhanced tumor growth and metastasis in vivo.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Interleukin-8; Melanoma; Mice; Mice, Nude; Skin Neoplasms; Up-Regulation; Vascular Endothelial Growth Factor A | 2004 |
Complete response of multiple melanoma brain metastases after treatment with temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Humans; Magnetic Resonance Imaging; Melanoma; Middle Aged; Neoplasms, Multiple Primary; Remission Induction; Skin Neoplasms; Temozolomide; Treatment Outcome | 2004 |
In vitro antitumour activity of resveratrol in human melanoma cells sensitive or resistant to temozolomide.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Resistance, Neoplasm; Humans; Inhibitory Concentration 50; Keratinocytes; Melanoma; Necrosis; Poly(ADP-ribose) Polymerases; Resveratrol; S Phase; Stilbenes; Temozolomide; Time Factors | 2004 |
Augmenting chemosensitivity of malignant melanoma tumors via proteasome inhibition: implication for bortezomib (VELCADE, PS-341) as a therapeutic agent for malignant melanoma.
Topics: Active Transport, Cell Nucleus; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Division; Cell Line, Tumor; Dacarbazine; Drug Synergism; Female; Gene Expression; Humans; Melanoma; Mice; Mice, Inbred BALB C; Neovascularization, Pathologic; NF-kappa B; Protease Inhibitors; Pyrazines; Temozolomide | 2004 |
Local control of primary oropharyngeal malignant melanomas with limited tissue excision: a report of three cases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Dacarbazine; Fatal Outcome; Female; Humans; Immunotherapy; Male; Melanoma; Middle Aged; Oropharyngeal Neoplasms; Radiotherapy, Adjuvant; Vincristine | 2005 |
Isolated limb infusion with fotemustine after dacarbazine chemosensitisation for inoperable loco-regional melanoma recurrence.
Topics: Aged; Aged, 80 and over; Amputation, Surgical; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Chemotherapy, Cancer, Regional Perfusion; Dacarbazine; Follow-Up Studies; Humans; Limb Salvage; Lower Extremity; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Nitrosourea Compounds; Organophosphorus Compounds; Remission Induction; Salvage Therapy; Skin Neoplasms; Treatment Outcome | 2004 |
Temozolomide is a novel regional infusion agent for the treatment of advanced extremity melanoma.
Topics: Analysis of Variance; Animals; Antineoplastic Agents, Alkylating; Chemotherapy, Cancer, Regional Perfusion; Dacarbazine; Disease Models, Animal; Dose-Response Relationship, Drug; Extremities; Female; Infusions, Parenteral; Melanoma; Melphalan; Probability; Random Allocation; Rats; Rats, Nude; Reference Values; Sensitivity and Specificity; Severity of Illness Index; Skin Neoplasms; Survival Rate; Temozolomide; Transplantation, Heterologous; Treatment Outcome | 2004 |
Breast metastases from cutaneous malignant melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Dacarbazine; Female; Humans; Melanoma; Middle Aged; Skin Neoplasms; Vincristine | 2004 |
The prognostic role of CD4+ and CD8+ lymphocytes during chemoimmunotherapy in metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Dacarbazine; Female; Humans; Immunotherapy; Interferon-alpha; Lomustine; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Prognosis; Skin Neoplasms; Survival Rate; T-Lymphocytes, Regulatory; Treatment Outcome; Vinblastine | 2004 |
Biochemotherapy in patients with advanced vulvovaginal mucosal melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Female; Follow-Up Studies; Humans; Interferon-alpha; Interleukin-2; Male; Medical Records; Melanoma; Middle Aged; Mucous Membrane; Retrospective Studies; Skin Neoplasms; Survival Rate; Tamoxifen; Temozolomide; Treatment Outcome; Vaginal Neoplasms; Vinblastine; Vulvar Neoplasms | 2004 |
Serum bcl-2 and survivin levels in melanoma.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Biomarkers, Tumor; Dacarbazine; Female; Gene Expression Regulation, Neoplastic; Humans; Inhibitor of Apoptosis Proteins; Interferon alpha-2; Interferon-alpha; Male; Melanoma; Microtubule-Associated Proteins; Middle Aged; Neoplasm Proteins; Prognosis; Proto-Oncogene Proteins c-bcl-2; Recombinant Proteins; Skin Neoplasms; Survivin | 2004 |
Relevance and necessity of studies on second-line chemotherapy in melanoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials as Topic; Dacarbazine; Doxorubicin; Drug Administration Schedule; Evidence-Based Medicine; Humans; Interleukin-2; Melanoma; Practice Patterns, Physicians'; Treatment Outcome | 2004 |
Chemotherapeutic induced fascial oedema.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Drug Eruptions; Edema; Fascia; Female; Humans; Melanoma; Middle Aged; Thigh | 2005 |
Multiple ground-glass opacity in metastasis of malignant melanoma diagnosed by lung biopsy.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Chemotherapy, Adjuvant; Dacarbazine; Diagnosis, Differential; Female; Humans; Lung Neoplasms; Melanocytes; Melanoma; Middle Aged; Nasal Cavity; Nose Neoplasms; Picibanil; Tegafur; Tomography, X-Ray Computed; Uracil | 2005 |
Prolonged survival after resection of liver metastases from uveal melanoma and intra-arterial chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Dacarbazine; Fatal Outcome; Female; Follow-Up Studies; Hepatectomy; Humans; Injections, Intra-Arterial; Liver Neoplasms; Melanoma; Neoplasm Metastasis; Nitrosourea Compounds; Organophosphorus Compounds; Survival Rate; Time Factors; Uveal Neoplasms | 2005 |
Impact of gene polymorphisms on clinical outcome for stage IV melanoma patients treated with biochemotherapy: an exploratory study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; DNA Helicases; DNA-Binding Proteins; Endonucleases; Female; Gene Frequency; Genotype; Humans; Interferon-alpha; Interferon-gamma; Interleukin-10; Interleukin-2; Male; Melanoma; Middle Aged; Neoplasm Staging; Pilot Projects; Polymorphism, Genetic; Survival Analysis; Transcription Factors; Treatment Outcome; Vinblastine; X-ray Repair Cross Complementing Protein 1; Xeroderma Pigmentosum Group D Protein | 2005 |
Cerebral metastases of malignant melanoma: contemporary treatment modalities and survival outcome.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; Female; Humans; Male; Melanoma; Middle Aged; Prognosis; Radiotherapy, Adjuvant; Retrospective Studies; Skin Neoplasms; Survival Analysis; Temozolomide; Treatment Outcome | 2005 |
[Malignant melanoma of nasal fossae: clinical and therapeutic considerations about three cases].
Topics: Aged; Antineoplastic Agents, Alkylating; Biopsy; Combined Modality Therapy; Dacarbazine; Diagnosis, Differential; Female; Humans; Immunohistochemistry; Male; Melanoma; Middle Aged; Nasal Mucosa; Nasal Septum; Neoplasm Metastasis; Nose Neoplasms; Prognosis; Radiotherapy Dosage; Time Factors; Turbinates | 2005 |
Clusterin regulates drug-resistance in melanoma cells.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Clusterin; Dacarbazine; Down-Regulation; Drug Resistance, Neoplasm; Glycoproteins; Humans; Melanocytes; Melanoma; Mice; Mice, SCID; Molecular Chaperones; Neoplasm Transplantation; Oligonucleotides, Antisense; Transplantation, Heterologous | 2005 |
Amelanotic malignant melanoma of the esophagus: report of a patient with recurrence successfully treated with chemoendocrine therapy.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Esophageal Neoplasms; Esophagectomy; Humans; Infusions, Intravenous; Interferon-beta; Male; Melanoma; Middle Aged; Nimustine; Survival Analysis; Treatment Outcome; Vincristine | 2005 |
Cardiac metastasis of melanoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Choroid Neoplasms; Dacarbazine; Female; Heart Neoplasms; Heart Ventricles; Humans; Magnetic Resonance Imaging; Melanoma; Temozolomide | 2005 |
O(6)-methylguanine DNA-methyltransferase (MGMT) overexpression in melanoma cells induces resistance to nitrosoureas and temozolomide but sensitizes to mitomycin C.
Topics: Antineoplastic Agents; Buthionine Sulfoximine; Cell Line, Tumor; Cell Survival; Dacarbazine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Glutathione; Humans; Inhibitory Concentration 50; Melanoma; Mitomycin; Nitrosourea Compounds; O(6)-Methylguanine-DNA Methyltransferase; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Temozolomide; Transfection | 2006 |
[Correlation between functional capability and phenotypic characteristics of peripheral blood lymphocytes in patients with malignant melanoma].
Topics: Adult; Antigens, CD; Antineoplastic Agents; Chemotherapy, Adjuvant; Dacarbazine; Female; Humans; Interferon-alpha; Killer Cells, Natural; Lymphocyte Activation; Lymphocytes; Male; Melanoma; Skin Neoplasms | 2002 |
Thalidomide enhances the anti-tumor activity of standard chemotherapy in a human melanoma xenotransplatation model.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Dacarbazine; Drug Therapy, Combination; Humans; Melanoma; Mice; Mice, SCID; Microcirculation; Skin Neoplasms; Thalidomide; Tumor Necrosis Factor-alpha; Xenograft Model Antitumor Assays | 2005 |
Complete remission of brain metastases in three patients with stage IV melanoma treated with BOLD and G-CSF.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Humans; Lomustine; Male; Melanoma; Middle Aged; Neoplasm Staging; Remission Induction; Skin Neoplasms; Treatment Outcome; Vincristine | 2005 |
Biochemotherapy with low doses of subcutaneous interleukin-2 in patients with melanoma: results of a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Female; Humans; Immunologic Factors; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Skin Neoplasms; Survival Analysis; Vinblastine | 2005 |
[Spinal and cerebral leptomeningeal seeding from a melanocytoma of the cerebello-pontine angle].
Topics: Administration, Oral; Adult; Antineoplastic Agents, Alkylating; Arachnoid; Cerebellar Diseases; Cerebellar Neoplasms; Cerebellopontine Angle; Combined Modality Therapy; Dacarbazine; Diagnosis, Differential; Disease Progression; Humans; Magnetic Resonance Imaging; Male; Melanocytes; Melanoma; Meningeal Neoplasms; Meninges; Neoplasm Recurrence, Local; Neoplasm Seeding; Pia Mater; Radiotherapy Dosage; Temozolomide; Time Factors | 2005 |
518A2 melanoma cells are protected by G3139 and other antineoplastic agents against the cytotoxic effects of DTIC.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cisplatin; Dacarbazine; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Guanine; Humans; Melanoma; Oligonucleotides, Antisense; Thionucleotides | 2005 |
Gastrin exerts pleiotropic effects on human melanoma cell biology.
Topics: Actins; Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Movement; Cholecystokinin; Cisplatin; Cytoskeleton; Dacarbazine; DNA Primers; DNA, Complementary; Flow Cytometry; Gastrins; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Immunohistochemistry; Melanoma; Mice; Neoplasm Invasiveness; Neoplasm Transplantation; Neovascularization, Pathologic; Oligonucleotide Array Sequence Analysis; Poly(ADP-ribose) Polymerases; Receptor, Cholecystokinin B; Receptors, Cholecystokinin; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Time Factors; Wound Healing | 2005 |
A retrospective study of biochemotherapy for metastatic melanoma: the importance of dose intensity.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Humans; Immunologic Factors; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Neoplasm Metastasis; Recombinant Proteins; Retrospective Studies; Temozolomide; Treatment Outcome; Vinblastine | 2005 |
Serial monitoring of circulating melanoma cells during neoadjuvant biochemotherapy for stage III melanoma: outcome prediction in a multicenter trial.
Topics: Adolescent; Adult; Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuvant; Cisplatin; Dacarbazine; Female; Humans; Interferon-alpha; Interleukin-2; Male; MART-1 Antigen; Melanoma; Middle Aged; N-Acetylgalactosaminyltransferases; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplastic Cells, Circulating; Paired Box Transcription Factors; PAX3 Transcription Factor; Prospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Risk Factors; RNA, Messenger; RNA, Neoplasm; Skin Neoplasms; Survival Rate; Treatment Outcome; Vinblastine | 2005 |
Artesunate in the treatment of metastatic uveal melanoma--first experiences.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Artemisia; Artemisinins; Artesunate; Dacarbazine; Fatal Outcome; Female; Humans; Liver Neoplasms; Lung Neoplasms; Male; Melanoma; Sesquiterpenes; Time Factors; Treatment Outcome; Uveal Neoplasms | 2005 |
Topical immunotherapy with diphenylcyclopropenone in combination with DTIC and radiation for cutaneous metastases of melanoma.
Topics: Adjuvants, Immunologic; Administration, Cutaneous; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cyclopropanes; Dacarbazine; Dose Fractionation, Radiation; Follow-Up Studies; Humans; Injections, Intravenous; Male; Melanoma; Radiotherapy, Adjuvant; Skin Neoplasms | 2005 |
Poly(ADP-ribose) glycohydrolase inhibitor as chemosensitiser of malignant melanoma for temozolomide.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Interactions; Fluorenes; Glycoside Hydrolases; Melanoma; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Skin Neoplasms; Temozolomide | 2005 |
Skin delivery potency and antitumor activities of temozolomide ester prodrugs.
Topics: Administration, Cutaneous; Animals; Antineoplastic Agents, Alkylating; Cell Membrane Permeability; Cell Proliferation; Dacarbazine; Drug Delivery Systems; Esterases; Esters; Humans; Liver; Melanoma; Mice; Mice, Inbred BALB C; Mice, Nude; Prodrugs; Rats; Skin; Skin Neoplasms; Swine; Temozolomide; Tumor Cells, Cultured | 2006 |
Clinical analysis of primary malignant melanoma of the cervix.
Topics: Adult; Antibodies, Monoclonal; Chemotherapy, Adjuvant; Dacarbazine; Diagnosis, Differential; Female; Follow-Up Studies; Humans; Hysterectomy; Interferon-gamma; Melanoma; Middle Aged; Prognosis; Retrospective Studies; S100 Proteins; Uterine Cervical Neoplasms | 2005 |
Biochemotherapy with temozolomide, cisplatin, vinblastine, subcutaneous interleukin-2 and interferon-alpha in patients with metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Recombinant Proteins; Skin Neoplasms; Survival Rate; Temozolomide; Treatment Outcome; Vinblastine | 2006 |
[Hypersensitivity to dacarbazine in patients with metastatic malignant melanoma].
Topics: Adult; Aged; Aged, 80 and over; Anemia, Aplastic; Antineoplastic Agents, Alkylating; Cross-Sectional Studies; Dacarbazine; Drug Hypersensitivity; Female; Humans; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Retrospective Studies; Skin Neoplasms; Time Factors | 2006 |
Primary malignant melanoma of the lung: a case report and review of the literature.
Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Dacarbazine; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Melanoma; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Temozolomide; Tomography, X-Ray Computed | 2006 |
Modulation of chemotherapy resistance in regional therapy: a novel therapeutic approach to advanced extremity melanoma using intra-arterial temozolomide in combination with systemic O6-benzylguanine.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusion; Dacarbazine; Deoxyguanosine; Drug Resistance, Neoplasm; Humans; Injections, Intra-Arterial; Melanoma; O(6)-Methylguanine-DNA Methyltransferase; Rats; Rats, Inbred Strains; Skin Neoplasms; Temozolomide; Xenograft Model Antitumor Assays | 2006 |
Acute myocardial infarction induced by cisplatin-based combination chemotherapy for malignant melanoma: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Calcinosis; Cisplatin; Coronary Artery Disease; Dacarbazine; Drug Administration Schedule; Female; Humans; Melanoma; Middle Aged; Myocardial Infarction; Nimustine; Skin Neoplasms; Tamoxifen | 2006 |
Whole brain irradiation and temozolomide based chemotherapy in melanoma brain metastases.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Cohort Studies; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; Drug Administration Schedule; Drug Evaluation; Female; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-2; Life Tables; Male; Melanoma; Middle Aged; Patient Selection; Proportional Hazards Models; Recombinant Proteins; Retrospective Studies; Survival Analysis; Temozolomide; Treatment Outcome; Vinblastine | 2006 |
Targeting the endothelin axis in human melanoma: combination of endothelin receptor antagonism and alkylating agents.
Topics: Alkylating Agents; Antineoplastic Agents; Apoptosis; Bosentan; Cell Line, Tumor; Cell Survival; Dacarbazine; Drug Delivery Systems; Drug Synergism; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelin-1; Fas Ligand Protein; Genetic Variation; Humans; Melanoma; Membrane Glycoproteins; Oligopeptides; Peptides, Cyclic; Piperidines; Receptor, Endothelin B; RNA, Messenger; Sulfonamides; Tumor Necrosis Factors | 2006 |
Adjuvant therapy of cutaneous melanoma -- current status.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Humans; Interferon-alpha; Melanoma; Randomized Controlled Trials as Topic; Skin Neoplasms | 2006 |
[Phototoxicity of dacarbazine (Deticene) not reinduced by temozolomide (Temodal)].
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Dermatitis, Phototoxic; Humans; Melanoma; Skin Neoplasms; Temozolomide | 2006 |
Implications of tissue transglutaminase expression in malignant melanoma.
Topics: Apoptosis; Cell Adhesion; Cell Line, Tumor; Cell Membrane; Cisplatin; Culture Media, Serum-Free; Dacarbazine; Disease Progression; Drug Resistance, Neoplasm; Fibronectins; GTP-Binding Proteins; Humans; Immunoprecipitation; Integrin beta Chains; Melanoma; Protein Glutamine gamma Glutamyltransferase 2; RNA, Small Interfering; Signal Transduction; Survival Rate; Transglutaminases | 2006 |
The course of melanoma-associated vitiligo: report of a case.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Humans; Interferon-alpha; Lung Neoplasms; Male; Melanoma; Middle Aged; Prognosis; Skin Neoplasms; Vinblastine; Vitiligo | 2006 |
[Effect of interferon alfa therapy on malignant melanoma of oral mucosa].
Topics: Antineoplastic Agents; Dacarbazine; Humans; Interferon alpha-2; Interferon-alpha; Lymphatic Metastasis; Maxilla; Melanoma; Mouth Mucosa; Mouth Neoplasms; Recombinant Proteins; Retrospective Studies; Survival Rate | 2006 |
Overall and progression-free survival in metastatic melanoma: analysis of a single-institution database.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Cisplatin; Dacarbazine; Databases, Factual; Disease-Free Survival; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Neoplasm Staging; Recombinant Proteins; Retrospective Studies; Skin Neoplasms; Survival Rate; Treatment Outcome; Vinblastine | 2006 |
A single cycle of treatment with temozolomide, alone or combined with O(6)-benzylguanine, induces strong chemoresistance in melanoma cell clones in vitro: role of O(6)-methylguanine-DNA methyltransferase and the mismatch repair system.
Topics: Antineoplastic Agents; Base Pair Mismatch; Dacarbazine; DNA Methylation; DNA Repair; Drug Resistance, Neoplasm; Enzyme Inhibitors; Guanine; Humans; Melanoma; O(6)-Methylguanine-DNA Methyltransferase; Promoter Regions, Genetic; Temozolomide; Tumor Cells, Cultured; Up-Regulation | 2006 |
Successful treatment of acute disseminated intravascular coagulation in a patient with metastatic melanoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Disseminated Intravascular Coagulation; Humans; Liver Neoplasms; Male; Melanoma; Skin Neoplasms; Treatment Outcome; Vinblastine | 2006 |
Hematoma-like metastases.
Topics: Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain; Dacarbazine; Diagnosis, Differential; Fatal Outcome; Hematoma; Hemorrhage; Humans; Liver Neoplasms; Male; Melanoma; Muscle Neoplasms; Paresis; Skin; Skin Neoplasms; Vascular Neoplasms | 2006 |
Combined effect of temozolomide and hyperthermia on human melanoma cell growth and O6-methylguanine-DNA methyltransferase activity.
Topics: Antineoplastic Agents, Alkylating; Base Pair Mismatch; Cancer Vaccines; Cell Line, Tumor; Cell Proliferation; Dacarbazine; DNA Methylation; DNA Repair; Dose-Response Relationship, Drug; Fever; Humans; Inhibitory Concentration 50; Melanoma; O(6)-Methylguanine-DNA Methyltransferase; Skin Neoplasms; Temozolomide | 2007 |
Chemoimmunotherapy for cutaneous melanoma with dacarbazine and epifocal contact sensitizers: results of a nationwide survey of the German Dermatologic Co-operative Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Dinitrochlorobenzene; Disease-Free Survival; Female; Germany; Humans; Irritants; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Retrospective Studies; Skin Neoplasms; Survival Analysis | 2007 |
Viability of a human melanoma cell after single and combined treatment with fotemustine, dacarbazine, and proton irradiation.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Survival; Dacarbazine; Humans; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Proton Therapy | 2007 |
Combined treatment with Ad-hTRAIL and DTIC or SAHA is associated with increased mitochondrial-mediated apoptosis in human melanoma cell lines.
Topics: Adenoviridae; Antineoplastic Agents; Apoptosis; bcl-X Protein; BH3 Interacting Domain Death Agonist Protein; Caspases; Cell Line, Tumor; Cell Survival; Dacarbazine; Down-Regulation; Drug Synergism; Humans; Hydroxamic Acids; Melanoma; Membrane Potential, Mitochondrial; Mitochondria; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Proto-Oncogene Proteins c-bcl-2; TNF-Related Apoptosis-Inducing Ligand; Transduction, Genetic; Vorinostat; X-Linked Inhibitor of Apoptosis Protein | 2007 |
Complex combination biochemotherapy regimen in advanced metastatic melanoma in a non-intensive care unit: toxicity or benefit?
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Drug Administration Schedule; Female; Humans; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Retrospective Studies; Skin Neoplasms; Treatment Outcome; Vindesine | 2007 |
Defining regional infusion treatment strategies for extremity melanoma: comparative analysis of melphalan and temozolomide as regional chemotherapeutic agents.
Topics: Animals; Antineoplastic Agents; Base Pair Mismatch; Cell Line, Tumor; Dacarbazine; Female; Gene Expression Regulation, Neoplastic; Glutathione; Humans; Infusions, Intravenous; Melanoma; Melphalan; Neoplasm Transplantation; Rats; Rats, Nude; Skin Neoplasms; Temozolomide | 2007 |
Galectin-1 knockdown increases sensitivity to temozolomide in a B16F10 mouse metastatic melanoma model.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Cathepsin B; Cell Line, Tumor; Cisplatin; Dacarbazine; Disease Models, Animal; Female; Galectin 1; Gene Expression Regulation, Neoplastic; HSP72 Heat-Shock Proteins; Melanoma; Mice; Mice, Knockout; RNA, Small Interfering; Skin Neoplasms; Temozolomide; Xenograft Model Antitumor Assays | 2007 |
Comparison of a treatment strategy combining CCI-779 plus DTIC versus DTIC monotreatment in human melanoma in SCID mice.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Dacarbazine; Drug Therapy, Combination; Humans; Melanoma; Mice; Mice, SCID; Oncogene Protein v-akt; Protein Kinases; PTEN Phosphohydrolase; Sirolimus; Skin Neoplasms; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2007 |
Molecular classification of patients with malignant melanoma for new therapeutic strategies.
Topics: Combined Modality Therapy; Dacarbazine; Extracellular Signal-Regulated MAP Kinases; Humans; Melanoma; Oligonucleotides, Antisense; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Skin Neoplasms; Thionucleotides | 2007 |
Radiochemotherapy for brain metastasis: how to define a role for temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Cranial Irradiation; Dacarbazine; Humans; Lung Neoplasms; Melanoma; Mouth Neoplasms; Neoplasms, Unknown Primary; Rectal Neoplasms; Research Design; Temozolomide; Treatment Outcome | 2007 |
Biochemotherapy of metastatic melanoma in patients with or without recently diagnosed brain metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Female; Humans; Infusions, Intravenous; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Patient Care Team; Radiosurgery; Recombinant Proteins; Retrospective Studies; Survival Analysis; Temozolomide; Treatment Outcome | 2007 |
Microemulsions as topical delivery vehicles for the anti-melanoma prodrug, temozolomide hexyl ester (TMZA-HE).
Topics: Administration, Cutaneous; Animals; Antineoplastic Agents, Alkylating; Dacarbazine; Detergents; Drug Carriers; Drug Delivery Systems; Emulsions; Esters; In Vitro Techniques; Melanoma; Mice; Mice, Hairless; Myristates; Oleic Acid; Permeability; Pharmaceutical Vehicles; Polyethylene Glycols; Prodrugs; Rats; Skin Absorption; Skin Neoplasms; Solubility; Temozolomide; Vitamin E | 2007 |
Local injection of interferon beta in malignant melanoma of the esophagus as adjuvant of systemic pre- and postoperative DAV chemotherapy: case report with 7 years of long-term survival.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Dacarbazine; Disease-Free Survival; Esophageal Neoplasms; Esophagoscopy; Female; Humans; Injections, Intralesional; Interferon-beta; Melanoma; Middle Aged; Nimustine; Vincristine | 2007 |
Hemorrhagic cystitis in a patient receiving conventional doses of dacarbazine for metastatic malignant melanoma: case report and review of the literature.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cystitis; Cystoscopy; Dacarbazine; Diagnosis, Differential; Dysuria; Fatal Outcome; Foot; Hematuria; Hemorrhage; Humans; Lung Neoplasms; Male; Melanoma; Middle Aged; Ultrasonography; Urinary Bladder | 2007 |
Microphthalmos associated with Dartmouth combination chemotherapy in pregnancy: a case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Female; Humans; Infant, Newborn; Liver Neoplasms; Male; Melanoma; Microphthalmos; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Trimester, First; Pregnancy Trimester, Second; Skin Neoplasms; Tamoxifen | 2007 |
Combining adenoviral oncolysis with temozolomide improves cell killing of melanoma cells.
Topics: Adenoviridae; Antineoplastic Agents, Alkylating; Cell Cycle; Cell Line, Tumor; Chemotherapy, Adjuvant; Dacarbazine; G2 Phase; Gene Amplification; Genome, Viral; Humans; Melanoma; Oncolytic Virotherapy; Skin Neoplasms; Temozolomide; Treatment Outcome; Tumor Cells, Cultured | 2007 |
Predictors of distant brain recurrence for patients with newly diagnosed brain metastases treated with stereotactic radiosurgery alone.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Dacarbazine; Female; Humans; Lung Neoplasms; Male; Melanoma; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Radiosurgery; Retrospective Studies; Temozolomide | 2008 |
O6-methylguanine-DNA-methyltransferase promoter demethylation is involved in basic fibroblast growth factor induced resistance against temozolomide in human melanoma cells.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Base Pair Mismatch; Blotting, Western; Dacarbazine; DNA Methylation; DNA Mismatch Repair; DNA Repair Enzymes; Drug Resistance, Neoplasm; Fibroblast Growth Factor 2; Guanine; Humans; Luciferases; Melanoma; O(6)-Methylguanine-DNA Methyltransferase; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Skin Neoplasms; Temozolomide; Tumor Cells, Cultured | 2007 |
[A case of liver metastasis from anorectal malignant melanoma on hemodialysis treated by chemotherapy].
Topics: Antineoplastic Agents, Alkylating; Anus Neoplasms; Dacarbazine; Humans; Kidney Failure, Chronic; Liver Neoplasms; Male; Melanoma; Middle Aged; Renal Dialysis | 2007 |
Genasense: it ain't over till the fat lady sings.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Drug Approval; Humans; Melanoma; Oligonucleotides, Antisense; Randomized Controlled Trials as Topic; Skin Neoplasms; Thionucleotides; United States; United States Food and Drug Administration | 2007 |
Evaluation of twenty-one human adenovirus types and one infectivity-enhanced adenovirus for the treatment of malignant melanoma.
Topics: Adenoviruses, Human; Animals; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Dacarbazine; Genetic Vectors; Humans; Melanoma; Membrane Cofactor Protein; Mice; Mice, Nude; Oncolytic Virotherapy; Recoverin; Skin Neoplasms; Viral Fusion Proteins; Viral Proteins; Virus Internalization; Virus Replication; Xenograft Model Antitumor Assays | 2008 |
Temozolomide induces senescence but not apoptosis in human melanoma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Benzothiazoles; Cell Division; Cellular Senescence; Dacarbazine; G2 Phase; Humans; Lymphoma; Melanoma; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide; Toluene; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2007 |
CD69 on CD56+ NK cells and response to chemoimmunotherapy in metastatic melanoma.
Topics: Adult; Aged; Antigens, CD; Antigens, Differentiation, T-Lymphocyte; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; CD56 Antigen; Dacarbazine; Female; Humans; Immunotherapy; Interferon alpha-2; Interferon Regulatory Factor-1; Interferon-alpha; Killer Cells, Natural; Lectins, C-Type; Male; Melanoma; Middle Aged; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; Skin Neoplasms; Tretinoin | 2007 |
Adjuvant use of interferon alpha 2b is not justified in patients with stage IIb/III melanoma.
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Dacarbazine; Disease-Free Survival; Follow-Up Studies; Humans; Immunologic Factors; Interferon alpha-2; Interferon-alpha; Lymphatic Metastasis; Melanoma; Meta-Analysis as Topic; Multicenter Studies as Topic; Neoplasm Staging; Patient Selection; Quality of Life; Randomized Controlled Trials as Topic; Recombinant Proteins; Risk; Skin Neoplasms; Survival Analysis; Treatment Failure | 2008 |
[Dacarbazine: deticene].
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Humans; Melanoma; Skin Neoplasms | 2007 |
Temozolomide-induced desquamative skin rash in a patient with metastatic melanoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Dacarbazine; Drug Eruptions; Female; Humans; Melanoma; Skin Neoplasms; Temozolomide | 2008 |
Interleukin-2-based biochemotherapy for patients with stage IV melanoma: long-term survivors outside a clinical trial setting.
Topics: Academic Medical Centers; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Interferon alpha-2; Interferon-alpha; Interleukin-2; Kaplan-Meier Estimate; Male; Melanoma; Middle Aged; Neoplasm Staging; Recombinant Proteins; Retrospective Studies; Skin Neoplasms; Treatment Outcome; Vinblastine | 2007 |
The integrin antagonist cilengitide increases the antitumor activity of temozolomide against malignant melanoma.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Dacarbazine; DNA Mismatch Repair; Drug Synergism; Endothelial Cells; Integrins; Male; Melanoma; Mice; Mice, Inbred C57BL; Snake Venoms; Temozolomide | 2008 |
Topical CpG enhances the response of murine malignant melanoma to dacarbazine.
Topics: Adjuvants, Immunologic; Administration, Topical; Animals; Antineoplastic Agents, Alkylating; Apoptosis; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Dacarbazine; Disease Models, Animal; Drug Therapy, Combination; Injections, Intraperitoneal; Melanoma; Mice; Mice, Inbred C57BL; Oligodeoxyribonucleotides; Skin Neoplasms; T-Lymphocytes, Cytotoxic; Treatment Outcome | 2008 |
Leser-Trelat sign in metastasized malignant melanoma.
Topics: Aged, 80 and over; Biomarkers, Tumor; Dacarbazine; Follow-Up Studies; Humans; Keratosis, Seborrheic; Lymphatic Metastasis; Male; Melanoma; Neoplasm Staging; Palliative Care; Paraneoplastic Syndromes; Risk Assessment; Skin Neoplasms | 2009 |
A rare case of melanoma recurring as subcutaneous metastatic melanoma with overlying ecchymoses.
Topics: Aged, 80 and over; Antineoplastic Agents, Alkylating; Biopsy; Dacarbazine; Ecchymosis; Female; Humans; Lung Neoplasms; Melanoma; Neoplasm Recurrence, Local; Neoplasms, Multiple Primary; Skin; Skin Neoplasms; Temozolomide; Treatment Outcome | 2008 |
Targeting N-cadherin enhances antitumor activity of cytotoxic therapies in melanoma treatment.
Topics: Animals; Antineoplastic Agents, Alkylating; Cadherins; Dacarbazine; DNA Adducts; Humans; Immunotherapy; Melanoma; Melphalan; Models, Biological; Neoplasm Transplantation; Phenotype; Rats; Rats, Nude; Temozolomide | 2008 |
Treatment and prognosis of malignant melanoma of the oral cavity: preoperative surgical procedure increases risk of distant metastasis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Contraindications; Dacarbazine; Female; Humans; Immunotherapy; Kaplan-Meier Estimate; Male; Melanoma; Middle Aged; Mouth Neoplasms; Neoplasm Metastasis; Nimustine; Picibanil; Prognosis; Risk Factors; Tooth Extraction; Vincristine | 2008 |
Radiation therapy for brain metastases from malignant melanoma.
Topics: Adult; Aged; Brain Neoplasms; Dacarbazine; Dose-Response Relationship, Radiation; Female; Humans; Lomustine; Male; Melanoma; Middle Aged; Prognosis | 1984 |
DTIC (dacarbazine)-induced hepatic damage. Possible pathogenesis and prevention.
Topics: Aged; Alanine Transaminase; Alkaline Phosphatase; Aspartate Aminotransferases; Chemical and Drug Induced Liver Injury; Dacarbazine; Female; gamma-Glutamyltransferase; Humans; Melanoma; Prednisone; Skin Neoplasms | 1981 |
Treatment of malignant melanoma with dacarbazin (DTIC-DOME) with special reference to urinary excretion of 5-S-cysteinyldopa.
Topics: Adult; Aged; Brain Neoplasms; Cysteinyldopa; Dacarbazine; Digestive System; Dihydroxyphenylalanine; Female; Humans; Infusions, Intra-Arterial; Male; Melanoma; Middle Aged; Palliative Care; Remission, Spontaneous | 1980 |
[Adjuvant chemotherapy in malignant melanoma after pretherapeutic sensitivity testing].
Topics: BCG Vaccine; Dacarbazine; Drug Therapy, Combination; Humans; Melanoma; Neoplasm Staging; Prognosis | 1981 |
Functional-group modifications of dextran for linkage to a diazonium group. A potential vehicle for tumour targeting of antineoplastic triazenes.
Topics: Animals; Antineoplastic Agents; Dacarbazine; Dextrans; Diazonium Compounds; Melanoma; Mice; Neoplasms, Experimental; Triazenes | 1982 |
Bleomycin, carmustine, vincristine, and dacarbazine in patients with metastatic malignant melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Dacarbazine; Female; Humans; Male; Melanoma; Neoplasm Metastasis; Vincristine | 1983 |
Management of malignant melanoma: a retrospective analysis of 182 patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Female; Humans; Lomustine; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Retrospective Studies; Skin Neoplasms | 1984 |
Phase II trial of vinblastine, bleomycin, and cisplatin (VBP) followed by dacarbazine and mitolactol in metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Dacarbazine; Drug Administration Schedule; Drug Evaluation; Female; Humans; Male; Melanoma; Middle Aged; Mitolactol; Neoplasm Metastasis; Vinblastine | 1984 |
Modern problems of clinical chemotherapy of malignant tumours.
Topics: Antineoplastic Agents; Carcinoma, Small Cell; Carubicin; Dacarbazine; Dactinomycin; Drug Therapy, Combination; Female; Humans; Lomustine; Lung Neoplasms; Male; Melanoma; Methylnitrosourea; Neoplasms; Sarcoma; Skin Neoplasms; Soft Tissue Neoplasms; Vincristine | 1980 |
Changes in T and B lymphocyte subpopulations before, during and after chemotherapy for malignant melanoma.
Topics: Aged; B-Lymphocytes; Dacarbazine; Female; Humans; Leukocyte Count; Lomustine; Lymphocytes; Male; Melanoma; Middle Aged; Neoplasm Metastasis; T-Lymphocytes | 1984 |
[Isolated hyperthermic extremity perfusion with vindesine, dacarbazine and cisplatin in the treatment of malignant melanomas].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusion; Cisplatin; Dacarbazine; Humans; Leg; Lymphatic Metastasis; Melanoma; Neoplasm Staging; Skin Neoplasms; Vinblastine; Vindesine | 1984 |
[Therapeutic evaluation of human malignant melanoma by urinary 5-S-cysteinyldopa dynamics: chemotherapy and surgery].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Cysteinyldopa; Dacarbazine; Dihydroxyphenylalanine; Female; Humans; Immunotherapy; Male; Melanoma; Middle Aged; Nimustine; Nitrosourea Compounds; Prognosis; Vincristine | 1984 |
Adverse photo reaction to decarbazine (DTIC).
Topics: Adult; Dacarbazine; Drug Eruptions; Female; Humans; Melanoma; Postoperative Complications; Skin Neoplasms | 1981 |
[Control of multiple skin and lung metastasis of malignant melanoma by combined DAV and OK-432 chemoimmunotherapy in association with large-scale administration of indomethacin].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Humans; Indomethacin; Lung Neoplasms; Male; Melanoma; Nimustine; Nitrosourea Compounds; Pain, Intractable; Picibanil; Skin Neoplasms; Suppositories; Vincristine | 1984 |
Veno-occlusive liver disease after dacarbazine therapy (DTIC) for melanoma.
Topics: Budd-Chiari Syndrome; Dacarbazine; Hepatic Veins; Humans; Male; Melanoma; Middle Aged; Necrosis | 1984 |
Epigenetic effects of the methylating agent 5-(3-methyl-1-triazeno) imidazole-4-carboxamide in human melanoma cells.
Topics: Alkylating Agents; Antineoplastic Agents; Cell Line; Dacarbazine; Deoxycytidine; Deoxyguanosine; Genes; Humans; Melanoma; Theophylline; Thymidine | 1984 |
Studies on drug resistance in a human melanoma xenograft system.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Disease Models, Animal; DNA; Drug Resistance; Humans; Ifosfamide; Kinetics; Melanoma; Melphalan; Mice; Mice, Nude; Neoplasm Transplantation; Semustine; Transplantation, Heterologous | 1984 |
Combination chemotherapy with cisplatin, carmustine, dacarbazine, and tamoxifen in metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Tamoxifen | 1984 |
[Malignant melanoma of the penile fossa navicularis].
Topics: Combined Modality Therapy; Dacarbazine; Humans; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoplasm Staging; Penile Neoplasms; Penis; Prognosis; Urethra; Urethral Neoplasms | 1984 |
DTIC and CPZ cytotoxicities on established human melanocyte cell lines.
Topics: Cell Division; Cell Line; Chlorpromazine; Dacarbazine; Drug Resistance; Humans; Melanocytes; Melanoma | 1984 |
[Case of metastatic malignant melanoma responded to combination chemotherapy with DTIC].
Topics: Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Drug Administration Schedule; Female; Humans; Melanoma; Middle Aged; Neoplasm Metastasis; Nimustine; Nitrosourea Compounds; Picibanil; Vincristine | 1984 |
Thymostimulin therapy in melanoma patients: correlation of immunologic effects with clinical course.
Topics: Adult; Aged; B-Lymphocytes; Dacarbazine; Female; Humans; Leukocyte Count; Lung Neoplasms; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Rosette Formation; Skin Neoplasms; T-Lymphocytes; Thymus Extracts | 1983 |
Intracarotid artery infusion of DTIC for invasive maxillofacial melanoma.
Topics: Aged; Carotid Artery, External; Dacarbazine; Dose-Response Relationship, Drug; Female; Head and Neck Neoplasms; Humans; Infusions, Intra-Arterial; Male; Melanoma; Middle Aged; Prognosis | 1983 |
Tourniquet infusion with DTIC in therapy-resistant melanoma on the extremities: a pilot study.
Topics: Aged; Combined Modality Therapy; Dacarbazine; Female; Humans; Infusions, Intra-Arterial; Leg; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Pilot Projects; Prognosis; Skin Neoplasms | 1983 |
In vitro activation of dacarbazine (DTIC) for a human tumor cloning system.
Topics: Animals; Biotransformation; Cell Line; Clone Cells; Dacarbazine; Drug Evaluation, Preclinical; Humans; Leukemia L1210; Light; Melanoma; Mice; Microsomes, Liver | 1983 |
[Results in the use of immunochemotherapy in patients with cutaneous malignant melanoma].
Topics: BCG Vaccine; Combined Modality Therapy; Dacarbazine; Humans; Melanoma; Skin Neoplasms | 1983 |
[Technic of isolated perfusion of the extremities. Experience with 171 cases].
Topics: Arm; Chemotherapy, Cancer, Regional Perfusion; Cisplatin; Dacarbazine; Drug Therapy, Combination; Extracorporeal Circulation; Humans; Hyperthermia, Induced; Leg; Mechlorethamine; Melanoma; Melphalan; Postoperative Care; Soft Tissue Neoplasms | 1983 |
Regional perfusion with cis-platinum and dacarbazine.
Topics: Chemotherapy, Cancer, Regional Perfusion; Cisplatin; Dacarbazine; Extremities; Follow-Up Studies; Humans; Melanoma; Skin Neoplasms | 1983 |
Antimetastatic action and hematological toxicity of p-(3,3-dimethyl-1-triazeno)benzoic acid potassium salt and 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide used as prophylactic adjuvants to surgical tumor removal in mice bearing B16 melanoma.
Topics: Animals; Antineoplastic Agents; Combined Modality Therapy; Dacarbazine; Melanoma; Mice; Mice, Inbred Strains; Triazenes | 1984 |
Regional isolated perfusion of high risk melanoma of the extremities with imidazole carboxamide.
Topics: Arm; Chemotherapy, Cancer, Regional Perfusion; Creatinine; Dacarbazine; Follow-Up Studies; Humans; Leg; Leukocyte Count; Liver Function Tests; Melanoma; Skin Neoplasms | 1984 |
[Malignant melanoma in Japan: unique distribution and effect of DAV chemoimmunotherapy (part II)].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biological Products; Child; Dacarbazine; Female; Foot; Hand; Humans; Japan; Male; Melanoma; Middle Aged; Nimustine; Nitrosourea Compounds; Picibanil; Proteoglycans; Skin Neoplasms; Vincristine | 1984 |
Scheduling of combination chemotherapy for a murine melanoma, with the subrenal capsular assay.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Drug Administration Schedule; Female; Melanoma; Mice; Neoplasm Transplantation; Semustine | 1984 |
[Marked regression of melanoma metastases under combined chemotherapy].
Topics: Abdominal Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Dacarbazine; Female; Humans; Hydroxyurea; Lung Neoplasms; Melanoma; Middle Aged; Skin Neoplasms | 1984 |
Triazene metabolism. III. In vitro cytotoxicity towards M21 cells and in vivo antitumour activity of the proposed metabolites of the antitumour 1-aryl-3,3-dimethyltriazenes.
Topics: Animals; Antineoplastic Agents; Biotransformation; Cell Line; Cell Survival; Chemical Phenomena; Chemistry; Dacarbazine; Half-Life; Humans; Leukemia P388; Melanoma; Mice; Triazenes | 1984 |
Cell kinetic studies of the effect of DTIC combined with fluorescent light or UVA irradiation on human melanoma cell line (SEKI, II).
Topics: Cell Cycle; Cells, Cultured; Dacarbazine; Fluorescence; Humans; Kinetics; Melanoma; Skin Neoplasms; Ultraviolet Rays | 1982 |
[Dacarbazine (DTIC) therapy and the Budd-Chiari syndrome].
Topics: Budd-Chiari Syndrome; Dacarbazine; Female; Humans; Melanoma; Middle Aged | 1980 |
Drug activity and therapeutic synergism in cancer treatment.
Topics: Animals; Antineoplastic Agents; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Female; Fluorouracil; Humans; Hydroxamic Acids; Lung Neoplasms; Male; Melanoma; Mice; Mitomycin; Mitomycins; Neoplasms; Neoplasms, Experimental; Rats; Razoxane; Teniposide | 1982 |
[Correlation of urinary 5-S-cysteinyldopa with repeated remission of melanoma induced by DTIC combination chemotherapy].
Topics: Cysteinyldopa; Dacarbazine; Dihydroxyphenylalanine; Female; Humans; Lymphoma; Melanoma; Middle Aged; Skin Neoplasms | 1982 |
Adjuvant dacarbazine in cutaneous melanoma.
Topics: Dacarbazine; Humans; Melanoma; Skin Neoplasms | 1983 |
In vivo drug sensitivity assay of clonogenic human melanoma cells and correlation with treatment outcome.
Topics: Animals; Biological Assay; Biotransformation; Cell Survival; Clone Cells; Dacarbazine; Drug Evaluation; Drug Tolerance; Humans; Kinetics; Melanoma; Mice; Mitolactol; Nitrosourea Compounds; Semustine; Specimen Handling | 1983 |
Acute liver dystrophy with thrombosis of hepatic veins: a fatal complication of dacarbazine treatment.
Topics: Chemical and Drug Induced Liver Injury; Dacarbazine; Female; Hepatic Veins; Humans; Liver Diseases; Male; Melanoma; Middle Aged; Necrosis; Skin Neoplasms; Thrombosis | 1983 |
[New modifications in isolated extremity perfusion ].
Topics: Antineoplastic Agents; Arm; Chemotherapy, Cancer, Regional Perfusion; Cisplatin; Dacarbazine; Dactinomycin; Drug Therapy, Combination; Hot Temperature; Humans; Leg; Mechlorethamine; Melanoma; Melphalan; Skin Neoplasms | 1982 |
Combination chemotherapy with AMSA on L1210 leukaemia and B16 melanoma.
Topics: Aminoacridines; Amsacrine; Animals; Antineoplastic Agents; Carmustine; Dacarbazine; Drug Therapy, Combination; Leukemia L1210; Male; Melanoma; Melphalan; Mice; Mice, Inbred Strains; Neoplasms, Experimental | 1981 |
[Malignant melanoma. Clinicopathological analysis of 37 cases (author's transl)].
Topics: Adult; Aged; BCG Vaccine; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Skin Neoplasms | 1982 |
Phase II study of cyclophosphamide, vincristine and D.T.I.C. +/- B.C.G. in the treatment of malignant melanoma.
Topics: Adolescent; Adult; Aged; BCG Vaccine; Cyclophosphamide; Dacarbazine; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Vincristine | 1982 |
[A case of malignant melanoma responded to chemotherapy including DTIC and local injection of OK-432].
Topics: Adult; Biological Products; Dacarbazine; Drug Therapy, Combination; Female; Humans; Melanoma; Nimustine; Nitrosourea Compounds; Picibanil; Skin Neoplasms; Vincristine | 1982 |
[A combination chemotherapy of ACNU and DTIC for advanced malignant melanoma].
Topics: Adult; Aged; Dacarbazine; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Melanoma; Middle Aged; Nimustine; Nitrosourea Compounds; Skin Neoplasms | 1982 |
[Cell kinetic studies on human melanoma cell line (SEKI II) under the effect of DTIC with fluorescent light and UVA irradiation (author's transl)].
Topics: Cell Cycle; Cell Line; Dacarbazine; Humans; Light; Melanoma; Neoplasms, Experimental; Photic Stimulation; Skin Neoplasms; Ultraviolet Rays | 1980 |
[Budd-Chiari syndrome during treatment with dacarbazine (DTIC) (author's transl)].
Topics: Budd-Chiari Syndrome; Dacarbazine; Humans; Male; Melanoma; Metoclopramide; Middle Aged; Mycobacterium bovis; Skin Neoplasms; Vomiting | 1980 |
Chemoimmunotherapy for disseminated malignant melanoma with DTIC, ACNU, VCR and OK432. Case presentation of two complete and one partial reponse out of fifteen attempts.
Topics: Adjuvants, Immunologic; Adult; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Drug Therapy, Combination; Female; Humans; Male; Melanoma; Nimustine; Nitrosourea Compounds; Picibanil; Skin Neoplasms; Vincristine | 1982 |
Thermochemotherapy for melanoma metastases in liver.
Topics: Adult; Aged; Dacarbazine; Female; Hot Temperature; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Melanoma; Middle Aged; Pilot Projects; Retrospective Studies | 1982 |
Pilot studies using melanoma tumor-associated antigens (TAA) in specific-active immunochemotherapy of malignant melanoma.
Topics: Adult; Aged; Antigens, Neoplasm; Chromatography, Affinity; Dacarbazine; Drug Administration Schedule; Female; Humans; Immunity, Cellular; Immunization; Male; Melanoma; Middle Aged; Neoplasm Staging; Pilot Projects; Prognosis; Random Allocation; Recurrence; Skin Neoplasms | 1982 |
Effect of scheduling of combinations of 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide and 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea on the Harding-Passey and Cloudman S91 mouse melanomas.
Topics: Animals; Cell Line; Dacarbazine; Drug Administration Schedule; Drug Therapy, Combination; Female; Melanoma; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Neoplasms, Experimental; Nitrosourea Compounds; Semustine; Time Factors | 1982 |
Properties of human melanoma cells resistant to 5-(3',3'-dimethyl-1-triazeno)imidazole-4-carboxamide and other methylating agents.
Topics: Alkylating Agents; Biotransformation; Cell Line; Dacarbazine; DNA, Neoplasm; Drug Resistance; Humans; Melanoma; Protein Biosynthesis | 1982 |
[Immunological aspects in the treatment of malignant melanoma].
Topics: Administration, Topical; BCG Vaccine; Dacarbazine; Humans; Injections, Intralymphatic; Injections, Intravenous; Injections, Jet; Lymphatic Metastasis; Melanoma; Prognosis | 1982 |
[Experience with adjuvant chemoimmunotherapy with DTIC and BCG in malignant melanoma (author's transl)].
Topics: BCG Vaccine; Dacarbazine; Drug Therapy, Combination; Humans; Melanoma; Skin Neoplasms | 1982 |
[Budd-Chiari syndrome in DTIC therapy].
Topics: Adult; Budd-Chiari Syndrome; Dacarbazine; Eosinophilia; Female; Humans; Melanoma | 1982 |
[Dacarbazine in malignant melanoma. Rare, severe side-effect: Budd-Chiari-syndrome (author's transl)].
Topics: Budd-Chiari Syndrome; Dacarbazine; Humans; Liver; Male; Melanoma; Middle Aged; Skin Neoplasms | 1982 |
Changes in the rosette forming capacity of lymphocytes after surgery or surgery and immunochemotherapy of malignant melanoma in man.
Topics: Adolescent; Adult; Aged; BCG Vaccine; Dacarbazine; Humans; Lymphocytes; Melanoma; Middle Aged; Rosette Formation | 1982 |
[Malignant melanoma in Japan: unique distribution and effect of DAV chemoimmunotherapy].
Topics: Adjuvants, Immunologic; Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Drug Therapy, Combination; Female; Humans; Leucine; Male; Melanoma; Middle Aged; Nimustine; Nitrosourea Compounds; Picibanil; Proteoglycans; Skin Neoplasms; Vincristine | 1982 |
Combination chemotherapy with ifosfamide and cis-dichlorodiammineplatinum (II) in advanced malignant melanoma.
Topics: Adult; Aged; Cisplatin; Cyclophosphamide; Dacarbazine; Drug Synergism; Drug Therapy, Combination; Female; Humans; Ifosfamide; Male; Melanoma; Middle Aged | 1980 |
Angiographic appearance of recurrent malignant melanoma before and after intra-arterial chemotherapy.
Topics: Angiography; Antineoplastic Agents; Cisplatin; Dacarbazine; Drug Therapy, Combination; Extremities; Humans; Infusions, Intra-Arterial; Melanoma; Neoplasm Recurrence, Local | 1982 |
Dacarbazine (DTIC) in malignant melanoma: reduced toxicity with protection from light.
Topics: Dacarbazine; Darkness; Female; Humans; Male; Melanoma; Neoplasm Recurrence, Local | 1981 |
In vitro sensitivity of human melanoma xenografts to cytotoxic drugs. Correlation with in vivo chemosensitivity.
Topics: Abrin; Animals; Antineoplastic Agents; Dacarbazine; Humans; Lomustine; Melanoma; Mice; Mice, Nude; Neoplasms, Experimental; Procarbazine; Ricin; Vinblastine | 1980 |
[Veno-occlusive syndrome with acute liver dystrophy following decarbazine therapy of malignant melanoma (author's transl)].
Topics: Aged; Budd-Chiari Syndrome; Chemical and Drug Induced Liver Injury; Dacarbazine; Hepatic Veins; Humans; Liver; Lymphatic Metastasis; Male; Melanoma; Skin Neoplasms | 1981 |
[Malignant melanoma of the esophagus (author's transl)].
Topics: Adult; BCG Vaccine; Brain Neoplasms; Dacarbazine; Esophageal Neoplasms; Humans; Male; Melanoma; Seizures | 1981 |
[Scintigraphy of liver after combined chemo-/immunotherapy with malignant melanoma (author's transl)].
Topics: Adult; BCG Vaccine; Dacarbazine; Female; Humans; Liver; Male; Melanoma; Middle Aged; Radionuclide Imaging; Skin Neoplasms | 1981 |
Dacarbazine-induced photosensitivity reaction.
Topics: Aged; Dacarbazine; Female; Humans; Melanoma; Middle Aged; Photosensitivity Disorders; Skin; Skin Neoplasms | 1981 |
[Influence and importance of dacarbazine and BCG in sonography of the liver (author's transl)].
Topics: BCG Vaccine; Dacarbazine; Female; Humans; Immunotherapy; Liver Neoplasms; Male; Melanoma; Middle Aged; Radiography | 1981 |
[Effect of DTIC on the level of various blood components in melanoma].
Topics: Adult; Aged; Alanine Transaminase; Aspartate Aminotransferases; Bilirubin; Blood Proteins; Dacarbazine; Female; Hematocrit; Humans; Male; Melanoma; Middle Aged; Skin Neoplasms | 1981 |
Comparison of two soft-agar methods for assaying chemosensitivity of human tumours in vitro: malignant melanomas.
Topics: Abrin; Agar; Animals; Cell Survival; Cells, Cultured; Dacarbazine; Drug Evaluation, Preclinical; Erythrocytes; Humans; Lomustine; Melanoma; Oxygen Consumption; Rats; Vinblastine | 1981 |
Chemoimmunotherapy for metastatic malignant melanoma using vincristine (NSC-67574), DTIC (NSC-45388) and Bacillus Calmette-Guerin.
Topics: Adult; Aged; BCG Vaccine; Dacarbazine; Drug Therapy, Combination; Female; Humans; Male; Melanoma; Middle Aged; Skin Neoplasms; Vincristine | 1981 |
The usefulness of human tumor cell lines in the study of chemosensitivity. A study of malignant melanomas.
Topics: Animals; Antineoplastic Agents; Cell Division; Cell Line; Dacarbazine; Drug Evaluation, Preclinical; Humans; Lomustine; Melanoma; Mice; Neoplasm Transplantation; Procarbazine; Ricin; Transplantation, Heterologous; Vinblastine | 1981 |
Metastatic tumor to the retina and vitreous cavity from primary melanoma of the skin: treatment with systemic and subconjunctival chemotherapy.
Topics: Adult; Carmustine; Dacarbazine; Eye Neoplasms; Female; Humans; Lomustine; Melanoma; Retina; Skin Neoplasms; Vitreous Body | 1981 |
Response to chemotherapy of human, malignant melanoma xenografts in athymic, nude mice.
Topics: Abrin; Animals; Antineoplastic Agents; Dacarbazine; Humans; Lomustine; Melanoma; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Procarbazine; Ricin; Skin Neoplasms; Time Factors; Transplantation, Heterologous; Vinblastine | 1980 |
Chemoimmunotherapy of disseminated malignant melanoma with DTIC-BCG, transfer factor + melphalan.
Topics: Adult; Aged; BCG Vaccine; Blood Cell Count; Dacarbazine; Drug Therapy, Combination; Female; Humans; Immunocompetence; Immunotherapy; Male; Melanoma; Melphalan; Middle Aged; Neoplasm Metastasis; Prognosis; Skin Tests; Time Factors; Transfer Factor | 1980 |
Hepatic veno-occlusive disease due to DTIC.
Topics: Budd-Chiari Syndrome; Chemical and Drug Induced Liver Injury; Dacarbazine; Humans; Liver; Male; Melanoma; Middle Aged; Necrosis | 1980 |
[Phototoxic dermatitis caused by DTIC-treatment].
Topics: Dacarbazine; Humans; Melanoma; Photosensitivity Disorders; Skin Neoplasms | 1980 |
[Chemotherapy and malignant melanoma].
Topics: Dacarbazine; Humans; Melanoma | 1980 |
[Results of immunochemotherapy in malignant melanoma].
Topics: BCG Vaccine; Dacarbazine; Humans; Levamisole; Melanoma; Transfer Factor | 1980 |
[Use of imidazole carboxamide in melanoblastoma of the eye].
Topics: Animals; Dacarbazine; Drug Evaluation; Drug Evaluation, Preclinical; Eye Neoplasms; Female; Humans; Imidazoles; Melanoma; Neoplasm Transplantation; Preoperative Care; Rabbits | 1980 |
Biologic behavior of ocular malignant melanoma and comparison with melanoma of the head and neck.
Topics: Adult; Aged; Dacarbazine; Eye Neoplasms; Female; Head and Neck Neoplasms; Humans; Male; Melanoma; Middle Aged | 1980 |
An inverse relationship between the growth rate of human melanoma xenografts and their response to some cytostatic drugs.
Topics: Animals; Dacarbazine; Humans; Lomustine; Melanoma; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Nitrosourea Compounds; Procarbazine; Transplantation, Heterologous | 1980 |
[Photosensitization with DTIC therapy in metastatic malignant melanoma].
Topics: Aged; Dacarbazine; Drug Therapy, Combination; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Photosensitivity Disorders; Skin Neoplasms | 1980 |
Chemotherapy against human melanoma in the hamster cheek pouch.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Carmustine; Cheek; Cricetinae; Cyclophosphamide; Dacarbazine; Doxorubicin; Fluorouracil; Humans; Male; Melanoma; Methotrexate; Middle Aged; Neoplasm Transplantation; Neoplasms, Experimental; Vincristine | 1980 |
Symptoms of occult brain metastases initiated by systemic Dacarbazine (DTIC-DOME) therapy in melanoma patients.
Topics: Adult; Aged; Brain Neoplasms; Dacarbazine; Dizziness; Female; Headache; Humans; Male; Melanoma; Middle Aged | 1980 |
[Anorectal malignant melanomas. Apropos of 5 cases. Review of the literature].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Female; Humans; Immunotherapy; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Palliative Care; Prognosis; Radiotherapy Dosage; Radiotherapy, Adjuvant; Rectal Neoplasms; Vindesine | 1995 |
Chemosensitivity testing of human malignant melanoma. A retrospective analysis of clinical response and in vitro drug sensitivity.
Topics: Antineoplastic Agents; Bleomycin; Carboplatin; Carmustine; Cisplatin; Dacarbazine; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance; Drug Screening Assays, Antitumor; Fluorouracil; Forecasting; Humans; In Vitro Techniques; Lymphatic Metastasis; Melanoma; Methotrexate; Nitrosourea Compounds; Organophosphorus Compounds; Pilot Projects; Remission Induction; Retrospective Studies; Skin Neoplasms; Tumor Cells, Cultured; Vindesine | 1994 |
Contribution of radiotherapy to the management of malignant melanoma. A ten year experience at the University of Illinois Hospital in Chicago.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Combined Modality Therapy; Dacarbazine; Dose-Response Relationship, Radiation; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Male; Melanoma; Middle Aged; Neoplasm Staging; Palliative Care; Survival Analysis; Survival Rate; Treatment Outcome | 1993 |
Decreasing CD4/CD8 ratio during prolonged four-drug chemotherapy plus interferon treatment for metastatic melanoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; CD4-CD8 Ratio; Dacarbazine; Humans; Interferon-alpha; Leukocyte Count; Lomustine; Melanoma; Middle Aged; Vincristine | 1994 |
Response of subcutaneous and cutaneous metastases of malignant melanoma to combined cytostatic plus interferon therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Dacarbazine; Female; Humans; Interferons; Lomustine; Male; Melanoma; Middle Aged; Skin Neoplasms; Vincristine | 1995 |
Statistical survey from 1982 to 1991 of 49 patients with malignant melanocytic tumors.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Child; Dacarbazine; Female; Humans; Interferon-beta; Male; Melanoma; Middle Aged; Nimustine; Prognosis; Skin Neoplasms; Survival Rate; Vincristine | 1995 |
[Combination of dacarbazine, vindesine and interferon alpha in the treatment of metastatic melanoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Dose-Response Relationship, Drug; Female; Humans; Interferon-alpha; Male; Melanoma; Treatment Outcome; Vindesine | 1994 |
Three-drug combination of cisplatin, dacarbazine, and tamoxifen in metastatic malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Remission Induction; Tamoxifen | 1995 |
Isolated pelvic perfusion for unresectable cancer using a balloon occlusion technique.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Catheterization; Chemotherapy, Cancer, Regional Perfusion; Cisplatin; Dacarbazine; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Melanoma; Middle Aged; Mitomycin; Neoplasm Recurrence, Local; Palliative Care; Pelvis; Rectal Neoplasms; Remission Induction | 1993 |
[Chemotherapy of malignant melanoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Dacarbazine; Drug Administration Schedule; Female; Humans; Melanoma; Middle Aged; Nimustine; Peplomycin; Skin Neoplasms; Vincristine | 1993 |
Chemoimmunotherapy of melanoma. Is it time for phase III trials?
Topics: Clinical Trials, Phase III as Topic; Combined Modality Therapy; Dacarbazine; Humans; Immunotherapy; Interleukin-2; Melanoma | 1995 |
Modification of the effect of tamoxifen, cis-platin, DTIC, and interferon-alpha 2b on human melanoma cells in culture by a mixture of vitamins.
Topics: Ascorbic Acid; beta Carotene; Carotenoids; Cell Division; Cisplatin; Dacarbazine; Drug Screening Assays, Antitumor; Humans; Interferon alpha-2; Interferon-alpha; Isotretinoin; Melanoma; Recombinant Proteins; Tamoxifen; Tocopherols; Tumor Cells, Cultured; Vitamin E; Vitamins | 1994 |
Combination chemotherapy of metastatic melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Humans; Melanoma; Neoplasm Metastasis; Tamoxifen | 1995 |
Pilot study of preoperative chemotherapy with cisplatin, vinblastine, and dacarbazine in patients with local-regional recurrence of melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Pilot Projects; Remission Induction; Skin Neoplasms; Survival Analysis; Vinblastine | 1994 |
Mouse subrenal capsule assay chemosensitivity and DNA flow cytometry parameters of human melanoma metastases.
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; DNA, Neoplasm; Etoposide; Female; Flow Cytometry; Humans; Male; Melanoma; Mice; Middle Aged; Subrenal Capsule Assay; Vincristine | 1994 |
[Melanoma metastasis in the oropharynx].
Topics: Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Humans; Interferon-alpha; Lymph Node Excision; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Nasopharyngeal Neoplasms; Nasopharynx; Skin Neoplasms | 1994 |
Hyperthermic isolation limb perfusion (HILP) in the management of extremity melanoma and sarcoma with particular reference to the dosage, pharmacokinetics, and toxicity of cisplatin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adjuvant; Chemotherapy, Cancer, Regional Perfusion; Cisplatin; Combined Modality Therapy; Dacarbazine; Dactinomycin; Evaluation Studies as Topic; Extremities; Humans; Hyperthermia, Induced; Incidence; Melanoma; Melphalan; Neoplasm Metastasis; Osteosarcoma; Rhabdomyolysis; Skin Neoplasms; Treatment Outcome | 1993 |
Clinical relevance of ICAM-1 expression in primary lesions and serum of patients with malignant melanoma.
Topics: Antibodies, Monoclonal; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Cell Adhesion Molecules; Dacarbazine; Humans; Immunoenzyme Techniques; Immunohistochemistry; Intercellular Adhesion Molecule-1; Interferon-beta; Liver Neoplasms; Lymphatic Metastasis; Melanoma; Neoplasm Metastasis; Neoplasm Staging; Skin Neoplasms; Vincristine | 1993 |
Antiphospholipid syndrome associated with immunotherapy for patients with melanoma.
Topics: Adult; Aged; Antibodies, Antinuclear; Antibodies, Antiphospholipid; Antineoplastic Combined Chemotherapy Protocols; Antiphospholipid Syndrome; Autoantibodies; Cardiolipins; Carmustine; Chemotherapy, Adjuvant; Cisplatin; Dacarbazine; Female; Humans; Immunoglobulin G; Immunotherapy; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Recombinant Proteins; Tamoxifen; Thromboembolism | 1994 |
Long term response to chemotherapy in patients with visceral metastatic melanoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Interferon-alpha; Lomustine; Male; Melanoma; Middle Aged; Remission Induction; Semustine; Survival Rate | 1994 |
Phenotypic and functional profile of peripheral blood mononuclear cells isolated from melanoma patients undergoing combined immunotherapy and chemotherapy.
Topics: Adult; Aged; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cell Division; Chemotherapy, Adjuvant; Concanavalin A; Dacarbazine; Dose-Response Relationship, Drug; Female; Humans; Immunophenotyping; Immunotherapy; Interferon Type I; Interleukin-2; Killer Cells, Lymphokine-Activated; Leukocytes, Mononuclear; Male; Melanoma; Middle Aged; Phytohemagglutinins; Pokeweed Mitogens; Recombinant Proteins | 1993 |
[Combination of fotemustine-dacarbazine and interferon alpha in the treatment of metastatic malignant melanoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Interferon-alpha; Karnofsky Performance Status; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms; Treatment Outcome | 1993 |
The chemohormonal therapy of metastatic melanoma: possible benefit of tamoxifen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Drug Administration Schedule; Female; Humans; Male; Melanoma; Middle Aged; Tamoxifen; Thrombophlebitis | 1993 |
Fotemustine-dacarbazine combinations in the treatment of metastatic melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Humans; Liver Neoplasms; Lung Neoplasms; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds | 1993 |
Brain metastases of metastatic malignant melanoma: response to DTIC and interferon-gamma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Female; Humans; Interferon-gamma; Melanoma; Remission Induction | 1993 |
Tamoxifen and chemotherapy for refractory metastatic malignant melanoma.
Topics: Adult; Antineoplastic Agents; Cisplatin; Dacarbazine; Female; Humans; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Tamoxifen | 1993 |
Long-term complete remissions in patients with disseminated melanoma treated by fotemustine and dacarbazine.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Remission Induction | 1993 |
Dosage and cycle effects of dacarbazine (DTIC) and fotemustine on O6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells.
Topics: Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance; Humans; Leukocytes, Mononuclear; Melanoma; Methyltransferases; Nitrosourea Compounds; O(6)-Methylguanine-DNA Methyltransferase; Organophosphorus Compounds | 1993 |
[Dramatic remission of a multiple metastasized melanoma caused by chemo-immunotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Dacarbazine; Female; Humans; Interferon alpha-2; Interferon-alpha; Interleukins; Liver Neoplasms; Melanoma; Middle Aged; Recombinant Proteins; Remission Induction; Skin Neoplasms; Splenic Neoplasms | 1993 |
Activity and unexpected lung toxicity of the sequential administration of two alkylating agents--dacarbazine and fotemustine--in patients with melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Lung; Lung Neoplasms; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Respiratory Distress Syndrome | 1993 |
Error in chemotherapy dosages.
Topics: Cisplatin; Dacarbazine; Drug Administration Schedule; Humans; Melanoma | 1993 |
From triazines and triazenes to temozolomide.
Topics: Animals; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Chemistry, Pharmaceutical; Dacarbazine; Humans; Melanoma; Mice; Nitrogen Mustard Compounds; Prodrugs; Temozolomide | 1993 |
Porcine splenic peptides (Polyerga) decrease the number of experimental lung metastases in mice.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Cell Survival; Dacarbazine; Dose-Response Relationship, Drug; Drug Combinations; Glycopeptides; Lung Neoplasms; Melanoma; Mice; Phenols; Tumor Cells, Cultured | 1996 |
Intracellular Localization and intercellular heterogeneity of the human DNA repair protein O(6)-methylguanine-DNA methyltransferase.
Topics: Animals; Cell Compartmentation; Cell Nucleus; Cytoplasm; Dacarbazine; DNA Repair; Enzyme Inhibitors; Fluorescent Antibody Technique, Indirect; Guanine; Humans; Image Processing, Computer-Assisted; Lung Neoplasms; Melanoma; Methyltransferases; Mice; Mice, Nude; Neoplasm Transplantation; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide; Transplantation, Heterologous | 1996 |
The CD4+/CD8+ ratio as a prognostic factor in patients with metastatic melanoma receiving chemoimmunotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; CD4-CD8 Ratio; Dacarbazine; Female; Humans; Immunotherapy; Interferon-alpha; Lomustine; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Prognosis; Survival Analysis; Vincristine | 1996 |
The effect of tirapazamine (SR-4233) alone or combined with chemotherapeutic agents on xenografted human tumours.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cell Division; Cisplatin; Dacarbazine; Drug Screening Assays, Antitumor; Etoposide; Fluorouracil; Humans; Melanoma; Mice; Mice, Nude; Rectal Neoplasms; Tirapazamine; Transplantation, Heterologous; Triazines | 1996 |
[Acquired myelodysplastic syndromes after treatment of melanoma with fotemustine and dacarbazine].
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Drug Therapy, Combination; Fatal Outcome; Female; Humans; Melanoma; Middle Aged; Myelodysplastic Syndromes; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms | 1995 |
Dacarbazine, vincristine, bleomycin and lomustine plus natural interferon-alpha for metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Dacarbazine; Female; Humans; Interferon-alpha; Lomustine; Male; Melanoma; Middle Aged; Pilot Projects; Vincristine | 1996 |
Subcutaneous recombinant interleukin-2 plus chemotherapy with cisplatin and dacarbazine in metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Female; Humans; Injections, Subcutaneous; Interleukin-2; Male; Melanoma; Middle Aged; Recombinant Proteins; Remission Induction; Survival Analysis | 1996 |
[A case of adrenal gland metastasis of a cutaneous melanoma treated by excision with 3-year survival].
Topics: Adrenal Gland Neoplasms; Adult; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Fatal Outcome; Follow-Up Studies; Humans; Male; Melanoma; Skin Neoplasms; Vindesine | 1996 |
Chemosensitivity of human melanoma metastases in mouse subrenal capsule assay--can it predict tumour response to combined cytostatic plus interferon therapy in metastatic melanoma?
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Confidence Intervals; Dacarbazine; Female; Humans; Interferons; Lomustine; Male; Melanoma; Mice; Mice, Inbred Strains; Neoplasm Metastasis; Sex Characteristics; Subrenal Capsule Assay; Vincristine | 1996 |
Ukrain with chemotherapy in malignant melanoma (case report).
Topics: Alkaloids; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Berberine Alkaloids; Dacarbazine; Female; Humans; Lung Neoplasms; Melanoma; Neoplasm Recurrence, Local; Phenanthridines | 1996 |
Pharmacokinetics of dacarbazine in the regional perfusion of extremities with melanoma.
Topics: Antineoplastic Agents; Arm; Dacarbazine; Drug Administration Schedule; Humans; Hyperthermia, Induced; Leg; Melanoma; Models, Biological; Perfusion | 1996 |
Immunohistochemical examination of the expression of O6-methylguanine-DNA methyltransferase in human melanoma metastases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cell Division; Cell Nucleus; Dacarbazine; Female; Humans; Immunoenzyme Techniques; Lymphatic Metastasis; Male; Melanoma; Methyltransferases; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Skin Neoplasms | 1997 |
Regional isolated perfusion of extremities for melanoma: a 20-year experience with drugs other than L-phenylalanine mustard.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carboplatin; Chemotherapy, Cancer, Regional Perfusion; Cisplatin; Dacarbazine; Extremities; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Skin Neoplasms; Survival Rate; Thiotepa | 1997 |
The effect of dacarbazine and vincristine sulfate on human melanoma cell lines. In vitro analysis of interaction on DNA synthesis, RNA synthesis and protein synthesis.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Cell Line; Dacarbazine; DNA, Neoplasm; Drug Screening Assays, Antitumor; Humans; Melanoma; Neoplasm Proteins; RNA, Neoplasm; Tumor Cells, Cultured; Vincristine | 1997 |
DNA flow cytometry and the outcome of chemoimmunotherapy in metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Dacarbazine; DNA, Neoplasm; Female; Flow Cytometry; Humans; Immunotherapy; Interferons; Lomustine; Male; Melanoma; Middle Aged; Ploidies; Treatment Outcome; Vincristine | 1997 |
Tourniquet infusion chemotherapy for extremity in-transit lesions in malignant melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Arm; Cisplatin; Combined Modality Therapy; Dacarbazine; Doxorubicin; Female; Follow-Up Studies; Humans; Infusions, Intra-Arterial; Leg; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Pilot Projects; Prospective Studies; Survival Rate | 1997 |
Prognostic value of serum 5-S-cysteinyldopa for monitoring human metastatic melanoma during immunochemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Cysteinyldopa; Dacarbazine; Disease Progression; Female; Humans; Immunotherapy; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Prognosis; Skin Neoplasms | 1997 |
Paralytic ileus associated with a combination of dacarbazine-nimustine hydrochloride-vincristine chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Intestinal Pseudo-Obstruction; Melanoma; Nimustine; Skin Neoplasms; Vincristine | 1997 |
Fatal hepatic toxicity of DTIC: a new case.
Topics: Chemical and Drug Induced Liver Injury; Dacarbazine; Fatal Outcome; Female; Humans; Melanoma; Middle Aged | 1997 |
Immunochemotherapy with recombinant interferon-alpha 2b plus dacarbazine in the treatment of advanced malignant melanoma.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Humans; Interferon alpha-2; Interferon-alpha; Lung Neoplasms; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Recombinant Proteins; Skin Neoplasms; Soft Tissue Neoplasms; Survival Rate; Time Factors | 1997 |
bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice.
Topics: Actins; Animals; Antineoplastic Agents; Apoptosis; Dacarbazine; Female; Humans; Melanoma; Mice; Mice, SCID; Neoplasm Transplantation; Oligonucleotides, Antisense; Proto-Oncogene Proteins c-bcl-2; Transplantation, Heterologous | 1998 |
[Immunochemotherapy of malignant melanoma. Epifocal administration of dinitrochlorobenzene (DNCB) combined with systemic chemotherapy with dacarbazine (DTIC)].
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Combined Modality Therapy; Dacarbazine; Dinitrochlorobenzene; Female; Follow-Up Studies; Humans; Immunotherapy; Infusions, Intravenous; Irritants; Male; Melanoma; Middle Aged; Skin; Skin Neoplasms; Treatment Outcome | 1998 |
Safety and efficacy of isolated perfusion of extremities for recurrent tumor in elderly patients.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Dacarbazine; Edema; Extremities; Female; Humans; Male; Melanoma; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Outcome Assessment, Health Care; Perfusion; Recurrence; Skin Neoplasms | 1998 |
Commentary: management of the patient.
Topics: Antineoplastic Agents; Dacarbazine; Decision Making; Ethics, Medical; Fatal Outcome; Female; Humans; Melanoma; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Spinal Neoplasms | 1998 |
Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Disease Progression; Female; Humans; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Survival Rate; Vinblastine | 1998 |
Primary malignant melanoma of the vagina: case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Dacarbazine; Female; Follow-Up Studies; Humans; Interferon alpha-2; Interferon-alpha; Liver Neoplasms; Lymph Node Excision; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Recombinant Proteins; Vaginal Neoplasms | 1998 |
[Combination of dacarbazine, cisplatin and interferon alpha in the treatment of metastatic melanoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Drug Therapy, Combination; Female; Humans; Interferon-alpha; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Treatment Outcome | 1996 |
[The role of glutathione and glutathione-S-transferase in neoplasm drug resistance].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Cyclophosphamide; Dacarbazine; Drug Resistance, Neoplasm; Erythrocytes; Etoposide; Female; Glutathione; Glutathione Transferase; Humans; Male; Melanoma; Ovarian Neoplasms; Propionates; Skin Neoplasms; Testicular Neoplasms | 1998 |
[At the front line of malignant melanoma, great maneuvers: to cut the road to Bcl2 and "attack with chemotherapy"].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Humans; Melanoma; Mice; Mice, SCID; Neoplasm Proteins; Neoplasm Transplantation; Oligonucleotides, Antisense; Proto-Oncogene Proteins c-bcl-2; Skin Neoplasms; Thionucleotides; Tumor Cells, Cultured | 1998 |
Syndrome of inappropriate secretion of antidiuretic hormone in a patient affected by metastatic melanoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; Facial Neoplasms; Fatal Outcome; Frontal Lobe; Humans; Inappropriate ADH Syndrome; Lymphatic Metastasis; Male; Melanoma; Middle Aged | 1998 |
Methyl DNA adducts, DNA repair, and hypoxanthine-guanine phosphoribosyl transferase mutations in peripheral white blood cells from patients with malignant melanoma treated with dacarbazine and hydroxyurea.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; DNA Adducts; DNA Repair; Female; Guanine; Humans; Hydroxyurea; Hypoxanthine Phosphoribosyltransferase; Leukocytes; Male; Melanoma; Middle Aged; Mutation; O(6)-Methylguanine-DNA Methyltransferase | 1996 |
Transgenic mice with pigmented intraocular tumors: tissue of origin and treatment.
Topics: Animals; Antigens, Neoplasm; Antigens, Polyomavirus Transforming; Dacarbazine; Fas Ligand Protein; Female; Immunohistochemistry; In Situ Hybridization; Male; Melanoma; Melanoma-Specific Antigens; Membrane Glycoproteins; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Transgenic; Neoplasm Proteins; Pigment Epithelium of Eye; S100 Proteins; Uveal Neoplasms | 1998 |
The behaviour of blood lymphocyte subsets in patients treated with immunochemotherapy for metastatic melanoma.
Topics: Antigens, CD; Dacarbazine; Female; Flow Cytometry; HLA-DR Antigens; Humans; Immunophenotyping; Interleukin-2; Lymphocyte Subsets; Male; Melanoma; Middle Aged | 1997 |
Primary malignant melanoma of the esophagus: report of a case successfully treated with pre- and post-operative adjuvant hormone-chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Dacarbazine; Esophageal Neoplasms; Esophagectomy; Humans; Lymph Node Excision; Male; Melanoma; Middle Aged; Nimustine; Tamoxifen | 1998 |
Treatment of metastatic malignant melanoma with dacarbazine plus fotemustine.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms; Treatment Outcome | 1998 |
[Chemotherapy of malignant melanoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Dacarbazine; Humans; Immunotherapy; Interleukins; Lomustine; Melanoma; Middle Aged; Palliative Care; Skin Neoplasms; Tamoxifen; Vincristine | 1998 |
Dacarbazine, nimustine hydrochloride, cisplatin and tamoxifen combination chemotherapy for advanced malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Nimustine; Skin Neoplasms; Tamoxifen; Tomography, X-Ray Computed; Treatment Outcome | 1999 |
Comments on: Treatment of metastatic malignant melanoma with dacarbazine plus fotemustine, Seeber, et al., Eur J Cancer 1998, 34, 2129-2131.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Humans; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds | 1999 |
Management of cerebral metastases from malignant melanoma: results of a combined, simultaneous treatment with fotemustine and irradiation.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Female; Humans; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Nitrosourea Compounds; Organophosphorus Compounds; Retrospective Studies; Survival Analysis | 1999 |
Advantages of concurrent biochemotherapy modified by decrescendo interleukin-2, granulocyte colony-stimulating factor, and tamoxifen for patients with metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Disease-Free Survival; Drug Therapy, Combination; Female; Granulocyte Colony-Stimulating Factor; Humans; Interleukin-2; Male; Melanoma; Middle Aged; Pilot Projects; Skin Diseases; Skin Neoplasms; Tamoxifen; Vinblastine | 1999 |
O(6)-(4-bromothenyl)guanine improves the therapeutic index of temozolomide against A375M melanoma xenografts.
Topics: Adenosine Triphosphatases; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Drug Synergism; Enzyme Inhibitors; Guanine; Male; Melanoma; Mice; Mice, Nude; Neoplasm Transplantation; Temozolomide; Transplantation, Heterologous | 2000 |
SODs are involved in the regulation of ICAM-1 expression in human melanoma and endothelial cells.
Topics: Cells, Cultured; Cytoplasm; Dacarbazine; Endothelium, Vascular; Gene Expression Regulation; Gene Expression Regulation, Neoplastic; Humans; Intercellular Adhesion Molecule-1; Isoenzymes; Melanoma; Metalloporphyrins; Mitochondria; Neoplasm Proteins; Oxidative Stress; Paraquat; Skin Neoplasms; Superoxide Dismutase; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha; Umbilical Veins | 1999 |
Effect of dacarbazine (DTIC) on cultures from malignant melanoma of the choroid: an immunohistochemical and electron microscopic study.
Topics: Antigens, Neoplasm; Antineoplastic Agents, Alkylating; Choroid Neoplasms; Dacarbazine; Humans; Immunohistochemistry; Melanoma; Melanoma-Specific Antigens; Microscopy, Electron; Neoplasm Proteins; S100 Proteins; Tumor Cells, Cultured | 1999 |
Evaluation of the alkaline comet assay and urinary 3-methyladenine excretion for monitoring DNA damage in melanoma patients treated with dacarbazine and tamoxifen.
Topics: Adenine; Adult; Aged; Antineoplastic Agents, Alkylating; Comet Assay; Dacarbazine; DNA Damage; Female; Humans; Lymphocytes; Male; Melanoma; Middle Aged; Predictive Value of Tests; Sensitivity and Specificity; Skin Neoplasms | 2000 |
The role of interleukin-2 in the management of stage IV melanoma: the EORTC melanoma cooperative group program.
Topics: Cisplatin; Clinical Trials as Topic; Dacarbazine; Humans; Interferon-alpha; Interleukin-2; Melanoma; Neoplasm Staging; Survival Rate; T-Lymphocytes | 2000 |
Myelodysplastic syndrome following treatment of malignant melanoma with vincristine, ACNU, and dacarbazine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Dacarbazine; Humans; Leukocyte Count; Male; Melanoma; Middle Aged; Myelodysplastic Syndromes; Nimustine; Skin Neoplasms; Vincristine | 2000 |
Temozolomide for advanced, metastatic melanoma.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Humans; Melanoma; Proportional Hazards Models; Quality of Life; Skin Neoplasms; Survival Analysis; Temozolomide | 2000 |
High dose inhalation interleukin-2 therapy for lung metastases in patients with malignant melanoma.
Topics: Administration, Inhalation; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Confounding Factors, Epidemiologic; Dacarbazine; Disease Progression; Female; Follow-Up Studies; Humans; Interleukin-2; Lung Neoplasms; Male; Melanoma; Recombinant Proteins; Remission Induction; Reproducibility of Results; Safety; Treatment Outcome | 2000 |
Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cisplatin; Dacarbazine; Humans; Melanoma; Neoplasm Metastasis; Retrospective Studies; Survival Analysis; Tamoxifen; Treatment Outcome | 2000 |
Analysis of G(1)/S checkpoint regulators in metastatic melanoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Female; G1 Phase; Gene Expression Regulation, Neoplastic; Humans; Lomustine; Male; Melanoma; Middle Aged; Polymerase Chain Reaction; Polymorphism, Single-Stranded Conformational; S Phase; Survival Analysis; Treatment Outcome; Vincristine | 2000 |
What can we learn from phase II adjuvant trials in melanoma?
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Controlled Clinical Trials as Topic; Dacarbazine; Drug Synergism; Humans; Immunologic Factors; Interferons; Interleukin-2; Melanoma; Neoplasm Metastasis; Randomized Controlled Trials as Topic; Research Design; Skin Neoplasms; Tamoxifen; Treatment Outcome; Vinblastine | 2000 |
Cutaneous malignant melanoma in children.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Chemotherapy, Adjuvant; Child; Child, Preschool; Cisplatin; Dacarbazine; Female; Follow-Up Studies; Humans; Infant; Male; Melanoma; Neoplasm Staging; Prognosis; Risk Factors; Skin Neoplasms; Survival Analysis; Time Factors; Treatment Outcome; Vindesine | 2000 |
Prognostic factors of overall survival in patients with delayed lymph node dissection for cutaneous malignant melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Dacarbazine; Disease-Free Survival; Female; Humans; Interferon-alpha; Lymph Node Excision; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Prognosis; Retrospective Studies; Skin Neoplasms; Survival Rate; Time Factors | 2000 |
Repeatable acute rhabdomyolysis with multiple organ dysfunction because of interferon alpha and dacarbazine treatment in metastatic melanoma.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Humans; Interferon alpha-2; Interferon-alpha; Male; Melanoma; Multiple Organ Failure; Recombinant Proteins; Recurrence; Rhabdomyolysis | 2001 |
What's new in the treatment of melanoma?
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Dacarbazine; Humans; Immunotherapy; Melanoma; Skin Neoplasms; Temozolomide | 2000 |
Prognostic factors in therapeutic lymphadenectomy in melanoma.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Disease-Free Survival; Humans; Lymph Nodes; Melanoma; Prognosis; Time Factors | 2001 |
Cisplatin and carboplatin combination as second-line chemotherapy in dacarbazine-resistant melanoma patients.
Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Cisplatin; Dacarbazine; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Survival Analysis | 2001 |
Necrosis in melanoma metastases with treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Disease-Free Survival; Follow-Up Studies; Humans; Lymph Node Excision; Male; Melanoma; Middle Aged; Necrosis; Skin Neoplasms; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2001 |
Treatment of brain metastases of malignant melanoma with temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Melanoma; Middle Aged; Skin Neoplasms; Temozolomide | 2001 |
Therapeutic implications of the kinetics of immunomodulation during single or combined treatment of melanoma patients with dacarbazine and interferon-alpha.
Topics: ADP-ribosyl Cyclase; ADP-ribosyl Cyclase 1; Adult; Antigens, CD; Antigens, Differentiation; Antineoplastic Agents, Alkylating; CD4-CD8 Ratio; Dacarbazine; Drug Administration Schedule; Female; Flow Cytometry; Humans; Immunologic Factors; Interferon-alpha; Killer Cells, Natural; Male; Melanoma; Membrane Glycoproteins; Middle Aged; NAD+ Nucleosidase; Skin Neoplasms; Treatment Outcome | 2001 |
Penetration of dacarbazine and its active metabolite 5-aminoimidazole-4-carboxamide into cutaneous metastases of human malignant melanoma.
Topics: Aged; Aminoimidazole Carboxamide; Antineoplastic Agents, Alkylating; Area Under Curve; Chromatography, High Pressure Liquid; Dacarbazine; Extracellular Space; Female; Humans; Male; Melanoma; Microdialysis; Middle Aged; Skin Neoplasms | 2001 |
Radiation recall dermatitis in a patient treated with dacarbazine.
Topics: Administration, Oral; Adult; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Glucocorticoids; Humans; Melanoma; Prednisolone; Radiodermatitis; Recurrence; Skin Neoplasms | 2001 |
Primary malignant melanoma of the esophagus treated by esophagectomy and systemic chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Combined Modality Therapy; Dacarbazine; Esophageal Neoplasms; Esophagectomy; Esophagoscopy; Follow-Up Studies; Humans; Male; Melanoma; Nimustine; Treatment Outcome; Vincristine | 2001 |
The role of glucocorticoids in the treatment of fulminant hepatitis induced by dacarbazine.
Topics: Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Eye Neoplasms; Glucocorticoids; Humans; Liver Failure; Male; Melanoma; Treatment Outcome | 2002 |
Treatment of metastatic melanoma in the brain with temozolomide and thalidomide.
Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Therapy, Combination; Female; Frontal Lobe; Humans; Melanoma; Remission Induction; Temozolomide; Thalidomide | 2001 |
Is there a standard for the palliative treatment of melanoma?
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Evidence-Based Medicine; Humans; Interferons; Interleukin-2; Melanoma; Palliative Care; Randomized Controlled Trials as Topic; Skin Neoplasms; Treatment Outcome | 2002 |
Biochemotherapy for advanced melanoma: maybe it is real.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Dacarbazine; Humans; Interleukin-2; Melanoma; Skin Neoplasms; Vincristine | 2002 |
Phase 1-11 study of DTIC and cyclocytidine in disseminated malignant melanoma.
Topics: Adult; Aged; Ancitabine; Brain Neoplasms; Cytarabine; Dacarbazine; Drug Therapy, Combination; Humans; Liver Neoplasms; Lung Neoplasms; Melanoma; Middle Aged; Neoplasm Metastasis; Retroperitoneal Neoplasms; Skin Neoplasms; Triazenes | 1976 |
Phase II study of subcutaneously administered 5-azacytidine (NSC-102816) in patients with metastatic malignant melanoma.
Topics: Azacitidine; Bone Marrow; Dacarbazine; Drug Evaluation; Drug Resistance; Female; Humans; Injections, Subcutaneous; Male; Melanoma; Neoplasm Metastasis; Vomiting | 1978 |
Combination chemotherapy with vinblastine, bleomycin and methotrexate in DTIC-resistant metastatic melanoma.
Topics: Adult; Antineoplastic Agents; Bleomycin; Dacarbazine; Drug Resistance; Drug Therapy, Combination; Female; Humans; Male; Melanoma; Methotrexate; Middle Aged; Neoplasm Metastasis; Vinblastine | 1979 |
Evaluation of a "nude" mouse-human tumor panel as a predictive secondary screen for cancer chemotherapeutic agents.
Topics: Animals; Antineoplastic Agents; Azacitidine; Carmustine; Dacarbazine; Doxorubicin; Drug Evaluation, Preclinical; Drug Resistance; Female; Humans; Male; Melanoma; Mice; Mice, Inbred C57BL; Mice, Nude; Neoplasms, Experimental | 1979 |
[Dacarbazin -- therapy of metastazising malignant melanoma (author's transl)].
Topics: Adult; Dacarbazine; Female; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Palliative Care; Skin Neoplasms | 1979 |
Adjuvant chemotherapy or chemoimmunotherapy in the management of primary malignant melanoma of level III, IV, or V.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Bacterial Vaccines; BCG Vaccine; Dacarbazine; Drug Therapy, Combination; Female; Humans; Male; Melanoma; Methotrexate; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Procarbazine; Propionibacterium acnes; Streptonigrin; Thiotepa; Vinblastine | 1978 |
Primary malignant melanoma of the esophagus: report of two cases.
Topics: BCG Vaccine; Dacarbazine; Esophageal Neoplasms; Female; Humans; Melanoma; Middle Aged; Radiotherapy, High-Energy; Smoking | 1979 |
Future prospects for immunotherapy.
Topics: Animals; BCG Vaccine; Carcinoma, Hepatocellular; Dacarbazine; Guinea Pigs; Humans; Immunotherapy; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Liver Neoplasms; Melanoma; Methotrexate; Mice; Neoplasms; Neoplasms, Experimental; Sarcoma | 1975 |
Chemotherapy in the treatment of malignant melanomas.
Topics: Antineoplastic Agents; Chemotherapy, Cancer, Regional Perfusion; Dacarbazine; Drug Therapy, Combination; Humans; Injections, Intra-Arterial; Melanoma; Neoplasm Metastasis | 1977 |
The survival of patients with malignant melanoma receiving BCG with or without chemotherapy.
Topics: BCG Vaccine; Dacarbazine; Drug Therapy, Combination; Humans; Hydroxyurea; Immunity, Cellular; Melanoma; Nitrosourea Compounds; Skin Tests; Time Factors; Triazenes | 1979 |
Massive upper gastrointestinal bleeding during chemotherapy for malignant melanoma.
Topics: Dacarbazine; Gastrointestinal Hemorrhage; Humans; Intestinal Neoplasms; Jejunum; Male; Melanoma; Middle Aged; Stomach Neoplasms; Triazenes | 1977 |
[T-lymphocytes in the peripheral blood. Study on 113 patients with malignant melanoma].
Topics: Adolescent; Adult; Aged; BCG Vaccine; Cell Count; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; T-Lymphocytes | 1978 |
Experimental intraocular penetration of dacarbazine.
Topics: Animals; Chorioretinitis; Choroid; Dacarbazine; Eye; Haplorhini; Macaca mulatta; Male; Melanoma; Rabbits; Retina; Retinal Diseases; Triazenes | 1977 |
Dacarbazine and melphalan. Enhancement by dosage scheduling of the effect in combination treatment on the Harding-Passey melanoma in C3D2F1 mice.
Topics: Animals; Dacarbazine; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Female; Melanoma; Melphalan; Mice; Mice, Inbred C57BL; Mice, Inbred Strains; Neoplasms, Experimental; Skin Neoplasms; Triazenes | 1979 |
Effects of 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide, 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea, and L-phenylalanine mustard on B16, Cloudman S91, and Harding-Passey mouse melanomas.
Topics: Animals; Cell Count; Dacarbazine; Female; Melanoma; Melphalan; Mice; Mice, Inbred Strains; Neoplasm Transplantation; Neoplasms, Experimental; Nitrosourea Compounds; Semustine; Time Factors; Transplantation, Isogeneic; Triazenes | 1979 |
Feasibility of integration of modalities in melanomas and sarcomas.
Topics: BCG Vaccine; Dacarbazine; Estramustine; Humans; Melanoma; Melphalan; Radiotherapy Dosage; Sarcoma; Skin Neoplasms | 1979 |
[Treatment of advanced malignant melanoma with DTIC].
Topics: Adult; Aged; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Skin Neoplasms; Triazenes | 1979 |
Adjuvant immunotherapy of malignant melanoma.
Topics: BCG Vaccine; Cholera Vaccines; Dacarbazine; Female; Humans; Lymphatic Metastasis; Male; Melanoma; Neoplasm Staging; Neoplasms; Neuraminidase; Vibrio cholerae | 1979 |
Amphotericin B effects in tissue culture cell lines.
Topics: Amphotericin B; Animals; Cell Line; Dacarbazine; Drug Interactions; Humans; Leukemia, Experimental; Melanoma; Mice; Mycosis Fungoides; Neoplasms, Experimental | 1979 |
Recurrent orbital and metastatic melanoma in a patient undergoing previous glaucoma surgery.
Topics: Choroid Neoplasms; Dacarbazine; Female; Glaucoma; Humans; Melanoma; Middle Aged; Neoplasm Metastasis; Orbital Neoplasms | 1979 |
A preliminary report of a pilot trial in adjuvant chemotherapy of primary melanoma.
Topics: Antineoplastic Agents; BCG Vaccine; Dacarbazine; Dactinomycin; Drug Therapy, Combination; Female; Humans; Male; Melanoma; Procarbazine; Skin Neoplasms; Vinblastine | 1979 |
Monocytopoiesis in malignant melanoma: untreated, during immunotherapy and chemoimmunotherapy.
Topics: Adult; Aged; BCG Vaccine; Dacarbazine; Female; Hematopoiesis; Humans; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Monocytes; Skin Neoplasms | 1979 |
Cytotoxicity studies of human melanoma cells and fibroblasts.
Topics: Animals; Cell Survival; Cells, Cultured; Cytarabine; Dacarbazine; DNA; DNA Repair; DNA, Neoplasm; Fibroblasts; Humans; Melanoma; Melphalan | 1979 |
Chemoimmunotherapy for meningeal melanocytoma of the thoracic spinal cord. Report of a case.
Topics: Aged; Dacarbazine; Dactinomycin; Female; Humans; Immunotherapy; Melanoma; Meningeal Neoplasms; Neoplasm Recurrence, Local; Postoperative Care; Propionibacterium acnes; Spinal Cord Neoplasms | 1979 |
Hepatic failure in a patient treated with dacarbazine (DTIC) for malignant melanoma.
Topics: Budd-Chiari Syndrome; Chemical and Drug Induced Liver Injury; Dacarbazine; Drug Hypersensitivity; Eosinophils; Female; Humans; Liver Diseases; Melanoma; Middle Aged; Skin Neoplasms | 1979 |
[BK-mole syndrome].
Topics: Adult; BCG Vaccine; Child; Dacarbazine; Female; Humans; Male; Melanoma; Nevus, Pigmented | 1979 |
[Chemotherapy of malignant melanoma using DTIC].
Topics: Adult; Dacarbazine; Female; Humans; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Skin Neoplasms; Triazenes | 1977 |
Lymphocyte function and response to chemo-immunotherapy in patients with metastatic melanoma.
Topics: Adult; Aged; BCG Vaccine; Cytotoxicity, Immunologic; Dacarbazine; Female; Humans; Leukocyte Count; Lymphocytes; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Rosette Formation | 1977 |
Use of methyl-CCNU and procarbazine in advanced malignant melanoma resistant to DTIC therapy.
Topics: Dacarbazine; Drug Evaluation; Drug Resistance; Humans; Melanoma; Nitrosourea Compounds; Procarbazine; Semustine | 1977 |
Adjuvant chemotherapy and immunotherapy in high risk patients with melanoma.
Topics: Adult; Aged; Aminoimidazole Carboxamide; BCG Vaccine; Dacarbazine; Evaluation Studies as Topic; Female; Follow-Up Studies; Humans; Lymph Node Excision; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Postoperative Care; Risk; Skin Neoplasms; Triazenes | 1978 |
Phase II study of ICRF-159 versus combination cis-dichlorodiammineplatinum(II) and DTIC in patients with disseminated malignant melanoma.
Topics: Cisplatin; Dacarbazine; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Kidney; Male; Melanoma; Middle Aged; Piperazines; Razoxane; Remission, Spontaneous; Triazenes | 1978 |
Specific active immunotherapy does not prolong survival in surgically treated patients with stage IIB malignant melanoma and may promote early recurrence.
Topics: Adult; Aged; Antigens, Neoplasm; BCG Vaccine; Dacarbazine; Female; Humans; Immunotherapy; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prospective Studies; Time Factors; Vincristine | 1978 |
Failure of lymphocyte microcytotoxicity to distinguish relapsers from non-relapsers in melanoma patients receiving post-surgical adjuvant chemotherapy.
Topics: Adult; Cytotoxicity, Immunologic; Dacarbazine; Female; Humans; Lymphocytes; Male; Melanoma; Middle Aged; Prognosis; Recurrence | 1978 |
[The malignant melanoma: criteria for the prognosis and therapy].
Topics: Dacarbazine; Female; Humans; Lymph Nodes; Male; Melanoma; Neoplasm Invasiveness; Neoplasm Staging; Patient Care Planning; Prognosis | 1978 |
[DTIC in the therapy of solid tumours (author's transl)].
Topics: Antineoplastic Agents; Dacarbazine; Drug Evaluation; Drug Therapy, Combination; Head and Neck Neoplasms; Humans; Melanoma; Neoplasm Metastasis; Neoplasms; Otorhinolaryngologic Diseases; Sarcoma, Kaposi; Soft Tissue Neoplasms; Thymoma; Thymus Neoplasms; Triazenes | 1978 |
[Combined immuno-chemotherapy of malignant melanoma: epidemiological elements].
Topics: Adolescent; Adult; Aged; Dacarbazine; Female; Follow-Up Studies; Humans; Immunotherapy; Male; Melanoma; Middle Aged; Remission, Spontaneous; Skin Neoplasms | 1978 |
New treatments for malignant melanoma.
Topics: Antineoplastic Agents; Dacarbazine; Drug Evaluation; Humans; Melanoma; Nitrosourea Compounds; Research Design | 1978 |
Positive phase II trial of dibromodulcitol in patients with metastatic melanoma refractory to DTIC and a nitrosourea.
Topics: Adult; Aged; Bone Marrow; Dacarbazine; Drug Evaluation; Drug Resistance; Female; Humans; Male; Melanoma; Middle Aged; Mitolactol; Neoplasm Metastasis; Nitrosourea Compounds; Remission, Spontaneous; Triazenes | 1978 |
Immunotherapy for recurrent malignant melanoma: efficacy of BCG in prolonging the postoperative disease-free interval and survival.
Topics: BCG Vaccine; Dacarbazine; Humans; Melanoma; Neoplasm Recurrence, Local; Postoperative Complications | 1978 |
Results of a nonrandomized trial in malignant melanoma patients (Clark's stages III--V) treated by post-surgical chemoimmunotherapy.
Topics: Antineoplastic Agents; BCG Vaccine; Dacarbazine; Drug Therapy, Combination; Humans; Lomustine; Melanoma; Neoplasm Staging; Vincristine | 1978 |
Value of adjuvant therapy with bacille Calmette Guerin (BCG) or dimethl triazeno imidazole carboximide (DTIC) in the control of minimal residual disease in stage II melanoma.
Topics: Adult; Aged; BCG Vaccine; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Triazenes | 1978 |
Controlled study for prolonged chemotherapy, immunotherapy, and chemotherapy plus immunotherapy as an adjuvant to surgery in malignant melanoma (Trial 6): preliminary report.
Topics: Adult; Aged; BCG Vaccine; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Triazenes | 1978 |
Adjuvant therapy in malignant melanoma: a trial of immunotherapy. chemotherapy, and combined treatment.
Topics: Adult; BCG Vaccine; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Triazenes | 1978 |
Chemotherapy of unresectable or recurrent metastatic malignant melanomas: an update.
Topics: Amphotericin B; BCG Vaccine; Dacarbazine; Drug Combinations; Estradiol Congeners; Female; Hot Temperature; Humans; Melanoma; Methotrexate; Neoplasm Metastasis; Nitrosourea Compounds; Skin Neoplasms | 1979 |
Bacillus Calmette-Guérin immunotherapy in combination with DTIC (NSC-45388) for the treatment of malignant melanoma.
Topics: BCG Vaccine; Blood Cell Count; Dacarbazine; Drug Therapy, Combination; Humans; Immunotherapy; Lomustine; Melanoma; Mycobacterium bovis; Neoplasm Metastasis; Propionibacterium acnes; Remission, Spontaneous; Triazenes; Vincristine | 1976 |
[Melanoma therapy].
Topics: BCG Vaccine; Dacarbazine; Humans; Immunotherapy; Lymph Node Excision; Lymphatic Metastasis; Melanoma; Mycobacterium bovis; Skin Neoplasms | 1976 |
Multimodal surgical adjuvant therapy for a broad spectrum of tumors in humans.?
Topics: Adult; Altretamine; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Carmustine; Colonic Neoplasms; Cyclophosphamide; Dacarbazine; Doxorubicin; Drug Evaluation; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Lomustine; Lung Neoplasms; Male; Melanoma; Mitolactol; Neoplasms; Osteosarcoma; Pancreatic Neoplasms; Rectal Neoplasms; Vincristine | 1976 |
Combination chemotherapy with bis chloroethyl nitrosourea (BCNU), vincristine and dimethyl triazeno imidazole carboxamide (DTIC) in disseminated malignant melanoma.
Topics: Carmustine; Dacarbazine; Drug Therapy, Combination; Eosinophils; Female; Humans; Leukocyte Count; Lymphocytes; Male; Melanoma; Neoplasm Metastasis; Remission, Spontaneous; Triazenes; Vincristine | 1977 |
Combination chemotherapy of malignant melanoma with imidazole carboxamide, BCNU and vincristine.
Topics: Adult; Aged; Carmustine; Dacarbazine; Drug Therapy, Combination; Female; Humans; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Triazenes; Vincristine | 1977 |
Bis chloroethyl nitrosourea, vincristine, dimethyl triazeno imidazole carboxamide and chlorpromazine combination chemotherapy in disseminated malignant melanoma.
Topics: Carmustine; Chlorpromazine; Dacarbazine; Drug Therapy, Combination; Eosinophils; Female; Humans; Leukocyte Count; Lymphocytes; Male; Melanoma; Monocytes; Neoplasm Metastasis; Remission, Spontaneous; Time Factors; Triazenes; Vincristine | 1977 |
Immunochemotherapy of malignant melanoma with chlorambucil-bound antimelanoma globulins: preliminary results in patients with disseminated disease.
Topics: Adolescent; Adult; Aged; Antibodies, Neoplasm; Chlorambucil; Dacarbazine; Female; Humans; Hypersensitivity, Delayed; Immunoglobulins; Immunotherapy; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Skin Neoplasms | 1977 |
Effect of cobalt-60 gamma rays and DTIC (5-(3,3 dimethyl-1-triazeno)-imidazole-r-carboxamide) on human malignant melanomas grown in athymic nude mice.
Topics: Animals; Cobalt Radioisotopes; Dacarbazine; Dose-Response Relationship, Radiation; Melanoma; Mice; Mice, Nude; Neoplasm Transplantation; Radiotherapy; Transplantation, Heterologous; Triazenes | 1977 |
Effect of chemotherapy and immunotherapy on tumor-specific immunity in melanoma.
Topics: Adult; Antilymphocyte Serum; BCG Vaccine; Cytotoxicity Tests, Immunologic; Dacarbazine; Drug Therapy, Combination; Female; Humans; Immunity, Cellular; Immunosuppressive Agents; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Skin Neoplasms; Structure-Activity Relationship; Triazenes | 1977 |
Single drug and combination chemotherapy in the treatment. Disseminated malignant melanoma.
Topics: Antineoplastic Agents; Carmustine; Dacarbazine; Drug Therapy, Combination; Humans; Hydroxyurea; Lomustine; Melanoma; Neoplasm Metastasis; Skin Neoplasms; Vincristine | 1977 |
Tumour regression and survival of patients with disseminated malignant melanoma treated with chemotherapy and specific active immunotherapy.
Topics: Adult; Antigens, Neoplasm; BCG Vaccine; Dacarbazine; Female; Humans; Immunotherapy; Lung Neoplasms; Lymph Nodes; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Prognosis; Skin Neoplasms; Triazenes | 1977 |
Dacarbazine (DTIC) in malignant melanoma.
Topics: Dacarbazine; Humans; Melanoma; Triazenes | 1976 |
[Modern trends in the therapy of malignant melanoblastoma (author's transl)].
Topics: Dacarbazine; Humans; Immunotherapy; Melanoma; Skin Neoplasms | 1976 |
[Results with new cytotoxic agents].
Topics: Carmustine; Dacarbazine; Gastrointestinal Neoplasms; Humans; Melanoma; Remission, Spontaneous; Triazenes | 1976 |
Combination cytotoxic chemotherapy for metastatic cutaneous malignant melanoma with DTIC, BCNU, and vincristine.
Topics: Adult; Aged; Carmustine; Dacarbazine; Drug Evaluation; Drug Therapy, Combination; Humans; Melanoma; Middle Aged; Neoplasm Metastasis; Skin Neoplasms; Triazenes; Vincristine | 1976 |
Chemoimmunotherapy of human solid tumors.
Topics: Animals; Antigens, Neoplasm; Antineoplastic Agents; BCG Vaccine; Breast Neoplasms; Colonic Neoplasms; Dacarbazine; Drug Therapy, Combination; Humans; Immunization Schedule; Immunotherapy; Lung Neoplasms; Lymphatic Metastasis; Lymphoma; Melanoma; Neoplasms; Neoplasms, Experimental; Osteosarcoma | 1976 |
Immunotherapy of human solid tumors with Bacillus Calmette-Guérin: prolongation of disease-free interval and survival in malignant melanoma, breast, and colorectal cancer.
Topics: BCG Vaccine; Breast Neoplasms; Colonic Neoplasms; Dacarbazine; Doxorubicin; Female; Fluorouracil; Humans; Immunotherapy; Melanoma; Neoplasm Metastasis; Rectal Neoplasms; Time Factors | 1976 |
Chemotherapy of a human malignant melanoma transplanted in the nude mouse.
Topics: Animals; Body Weight; Dacarbazine; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Female; Fluorouracil; Lomustine; Male; Melanoma; Mice; Mice, Nude; Models, Biological; Neoplasm Transplantation; Nitrosourea Compounds; Transplantation, Heterologous; Triazenes | 1975 |
Multimodality therapy in the treatment of regionally inoperable melanomas and sarcomas.
Topics: Adult; Aged; BCG Vaccine; Chemotherapy, Cancer, Regional Perfusion; Dacarbazine; Dactinomycin; Female; Humans; Lymphatic Metastasis; Male; Melanoma; Melphalan; Middle Aged; Sarcoma | 1975 |
Active immunotherapy as an adjunct to chemotherapy in the treatment of disseminated malignant melanoma: a pilot study.
Topics: Adult; Aged; Antigens, Neoplasm; BCG Vaccine; Dacarbazine; Female; Humans; Immunization; Immunotherapy; Male; Melanoma; Middle Aged; Retroperitoneal Neoplasms; Skin Neoplasms; Vincristine | 1975 |
[Dimethyl-triazeno-imidazol-carboxamide (DTIC)--a new cytostatic agent].
Topics: Dacarbazine; Hodgkin Disease; Humans; Melanoma; Sarcoma; Triazenes | 1975 |
Letter: Chemoimmunotherapy of malignant melanoma.
Topics: BCG Vaccine; Dacarbazine; Humans; Melanoma; Triazenes | 1975 |
[Treatment of malignant melanomas. Trial of D.T.I.C. by intra-arterial infusion].
Topics: Adult; Aged; Antineoplastic Agents; Dacarbazine; Drug Evaluation; Female; Humans; Injections, Intra-Arterial; Male; Melanoma; Middle Aged; Skin Neoplasms; Triazenes | 1975 |
A clinical trial of procarbazine plus vincristine plus bis-chloroethyl-nitrosourea plus imidazole carboxamide dimethyl triazeno in metastatic malignant melanoma.
Topics: Adult; Aged; Carmustine; Dacarbazine; Drug Therapy, Combination; Female; Humans; Liver Neoplasms; Lung Neoplasms; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Procarbazine; Remission, Spontaneous; Skin Neoplasms; Triazenes; Vincristine | 1975 |
Evaluation of cell-mediated reactivity and serum blocking factors in melanoma patients on chemotherapy.
Topics: Adult; Antibodies; Cell Division; Clone Cells; Cytotoxicity Tests, Immunologic; Dacarbazine; Female; Humans; Imidazoles; Immunity, Cellular; Lymphocytes; Male; Melanoma; Middle Aged; Nitrogen Mustard Compounds | 1975 |
Chemotherapy of melanoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carmustine; Cyclophosphamide; Dacarbazine; Dactinomycin; Drug Therapy, Combination; Female; Humans; Hydroxyurea; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Nitrosourea Compounds; Semustine; Skin Neoplasms; Vinca Alkaloids | 1975 |
[Non-surgical treatment of melanoma].
Topics: Antineoplastic Agents; Chemotherapy, Cancer, Regional Perfusion; Dacarbazine; Humans; Immunotherapy; Male; Melanoma; Middle Aged; Skin Neoplasms | 1976 |
Letter: Disseminated intravascular coagulation syndrome with metastatic melanoma: Remission after treatment with 5-(3,3-dimethyl-1-triazeno) imidazole-4-carboxamide (DTIC).
Topics: Aged; Dacarbazine; Disseminated Intravascular Coagulation; Humans; Male; Melanoma; Neoplasm Metastasis; Triazenes | 1976 |
[Treatment of metastasising melanoma with a combination of cytostatic agents (author's transl)].
Topics: Adult; Bone Neoplasms; Carmustine; Dacarbazine; Drug Therapy, Combination; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Remission, Spontaneous; Skin Neoplasms; Soft Tissue Neoplasms; Triazenes; Vincristine | 1976 |
A promising interferon plus four-drug chemotherapy regimen for metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Drug Administration Schedule; Female; Humans; Interferon-alpha; Lomustine; Male; Melanoma; Middle Aged; Treatment Outcome; Vincristine | 1992 |
Nine years' experience of BELD combination chemotherapy (bleomycin, vindesine, CCNU and DTIC) for metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Female; Humans; Lomustine; Male; Melanoma; Middle Aged; Neoplasm Staging; Survival Rate; Vindesine | 1992 |
Cerebral metastatic melanoma: correlation between clinical and CT findings.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Tomography, X-Ray Computed | 1992 |
Efficacy of ondansetron against nausea and vomiting caused by dacarbazine-containing chemotherapy.
Topics: Adolescent; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Female; Humans; Imidazoles; Male; Melanoma; Middle Aged; Nausea; Ondansetron; Vinblastine; Vomiting | 1992 |
Malignant melanoma treated with natural interferons alfa and beta and DAV.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Humans; Interferon-alpha; Interferon-beta; Male; Melanoma; Middle Aged; Nimustine; Vincristine | 1992 |
Fotemustine plus dacarbazine for malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Drug Evaluation; Female; Humans; Leukopenia; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms; Thrombocytopenia | 1992 |
Fotemustine plus dacarbazine in advanced stage III malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Leukopenia; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms; Thrombocytopenia | 1992 |
[A case of malignant melanoma of the clitoris].
Topics: Adult; Clitoris; Combined Modality Therapy; Dacarbazine; Female; Humans; Lymph Node Excision; Melanoma; Vulvar Neoplasms | 1992 |
[Enhancement of the effects of anticancer agents on B16 melanoma cells by combination with cepharanthine--II. Antimetabolite, alkylating agent, nitrosourea].
Topics: Alkaloids; Antineoplastic Agents; Benzylisoquinolines; Dacarbazine; Drug Synergism; Humans; Hydroxyurea; Melanoma; Nitrosourea Compounds; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1992 |
[Primary intracranial melanoma: a case report].
Topics: Adult; Amphetamines; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Dacarbazine; Diagnosis, Differential; Humans; Interferon-beta; Iodine Radioisotopes; Iofetamine; Magnetic Resonance Imaging; Male; Melanoma; Nimustine; Prognosis; Tomography, Emission-Computed, Single-Photon; Vincristine | 1992 |
Modulation of cisplatin resistance in human malignant melanoma cells.
Topics: Carboplatin; Cisplatin; Dacarbazine; DNA; Drug Resistance; Drug Synergism; Humans; Melanoma; Metallothionein; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Tumor Cells, Cultured | 1992 |
Splenic lymphoma in a patient treated with interleukin-2 and dacarbazine for metastatic melanoma.
Topics: Adult; Dacarbazine; Humans; Interleukin-2; Lymphatic Metastasis; Lymphoma; Male; Melanoma; Skin Neoplasms; Splenic Neoplasms | 1992 |
Metastases to skeletal muscles and interferon treatment.
Topics: Aged; Carcinoma, Renal Cell; Combined Modality Therapy; Dacarbazine; Humans; Interferon alpha-2; Interferon-alpha; Kidney Neoplasms; Male; Melanoma; Middle Aged; Muscular Diseases; Recombinant Proteins | 1992 |
Multifocal neurotoxicity during interleukin-2 therapy for malignant melanoma.
Topics: Adult; Brain; Combined Modality Therapy; Dacarbazine; Female; Humans; Interleukin-2; Lymphatic Metastasis; Magnetic Resonance Imaging; Melanoma; Quadriplegia; Skin Neoplasms; Tomography, X-Ray Computed | 1992 |
Impaired levodopa response in Parkinson's disease during melanoma therapy.
Topics: Adult; Dacarbazine; Dopamine; Drug Interactions; Humans; Levodopa; Male; Melanins; Melanoma; Parkinson Disease; Skin Neoplasms | 1992 |
Sequential administration of dacarbazine and fotemustine in patients with disseminated malignant melanoma--an effective combination with unexpected toxicity.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Pneumonia | 1992 |
Chemo-adoptive immunotherapy of nude mice implanted with human colorectal carcinoma and melanoma cell lines.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therapy; Cytotoxicity, Immunologic; Dacarbazine; Drug Administration Schedule; Female; Fluorouracil; Humans; Immunotherapy, Adoptive; Interferon Type I; Interleukin-2; Killer Cells, Lymphokine-Activated; Lymphocytes, Tumor-Infiltrating; Male; Melanoma; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Recombinant Proteins; T-Lymphocytes; Tumor Cells, Cultured | 1992 |
Determination of N7-methylguanine in DNA of white blood cells from cancer patients treated with dacarbazine.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; DNA; Enzyme-Linked Immunosorbent Assay; Female; Guanine; Humans; Leukocytes; Male; Melanoma; Middle Aged; Sarcoma | 1992 |
Adjuvant chemotherapy in malignant melanoma using dacarbazine, carmustine, cisplatin, and tamoxifen: a University of South Florida and H. Lee Moffitt Melanoma Center Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chemotherapy, Adjuvant; Cisplatin; Dacarbazine; Female; Florida; Follow-Up Studies; Hospitals, University; Humans; Lymph Node Excision; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prospective Studies; Skin Neoplasms; Survival Rate; Tamoxifen | 1992 |
Treatment of stage IV malignant melanoma with dacarbazine, carmustine, cisplatin, and tamoxifen regimens: a University of South Florida and H. Lee Moffitt Melanoma Center Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Female; Florida; Follow-Up Studies; Hospitals, University; Humans; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Survival Analysis; Survival Rate; Tamoxifen | 1992 |
Chemotherapy for malignant melanoma: combinations and high doses produce more responses without survival benefit.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Transplantation; Dacarbazine; Female; Humans; Lomustine; Male; Melanoma; Melphalan; Middle Aged; Neoplasm Metastasis; Retrospective Studies; Vincristine; Vindesine | 1990 |
[Breast metastases of skin melanoma].
Topics: Adult; Aged; Aged, 80 and over; Breast; Breast Neoplasms; Dacarbazine; Female; Humans; Interferons; Male; Melanoma; Skin; Skin Neoplasms | 1990 |
New approaches to the chemotherapy of melanoma.
Topics: Alkaloids; Amifostine; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Transplantation; Carmustine; Cisplatin; Cyclophosphamide; Dacarbazine; Daunorubicin; Humans; Lomustine; Melanoma; Nitrosourea Compounds; Paclitaxel; Procarbazine; Tamoxifen; Taurine; Thiotepa; Vincristine; Vindesine | 1991 |
Malignant melanoma: primary presentation in bone marrow and lymph node.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carmustine; Cisplatin; Dacarbazine; Humans; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Tamoxifen | 1992 |
Effective chemotherapy for melanoma after treatment with interleukin-2.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Female; Humans; Interleukin-2; Male; Melanoma; Middle Aged; Remission Induction; Tamoxifen | 1992 |
Site-dependent differences in sensitivity of LOX human melanoma tumors in nude rats to dacarbazine and mitozolomide, but not to doxorubicin and cisplatin.
Topics: Animals; Antineoplastic Agents; Bone Marrow; Bone Neoplasms; Cisplatin; Dacarbazine; Doxorubicin; Drug Screening Assays, Antitumor; Humans; Lung Neoplasms; Melanoma; Nitrogen Mustard Compounds; Rats; Rats, Nude; Skin Neoplasms; Transplantation, Heterologous | 1992 |
Dacarbazine (DTIC), human recombinant interferon alpha 2a (Roferon) and 5-fluorouracil for disseminated malignant melanoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Drug Administration Schedule; Female; Fluorouracil; Humans; Interferon-alpha; Male; Melanoma; Middle Aged | 1992 |
[Immunophenotype of lymphocytes of patients with malignant melanoma and its dynamics during immunotherapy with interleukin-2].
Topics: Antibodies, Monoclonal; B-Lymphocytes; Dacarbazine; Drug Therapy, Combination; Humans; Immunophenotyping; Interleukin-2; Lymphocyte Activation; Lymphocyte Subsets; Lymphocytes; Melanoma; T-Lymphocytes | 1991 |
O6-alkylguanine-DNA alkyltransferase depletion and regeneration in human peripheral lymphocytes following dacarbazine and fotemustine.
Topics: Adenosine Triphosphatases; Adult; Aged; Antineoplastic Agents; Dacarbazine; Female; Humans; Kinetics; Lymphocytes; Male; Melanoma; Methyltransferases; Middle Aged; Nitrosourea Compounds; O(6)-Methylguanine-DNA Methyltransferase; Organophosphorus Compounds | 1991 |
Interferon plus dacarbazine in advanced malignant melanoma: a phase I-II study.
Topics: Combined Modality Therapy; Dacarbazine; Drug Evaluation; Humans; Interferon Type I; Melanoma | 1991 |
Malignant melanoma and renal cell carcinoma: immunological and haematological effects of recombinant human interleukin-2.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Carcinoma, Renal Cell; Cytotoxicity, Immunologic; Dacarbazine; Female; Humans; Interleukin-2; Kidney Neoplasms; Killer Cells, Lymphokine-Activated; Killer Cells, Natural; Melanoma; Mitosis; Recombinant Proteins | 1991 |
Fotemustine with or without dacarbazine for brain metastases of malignant melanoma.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Drug Evaluation; Humans; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds | 1991 |
The prognosis of melanoma patients with metastases to two or more lymph node areas.
Topics: Adolescent; Adult; BCG Vaccine; Combined Modality Therapy; Dacarbazine; Female; Humans; Immunotherapy; Lomustine; Lymph Node Excision; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoplasm Invasiveness; Prognosis; Skin Neoplasms; Survival Rate | 1991 |
Treatment of advanced malignant melanoma with recombinant interferon alfa-2a in combination with DTIC: long-term follow-up of two phase II studies.
Topics: Adolescent; Adult; Aged; Combined Modality Therapy; Dacarbazine; Drug Administration Schedule; Drug Evaluation; Female; Follow-Up Studies; Humans; Interferon alpha-2; Interferon-alpha; Male; Melanoma; Middle Aged; Prognosis; Prospective Studies; Recombinant Proteins | 1991 |
Treatment of metastatic malignant melanoma with 24 hours continuous venous infusion of dacarbazine and cisplatin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Melanoma; Middle Aged; Pilot Projects; Remission Induction; Survival Analysis | 1991 |
Sequential chemoimmunotherapy for metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Autoimmune Diseases; Carmustine; Cisplatin; Dacarbazine; Drug Administration Schedule; Female; Humans; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Skin Neoplasms; Survival Rate; Tamoxifen; Thrombocytopenia | 1991 |
Practical spontaneous metastasis model for in vivo therapeutic studies using a human melanoma.
Topics: Animals; Cyclophosphamide; Dacarbazine; Humans; Lung Neoplasms; Melanoma; Mice; Mice, Nude; Neoplasm Metastasis; Neoplasm Transplantation; Tumor Cells, Cultured | 1991 |
Sequential dacarbazine/cisplatin and interleukin-2 in metastatic melanoma: immunological effects of therapy.
Topics: Adolescent; Adult; Aged; Cisplatin; Combined Modality Therapy; Dacarbazine; Drug Evaluation; Female; Humans; Immunophenotyping; Immunotherapy; Interleukin-2; Killer Cells, Lymphokine-Activated; Killer Cells, Natural; Leukocyte Count; Lymphocytes; Male; Melanoma; Middle Aged | 1991 |
Phase II study of carboplatin and cytosine arabinoside in patients with disseminated malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cytarabine; Dacarbazine; Drug Evaluation; Female; Humans; Male; Melanoma; Middle Aged; Organoplatinum Compounds | 1990 |
Metastatic malignant melanoma in pregnancy.
Topics: Dacarbazine; Female; Humans; Infant, Newborn; Melanoma; Pregnancy; Pregnancy Complications, Neoplastic; Skin Neoplasms | 1990 |
Alteration of dacarbazine pharmacokinetics after interleukin-2 administration in melanoma patients.
Topics: Chromatography, High Pressure Liquid; Dacarbazine; Drug Interactions; Humans; Injections, Intravenous; Interleukin-2; Melanoma | 1990 |
Dacarbazine (DTIC) and human recombinant interferon alpha 2a (Roferon) in the treatment of disseminated malignant melanoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Interferon alpha-2; Interferon-alpha; Male; Melanoma; Middle Aged; Recombinant Proteins | 1990 |
[Fotemustine in the treatment of metastatic malignant melanoma. Overall analysis of results].
Topics: Antineoplastic Agents; Dacarbazine; Drug Synergism; Drug Therapy, Combination; Humans; Melanoma; Neoplasm Metastasis; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms | 1990 |
[The prevention of skin melanoma metastases to the regional lymph nodes].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Dacarbazine; Humans; Injections, Intralymphatic; Lymphatic Metastasis; Melanoma; Methotrexate; Postoperative Care; Prospidium; Remission Induction; Skin Neoplasms | 1990 |
[Study of procreation capacity of men after treatment of their malignant tumors (melanoblastoma, thyroid carcinoma) with ionizing radiation and cytostatic agents].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cobalt Radioisotopes; Cyclophosphamide; Dacarbazine; Fertility; Fluorouracil; Humans; Male; Melanoma; Methotrexate; Radiotherapy Dosage; Sperm Count; Sperm Motility; Spermatozoa; Thyroid Neoplasms | 1990 |
[Hepatic veno-occlusive disease caused by Deticene: a cause of acute hypovolemic shock].
Topics: Abdominal Pain; Ascites; Dacarbazine; Female; Hemodynamics; Hepatic Veno-Occlusive Disease; Humans; Hydrocortisone; Melanoma; Middle Aged; Shock; Skin Neoplasms | 1990 |
Sequential treatment of melanoma patients who progressed on interleukin-2 and dacarbazine by alpha-interferon and dacarbazine--a preliminary report.
Topics: Adult; Dacarbazine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Immunologic Factors; Interferon Type I; Interleukin-2; Male; Melanoma; Middle Aged; Neoplasms; Recombinant Proteins | 1990 |
Nude rat model for studying metastasis of human tumor cells to bone and bone marrow.
Topics: Age Factors; Animals; Bone Marrow; Bone Neoplasms; Dacarbazine; Disease Models, Animal; Heart Ventricles; Humans; Injections; Melanoma; Microspheres; Neoplasm Transplantation; Paraplegia; Rats; Rats, Nude; Tissue Distribution; Transplantation, Heterologous | 1990 |
In vitro chemosensitivity testing of Fotemustine (S 10036), a new antitumor nitrosourea.
Topics: Antineoplastic Agents; Carmustine; Cell Division; Cisplatin; Dacarbazine; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Lomustine; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Thymidine; Tumor Cells, Cultured | 1990 |
Intraarterial infusion chemotherapy in regionally advanced malignant melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Dacarbazine; Female; Humans; Infusions, Intra-Arterial; Male; Melanoma; Survival Rate | 1990 |
A phase I-II study of dacarbazine in combination with outpatient interleukin-2 in metastatic malignant melanoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Drug Evaluation; Female; Humans; Interleukin-2; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Recombinant Proteins; T-Lymphocytes | 1990 |
Hypothyroidism and goiter in a patient during treatment with interleukin-2.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Goiter; Humans; Hypothyroidism; Interleukin-2; Melanoma; Middle Aged; Recombinant Proteins; Thyroiditis, Autoimmune | 1990 |
Dacarbazine-vindesine-cisplatin in disseminated malignant melanoma. A phase I-II trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Drug Evaluation; Humans; Melanoma; Neoplasm Metastasis; Remission Induction; Vindesine | 1990 |
Case report: development of Hodgkin's disease in patient receiving long-term administration of dacarbazine and interleukin-2 for metastatic melanoma.
Topics: Combined Modality Therapy; Dacarbazine; Female; Hodgkin Disease; Humans; Interleukin-2; Melanoma; Middle Aged | 1990 |
[Diagnosis and treatment of malignant melanoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Dacarbazine; Humans; Lymph Node Excision; Melanoma; Nimustine; Nitrosourea Compounds; Peplomycin; Prognosis; Skin; Skin Neoplasms; Vincristine | 1985 |
Basic studies of cryochemotherapy in a murine tumor system.
Topics: Animals; Antineoplastic Agents; Bleomycin; Cell Line; Combined Modality Therapy; Cryosurgery; Dacarbazine; Doxorubicin; Female; Melanoma; Mice; Peplomycin | 1985 |
Angiotensin-induced hypertension and chemotherapy for multiple lesions of malignant melanoma.
Topics: Adult; Aged; Angiotensin II; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Blood Flow Velocity; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Peplomycin; Vincristine | 1985 |
Treatment of metastatic malignant melanoma with vinblastine, dacarbazine, and cisplatin: a report from the Cancer and Leukemia Group B.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Dacarbazine; Humans; Melanoma; Middle Aged; Vinblastine | 1986 |
[Therapeutic response of interferon-beta in malignant melanoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Female; Humans; Indomethacin; Infusions, Parenteral; Interferon Type I; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Skin Neoplasms; Vincristine | 1986 |
Phase II study of bleomycin, actinomycin D, DTIC and vindesine in disseminated malignant melanoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Dactinomycin; Drug Evaluation; Female; Humans; Lung Neoplasms; Male; Melanoma; Middle Aged; Vindesine | 1986 |
Expression of the c-src protooncogene in human skin tumors.
Topics: Adult; Aged; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Nevus; Protein Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins pp60(c-src); RNA, Messenger; Skin Neoplasms | 1987 |
[Primary malignant melanoma of the female urethra: a case report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Combined Modality Therapy; Dacarbazine; Female; Humans; Melanoma; Peplomycin; Urethral Neoplasms | 1987 |
[Successful therapy of secondary melanoma of the orbit with DTIC].
Topics: Aged; Dacarbazine; Facial Neoplasms; Humans; Male; Melanoma; Orbital Neoplasms; Palliative Care; Skin Neoplasms | 1987 |
Bleomycin, vincristine, lomustine, and DTIC chemotherapy for metastatic melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Humans; Lomustine; Melanoma; Neoplasm Metastasis; Vincristine | 1988 |
A phase II trial of vinblastine, bleomycin, and cisplatin induction followed by dacarbazine and dibromodulcitol maintenance in the treatment of metastatic melanoma. A follow-up study of twenty-two patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Dacarbazine; Drug Evaluation; Female; Follow-Up Studies; Humans; Male; Melanoma; Middle Aged; Mitolactol; Vinblastine | 1988 |
Phase II study of bleomycin, dacarbazine (DTIC) and vindesine in disseminated malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Vindesine | 1989 |
Chemotherapy of disseminated melanoma with bleomycin, vincristine, CCNU, and DTIC (BOLD regimen). The Prudente Foundation Melanoma Study Group.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Drug Administration Schedule; Female; Humans; Lomustine; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoplasm Staging; Skin Neoplasms; Vincristine | 1989 |
Malignant melanoma infiltrating the reticular dermis at level IV.
Topics: Dacarbazine; Female; Humans; Interferons; Melanoma; Middle Aged; Referral and Consultation; Skin Neoplasms; Wrist | 1989 |
Effectiveness and toxicity of "BELD" polychemotherapy in advanced malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Female; Humans; Lomustine; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Remission Induction; Skin Neoplasms; Vindesine | 1989 |
Relationships among cell survival, O6-alkylguanine-DNA alkyltransferase activity, and reactivation of methylated adenovirus 5 and herpes simplex virus type 1 in human melanoma cell lines.
Topics: Adenoviruses, Human; Alkylating Agents; Cell Survival; Dacarbazine; DNA Damage; DNA Repair; DNA, Neoplasm; Drug Resistance; Humans; Melanoma; Methylation; Methyltransferases; O(6)-Methylguanine-DNA Methyltransferase; Simplexvirus; Tumor Cells, Cultured | 1989 |
The use of BELD combination chemotherapy (bleomycin, vindesine, CCNU, and DTIC) in advanced malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Drug Administration Schedule; Female; Humans; Lomustine; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Pilot Projects; Skin Neoplasms; Vinblastine; Vindesine | 1985 |
Spermidine level as a parameter in the treatment of patients with malignant melanoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Dactinomycin; Drug Administration Schedule; Female; Humans; Male; Melanoma; Middle Aged; Spermidine; Vinblastine; Vindesine | 1985 |
High-dose, double alkylating agent chemotherapy with DTIC, melphalan, or ifosfamide and marrow rescue for metastatic malignant melanoma.
Topics: Adult; Aged; Alkylating Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transplantation; Dacarbazine; Humans; Ifosfamide; Lung Neoplasms; Melanoma; Melphalan; Middle Aged; Neoplasm Metastasis; Skin Neoplasms | 1989 |
Hepatic vascular toxicity of dacarbazine (DTIC): not a rare complication.
Topics: Budd-Chiari Syndrome; Dacarbazine; Humans; Melanoma | 1989 |
Tourniquet infusion chemotherapy of the lower extremities--clinical and pharmacokinetic results.
Topics: Adult; Aged; Dacarbazine; Doxorubicin; Female; Humans; Infusions, Intra-Arterial; Leg; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Sarcoma, Kaposi; Skin Neoplasms; Time Factors; Tourniquets | 1989 |
Isolated limb perfusion for stage I melanoma of the extremity: a comparison of melphalan and dacarbazine (DTIC).
Topics: Adult; Chemotherapy, Cancer, Regional Perfusion; Cicatrix; Dacarbazine; Extremities; Female; Follow-Up Studies; Humans; Lymphatic Metastasis; Male; Melanoma; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Retrospective Studies | 1989 |
Reduced DNA damage induced in human melanoma cells by dacarbazine in the presence of deoxyribonucleosides.
Topics: Dacarbazine; Deoxyadenosines; Deoxycytidine; Deoxyguanosine; DNA Damage; DNA, Neoplasm; Humans; Melanoma; Thymidine | 1989 |
Alternating recombinant human interleukin-2 and dacarbazine in advanced melanoma. A multicentric phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Drug Administration Schedule; Drug Evaluation; Drug Synergism; Female; Humans; Interleukin-2; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Monitoring, Physiologic; Recombinant Proteins; Remission Induction | 1989 |
Treatment of metastatic malignant melanoma with dacarbazine, vindesine and cisplatin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Female; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Skin Neoplasms; Vindesine | 1989 |
A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Staging; Prospective Studies; Vincristine | 1989 |
Seven years experience with hyperthermic perfusions in extracorporeal circulation for melanoma of the extremities.
Topics: Antineoplastic Agents; Chemotherapy, Cancer, Regional Perfusion; Cisplatin; Dacarbazine; Extracorporeal Circulation; Extremities; Female; Humans; Hyperthermia, Induced; Male; Melanoma; Melphalan; Neoplasm Staging; Risk Factors; Time Factors | 1989 |
Summary of recent clinical experience in whole-body hyperthermia combined with chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Dacarbazine; Doxorubicin; Etoposide; Evaluation Studies as Topic; Female; Humans; Hyperthermia, Induced; Lung Neoplasms; Male; Melanoma; Vincristine; Vindesine | 1988 |
The importance of tamoxifen to a cisplatin-containing regimen in the treatment of metastatic melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Female; Hematologic Diseases; Humans; Male; Melanoma; Middle Aged; Pulmonary Embolism; Skin Neoplasms; Tamoxifen; Thrombophlebitis | 1989 |
Peripheral DTIC neurotoxicity: a case report.
Topics: Aged; Dacarbazine; Humans; Lung Neoplasms; Male; Melanoma; Peripheral Nervous System Diseases; Skin Neoplasms | 1987 |
Inhibition of poly(ADP-ribose) synthetase potentiates cell dacarbazine cytotoxicity.
Topics: Antineoplastic Agents; Aphidicolin; Benzamides; Cell Line; Dacarbazine; Diterpenes; DNA; DNA Repair; Drug Synergism; Humans; Melanoma; Poly(ADP-ribose) Polymerase Inhibitors | 1987 |
Suicide enzyme inhibition as a chemotherapeutic strategy for controlling metastases derived from intraocular melanomas.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Eflornithine; Enzyme Inhibitors; Eye Neoplasms; Female; Injections, Intravenous; Lung Neoplasms; Melanoma; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Time Factors | 1987 |
[Regional intra-arterial chemotherapy].
Topics: Cisplatin; Dacarbazine; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Melanoma; Mitomycin; Mitomycins | 1988 |
Alpha-interferons in malignant melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cimetidine; Dacarbazine; Humans; Interferon Type I; Melanoma | 1988 |
[Problems and results of treatment of 43 patients with melanomas of the head and neck].
Topics: Adult; Aged; Aged, 80 and over; Combined Modality Therapy; Dacarbazine; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Skin Neoplasms; Surgical Flaps | 1988 |
Evaluation of cis-platinum and DTIC combination chemotherapy in disseminated melanoma. A Southwest Oncology Group Study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Drug Administration Schedule; Drug Evaluation; Female; Humans; Male; Melanoma; Middle Aged; Prospective Studies | 1988 |
Predictive chemosensitivity testing in malignant melanoma: reliable methodology--ineffective drugs.
Topics: Dacarbazine; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Lomustine; Melanoma; Predictive Value of Tests; Prospective Studies; Retrospective Studies; Vinblastine | 1988 |
Heterogeneity of the response to inducers of differentiation and to cytostatics of tumor cell populations.
Topics: Antineoplastic Agents; Cell Differentiation; Cisplatin; Cytarabine; Dacarbazine; Dimethyl Sulfoxide; Dose-Response Relationship, Drug; Doxorubicin; Fluorouracil; Humans; Leukemia, Erythroblastic, Acute; Leukemia, Promyelocytic, Acute; Melanoma; Neoplasms; Tetradecanoylphorbol Acetate; Tretinoin; Tumor Cells, Cultured | 1988 |
[Systemic therapy of metastatic malignant melanoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Humans; Immunotherapy; Interferon Type I; Interleukin-2; Killer Cells, Natural; Lomustine; Melanoma; Skin Neoplasms | 1988 |
[Regional intra-arterial chemotherapy with Dacarbazine in isolated liver metastases of a malignant melanoma].
Topics: Chemotherapy, Cancer, Regional Perfusion; Dacarbazine; Female; Humans; Liver Neoplasms; Melanoma; Middle Aged; Skin Neoplasms | 1988 |
Fatal hepatic vascular toxicity of DTIC. Is it really a rare event?
Topics: Aged; Budd-Chiari Syndrome; Combined Modality Therapy; Dacarbazine; Eosinophilia; Fever; Humans; Male; Melanoma; Middle Aged; Necrosis; Skin Neoplasms | 1988 |
[Multiple BCG-induced ulcers after subcutaneous vaccination in the framework of immunochemotherapy in malignant melanoma].
Topics: BCG Vaccine; Combined Modality Therapy; Dacarbazine; Female; Humans; Injections, Subcutaneous; Melanoma; Middle Aged; Skin Neoplasms; Skin Ulcer | 1988 |
Treatment of advanced malignant melanoma with interferon alpha and etretinate.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Etretinate; Female; Humans; Interferon Type I; Male; Melanoma; Middle Aged; Skin Neoplasms; Vindesine | 1988 |
[Adjuvant chemotherapy of malignant melanoma with DTIC. Lack of effect in stage I. Possible improvement of the prognosis for survival in stage IIb].
Topics: Combined Modality Therapy; Dacarbazine; Humans; Lymphatic Metastasis; Melanoma; Neoplasm Staging; Prognosis; Skin Neoplasms | 1988 |
Combination of cisplatin, vindesine, and dacarbazine in advanced malignant melanoma. A Phase II Study of the EORTC Malignant Melanoma Cooperative Group.
Topics: Actuarial Analysis; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Drug Evaluation; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Vindesine | 1988 |
[Adjuvant chemotherapy of malignant melanoma of the female genital organs].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dacarbazine; Female; Humans; Melanoma; Middle Aged; Nimustine; Nitrosourea Compounds; Picibanil; Vaginal Neoplasms; Vincristine; Vulvar Neoplasms | 1986 |
Recombinant interferon alfa-2a in advanced malignant melanoma. A phase I-II study in combination with DTIC.
Topics: Adolescent; Adult; Aged; Combined Modality Therapy; Dacarbazine; Dose-Response Relationship, Drug; Drug Evaluation; Female; Humans; Interferon Type I; Male; Melanoma; Middle Aged; Prospective Studies; Recombinant Proteins | 1987 |
Adenovirus replication as an in vitro probe for drug sensitivity in human tumors.
Topics: Adenoviridae; Antigens, Viral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cell Division; Cell Line; Dacarbazine; Humans; Immunoenzyme Techniques; Melanoma | 1986 |
[DTIC: effect on fibrinolysis and thrombocyte function].
Topics: Blood Coagulation Tests; Budd-Chiari Syndrome; Dacarbazine; Fibrinolysis; Humans; Melanoma; Platelet Aggregation; Platelet Count; Skin Neoplasms | 1986 |
Hyperthermic antiblastic perfusion with DTIC in stage IIIA-IIIAB melanoma of the extremities.
Topics: Adult; Chemotherapy, Cancer, Regional Perfusion; Dacarbazine; Extremities; Female; Follow-Up Studies; Humans; Hyperthermia, Induced; Male; Melanoma; Middle Aged; Skin Neoplasms | 1987 |
[Late results of the conservative treatment of melanoma of the skin].
Topics: Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Dactinomycin; Humans; Melanoma; Skin Neoplasms; Vincristine | 1986 |
Adjuvant chemoimmunotherapy after regional lymphadenectomy for malignant melanoma.
Topics: Adjuvants, Immunologic; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Carmustine; Combined Modality Therapy; Dacarbazine; Humans; Hydroxyurea; Lymph Node Excision; Lymphatic Metastasis; Melanoma; Neoplasm Recurrence, Local; Postoperative Care; Skin Neoplasms; Time Factors | 1987 |
Combination chemotherapy and hormonal therapy in the treatment of malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Female; Humans; Kidney Diseases; Leukopenia; Male; Melanoma; Middle Aged; Nausea; Pulmonary Embolism; Skin Neoplasms; Tamoxifen; Thrombocytopenia; Thromboembolism; Vomiting | 1987 |
W-7, a calmodulin inhibitor, potentiates dacarbazine cytotoxicity in human neoplastic cells.
Topics: Calmodulin; Cell Division; Cell Line; Cell Survival; Dacarbazine; DNA Repair; DNA Replication; DNA, Neoplasm; Drug Synergism; Humans; Melanoma; Sulfonamides | 1987 |
Acute non-lymphocytic leukemia (ANLL) following treatment with dacarbazine for malignant melanoma.
Topics: Acute Disease; Dacarbazine; Humans; Leukemia; Male; Melanoma; Middle Aged; Muramidase; Scalp; Skin Neoplasms | 1987 |
[Clinical trials of supplementary chemotherapy in cases of malignant melanoma of the skin with unfavorable prognosis after surgical treatment].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Prognosis; Skin Neoplasms; Vinblastine | 1987 |
Treatment of metastatic malignant melanoma with dacarbazine and cisplatin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Drug Evaluation; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Pilot Projects | 1987 |
Adjuvant and neoadjuvant chemotherapy with dacarbazine in high-risk childhood melanoma.
Topics: Child; Combined Modality Therapy; Dacarbazine; Female; Follow-Up Studies; Humans; Infant; Male; Melanoma; Retrospective Studies; Skin Neoplasms | 1987 |
Dacarbazine, vindesine, and cisplatin combination chemotherapy in advanced malignant melanoma: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cisplatin; Dacarbazine; Drug Evaluation; Female; Humans; Male; Melanoma; Middle Aged; Nausea; Vindesine; Vomiting | 1987 |
Treatment of metastatic melanoma by 24-hour DTIC infusions and hemibody irradiation.
Topics: Adult; Aged; Combined Modality Therapy; Dacarbazine; Evaluation Studies as Topic; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Radiotherapy Dosage; Skin Neoplasms; Time Factors | 1986 |
[5-year results of a chemo-immunotherapeutic treatment in stage-I and -II malignant melanoma].
Topics: Actuarial Analysis; Adult; Aged; BCG Vaccine; Combined Modality Therapy; Dacarbazine; Female; Follow-Up Studies; Humans; Lymph Node Excision; Melanoma; Middle Aged; Neoplasm Staging; Postoperative Care; Urinary Bladder Neoplasms | 1986 |
[Phase II study of decarbazine (DTIC) in malignant melanoma. DTIC Research Group].
Topics: Adolescent; Adult; Aged; Child; Dacarbazine; Drug Administration Schedule; Drug Evaluation; Female; Humans; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Skin Neoplasms | 1986 |
Phase II study: the combination DTIC, BCNU, actinomycin D, and vincristine in disseminated malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Dacarbazine; Dactinomycin; Drug Evaluation; Female; Humans; Male; Melanoma; Middle Aged; Vincristine | 1986 |
Combination chemotherapy with dacarbazine and vindesine in the treatment of metastatic malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Skin Neoplasms; Vindesine | 1986 |
Radiation in combination with intra-arterial infusion therapy with dacarbazine for metastatic malignant melanoma localized to a lower extremity.
Topics: Aged; Combined Modality Therapy; Dacarbazine; Female; Humans; Leg; Male; Melanoma; Middle Aged; Nausea; Neoplasm Recurrence, Local; Radiography; Skin Neoplasms | 1986 |
[Prognosis-oriented therapy of malignant melanoma. New concepts].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dacarbazine; Female; Humans; Immunotherapy; Lymph Node Excision; Lymph Nodes; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Risk; Skin; Skin Neoplasms | 1986 |
Dose-response relationship to dacarbazine demonstrated in a patient with malignant melanoma.
Topics: Dacarbazine; Dose-Response Relationship, Drug; Hepatic Artery; Humans; Liver Neoplasms; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local | 1986 |
Combination of fibroblast interferon (HuIFN beta), carboxamide (DTIC), and cimetidine for advanced malignant melanoma.
Topics: Adult; Cimetidine; Combined Modality Therapy; Dacarbazine; Female; Humans; Immunotherapy; Interferon Type I; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Recombinant Proteins | 1986 |
[Therapy and prognosis of malignant melanoma of the skin].
Topics: Adult; BCG Vaccine; Combined Modality Therapy; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Prognosis; Skin Neoplasms | 1986 |
[Chemotherapy of malignant melanoma].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Chemotherapy, Cancer, Regional Perfusion; Combined Modality Therapy; Dacarbazine; Humans; Melanoma; Neoplasm Metastasis; Prognosis; Skin Neoplasms; Tamoxifen | 1986 |
Allergy-induced hepatic toxicity associated with dacarbazine.
Topics: Autopsy; Budd-Chiari Syndrome; Chemical and Drug Induced Liver Injury; Combined Modality Therapy; Dacarbazine; Drug Hypersensitivity; Humans; Laparotomy; Liver Diseases; Male; Melanoma; Middle Aged; Skin Diseases | 1987 |
Prognostic factors in advanced metastatic and recurrent melanoma treated with DTIC.
Topics: Dacarbazine; Humans; Melanoma; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prognosis | 1987 |
Sequential treatment with interferon and chemotherapy of metastatic malignant melanoma. Total remission of cutaneous and visceral metastasis, but not of cerebral metastasis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Carmustine; Combined Modality Therapy; Dacarbazine; Drug Evaluation; Female; Humans; Interferon Type I; Lomustine; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Recombinant Proteins; Skin Neoplasms; Vincristine | 1987 |
Dibromodulcitol (DBD), DTIC, and actinomycin-D in disseminated malignant melanoma. A phase I-II clinical trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Dactinomycin; Drug Evaluation; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Male; Melanoma; Middle Aged; Mitolactol | 1985 |
Applicability of high-dose chemotherapy with autologous marrow transplantation for malignant melanoma.
Topics: Alkylating Agents; Antineoplastic Agents; Bone Marrow Transplantation; Dacarbazine; Humans; Leukemia; Melanoma; Skin Neoplasms | 1985 |
[Adjuvant chemotherapy of intraocular malignant melanoma. Apropos of 20 cases].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dacarbazine; Eye Neoplasms; Female; Humans; Liver Neoplasms; Male; Melanoma; Methotrexate; Middle Aged; Procarbazine; Thiotepa; Vinblastine | 1985 |
Assessment of survival rates with metastatic malignant melanomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dacarbazine; Female; Humans; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Skin Neoplasms | 1986 |
Toxicity and complications of vascular isolation and hyperthermic perfusion with imidazole carboxamide (DTIC) in melanoma.
Topics: Adult; Aged; Chemotherapy, Cancer, Regional Perfusion; Dacarbazine; Female; Humans; Hyperthermia, Induced; Leukopenia; Liver; Male; Melanoma; Middle Aged; Skin Neoplasms; Technetium Tc 99m Aggregated Albumin | 1986 |
Single-dose dacarbazine and dactinomycin in advanced malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Dactinomycin; Female; Humans; Leukocyte Count; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Platelet Count; Urinary Tract Infections | 1985 |
[Budd-Chiari syndrome following dacarbazine therapy of malignant melanoma--an avoidable complication?].
Topics: Budd-Chiari Syndrome; Dacarbazine; Female; Humans; Melanoma; Middle Aged; Skin Neoplasms | 1985 |
Simultaneous determination of dacarbazine, its photolytic degradation product, 2-azahypoxanthine, and the metabolite 5-aminoimidazole-4-carboxamide in plasma and urine by high-pressure liquid chromatography.
Topics: Aminoimidazole Carboxamide; Chromatography, High Pressure Liquid; Dacarbazine; Humans; Hypoxanthines; Imidazoles; Kinetics; Melanoma | 1985 |
Arterial infusion of dacarbazine and cisplatin for recurrent regionally confined melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arm; Cisplatin; Dacarbazine; Female; Humans; Infusions, Intra-Arterial; Leg; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Skin Neoplasms; Vulvar Neoplasms | 1985 |
[Therapy of malignant melanoma].
Topics: Combined Modality Therapy; Dacarbazine; Humans; Lymphatic Metastasis; Melanoma; Methods; Neoplasm Metastasis | 1985 |
[Radiotherapy with intra-arterial chemotherapy. Treatment with 5-(3,3 dimethyl-1-triazeno)imidazole-4-carboxamide. Effect in malignant melanoma of the extremities].
Topics: Aged; Combined Modality Therapy; Dacarbazine; Female; Humans; Leg; Male; Melanoma; Middle Aged; Skin Neoplasms | 1985 |